Cellular Transplantation from Laboratory to Clinic
This page intentionally left blank
Cellular Transplantation from Laboratory to Clinic
Editors Craig Halberstadt Dwaine Emerich
Amsterdam • Boston • Heidelberg • London • New York Oxford • Paris • San Diego • San Francisco • Singapore Sydney • Tokyo
Academic Press is an imprint of Elsevier 30 Corporate Drive, Suite 400, Burlington, MA 01803, USA 525 B Street, Suite 1900, San Diego, California 92101-4495, USA 84 Theobald’s Road, London WC1X 8RR, UK This book is printed on acid-free paper. Copyright © 2007, Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, E-mail:
[email protected]. You may also complete your request on-line via the Elsevier homepage (http://elsevier.com), by selecting “Support & Contact” then “Copyright and Permission” and then “Obtaining Permissions.” Library of Congress Cataloging-in-Publication Data APPLICATION SUBMITTED ISBN 13: 978-0-12-369415-7 ISBN 10: 0-12-369415-9 For information on all Academic Press publications visit our Web site at www.books.elsevier.com Printed in the United States of America 07 08 09 10 9 8 7 6 5 4
3
2
1
Contents
Contributors .................................................... vii Preface ........................................................... xiii
6. Characterization of Islet Preparations ................... 85 Clark K. Colton, Klearchos K. Papas, Anna Pisania, Michael J. Rappel, Daryl E. Powers, Jack J. O’Neil, Abdulkadir Omer, Gordon Weir, and Susan Bonner-Weir
A. The Basic Biology of Cell Therapy 1. Immunology of Cell and Tissue Xenotransplantation ...................................... Jeffrey L. Platt
7. Encapsulated Human Islet Allografts: Providing Safety with Efficacy .......................................... 135 David W. Scharp
3
8. Strategies for Cell Replacement for Kidney Failure ................................................. 155 Marc R. Hammerman
2. Current Immunosuppressive Drugs and Clinical Use .................................................... 13 Harrison S. Pollinger, Justin M. Burns, Vince P. Casingal, and Paul F. Gores
9. Strategies for Extracorporeal Devices for Kidney Failure ............................................................ 169 Khajohn Tiranathanagul and H. David Humes 10. Transplants for Hemophilia ................................ 187 Andrew Gómez-Vargas and Gonzalo Hortelano
3. Stem and Precursor Cells for Transplant Therapy ... 29 Jingli Cai and Mahendra Rao
11. Cell Therapy for Peripheral Diseases and Reconstructive Applications: Transplants for Lysosomal Storage Disease ................................ 205 Toya Ohashi and Yoshikatsu Eto
4. Creating Animals for Cell Xenotransplantation ...... 43 David White
12. Cellular Transplants for Liver Diseases ................ 215 Nicholas J. Krebs, Craig Neville, and Joseph P. Vacanti
B. Cell Therapy for Peripheral Diseases and Reconstructive Applications
13. Stem Cell Transplantation for Autoimmune Diseases ....................................... 241 Alan Tyndall and Katarina Le Blanc
5. Islet Transplants for Diabetes: The Edmonton Protocol .......................................................... 59 Peter A. Senior and A. M. James Shapiro
14. Cardiac Cell Transplantation .............................. 259 Bryce H. Davis, Harald C. Ott, and Doris A. Taylor v
Contents 15. Cylindrical Cartilage Transplantation as Tracheal Replacement .................................................... 275 Koji Kojima and Charles A. Vacanti
25. Neural Transplantation in Parkinson’s Disease ....... 439 Stephen B. Dunnett and Anne E. Rosser 26. Transplants for Chronic Pain .............................. 455 Jacqueline Sagen, Daniel A. Castellanos, and Shyam Gajavelli
16. Muscle Cell Transplants .................................... 289 Mitra Lavasani, Jonathan Pollett, and Johnny Huard
27. Cell Grafting for Spinal Cord Injury Repair: Cell Replacement and Bridging Strategies ................... 477 D. D. Pearse and D. J. Barakat
C. Cell Therapy for CNS Diseases
28. Human Embryonic Stem Cells, Dopaminergic Neurons, and Pathways for Developing a Parkinson’s Disease Therapy .............................. 523 William J. Freed, Joseph F. Sanchez, Chun-Ting Lee, Tandis Vazin, Rose Amable, Cynthia Schoen, Catherine Schwartz, Mahendra Rao, and Xianmin Zeng
17. Immunological Considerations in CNS Transplants ...................................................... 305 Kai-Christian Sonntag 18. Neurotrophic Cell Transplants for Degenerative Diseases of the Eye .......................................... 327 Chris Thanos and Dwaine F. Emerich
D. Future Avenues of Cell Therapy
19. Transplants for Glioblastoma .............................. 345 Jian Wang, A. J. A. Terzis, Karen S. Aboody, Per Oyvind Enger, and Rolf Bjerkvig
29. Concepts in Cell Therapy: From Cord Blood to Sertoli Cells .................................................... 547 Paul R. Sanberg, Denis K. English, Amal Hakki, Don F. Cameron, Svitlana Garbuzova-Davis, Alison E. Willing, Cesario V. Borlongan, Robert Henning, Stephen K. Klasko, and Nagwa S. El-Badri
20. NT2N Cell Transplantation and GDNF Treatment in Stroke: Linking Neurotrophic Factor Therapy and Neuroprotection .......................................... 353 Cesario V. Borlongan, Christine E. Stahl, Guolong Yu, Lin Xu, Takao Yasuhara, Koichi Hara, Noriyuki Matsukawa, Paul R. Sanberg, Yun Wang, and David C. Hess
30. Immunologically Privileged Environments ............ 567 Mark P. Hedger
21. NGF-Producing Cell Transplants for Alzheimer’s Disease ........................................................... 373 Ann-Charlotte Granholm
31. Converging Cell Therapy with Biomaterials .......... 591 Omar A. Ali and David J. Mooney 32. Nanotechnology’s Impact on Cell Transplantation ................................................ 611 Dwaine F. Emerich and Craig Halberstadt
22. Transplants of CNTF-producing Cells for the Treatment of Huntington’s Disease ...................... 385 Carole Escartin, Philippe Hantraye, and Nicole Déglon
33. Design and Implementation of a Cell Processing Facility ........................................................... 629 Tatsuya Kin, Mohammadreza Mirbolooki, and Jonathan R. T. Lakey
23. Choroid Plexus Epithelial Cell Transplants for Repair of the Brain ........................................... 399 Christopher G. Thanos and Dwaine F. Emerich
34. Developing Cell Therapy Products ...................... 635 Alfred V. Vasconcellos
24. Neural Transplantation in Huntington’s Disease ........................................................... 417 Anne E. Rosser and Stephen B. Dunnett
Index ................................................................... 647
vi
Contributors
The number in parentheses indicates the chapter to which the author contributed.
Susan Bonner-Weir (6) Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
Karen S. Aboody (19) The Divisions of Hematology/Hematopoietic Cell Transplantation and Neurosciences, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
Cesario V. Borlongan (20) Research and Affiliations Service Line, Augusta VAMC, Augusta, Georgia Department of Neurology and Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA
Omar A. Ali (31) Division of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts Rose Amable (28) Development and Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
Justin M. Burns (2) Division of Transplantation Surgery, Carolinas Medical Center, Charlotte, North Carolina Jingli Cai (3) National Institute on Aging, Triad Technology Center, Baltimore, Maryland
D. J. Barakat (27) The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida
Don F. Cameron (29) Center for Excellence for Aging and Brain Repair, Department of Anatomy, USF Health, Tampa, Florida
Rolf Bjerkvig (19) NorLux Neuro-Oncology, Department of Biomedicine, University of Bergen, Norway and NorLux Neuro-Oncology, Centre Recherche Public Santé, Luxembourg
Vince P. Casingal (2) Division of Transplantation Surgery, Carolinas Medical Center, Charlotte, North Carolina
Katarina Le Blanc (13) Dept of Allogeneic Stem Cell Transplantation, Karolinska Institute, Stockholm, Sweden
Daniel A. Castellanos (26) Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida vii
Contributors
Clark K. Colton (6) Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
Svitlana Garbuzova-Davis (29) Center for Excellence for Aging and Brain Repair, Department of Neurosurgery, USF Health, Tampa, Florida
Bryce H. Davis (14) Duke University, Department of Biomedical Engineering, Durham, North Carolina
Andrew Gómez-Vargas (10) Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
Nicole Déglon (22) Atomic Energy Commission, CEA CNRS URA 2210 Unit and MiRcen ImaGene Program Stephen B. Dunnett (24, 25) School of Biosciences, Cardiff University, Cardiff, Wales, UK Nagwa S. El-Badri (29) Center for Excellence for Aging and Brain Repair, Department of Neurosurgery, USF Health, Tampa, Florida Dwaine F. Emerich (18, 23, 32) LCT BioPharma, Providence, Rhode Island Per Oyvind Enger (19) NorLux Neuro-Oncology, Department of Biomedicine, University of Bergen, Norway and NorLux Neuro-Oncology, Centre Recherche Public Santé, Luxembourg Denis K. English (29) Center for Excellence for Aging and Brain Repair, Departments of Neurosurgery, USF Health, Tampa, Florida Carole Escartin (22) Atomic Energy Commission, CEA CNRS URA 2210 Unit and MiRcen ImaGene Program Yoshikatsu Eto (11) Department of Gene Therapy, Institute of DNA Medicine, Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan William J. Freed (28) Development and Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland Shyam Gajavelli (26) Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida
Paul F. Gores (2) Division of Transplantation Surgery, Carolinas Medical Center, Charlotte, North Carolina Ann-Charlotte Granholm (21) Department of Neurosciences and the Center on Aging, Medical University of South Carolina, Charleston, South Carolina Amal Hakki (29) Center for Excellence for Aging and Brain Repair, Department of Neurosurgery, USF Health, Tampa, Florida Craig Halberstadt (32) Carolinas Medical Center, Charlotte, North Carolina Marc R. Hammerman (8) Renal Division, Departments of Medicine, and Cell Biology and Physiology, Washington, University School of Medicine, St. Louis, Missouri Philippe Hantraye (22) Atomic Energy Commission, CEA CNRS URA 2210 Unit and MiRcen ImaGene Program Isotopic Imaging, Biochemical and Pharmacological Unit, Service Hospitalier Frederic Joliot, CEA, Orsay, France Koichi Hara (20) Research and Affiliations Service Line, Augusta VAMC, Augusta, Georgia Mark P. Hedger (30) Monash Institute of Medical Research, Monash University, Melbourne, Australia Robert Henning (29) Center for Excellence for Aging and Brain Repair, Department of Internal Medicine, USF Health, Tampa, Florida viii
Contributors
David C. Hess (20) Research and Affiliations Service Line, Augusta VAMC, Augusta, Georgia Department of Neurology and Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA
Chun-Ting Lee (28) Development and Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
Gonzalo Hortelano (10) Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada Research and Development, Canadian Blood Services
Noriyuki Matsukawa (20) Research and Affiliations Service Line, Augusta VAMC, Augusta, Georgia Mohammadreza Mirbolooki (33) Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
Johnny Huard (16) Department of Bioengineering, University of Pittsburgh Growth and Development Laboratory, Children’s Hospital of Pittsburgh Departments of Orthopaedic Surgery and Molecular Genetics and Biochemistry, University of Pittsburgh
David J. Mooney (31) Division of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts Craig Neville (12) The Center for Regenerative Medicine, Massachusetts General Hospital Department of Pediatric Surgery, Mass General Hospital for Children and Harvard Medical School
David H. Humes (9) Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan Tatsuya Kin (33) Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
Toya Ohashi (11) Department of Gene Therapy, Institute of DNA Medicine, Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan
Stephen K. Klasko (29) Center for Excellence for Aging and Brain Repair, University of South Florida College of Medicine, USF Health, Tampa, Florida
Abdulkadir Omer (6) Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
Koji Kojima (15) Laboratory for Tissue Engineering and Regenerative Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts Nicholas J. Krebs (12) The Center for Regenerative Medicine, Massachusetts General Hospital
Jack J. O’Neil (6) Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts Lifescan, Inc., Johnson and Johnson, Skillman, New Jersey
Jonathan R. T. Lakey (33) Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
Harald C. Ott (14) University of Minnesota Medical School, Center for Cardiovascular Repair, Minneapolis, Minnesota
Mitra Lavasani (16) Department of Bioengineering, University of Pittsburgh Growth and Development Laboratory, Children’s Hospital of Pittsburgh
Klearchos K. Papas (6) Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts Diabetes Institute, University of Minnesota, Minneapolis, Minnesota ix
Contributors
Joseph F. Sanchez (28) Development and Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
D. D. Pearse (27) The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami School of Medicine, Miami, Florida Anna Pisania (6) Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
David W. Scharp (7) Executive Vice President and Chief Medical Officer Novocell, Inc., 31 Technology Dr., Suite 100, Irvine, CA 92618
Jeffrey L. Platt (1) Transplantation Biology and the Department of Surgery, Immunology and Pediatrics, Mayo Clinic College of Medicine, Rochester, Minnesota
Cynthia Schoen (28) Development and Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
Jonathan Pollett (16) Growth and Development Laboratory, Children’s Hospital of Pittsburgh Harrison S. Pollinger (2) Division of Transplantation Surgery, Carolinas Medical Center, Charlotte, North Carolina
Catherine Schwartz (28) Laboratory of Neuroscience, National Institute of Aging, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
Daryl E. Powers (6) Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts
Peter A. Senior (5) Assistant Professor, Department of Medicine, Clinical Islet Transplant Program, University of Alberta
Mahendra Rao (3, 28) National Institute on Aging, Triad Technology Center, Baltimore, Maryland Laboratory of Neuroscience, National Institute of Aging, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
James A.M. Shapiro (5) Associate Professor, Department of Surgery, Clinical Islet Transplant Program, University of Alberta Kai-Christian Sonntag (17) Assistant Professor in Psychiatry/Neuroscience, Harvard Medical School, Center for Neuroregeneration Research, Udall Parkinson’s Disease Center of Excellence, McLean Hospital, Belmont, Massachusetts
Michael J. Rappel (6) Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts Anne E. Rosser (24, 25) School of Biosciences, Cardiff University, Cardiff, Wales, UK
Christine E. Stahl (20) Department of Internal Medicine, Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia
Jacqueline Sagen (26) Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida
Doris A. Taylor (14) Duke University, Department of Biomedical Engineering, Durham, North Carolina University of Minnesota Medical School, Bakken Professor and Director, Center for Cardiovascular Repair, Minneapolis, Minnesota
Paul R. Sanberg (20, 29) Center of Excellence for Aging and Brain Repair, University of South Florida, College of Medicine, Tampa, Florida x
Contributors
A. J. A. Terzis (19) NorLux Neuro-Oncology, Department of Biomedicine, University of Bergen, Norway and NorLux Neuro-Oncology, Centre Recherche Public Santé, Luxembourg
Jian Wang (19) NorLux Neuro-Oncology, Department of Biomedicine, University of Bergen, Norway and NorLux Neuro-Oncology, Centre Recherche Public Santé, Luxembourg
Chris Thanos (18, 23) LCT BioPharma, Providence, Rhode Island Brown University, Dept. of Molecular Pharmacology, Physiology, and Biotechnology, Providence, Rhode Island
Yun Wang (20) Neural Protection and Regeneration, NIDA, NIH, DHHS, Baltimore, Maryland Gordon Weir (6) Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
Khajohn Tiranathanagul (9) Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand
Alison E. Willing (29) Center for Excellence for Aging and Brain Repair, Department of Neurosurgery, USF Health, Tampa, Florida
Alan Tyndall (13) Dept of Rheumatology, University Hospital, Basle, Switzerland
David White (4) Robarts Research Institute, University of Western Ontario Siebens Drake Centre, London, Ontario, Canada
Charles A. Vacanti (15) Laboratory for Tissue Engineering and Regenerative Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Lin Xu (20) Research and Affiliations Service Line, Augusta VAMC, Augusta, Georgia Takao Yasuhara (20) Research and Affiliations Service Line, Augusta VAMC, Augusta, Georgia
Joseph P. Vacanti (12) The Center for Regenerative Medicine, Massachusetts General Hospital Department of Pediatric Surgery, Mass General Hospital for Children and Harvard Medical School
Guolong Yu (20) Research and Affiliations Service Line, Augusta VAMC, Augusta, Georgia
Alfred V. Vasconcellos (34) LCT Biopharma
Xianmin Zeng (28) Development and Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
Tandis Vazin (28) Development and Plasticity Section, Cellular Neurobiology Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland
xi
This page intentionally left blank
Preface
relieved, and then the bone was grafted back into the skull. Modern organ transplantation relied on the development of anesthetics (earliest development in 1540 by Valerius Cordus discovering the effects of ether), the development of aseptic surgical techniques in the 1800s by Joseph Lister, and the discovery of cyclosporine in the 1970s by Jean-Francois Borel with the subsequent trials in transplant patients by Roy Calne. These were only some of the discoveries that have led to today’s successful whole-organ transplantation of kidneys, lungs, livers, pancreases, heart, and other peripheral organs. Bone marrow transplantation of matched HLA donors became a successful procedure in the 1970s and 1980s. In the 1980s and into the 1990s, it was demonstrated that autologous bone marrow transplantation on irradiated patients could be used for cancer therapy. During this period, a subset population of cells (the stem cell) was identified and methods for expansion and further differentiation into the various myeloid lineages were developed. This therapy has revolutionized modern methods of treating several cancer phenotypes. Hence, the success of this cell therapy has led the impetus to develop other cell-based therapies. The complexity of whole-organ transplantation for diseases such as diabetes and neuromuscular disorders has led to the final push in cell therapy. Over the past 20 years hundreds of clinical trials have been performed to evaluate the safety and efficacy of cell transplantation ranging from pancreatic islet transplantation for diabetes to dopamine-producing cells for Parkinson’s disease.
These are exciting times for everyone involved in and interested in cell transplantation. Great progress has been made using cellular transplants for the amelioration of diseases over the last three decades. Indeed, the field has grown to its current-day accepted practice for certain diseases. As you will read, however, this scientific and clinical field continues to mature and many hurdles remain that must be overcome for cell transplantation to be routinely accepted in clinical practice. Significant advances in cell sourcing (both stem cells and/or animal cell sources), gene therapy, and immunoprotectior/novel-immunosuppressants will be focal areas for the foreseeable future. In addition, the ability to scale up these technologies and package the cells is a difficult task for the eventual delivery of viable cells to the clinician. Finally, developing reproducible transplantation strategies that will ensure high-percentage outcomes without complications also has to be developed. These obstacles are embraced by the authors of the chapters in this text as challenges that will be overcome with a greater understanding of disease mechanisms and transplantation biology. These authors provide their insights into the accomplishments and challenges of cell transplantation in specific clinical applications. Cell transplantation has passed through several revolutions in its surprisingly long history. One of the earliest recorded autograft transplants was performed to relieve cranial pressure in the Bronze age. A hole was bored in the skull, the bone removed, pressure xiii
Preface
Both successful and unsuccessful outcomes have been observed. It is the goal of this book to introduce the reader to many different potential applications of this therapy and to demonstrate not only the challenges but the clinical successes that have been achieved to date. Because the field of cell transplantation has become so broad, researchers and clinicians are finding it increasingly difficult to remain familiar with all of the different multidisciplinary aspects. Although several books exist on the topic, they tend to cover the field from a specialized perspective. A major impetus for this book was the belief that there is a need for a more inclusive approach that illuminates the rapid advances and developments that are pushing cell transplantation forward. We have organized the book into several parts to help ensure that as many aspects as possible could be covered by leading experts. In Part I, some basic biology of cell transplantation is identified, including transplant immunology, the use of immunosuppressive drugs, stem cell biology, and the development of uniquely suitable donor animals for transplantation. In Part II, recent advances in cell transplantation for peripheral and reconstructive
applications are identified, focusing on diabetes, kidney transplants, hemophilia, liver failure, autoimmune diseases, cardiac and orthopedic, and muscle transplantation. Part III describes the current state of central nervous system transplantation, describing the strategies under investigation for Parkinson’s, Alzheimer’s, and Huntington’s disease, as well as stroke and spinal cord trauma. Finally, Part IV attempts to be somewhat prescient describing future developments in the field, ranging from identifying novel transplantable cells to the combined use of biomaterials and nanotechnology with cell matrices. We find ourselves in the midst of a new era in cell transplantation. The focus of cell transplantation is shifting from an intuitively appealing but speculative concept to clinical reality. With continued time and effort our hope is that one day off-the-shelf cell-based products will exist that will be able to treat hundreds of diseases and tissue malfunctions.
xiv
Craig R. Halberstadt Dwaine F. Emerich
A The Basic Biology of Cell Therapy
This page intentionally left blank
1 Immunology of Cell and Tissue Xenotransplantation Jeffrey L. Platt Transplantation Biology and the Department of Surgery, Immunology, and Pediatrics, Mayo Clinic College of Medicine, Rochester, Minnesota
Introduction The early attempts at xenotransplantation failed, as did early attempts at human-to-human transplantation (allotransplantation). The reason for failure of xenografts and allografts was not understood until the 1940s, when the immune response of the recipient against the graft was found to be the principal biological barrier to transplantation [11]. With the advent of immunosuppressive drugs in the late 1950s, this barrier was overcome and the era of clinical allotransplantation began soon thereafter. The application of organ transplantation for the treatment of disease was among the most exciting advances in medicine and surgery. However, as in the early years of the twentieth century the availability of human donors was quite limited. Hence, efforts were made once again to use animals, such as chimpanzees and baboons, as a source of organs [31, 34]. When the recipient was treated with immunosuppressive agents, primate-tohuman xenografts functioned for weeks to months, but ultimately failed. Human-to-human transplants, however, would sometimes function indefinitely. This experience suggested that although xenotransplantation was a potential solution to organ failure xenotransplantation was impaired by an immunological barrier more severe than the barrier hindering human-to-human transplantation. Recent years have brought a better understanding of the immunological barriers to xenotransplantation and allotransplantation, and the possibility of applying genetic engineering to better address that barrier, at least in part [6]. The material following reviews the immunological barriers to xenotransplantation and discusses
Xenotransplantation refers to the transplanting of cells, tissues, or organs from individuals of one species into individuals of another species. Xenotransplantation has long been envisioned as a way of treating human diseases because animals are available in large numbers and at little expense. In contrast, when humans are used as a source of transplants for human recipients (allotransplants), the number of transplants that can be performed is limited by the availability of human donors (as low as 5% of the number needed) and the cost of these transplants can be very high [10]. The first serious efforts at xenotransplantation were made in the early years of the twentieth century. With the development of the surgical technique that could enable organ transplants to be performed (the vascular anastomosis), experimental surgeons sought a ready source of organs to treat subjects with organ failure, particularly kidney failure. Humans, living and recently deceased, were not viewed as a potential source of such organs because of such ethical questions as whether and under what conditions one could define death and whether and in what ways one could meddle with the deceased. Hence, the first attempts at clinical transplantation used animals as a source of organs [36]. The first animals used for xenotransplants were pigs and sheep (Table 1.1) [14]. The ethical hurdles to using humans as a source of organs for transplantation did not last very long. The year 1911 brought what may be the first recorded attempt to transplant an organ from one person to another [2].
Cellular Transplantation: From Laboratory to Clinic
3
Copyright © 2007, Elsevier Inc. All rights of reproduction in any form reserved.
Jeffrey L. Platt
is more remote. On the other hand, cell transplantation, stem cell transplantation, and tissue engineering seem less promising for replacement of the function of structurally complex organs such as the kidney, lungs, and heart. For replacement of these organs, organogenesis (the de novo formation of organs) or xenotransplantation may be necessary. Xenotransplantation may also find application in conjunction with organogenesis. For example, one might envision “growing” human organs (perhaps derived from stem cells as a xenograft in an animal host) and then transplanting the organs to human patients [7, 24].
TABLE 1.1 Some clinical attempts at xenotransplantation. Year
Donor
Organ
Maximum Survival
1906 1964 1964 1984 1992
Pig Chimpanzee Baboon Baboon Baboon
Kidney Kidney Kidney Kidney Liver
2 days 9 months 60 days 20 days 70 days
the various approaches proposed for overcoming those barriers.
Source of Xenografts Many species have been used as sources of tissues and organs for xenotransplantation. Xenografts from sources phylogenetically closer to the recipient would be expected to provoke less immunity and to be more physiologically compatible with the recipient. Consistent with that idea, experimental cardiac xenografts from monkeys to baboons have survived greater than a year, and renal xenografts from chimpanzees to humans have survived and functioned up to nine months (Table 1.1). However, some biological barriers to xenotransplantation derive from expression of one or very few genes in the donor or recipient. These barriers do not relate directly to overall genetic difference. The genetic barrier of greatest current interest and importance is expression of a1-3 galactosyltransferase, a glycosyltransferase that catalyzes synthesis of Gala13Gal. Gala1-3Gal is a saccharide expressed by lower mammals and New World monkeys, but not by humans and old-world monkeys. Humans and old-world monkeys have “natural” antibodies specific for this saccharide, and these antibodies trigger severe reactions when organs containing Gala1-3Gal are transplanted. Indeed, many of the efforts in genetic engineering and immunosuppression for xenotransplantation are directed respectively at eradicating expression of the sugar or suppressing immunity directed against it. Today, most efforts in xenotransplantation focus on the pig as a potential source of tissues and organs. The most important reason for favoring the pig is that pigs are available in large numbers (it is estimated that more than one million would be needed for transplants each year on a worldwide basis). Another reason for favoring pigs as a source of xenografts is that pigs can be bred and genetically manipulated, as described
The Rationale for Xenotransplantation Before the barriers to xenotransplantation are discussed, one may usefully consider why with the availability of allotransplantation we should pursue xenotransplantation today. The main rationale for xenotransplantation is that animals could potentially provide a limitless source of organs and tissues for transplantation. In addition, the cost of xenotransplantation might be very much lower than the cost of allotransplantation if the latter includes the costs of additional intensive care and clinical organ harvesting. Further, under some circumstances xenotransplantation may be preferred over allotransplantation. Where organ failure is caused by a viral infection (e.g., hepatitis), xenotransplantation might be preferred because the transplant would resist reinfection by the virus that caused organ failure [21, 25, 27]. Xenotransplantation might also be preferred as a way of delivering genes of therapeutic importance [7, 27]. For example, an animal source might be genetically engineered to express a gene at a high level or under regulated conditions. An important consideration today is how to weigh xenotransplantation against other potential approaches to treating organ failure [5]. Although some new technologies (such as stem cells, tissue engineering, and cardiac assist devices) have received much attention, they have also received less scrutiny than xenotransplantation because they are so recent in their development. Most likely, these technologies will be applied in ways that fill therapeutic niches, such as repairing local defects or injury of tissues. Devices may eventually be used to replace the heart, but application for other organs 4
1.
Immunology of Cell and Tissue Xenotransplantation
by genetic engineering, is now considered routine in xenotransplantation. Another reason for this more encouraging view of the prospects for overcoming the immunological barriers to xenotransplantation stems from the fact that the barrier to successful transplantation of xenogeneic cells may be much less daunting than the barrier to successful transplantation of xenogeneic organs.
in material following. Still another reason for favoring the pig is that the organs are large enough to fulfill the needs of full-sized humans, and some strains of pigs (such as the mini-pig) may at maturity approximate human size. Finally, the microorganisms harbored by pigs and potentially infectious for humans are well known, and measures for screening for these organisms are well established. In contrast, some viruses of nonhuman primates are poorly known and potentially lethal to humans. Although the experience is limited, best present evidence would suggest that the heart, lung, and kidneys of the pig would function sufficiently to sustain the life of the human. Whether the liver would function sufficiently is a matter of controversy because of the metabolic complexity of that organ and because of the possibility that complex cascades, such as complementing coagulation, could be incompatible between pig and human.
The Type of Transplant and the Barrier to Xenotransplantation No factor has a greater bearing on the barrier to xenotransplantation than the type of transplant: isolated cells or tissues on the one hand or intact organs on the other. All transplants can arouse immune responses, and by every measure the immune response to cell and tissue grafts may be quite comparable to the immune response to organ grafts. However, the impact of the immune response on cell and tissue grafts is profoundly different than the impact on organ grafts. This difference is summarized in Figure 1.1.
The Immunological Barriers to Xenotransplantation: An Overview Xenotransplantation excites nearly every immune and inflammatory pathway known. Among the inflammatory pathways are complement, coagulation, neutrophils, and natural killer cells. The immunological pathways include both innate and elicited responses by B-cells and T-cells. So intense is the response to xenotransplantation that no approach yet used has allowed the enduring survival of a xenogeneic organ transplant in a human subject, or in an animal for that matter. One might argue cynically that this failure of success drives even more daunting regulatory hurdles (put another way, one doubts that governments would impose such severe regulatory hurdles if xenotransplantation could clearly succeed). However, despite this discouraging picture there are reasons to think that the immunological barriers to xenotransplantation can be overcome. One reason for this more encouraging view of the prospects for overcoming the immunological barriers to xenotransplantation is that in contrast to humanto-human transplantation genetic engineering might be applied to some of the barriers. For example, the author and co-workers suggested more than a decade ago that intrinsic susceptibility of a xenograft to the complement system of the recipient might be overcome by expressing human complement regulatory proteins in the graft [30]. This approach, the addressing of immunological hurdles
The Immune Response to Cell and Tissue Transplants Cell and tissue grafts provoke cell-mediated immune responses and humoral immune responses. Cellmediated immune responses give rise to cellular rejection and possibly to primary nonfunction. Humoral immune responses provide a reliable marker of immunity to the transplant, but as we shall see these responses have little or no impact on the fate of the graft. That is not to say that B-cells are unimportant in cell and tissue transplantation. As we shall discuss, B-cells have functions other than the production that may influence the fate of cell and tissue grafts. Although any antigen carried by the graft and not by the recipient can elicit an immune response, responses to major histocompatibility complex (MHC) antigens are most pronounced and have the greatest impact on the fate of the graft [28]. A complete consideration of the immune response to MHC is quite beyond the scope of this chapter. Here it is pertinent to say that transplants generate cellular and humoral responses to MHCencoded proteins. The cellular responses occur in nearly every instance and reliably and rapidly cause rejection. In fact, so reliable and rapid is rejection that the antigens 5
Jeffrey L. Platt Free tissue or cell transplant
Primary nonfunction failure of neovascularization microenvironment incompatibility
Cellular rejection
(a) Organ transplantation
Acute vascular rejection Cellular rejection
Hyperacute rejection
Chronic rejection
Accommodation
(b) Figure 1.1. The biological outcome of xenografts: impact of mechanism of vascularization. Cell and tissue xenografts derive their blood supply through the in-growth of blood vessels of the recipient. Because the blood vessels of these grafts are constructed from cells of the recipient, antibodies of the recipient do not generally bind to the blood vessels and vascular diseases of organ grafts such as hyperacute and acute vascular rejection are not observed. Rather, the grafts are mainly subject to injury by T-cells that have the ability to migrate effectively through blood vessel walls. (a) Outcome of cell and tissue xenografts. Cell and tissue xenografts are subject to primary nonfunction and cellular rejection. Primary nonfunction, the immediate failure of the newly implanted cells or tissues, may be caused by various factors, including T-cells. (b) Outcome of organ xenografts. Like cell and tissue xenografts, organ xenografts are subject to cellular rejection, and to vascular types of rejection, including hyperacute, acute vascular, and chronic rejection. Vascular rejection, particularly hyperacute and acute vascular rejection, are caused by the binding of antibodies and activation of complement of the recipient on xenogeneic blood vessels. Having blood vessels originating with the recipient, cell and tissue xenografts are not subject to this type of problem.
highly immunogenic. The factors that make an amino acid sequence more or less immunogenic are incompletely understood but include the presence of amino acids at key points that allow a peptide to be loaded onto MHC class I or class II complexes and probably the presence of consensus domains that allow the proteins to be cleaved in ways that will encourage such loading. Beyond these factors, however, is evidence that MHCencoded proteins may have evolved in ways that make them better targets for T-cell receptors. A third reason MHC-encoded proteins are such potent antigens is that when they are presented in grafts the proteins can be recognized in native form by T-cell receptors of the recipient [18]. All other antigens of the graft must be degraded and presented in association with MHC complexes of the recipient. This type of antigen presentation is known as “direct antigen presentation,” and it is thought to be quite potent. Thus, up to 10% of the T-cells in a person’s blood can recognize foreign MHC by direct antigen presentation, whereas only a very much smaller fraction (perhaps less than 0.1% of a person’s T-cells) would recognize peptides from that MHC antigen presently in association with MHC on antigen-presenting cells of the responding individual. This second type of antigen presentation is referred to as indirect antigen presentation.
were named major histocompatibility antigens [8]. The antibodies produced in response to MHC-encoded proteins were used to map the MHC locus. Other antigens (in contrast to MHC antigens) tend to trigger rejection less reliably and more slowly than MHC antigens, and hence these antigens are called minor histocompatibility antigens. However, in a given combination of donor and recipient strains some minor histocompatibility antigens cause rejection just as quickly and reliably as MHC antigens. Responses to MHC antigens are quite vigorous for several reasons. One factor accounting for the importance of MHC antigens is that they are highly polymorphic. Thus, transplants between out-bred individuals are nearly certain to contain at least one MHC antigen not present in the recipient and are thus able to generate an immune response. Most other proteins are quite similar if not identical between different individuals, and hence any other given protein is unlikely to arouse a response. However, at least some protein allotypes will distinguish the donor and recipient, and therefore polymorphism alone (although necessary) does not account for the importance of MHC-encoded proteins as antigens. A second reason MHC-encoded proteins are such potent antigens is that the polymorphic sequences are 6
1.
Immunology of Cell and Tissue Xenotransplantation
The same cannot be said for xenotransplantation. Most or all proteins are immunogenic in xenogeneic species. Therefore, one might predict that the response to xenogeneic proteins would add significantly to the immune response to a xenograft. Consistent with this concept, some have found that T-cells will proliferate to these non-MHC-encoded proteins, whereas they do not proliferate to non-MHC alloantigens. The reason T-cells do not proliferate to non-MHC alloantigens is thought to be that the number of such antigens is so small that the fraction of the T-cell repertoire that can respond is too low to be detected.
It is the usual way in which foreign antigens are recognized [33]. Following cell and tissue transplantation, both direct and indirect pathways of MHC antigen presentation can be used in stimulating responses of the recipient. If the transplant contains cells expressing MHC class II (in mice, MHC class II is expressed mainly on dendritic cells and B-cells; in humans it is expressed on these cells and also on monocytes and endothelial cells), the cell may migrate to regional lymph nodes and there stimulate T-cells of the recipient directly. However, the T-cells activated through this pathway may find relatively few cells in the transplant expressing the allogeneic MHC class II. Of course, most or all parenchymal cells will express allogeneic MHC class I. However, the T-cells of the recipient are usually found near blood vessels and not parenchymal cells — at least during the early days after transplantation — and the blood vessels derive mainly from the recipient (by in-growth). Thus, in cell and tissue grafts the main pathway of antigen presentation leading to rejection may be the indirect pathway. The pathway through which antigen presentation occurs is especially pertinent for xenografts. T-cells respond poorly to direct antigen presentation by xenogeneic antigen-presenting cells [1, 30]. The defective response is owed in part to species’ specificity of adhesion molecules that promote interaction of T-cells and antigen-presenting cells and in part to species specificity of cytokines. Thus, if rejection depended on the response of the direct pathway xenografts might be less susceptible to cellular rejection. Some have thought that these defects might allow xeonografts to be better accepted than allografts and that this susceptibility might be further improved by genetic engineering (to further dissuade interactions of recipient cells with the graft). Sadly, these hopes have not been realized. Cell and tissue xenografts are as susceptible as allografts to cellular rejection. Some differences between xenografts and allografts can still be exploited. Xenografts may depend to an even greater extent on the indirect pathway, and hence therapies that disrupt interaction of T-cells with MHC class II may be especially effective [26]. Still another consideration in the immune response to cell and tissue xenografts may be the possibility that cellular immune response will be generated to multiple proteins of the xenogeneic source. It was previously stated that most proteins of the donor will be the same (or at least not immunogenic) in an allogeneic recipient.
The Impact of Immunity on Cell and Tissue Grafts Cell and tissue grafts are subject mainly to primary nonfunction and cellular rejection. The mechanisms underlying cellular rejection have been considered elsewhere in detail [29] and will not be discussed here except as an index of the immune response.
PRIMARY NONFUNCTION If a graft fails to show evidence of engraftment or function, it is considered to have primary nonfunction. Primary nonfunction may have a variety of causes, and these causes may differ depending on the type of graft and location in which it is placed. For example, engraftment of bone marrow and hepatocytes depends very much on the microenvironment in which the graft is placed. Bone marrow appears to require healthy stromal cells to support hematopoietic stem cells (hepatocytes engraft poorly in the microenvironment of the cirrhotic liver). When cellular grafts are administered into blood vessels such as the portal vein, the grafts may be subject to injury or destruction by antibodies and complement of the recipient. All of these factors may cause failure of engraftment or failure of function. Cell and tissue grafts are also subject to allogeneic resistance caused by the action of natural killer cells of the recipient and manifest as failure of engraftment. Natural killer cells have killer inhibitory receptors that recognize self-MHC and upon doing so prevent natural killer cells from exerting cytotoxicity against cells expressing this MHC. For example, bone marrow from parental strain (homozygous for MHC) may not engraft in F1 (MHC heterozygotes) individuals because natural 7
Jeffrey L. Platt
by CD4+ T-cells and mediated by macrophages predominates in rejection. Each of these mechanisms finds experimental support. For xenografts, the question of whether cytotoxicity or delayed-type hypersensitivity is of greater importance in causing tissue injury has not been addressed specifically. However, because xenografts usually contain a great many macrophages and seem especially to benefit from treatments aimed at CD4+ T-cells one might anticipate that delayedtype hypersensitivity might be more important than cytotoxicity as a mechanism of rejection. Consistent with this concept is the observation that CD8 binding to MHC class I may be especially impaired across species.
killer cells of the recipient lack killer inhibitory receptors that would suppress responses to the MHC class I missing in the parent. Resistance of this type would presumably be even more pronounced for xenografts because natural killer cells are stimulated by these grafts through multiple pathways [13]. Primary nonfunction may also be caused by T-cells [16]. How T-cells might cause primary nonfunction, however, is not entirely clear. Certainly T-cells respond vigorously and rapidly to allografts and xenografts. However, the kinetics of the best characterized response are seemingly too slow to account for primary nonfunction. The kinetics of the cellular immune response to allogeneic transplants have been thoroughly investigated. Typically, a cellular or tissue graft becomes vascularized over a period of three to five days and for a period of time functions normally. Only after a period of vascularization (often eight days to two weeks after engraftment) is cellular rejection and failure of function observed. This picture of function followed by failure differs from primary nonfunction, in which function is never observed. Two recent observations may help explain how T-cells could cause primary nonfunction. First, contrary to the kinetics of T-cell activation in vitro or to the kinetics of rejection, T-cell activation in lymph nodes occurs within minutes of the introduction of antigen [35]. The T-cells activated most rapidly may be memory T-cells or some other population, the role of which may be more that of helping the activation of T-cells that will contribute to the effector response. However, these firstactivated cells can produce cytokines, and it may be these cytokines that account at least in part for primary nonfunction. Second, T-cells were recently found to act on grafts nonspecifically during the period of reperfusion and doing so to contribute to ischemia-reperfusion injury. Perhaps T-cells might cause primary nonfunction through this nonspecific action.
B-cells, Antibodies, and the Barrier to Cell and Tissue Transplantation Although cell and tissue grafts stimulate a vigorous humoral immune response, antibodies appear to have a limited impact on the fate of cell and tissue grafts. For instance, studying porcine hepatocytes transplanted into rats [22], we found no evidence that humoral immune responses compromised graft function. Similar results have been observed in nonhuman primates. How does humoral immunity have such a profound impact on organ grafts and such a limited impact on cell and tissue grafts? Organ grafts are vascularized by anastomosis of graft blood vessels with the blood vessels of the recipient. Hence, the vascular supply of the organ graft is that of the organ. As the graft is perfused with the blood of the recipient, antibodies in the blood specific for antigens of the graft can bind to endothelium, activate complement, and initiate vascular diseases such as hyperacute and acute vascular rejection and possibly chronic rejection [6, 25, 27]. These diseases of organ grafts — hyperacute and acute vascular rejection and chronic rejection — are diseases of blood vessels that are not observed in cell and tissue grafts. In fact, there exists no evidence that cell and tissue xenografts would benefit from genetic manipulations such as the expression of human complement regulatory proteins or the knocking out of the enzyme that catalyzes synthesis of Galα1-3Gal (the antigen targeted by natural antiswine) that has advanced the transplantation of organ grafts [20, 37]. The reasons vascular diseases (such as hyperacute and acute vascular rejection) are not observed, and expression of human complement regulatory proteins
CELLULAR REJECTION The most important type of rejection to afflict cell and tissue grafts is acute cellular rejection. Of course, cellular rejection depends on recognition of the graft and graft antigens by T-cells. To what extent and in which way(s) tissue damage depends on the function of T-cells are less clear. For allografts, the question is whether cytotoxicity mediated by CD8+ T-cells or a reaction such as delayed-type hypersensitivity initiated 8
1.
Immunology of Cell and Tissue Xenotransplantation
stem cells success may be limited by incompatibility of xenogeneic stem cells with recipient bone marrow stroma and cytokines, and by the action of complement and of natural killer cells. Despite the difficulties in inducing tolerance between species, however, cell and tissue xenografts have achieved at least some measure of success in recipients treated with conventional types of immunosuppression. As two examples, swine hepatocytes have been transplanted into rabbits [12] and into rats [22] with enduring function and survival observed in recipients treated with only cyclosporine or with no immunosuppression. Swine substantia nigra cells have survived for months in human subjects treated only with cyclosporine [9]. Soon to be published are accounts of engrafting of pancreatic islets and hepatocytes for many months in nonhuman primates. In neither case was genetic engineering, either expression of human complement regulatory protein or knocking out of a1,3-galactosyltransferase, needed. Thus, the hurdles to the transplantation of xenogeneic cells and tissues may be far less than might be thought based on the difficulties observed with intact organs. Indeed, from the perspective that can now be suggested the greatest hurdles to successful xenotransplantation of cells and tissues may be finding appropriate clinically advantageous applications and gaining regulatory approval.
or abolished synthesis of Gala1-3Gal is not particularly beneficial in cell and tissue xenografts, are several. First, the diseases are caused by binding of antibodies of the recipient to donor blood vessels (cell and tissue grafts receive their blood supply by in-growth of blood vessels of the recipient). Second, cell and tissue grafts generally reside outside blood vessels, where the concentration of antibodies and complement are considerably lower than the concentrations in the blood. Although antibodies and complement may not contribute importantly to rejection of cell and tissue grafts, B-cells may play an important role. B-cells can specifically capture, concentrate, and present foreign antigens. B-cells also help to generate the lymphoid tissues in which antigens are presented [19, 23]. Finally, B-cells promote diversification of the T-cell repertoire [15, 17]. Given these considerations, it may not be surprising that therapies directed at B-cells may have value for promoting survival of cell and tissue grafts.
Therapeutic Approaches to Cell and Tissue Transplantation Although some important aspects of the cellular immune response to cell and tissue xenotransplantation are understood, the most important practical question — whether cell and tissue xenotransplants can be sustained by administration of available immunosuppressive drugs — is still not clear. Although in vitro studies may suggest that immune response to xenografts may be weaker than the immune response to allografts, cell and tissue xenografts are clearly subject to cellular rejection, and the kinetics of rejection of cell and tissue xenografts in untreated recipients are at least as rapid as the kinetics of rejection of allografts. Some have proposed that the cellular immune response to xenografts may be so strong that success may depend on the induction of immunological tolerance [32]. Unfortunately, the induction of an enduring state of tolerance between widely disparate species, particularly for swine transplants in primates, has not been accomplished. In part, the failure to achieve immunological tolerance between disparate species reflects the enormously difficult hurdle to achieving durable engraftment of hematopoietic stem cells [3, 4]. The difficulty in achieving tolerance between species, at least as it is pursued today, may reflect in part on mechanisms underlying primary nonfunction. Thus, if tolerance is sought by engraftment of hematopoietic
Acknowledgments Work in the author’s laboratory described in this chapter has been supported by grants from the National Institutes of Health (HL46810 and HL52297).
REFERENCES 1. Alter, B. J., Bach, F. H. Cellular basis of the proliferative response of human T-cells to mouse xenoantigens. Journal of Experimental Medicine 191:333–338; 1990. 2. Anonymous: Dr. Hammond gives patient new kidney. In: The New York Times. New York, 1911. 3. Buhler, L., Awwad, M., Basker, M., Gojo, S., Watts, A., Treter, S., Nash, K., Oravec, G., Chang, Q., Thall, A., Down, J. D., Sykes, M., Andrews, D., Sackstein, R., White-Scharf, M. E., Sachs, D. H., Cooper, D. K. C. Highdose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. Transplantation 69:2296–2304; 2000.
9
Jeffrey L. Platt 4. Buhler, L., Goepfert, C., Kitamura, H., Basker, M., Gojo, S., Alwayn, I. P., Chang, Q., Down, J. D., Tsai, H., Wise, R., Sachs, D. H., Cooper, D. K., Robson, S. C., Sackstein, R. Porcine hematopoietic cell xenotransplantation in nonhuman primates is complicated by thrombotic microangiopathy. Bone Marrow Transplant 27:1227–1236; 2001. 5. Cascalho, M., Platt, J. New technologies for organ replacement and augmentation. Mayo Clinic Proceedings 80:370–378; 2005. 6. Cascalho, M., Platt, J. L. The immunological barrier to xenotransplantation. Immunity 14:437–446; 2001. 7. Cascalho, M., Platt, J. L. Xenotransplantation and other means of organ replacement. Nature Reviews Immunology 1:154–160; 2001. 8. Counce, S., Smith, P., Barth, R., Snell, G. D. Strong and weak histocatibility gene differences in mice and their role in the rejection of homografts of tumors and skin. Annals of Surgery 144:198–204; 1956. 9. Deacon, T., Schumacher, J., Dinsmore, J., Thomas, C., Palmer, P., Kott, S., Edge, A., Penney, D., Kassissieh, S., Dempsey, P., Isacson, O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson’s disease. Nature Medicine 3:350–353; 1997. 10. Evans, R. W. Coming to terms with reality: Why xenotransplantation is a necessity. In: Xenotransplantation, pp 29–51. Ed by Platt, J. L., Washington, D. C., ASM Press, 2001. 11. Gibson, T., Medawar, P. B. The fate of skin homografts in man. Journal of Anatomy 77:299–310; 1943. 12. Gunsalus, J. R., Brady, D. A., Coulter, S. M., Gray, B. M., Edge, A. S. B. Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation. Nature Medicine 3:48–53; 1997. 13. Inverardi, L., Clissi, B., Stolzer, A. L., Bender, J. R., Sandrin, M. S., Pardi, R. Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 63: 1318–1330; 1997. 14. Jaboulay, M. De reins au pli du coude par soutures arterielles et veineuses. Lyon Med 107:575–577; 1906. 15. João, C. M., Ogle, B. M., Gay–Rubenstein, C., Platt, J. L., Cascalho, M. B cell-dependent TCR diversification. Journal of Immunology 172:4709–4716; 2004. 16. Kaufman, D. B., Platt, J. L., Rabe, F. L., Stock, P. G., Sutherland, D. E. R. The immunological basis of islet allograft primary non-function. Journal of Experimental Medicine 172:291–302; 1990. 17. Keshavarzi, S., Rietz, C., Simoes, S., Shih, S., Platt, J. L., Wong, J., Wabl, M., Cascalho, M. The possibility of B-cell dependent T-cell development and function. Scandinavian Journal of Immunology 57:446–452; 2003. 18. Lechler, R. I., Lombardi, G., Batchelor, J. R., Reinsmoen, N., Bach, F. H. The molecular basis of alloreactivity. Immunology Today 11:83–88; 1990. 19. Luther, S. A., Lopez, T., Bai, W., Hanahan, D., Cyster, J. G. BLC expression in pancreatic islets causes B cell recruitment
10
20.
21.
22.
23.
24.
25.
26.
27. 28.
29.
30.
31.
32. 33.
34.
and Lymphotoxin-dependent lymphoid neogenesis. Immunity 12:471–481; 2000. McCurry, K. R., Kooyman, D. L., Alvarado, C. G., Cotterell, A. H., Martin, M. J., Logan, J. S., Platt, J. L. Human complement regulatory proteins protect swine-toprimate cardiac xenografts from humoral injury. Nature Medicine 1:423–427; 1995. Mueller, Y. M., Davenport, C., Ildstad, S. T. Xenotransplantation: Application of disease resistance. Clinical & Experimental Pharmacology & Physiology 26:1009–1012; 1999. Nagata, H., Ito, M., Cai, J., Edge, A., Platt, J. L., Fox, I. J. Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation. Gastroenterology 124:422–431; 2003. Ngo, V. N., Cornall, R. J., Cyster, J. G. Splentic T zone development is B cell dependent. Journal of Experimental Medicine 194:1649–1660; 2001. Ogle, B. M., Cascalho, M., Platt, J. L. Fusion of approaches to the treatment of organ failure. American Journal of Transplantation 4 Suppl 6:74–77; 2004. Parker, W., Saadi, S., Lin, S. S., Holzknecht, Z. E., Bustos, M., Platt, J. L. Transplantation of discordant xenografts: A challenge revisited. Immunology Today 17:373–378; 1996. Pierson, R. N., Winn, H. J., Russell, P. S., Auchincloss, H. Xenogeneic skin graft rejection is especially dependent on CD4+ T-cells. Journal of Experimental Medicine 170:991–996; 1989. Platt, J. L. New directions for organ transplantation. Nature 392:11–17; 1998. Platt, J. L., Rubinstein, P. The immunology of transplant antigens. In: Textbook of Surgery, 15 ed, pp 389–399. Ed by Lyerly, H. K., Philadelphia, W.B. Saunders Company, 1997. Platt, J. L., Rubinstein, P. Mechanisms and characteristics of allograft rejection. In: Textbook of surgery: The biological basis of modern surgical practice, 15th ed, pp 400–408. Ed by Sabiston, D. C. Jr., and Lyerly, H. K., Orlando, Textbook of Surgery, 1997. Platt, J. L., Vercellotti, G. M., Dalmasso, A. P., Matas, A. J., Bolman, R. M., Najarian, J. S., Bach, F. H. Transplantation of discordant xenografts: A review of progress. Immunology Today 11:450–456; 1990. Reemtsma, K., McCracken, B. H., Schlegel, J. U., Pearl, M. A., Pearce, C. W., DeWitt, C. W., Smith, P. E., Hewitt, R. L., Flinner, R. L., Creech, O. Renal heterotransplantation in man. Annals of Surgery 160:384–410; 1964. Sachs, D. H., Sablinski, T. Tolerance across discordant xenogeneic barriers. Xenotransplantation 2:234–239; 1995. Shoskes, D. A., Wood, K. J. Indirect presentation of MHC antigens in transplantation. Immunology Today 15:32–38; 1994. Starzl, T. E., Marchioro, T. L., Peters, G. N., Kirkpatrick, C. H., Wilson, W. E. C., Porter, K. A., Rifkind, D., Ogden, D. A., Hitchcock, C. R., Waddell, W. R. Renal heterotransplantation from baboon to man: Experience with 6 cases. Transplantation 2:752–776; 1964.
1.
Immunology of Cell and Tissue Xenotransplantation
35. Stefanova, I., Dorfman, J. R., Germain, R. N. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420:429–434; 2002. 36. Ullman, E. Tissue and organ transplantation. Annals of Surgery 60:195–219; 1914. 37. Yamada, K., Yazawa, K., Shimizu, A., Iwanaga, T., Hisashi, Y., Nuhn, M., O’Malley, P., Nobori, S., Vagefi, P. A., Patience C.,
11
Fishman, J., Cooper, D. K., Hawley, R. J., Greenstein, J., Schuurman, H. J., Awwad, M., Sykes, M., Sachs, D. H. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase geneknockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 11:32–34; 2005.
This page intentionally left blank
2 Current Immunosuppressive Drugs and Clinical Use Harrison S. Pollinger, D.O.[1] Justin M. Burns, M.D.[2] Vince P. Casingal, M.D.[2] Paul F. Gores, M.D.[2] [1]Division of Transplantation Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota. [2]Division of Transplantation Surgery, Carolinas Medical Center, Charlotte, North Carolina
The clinical application of cell transplantation is still in its infancy. However, the immunosuppressive drugs that make allotransplantation possible have been in use for over 50 years. During the latter half of the twentieth century, organ trasplantation evolved from an experimental technique performed in the animal laboratory to a mature clinical discipline affording improved health and a better quality of life for thousands of individuals. The fulcrum underpinning this successful transformation was the development of small molecule immunosuppressive agents which modulate the immune response in a non-antigen specific manner. Each of these molecules, aside from their immunosuppressive qualities, is associated with significant toxicities which precludes their use in high enough doses to provide effective prophylaxis as monotherapy against rejection. Fortunately, these drugs differ with respect to the way in which they interfere with the immune response. Thus it has been possible to implement combination therapies; minimizing drug specific side effects while taking advantage of synergies to potentiate suppression of the rejection response by the immune system. More recently biologic agents have been introduced which offer the promise of providing more specific immunomodulation. Refinement of these strategies will be essential for the continued development of cell transplantation which, in general, is a less invasive form of therapy than is solid organ transplantation.
Cellular Transplantation: From Laboratory to Clinic
The Alloimmune Response An appreciation of the host response to donor antigen is essential for understanding the mechanism of action and rationale of combination therapies. Rejection of organ and tissue allografts is dependent on the generation of cytotoxic T-lymphocytes. Effective T-lymphocyte activation requires the delivery of two signals. The first signal is provided by engagement of the T-cell receptor with donor antigen presented in context with major histocompatibility molecules on antigenpresenting cells (APC) of either host or donor origin. The second (co-stimulatory) signal is delivered by the interaction of co-stimulatory ligands of the B7 family on the APC. B7-1 (CD80) and B7-2 (CD86) bind with CD28 expressed on T-cells. When two signals are delivered, activation triggers three signal transduction pathways: (1) the calcium-calcineurin pathway, (2) the RAS-mitogen-activated protein (MAP) kinase pathway, and (3) the nuclear factor-κβ pathway. Initiation of these pathways leads to the generation of numerous cytokines that in turn leads to activation of the “target of rapamycin” and cell proliferation. Conversely, in the absence of this second signal the T-cell becomes anergic [59]. The spectrum of immunosuppressive agents currently utilized includes small-molecule drugs, glucocorticoids, depleting and nondepleting protein drugs (polyclonal
13
Copyright © 2007, Elsevier Inc. All rights of reproduction in any form reserved.
Harrison S. Pollinger et al.
and monoclonal antibodies), and fusion proteins [43]. These drugs deplete lymphocyte populations, divert or manipulate lymphocyte function, or block lymphocyte end products. Small-molecule immunosuppressive agents target intracellular proteins and include azathioprine, cyclosporine, tacrolimus, sirolimus, everolimus, and mycophenolate mofetil6 [43].
Azathioprine Azathioprine (Imuran) is an antimetabolite derived from the imidazole derivative 6-mercaptopurine. This agent was responsible for the initial advancement of solid organ transplantation more than 30 years ago [31]. Gertrude Elion and George Hitchings are credited with its development, for which they were awarded the Nobel Prize in 1988. However, since the introduction of cyclosporine in the early 1990s azathioprine has been relegated to the role of an adjunctive second-line drug. This purine analogue is incorporated into cellular deoxyribonucleic acid (DNA), where it functions to inhibit purine nucleotide synthesis and ultimately the synthesis of ribonucleic acid (RNA). This translates into the suppression of T-cell replication and activation. Unfortunately, azathioprine is not specific to T-cells. It is broadly myelosuppressive and is associated with a doserelated, generally reversible, depression of bone marrow function usually manifested as leukopenia and thrombocytopenia. It is an uncommon cause of anemia but can in rare cases lead to agranulocytosis, pancytopenia, and aplastic anemia. Azathioprine can be administered either orally or intravenously. Half the orally administered dose is absorbed. Serum levels are not of importance clinically because its efficacy is not concentration dependent. The kidney does not excrete the drug. Neither is the drug dialyzable. The daily oral dose is 2 to 3 mg/kg when employed as a primary immunosuppressive agent and 1 to 2 mg/kg when used as an adjunctive agent in combination with a calcineurin inhibitor. Azathioprine administration is associated with a major drug interaction. It is converted to its inactive form, 6-thiouric acid, by xanthine oxidase. Therefore, allopurinol (a powerful xanthine oxidase inhibitor) should be avoided or given with extreme care. The dose of azathioprine should be reduced by 50% and the white blood cell and platelet counts monitored more frequently when allopurinol is prescribed.
Cyclosporine Cyclosporine belongs to a family of compounds known as calcineurin inhibitors, which currently serve as the backbone of solid organ immunosuppression. Cyclosporine is a small 11-amino-acid cyclic polypeptide derived from the fungus Tolypocladium inflatum [13], which binds to cyclophilin, an intracellular protein of the immunophilin family. The resulting complex targets the protein phosphatase calcineurin, which is required for the translocation of an activation factor (NF-ATc) from the cytosol to the nucleus [17]. In the presence of a calcineurin inhibitor, the cytosolic activation factor is unable to reach the nucleus and the transcription of interleukin-2 (IL-2) and other cytokines is strongly inhibited, resulting in a significant reduction in lymphocyte activation and proliferation. The advantage of calcineurin inhibitors is the selective inhibition of the immune response. They do not hinder neutrophil function, as do corticosteroids, nor are they myelosuppressive. Patients receiving cyclosporine-based immunosuppression still possess adequate immune responsiveness to maintain host defense. This can be attributed to the fact that calcineurin inhibitors only inhibit approximately 50% of total calcineurin activity, thus enabling immune response to strong triggers of cytokine expression. The original oil-based formulation of cyclosporine (Sandimmune) has been largely replaced by a microemulsion formulation (Neoral). The new microemulsion combines a lipophilic solvent, hydrophilic solvent, and surfactant, and is available in both liquid and gel cap forms [80]. The absorption of Neoral occurs in the proximal gastrointestinal (GI) tract at a constant rate, independent of drug concentration at the absorption site. Local metabolism of cyclosporine occurs immediately in the intestinal epithelium, via the cytochrome P450-IIIa system, reducing the amount of prodrug available for uptake [52]. The remaining compound is absorbed via the portal system, with very little drug transported through lymphatics [33]. The absorption of Sandimmune from the GI tract is bile dependent and is unreliable when compared to Neoral [33]. Peak concentration in the blood is achieved in 3 to 4 hours, with only 30% of the drug reaching systemic circulation. In contrast, the absorption of Neoral is more rapid, complete, and consistent due to the more homogenous dispersion of the uniform particles of the suspension [69]. The trough concentration of Neoral does not differ significantly from Sandimmune. However, the
14
2.
Current Immunosuppressive Drugs and Clinical Use
microemulsion possesses a maximum absorption of 60% and has an overall bioavailability 50% greater than the oil-based formulation [53]. Patients experiencing gastroparesis, cholestasis, biliary diversion, malabsorption, and diarrhea will all have variability with respect to the absorption of cyclosporine, especially the oil-based formulation [39, 58, 73]. Regardless of the cyclosporine formulation used, 50% is bound to erythrocytes, 10% to leukocytes, and 30 to 40% to plasma proteins. Only 1 to 5% exists in the free state [57]. Up to 46% of cyclosporine is associated with high-density lipoprotein, 35% with low-density lipoproteins, and 20% with very low-density lipoproteins in plasma. The close association of cyclosporine with the low-density lipoprotein receptor may account for the hyperlipidemia often experienced with its use [84]. Cyclosporine readily accumulates in fat, liver, pancreas, heart, lung, kidney, spleen, lymph nodes, and blood. Drug concentrations remain low in the cerebrospinal fluid and central nervous system, and very small amounts can be detected in the fetal circulation [72]. The liver and bowel epithelia are the primary sites for cyclosporine metabolism. This process is under the influence of the cytochrome P450-IIIA system via demethylation [54]. More than 25 active metabolites of cyclosporine have been isolated in human blood, bile, and urine. All of these retain the functional cyclic oligopeptide structure, and all are less immunosuppressive than the parent compound [48]. Cyclosporine is eliminated by biliary excretion, with a half-life of 6 to 8 hours. Clearance is significantly decreased in patients with hepatic impairment, thus mandating longer dosing intervals and/or reduction in the dose. Any agent that alters cytochrome P450 enzyme activity will affect the metabolism and clearance of cyclosporine [103] (Table 2.1). Phenytoin and rifampin are two classic drugs that induce mixed-function oxidases of the cytochrome P450 system and cause a major fall in cyclosporine levels. This may lead to a rejection episode unless the interaction is recognized in a timely manner. Inhibitors of the cyctochrome P450 system will increase cyclosporine levels and may result in acute nephrotoxicity. Examples of cytochrome P450 inhibitors are erythromycin, ketoconazole, diltiazem, colchicine, and the fluoroquinolones [61]. The most significant and worrisome side effect of cyclosporine is nephrotoxicity. This is of critical importance with respect to renal transplant recipients because it can be difficult to distinguish cyclosporine nephrotoxicity from rejection. The toxic effects to the kidney can be
TABLE 2.1 Drug interactions with cyclosporine. Agent
Pharmacokinetic Action
Consequences
Carbamazepine Nafcillin Phenobarbital Phenytoin Rifampin
Induce cytochrome P450 enzymes
Decrease half-life blood levels, and immunosuppressive effect
Colchicine Diltiazem Fluconazole Fluoroquinolones Ketoconazole Macrolide antibiotics Oral contraceptives Verapamil
Inhibit cytochrome P450 enzymes
Increase half-life, blood levels, and toxicity or immunosuppression
Aminoglycosides Amphotericin B Cimetidine Nonsteroidals Sulfur
Interact at a glomerular or tubular level
Increase nephrotoxicity
seen early after transplantation, as the ischemic kidney is particularly susceptible to the deleterious effects of cyclosporine. There is an increased incidence of delayed renal allograft function when cyclosporine is used. After the kidney has recovered and baseline renal allograft function has been reached, high cyclosporine serum levels can lead to an increase in serum creatinine that needs to be distinguished from an acute allograft rejection episode. Often a percutaneous biopsy of the graft is required [3]. Microvascular thrombosis is another uncommon phenomenon associated with cyclosporine. These lesions mimic hemolytic-uremic syndrome and can be completely reversible if diagnosed early with the subsequent reduction in the cyclosporine level [82]. Chronic cyclosporine toxicity is associated with a slow decline of renal function and may be difficult to distinguish from chronic rejection. The major finding on biopsy is interstitial fibrosis. This chronic toxicity is not limited to renal allografts but is also seen in the native kidneys of recipients of a nonrenal organ [79]. The mechanism of cyclosporine nephrotoxicity has not been completely elucidated. It has been hypothesized that injury results from decreased renal blood
15
Harrison S. Pollinger et al.
flow with increased renal vascular resistance. The site of major insult is the afferent arteriole of the glomerular apparatus [83]. An alternative mechanism involves the decreased production of prostaglandins in the local environment of the kidney associated with cyclosporine use. This mechanism could also explain the functional and histological changes seen with the chronic use of cyclosporine [75]. Cyclosporine has been associated with a number of side effects as well. Hypertrichosis and gingival hyperplasia are cosmetically distressing to patients. These are both enhanced when cyclosporine is used in conjunction with calcium channel blockers. Cyclosporine is also linked with neurological, endocrine, and hepatic toxicity. Neurologic toxicities include fine motor tremor, headache, seizures, and a demyelinating neuropathic syndrome. Hepatic toxicities seem to correlate with elevated cyclosporine levels and are manifested by elevation of hepatic transaminase enzymes. Hypertension is a major adverse effect associated with cyclosporine-based immunosuppression. Eightyfive percent of renal transplant recipients maintained on cyclosporine require antihypertension medication [22]. The mechanism appears to be multifactorial, but can be attributed to (1) increased intracellular calcium concentrations sensitizing resistance vessels, (2) increased sodium and water retention, and (3) increased sensitivity to adrenergic stimulation.
concentrations do not need to be modified in the face of renal dysfunction. Tacrolimus resembles cyclosporine in that it is nephrotoxic and can induce hemolytic-uremic syndrome, but it is less likely to cause hyperlipidemia, hypertension, or cosmetic side effects. Tacrolimus has been associated with increased rates of posttransplantation diabetes and is more likely to induce BK-related polyomavirus nephropathy [64]. The common adverse effects of tacrolimus are listed in Table 2.2 and a side effect comparison of the calcineurin inhibitors is outlined in Table 2.3. New onset diabetes mellitus occurs significantly more often with tacrolimus than with cyclosporine, as demonstrated by both U.S. and European trials [2, 99]. These studies also demonstrated an increased incidence of neurologic sequelae (convulsions, confusion, psychosis, encephalopathy, and coma) with tacrolimus, but these events tended to be mild. TABLE 2.2 Common adverse events with tacrolimus. Gastrointestinal
Metabolic
Nephrotoxicity Neurologic
Anorexia Diarrhea Dyspepsia Nausea
Hyperglycemia Decrease in Hyperkalemia creatinine clearance
Tacrolimus Tacrolimus (FK506) is a metabolite of the fungus Streptomyces tsukubaensis. It is a macrolide antibiotic with a mechanism of action very similar to that of cyclosporine, but tacrolimus inhibits cytokine production with a potency 100 times that of cyclosporine [90]. Tacrolimus is available in an intravenous formulation and as an enteric capsule. Gastrointestinal absorption is independent of bile metabolism and occurs primarily in the small intestine. Oral bioavailability approaches 25% and is relatively consistent. Subsequently, it is rarely necessary to administer tacrolimus parenterally. Onethird of absorbed tacrolimus is bound to lipoproteins, and the remainder of the drug is bound to erythrocytes in serum. Tacrolimus differs from cyclosporine in that it is not significantly bound to lipoproteins and thus has less of an adverse effect on cholesterol metabolism [92, 93]. Metabolites are excreted in bile, with virtually no renal excretion. Therefore, drug
Confusion Encephalopathy Headache Paresthesia Psychosis Seizure Tremor
TABLE 2.3 Nonimmunologic side effect profile of tacrolimus versus cyclosporine. Parameter
Tacrolimus
Cyclosporine
Nephrotoxicity
++
++
Neurotoxicity
+
+
Diabetogenicity
++
+
Growth effects Hirsutism Gingival hyperplasia Facial brutalization Hepatotrophic effects Gynecomastia
0 0 0 + + ++ 0
+++ ++ + +++ +
Other metabolic effects Cholesterol increase Uric acid increase
0 +
++ ++
16
2.
Current Immunosuppressive Drugs and Clinical Use
There have been many studies over the past decade designed to examine the effects of tacrolimus in renal transplant recipients. The European Tacrolimus Multicenter Renal Study Group trial reported that the graft survival for tacrolimus versus cyclosporine was the same. However, the incidence of histologically confirmed acute rejection was lower for the tacrolimus group (25.9% versus 45.7%, p < 0.001) [63]. The complication rates encountered during the trial were similar, but each agent had a higher incidence of specific adverse events. Nephrotoxicity, tremor, diarrhea, hyperglycemia, and angina pectoris were higher in the tacrolimus group, whereas gingival hyperplasia, hirsutism, and arrhythmia were more common with cyclosporine [63]. The U.S. renal trial demonstrated a significantly higher number of patients requiring insulin therapy one year posttransplant if they were maintained on tacrolimus. However, 50% of those patients were reported as being off insulin therapy as of two years posttransplant [46]. The development of diabetes was dependent on the dose of tacrolimus and corticosteroids used to maintain graft function. Lower doses (0.18 mg/kg versus 0.3 mg/kg) were associated with a lower incidence of diabetes (10%) [30].
Sirolimus Sirolimus (rapamycin) is a macrolide triene antibiotic produced by Streptomyces hygroscopicus. It is structurally related to tacrolimus, but differs because of its unique triene ring [32]. This compound was isolated from soil found on Rapa Nui (Easter Island) in 1968. The immunosuppressive properties of sirolimus were first discovered by Suren Sehgal and co-workers in 1972 [85]. Similar to cyclosporine and tacrolimus, sirolimus is also an immunophilin binding drug. Sirolimus differs from the calcineurin inhibitors in that it does not inhibit the phosphatase calcineurin nor does it inhibit cytokine transcription. Rather, sirolimus binds FK binding proteins, which form a unique ligand complex with an enzyme termed the target of rapamycin (TOR). TOR is a protein kinase vital to the regulation of cell growth factor receptors and cell proliferation. The cumulative effect of sirolimus is inhibition of these protein kinases, which then interfere with the progression of T-cells from the G1 to S phase of the cell cycle [68]. Sirolimus is rapidly absorbed from the GI tract, reaching peak serum concentration within 2 hours. Sirolimus
has an extremely long half-life (mean 62 hours). Most of the drug is found within whole blood and tissue with less than 3% distributed within plasma [104]. It is largely metabolized by the hepatic cytochrome P450-IIIA4 system and does not require dose adjustment for renal impairment. Sirolimus and the calcineurin inhibitors are metabolized by the same enzyme systems and therefore significant drug interactions can be encountered. Cyclosporine can raise the blood level of sirolimus by as much as 80% when administered concomitantly. It is recommended that sirolimus be administered at least 4 hours after cyclosporine to limit this interaction. The side effect profile of sirolimus has a spectrum best characterized by its metabolic, hematologic, and dermatologic derangements. Most adverse effects are directly related to the inhibition of growth factors [67]. Increased low-density lipoproteins and serum triglycerides are the principal metabolic side effect. All blood elements are also affected, with anemia, neutropenia, and thrombocytopenia being the most common. In a double-blind randomized trial thirty renal transplant patients were divided into three groups to better understand the side effect profile of sirolimus [70]. All patients had stable renal function maintained on a cyclosporine/steroid regimen and were randomized to low-dose (1 to 3 mg/m2 /day), medium-dose (5 to 6 mg/m2 /day), or high-dose (7 to 13 mg/m2 /day) sirolimus therapy. The major toxic side effects were seen in the high-dose group and were predominantly hypertriglyceridemia and thrombocytopenia [70]. A deleterious effect unique to sirolimus therapy is delayed wound healing. Several reports in the literature correlate sirolimus usage with increased rates of wound complications, including fascial dehiscence [38]. Proposed mechanisms linking sirolimus to impaired wound healing include drastic reductions in the pro-inflammatory cytokines plateletderived growth factor (PDGF) and basic fibroblast growth factor (bFGF) [66]. Another postulated complication with sirolimus is an association with hepatic artery thrombosis, although this is controversial [28]. Several multicenter trials have been performed documenting the efficacy of sirolimus in combination with other agents in preventing acute rejection. Sirolimus, when used in combination with cyclosporine and prednisone, reduced rejection rates to 7% from nearly 40% when cyclosporine and prednisone were used alone [37]. The safety profile of sirolimus compared with cyclosporine was favorable, with a decreased incidence of tremor, hirsutism, and renal dysfunction but an increased incidence in aberrations of cholesterol
17
Harrison S. Pollinger et al.
metabolism [37]. There are several other trials currently underway designed to investigate the risks and benefits of sirolimus.
Mycophenolate Mofetil Mycophenolate acid (MPA) is a fermentation product of Penicillium brevicompactum and related fungi. It was found to inhibit inosine 5 -monophosphate dehydrogenase (IMPDH) and to decrease the proliferation of some cancer cells. The mofetil moiety was added later to improve its bioavailability. Interest in its mechanism of action derived from research with inborn errors of metabolism and the finding that deficiency in enzymes involved with de novo purine synthesis resulted in profound immunodeficiency [7]. Allison and colleagues discovered that lymphocytes are especially dependent on de novo purine synthesis [8]. Essentially functioning as an antimetabolite, mycophenolate mofetil (MMF) exerts its immunosuppressant effects by selectively inhibiting the formation of guanosine and adenosine, two purine nucleosides. More specifically, the conversion of inosine monophosphate into guanosine monophosphate is blocked by MPA, which depletes lymphocytes of DNA. The ability of other cells to implement the salvage pathway for purine synthesis allows MMF to target the immune system specifically. MMF has also been shown to have several secondary characteristics that contribute to its immunosuppressive properties. By depleting nucleotide pools, MMF decreases the production of several adhesion molecules (integrins and selectins), which are crucial to the inflammatory response [9]. Although the major effects of MMF are on lymphocytes, it also significantly depletes guanosine triphosphate (GTP) levels in all mononuclear cells — effectively decreasing the levels of circulating cytokines, including IL-2 and tumor necrosis factor (TNF). Allison et al. have shown that MMF can also inhibit antibody production in vitro [6]. His group concluded that MMF can inhibit primary humoral responses in vivo, but does not effectively inhibit secondary antibody responses. MMF is available for clinical use in both oral and intravenous formulations, and is generally well tolerated. The intravenous formulation is rarely needed. Oral formulations are available in both 250-mg and 500-mg capsules. The standard dose is 1 twice daily. The bioavailability of MMF is 90%, with a half-life of 12 hours. It is readily absorbed from the GI tract
and hydrolyzed to MPA in the liver. The most common side effects associated with MMF involve the GI tract. Diarrhea has been reported in up to 1/3 of patients, with nausea, dyspepsia, vomiting, and dysphagia occurring in up to 20% of patients. Most of the GI-related adverse events resolve with reduction of the daily dose. Although the action of MMF is specific to lymphocytes, the incidence of anemia, leukopenia, and thrombocytopenia is similar to that of azathioprine. The incidence of posttransplant lymphoproliferative disorder (PTLD) and opportunistic infections is similar to that of other immunosuppressive agents. Epstein-Barr virus (EBV) infection (primary or reactivated) is a major risk factor associated with development of PTLD. The European MMF trial reported a slightly increased incidence of PTLD with patients treated in the MMF group compared to patients receiving azathioprine or placebo, with an overall frequency of less than 2%. In addition, there is a slight increase in the incidence of tissue invasive cytomegalovirus (CMV) infection in patients treated with MMF, especially in patients who receive more than 3 g/day. However, this observation could be related to more frequent endoscopic surveillance in patients who received higher doses of MMF [1]. Most adverse effects of MMF are self-limited or will resolve with a reduction in dose. Only 113 of 910 (12.4%) patients enrolled in renal transplant trials examining the effects of MMF discontinued the drug because of symptoms attributable to MMF [1, 50, 88, 89]. Unlike sirolimus and the calcineurin inhibitors, MMF is not metabolized by the cytochrome P450 system, resulting in fewer significant drug interactions. MMF should be administered with caution with sirolimus and tacrolimus because both of these medications have been shown to elevate the trough level of MMF [86]. The primary goal of adding MMF to maintenance immunosuppression regimens is to decrease the incidence of acute allograft rejection. A secondary objective is to minimize the need for more toxic agents, while not precipitating increased rates of rejection. Most of the data on MMF comes from experience in renal transplantation looking at combination therapy of MMF/cyclosporine versus azathioprine/cyclosporine. The U.S. and European trials had very defined end points: biopsy-proven rejection, incidence of graft loss, and patient death [1, 88, 89]. The incidence of graft loss was significantly reduced in the MMF group when compared to the azathioprine group (1.8% versus 8.6%) [88]. Biopsy-proven rejection occurred in 79 patients (47.6%) in the azathioprine group and in
18
2.
Current Immunosuppressive Drugs and Clinical Use
52 patients (31.3%) in the MMF group [88]. Analysis of the data of all three renal transplant MMF trials confirmed that MMF at 2 or 3 g/day was superior to azathioprine or placebo, with an absolute reduction in the incidence of graft loss due to acute rejection of 50% [42]. This finding has profound implications, in that acute rejection episodes act as a surrogate for long-term graft survival [62]. However, despite showing significantly lower rates of acute rejection and graft loss these trials were unable to show a difference in patient or graft survival at 1 year with combination therapy of MMF/cyclosporine versus azathioprine/cyclosporine. MMF has had a major impact on solid organ transplantation. None of the long-term trials with MMF have demonstrated significant end organ toxicity, and its use has been definitively associated with decreased rates of acute rejection. Future studies will be required to determine its long-term benefits and to see if it has any effect on chronic allograft nephropathy.
Corticosteroids Corticosteroids have a profound anti-inflammatory effect and historically have formed the mainstay of immunosuppressive therapy for transplantation. However, they are associated with severe and debilitating side effects with long-term use, and with the advent of more specific immunosuppressant agents interest has grown in steroid-sparing protocols. Steroids have an effect on all mammalian tissue, which is a reflection of the fact that all cells have glucocorticoid receptors within their cytoplasm [21]. Corticosteroids have been shown to block Ca2+ ionophore-induced lymphocyte proliferation by a mechanism different from that of the calcineurin inhibitors, and have been shown to inhibit the migration of mononuclear cells from the intravascular compartment into the tissue [65]. Once within the cell membrane, steroids bind to cytoplasmic receptors and travel to the nucleus, where the complex binds to DNA sequences referred to as glucocorticoid response elements (GREs). GREs are promotor regions essential to the transcription of many cytokine genes. As a result of this interaction, all stages of T-cell activation and proliferation are inhibited. There are many adverse effects of long-term corticosteroid usage. Severe growth retardation is seen in children, and all phases of wound healing are inhibited. Steroids are associated with increased risk of avascular
necrosis (AVN) and osteoporosis. The incidence of AVN is as high as 10% in transplant patients treated with highdose protocols, and likely 1 to 2% in patients receiving low-dose regimens [101]. The AVN region most commonly seen in transplant patients involves the hips and is frequently bilateral. Eventually, most patients diagnosed with steroid-associated AVN require total hip replacement. Osteoporosis is accelerated after transplantation and can lead to pathologic fractures [45]. Diabetes is another consequence of chronic steroid use. Up to 60% of transplant patients will develop glycosuria in the first 6 months following transplantation. Of these patients, only 5 to 10% will require chronic insulin therapy [24]. Cushingoid facies and truncal obesity are common with high-dose steroid regimens. The severity of these lesions is variable and dose dependent. Peptic ulceration, colonic perforation, pancreatitis, hypertension, and psychiatric disturbances are all more frequent, especially in the early posttransplant period when steroid doses tend to be higher. Infections continue to plague transplant patients, especially those on high-dose steroid protocols. The incidence of infections in patients on “conventional” low-dose regimens is less than that found with high-dose regimens [23]. Prednisolone and prednisone (11-keto metabolite) are the most commonly used oral preparations in clinical transplantation. Methylprednisolone is the most commonly used intravenous form. Prednisone and prednisolone are rapidly absorbed from the GI tract. Peak plasma concentrations usually occur within 1 to 3 hours of ingestion [56]. Prednisone is metabolized to prednisolone by the liver. Once within the blood, prednisolone is bound to both cortisol-binding globulin and albumin. Because only the unbound fraction is available to bind to the intracytoplasmic receptors, hypoalbuminemia is associated with greater bioavailability and an increased incidence of steroid-related complications [56]. The half-life of prednisone is 60 minutes, and that of prednisolone is 200 minutes. Glucocorticoids are completely metabolized by the hepatic microsomal system. Therefore, drugs that affect hepatic metabolism will directly affect the circulating half-life of steroids [25]. One area in which steroids still have a firm indication is the treatment of acute rejection. Despite the introduction of the powerful antilymphocyte globulins and anti-T-cell monoclonal antibodies as antirejection therapy, steroids continue to be a first-line modality. For most cases, if diagnosed early acute rejection can be
19
Harrison S. Pollinger et al.
reversed with intravenous or oral prednisolone therapy [94]. The risk of serious complications increases with each course of steroid therapy, and those cases resistant to steroids should be treated with polyclonal or monoclonal anti-T-cell globulins. Regardless of how the role of steroids evolves in the management of acute rejection, they may play a more pronounced role in the prevention of chronic rejection. Support of this hypothesis stems from studies reporting an increased rate of sclerosing arteriopathy and interstitial fibrosis in patients in which steroids were withdrawn compared to the steroid-treated controls [78]. Thus, preventing chronic rejection may involve not only the degree of immunosuppression but more specifically the agent employed and the innate ability of that agent to block the inflammatory response.
Protein Drugs In 1960, polyclonal antilymphocyte sera was introduced for both the prevention and treatment of acute allograft rejection [91]. This event was novel at the time because unlike any of the chemical agents used previously these biologic agents were specific and selective for immune cells. The development of hybridoma technology in the early 1970s permitted large volumes of monoclonal antibody (MAb) to be produced against T-lymphocyte receptors and other cell membrane determinants [51]. This new field of biologic immunopharmacology has allowed for the targeting of specific cell surface markers. Moreover, newer agents are even being targeted against distinct cell protein products (cytokines). The first MAb preparation to be used clinically was OKT3, derived from a mouse source. It is reactive against the T-cell receptor (TCR) [19]. These biologic agents possess distinct characteristics from conventional immunosuppressive agents. They have been shown under certain conditions to promote a state of immunologic unresponsiveness that is long lasting despite the absence of immunosuppression [100]. Several animal model experiments over the last two decades [11, 40] have been successful in inducing immunological unresponsiveness with anti-T-cell monoclonal antibodies.
Polyclonal Antilymphocyte Sera Antithymocyte globulin is produced by immunizing either horses (Atgam) or rabbits (Thymoglobulin) with
human thymocytes. Thymocytes are either obtained from cadaveric sources or procured from the thymus gland of patients undergoing open cardiac surgery. The preparation process of the polyclonal sera involves immunizing the host animal with the selected immunogen, collecting the serum, and removing unwanted antibodies. Despite the extensive preparation process, more than 95% of the final product contains nonspecific rabbit or horse immunoglobulins. It has been estimated that less than 2% of the antibody contained within the antisera is specific for human T-lymphocytes [87]. The antibody specificity of polyclonal sera is highly variable. Most consistently there are antibodies detected against CD-2, CD-3, CD-4, CD-28, and the TCR [12]. The exact mechanism of action by which these preparations prolong graft survival is not known. Absolute lymphopenia is not a prerequisite for effective immunosuppression, although profound lymphopenia is sometimes observed after the initial injections with these agents. The lymphopenia is induced by complementmediated lysis of lymphocytes and their uptake by the reticuloendothelial system after the lymphocytes have been opsonized. The proliferation of circulating T-cells is impaired and may be due to a direct effect as well as to the induction of nonspecific suppressor T-lymphocytes [60]. Polyclonal preparations have been used as induction agents and to treat acute rejection when it occurs. In animal models, they have been employed in preconditioning protocols to induce donor-specific tolerance. Long-term renal allograft survival without long-term immunosuppression has been achieved in a nonhuman primate model with an anti-lymphocyte globulin regimen. This protocol incorporated a posttransplant course of polyclonal serum and donor bone marrow infusion to the recipient, and no further immunosuppression after posttransplant day 5 [95]. This data has provided the rationale for several human tolerance trials utilizing similar protocols. Results have been mixed, allowing steroid withdrawal in some patients in the bone marrow group. However, no attempt was made to withdraw all immunosuppression, as in the nonhuman trial [10]. The route of administration of polyclonal antibody preparations is usually intravenously through a large central vessel or arteriovenous fistula because peripheral administration can result in a painful chemical phlebitis. Polyclonal antiserum must be infused slowly over several hours. If infused too rapidly, it may result in systemic hypotension. The dose depends on the source of the preparation. The typical dose for
20
2.
Current Immunosuppressive Drugs and Clinical Use
the rabbit-derived preparation is 1.5 mg/kg/day, and 15 mg/kg/day for the equine-derived product. The total duration of therapy varies but typically ranges from 5 to 14 days. The degree of immunosuppression can vary widely between different preparations, as well as between different patients who receive the identical preparation. Attempts to follow the degree of immunosuppression have been made by following the absolute T-cell counts in peripheral blood. This has been helpful in predicting the likelihood of rejection resolution. Delmonico et al. reported that depression of the CD-3+ cell number to less than 10% of pretreatment values correlates with clinical recovery from rejection [26]. It must be noted that after a course of therapy with antilymphocyte serum antibodies to the preparation can be detected in many patients. If these antibodies are present in a high enough titer, they can neutralize the beneficial effects of the drug. Adverse reactions vary in incidence and severity depending on the preparation used. The most common reaction reported is fever and chills, which can occur up to 80% of the time with the first infusion. This so-called “first-dose” response is likely due to lymphocytolysis and cytokine release [16]. To help limit this phenomenon, patients can be premedicated with antihistamines, antipyretics, and steroids. Fifty percent of patients will experience thrombocytopenia and/or anemia during a course of antilymphocyte therapy, which is almost always dose related. One major complication that has been linked to over-immunosuppression with these agents is PTLD. Gaber et al. reported no clinically significant differences with adverse events between Thymoglobulin and Atgam [34]. Malignancies were reported in three patients who received Thymoglobulin and three patients who received Atgam during the one-year follow-up period. These included two cases of PTLD in each group. To date, polyclonal antilymphocyte preparations maintain a vital role in most immunosuppressive regimens both as induction agents and for the treatment of acute rejection.
Monoclonal Antibody Preparations ANTI-CD-3 Muromonab-CD3 (OKT-3) was the first monoclonal antibody approved (in 1986) for human use by the Food
and Drug Administration (FDA) [100]. Initially, their sole indication was to treat acute rejection, but monoclonal antibodies are now used to both treat and prevent acute rejection in solid organ transplantation. The biologic target of OKT-3 is the e chain of CD-3, which is closely associated with T-cell receptors on T-cells. Once bound, these antibodies prevent activation of CD-4 and CD-8 T-cells. The recommended adult dosage of OKT-3 is 5 mg/kg/day. The usual course of therapy is 7 to 10 days, but is dependent on whether the agent is being used as an induction agent or to treat steroid-resistant rejection. One advantage of OKT-3 is that it can be administered via a peripheral vein. However, it does require filtration prior to administration to remove particulate matter in the preparation. As with the polyclonal agents, antihistamines, acetaminophen, and steroids should be administered concomitantly to help reduce the incidence of the “first-dose” response. Although OKT-3 remains the prototype monoclonal antibody to which all others are compared, it does possess some innate limitations. Two of the most significant shortcomings are the cytokine release phenomenon associated with the first few infusions and the nonspecific T-cell depletion that can result in over-immunosuppression, leading to the increased risk of infection and PTLD (Table 2.4) [29]. Several multicenter trials have confirmed the efficacy of OKT-3 as an induction agent. When comparing triple therapy with cyclosporine, azathioprine, and steroids with and without OKT-3, there was a significant delay in time to the first rejection episode, decreased incidence of rejection, and fewer instances of rejection in the OKT-3 treatment group [77]. OKT-3 has also proven efficacious as a treatment alternative for acute rejection. The initial trial examining OKT-3 as a treatment for allograft rejection was conducted in Boston in the early 1980s, in the era of azathioprine and steroids [19]. This pilot trial concluded that renal allograft rejection could be reversed in the majority of recipients with a relatively small dose of OKT-3 (1 to 2 mg/kg/day). This smaller trial led to a multicenter randomized trial that demonstrated that OKT-3 could reverse 94% of initial rejection episodes compared to 74% when conventional therapy was instituted [4]. One of the initial shortcomings of the use of OKT-3 for the treatment of acute rejection was that in the azathioprine era 50% of these patients would develop a repeat episode of rejection. With the introduction of cyclosporine, this recurrent rejection rate was reduced to 20% [81].
21
Harrison S. Pollinger et al. TABLE 2.4 Toxicity profile of OKT-3 therapy. Cytokine Release Syndrome
Over Immunosuppression
Immunogenicity
Reaction Chills, fever 1st dose 2nd dose Nephrotoxicity Vomiting, diarrhea Dyspnea Pulmonary edema Aseptic meningitis Arterial thrombosis
Reaction CMV infection Fungal infection Herpes simplex PTLD
Reaction Rash Anaphylaxis
Incidence (%) 70–90 10–20 30–40 15–30 10–20 0 –4 0 –3 <1
In a multicenter trial with a cohort of 300 patients diagnosed with severe rejection refractory to highdose steroids (and in some instances anti-lymphocyte therapy), a 65% response rate was demonstrated to OKT-3, with 56% of those allografts remaining functional at 6 months [76]. OKT-3 has also been shown to be beneficial in the treatment of hepatic allograft rejection. A prospective randomized trial conducted at Massachusetts General Hospital randomized liver transplant patients with biopsy-proven rejection to 10 days of OKT-3 therapy versus high-dose steroids alone. The OKT-3 group had a significantly better allograft outcome. However, the infection rate in the OKT-3 group was higher. The recommendation was, therefore, to limit the use of OKT-3 to steroid-resistant rejection in the liver transplant population [20]. If repeated doses of OKT-3 treatment are required, there is increased risk of xenosensitization. This is due to the fact that this agent is of murine origin and can trigger the production of human anti-mouse antibodies (HAMA). The incidence of a HAMA response is 25 to 30% per exposure to OKT3 [15]. This number can be reduced to 21% if the patient is on concomitant triple therapy immunosuppression [18]. Most patients will mount a HAMA response 7 to 10 days after OKT-3 therapy has ceased. The neutralizing effect of these anti-idiotypic antibodies can often be overcome by escalating the dose of OKT-3. Many centers have adopted the philosophy of routine escalation of doses of OKT-3 without monitoring to ensure adequate serum levels and to avoid the cost associated with frequent in vitro monitoring of CD-3+ cells.
Incidence (%) 20–60 15–35 5–25 0 –8
Incidence (%) 0–5 <1
ANTI-CD-25 In the early 1990s, other potential targets of the immune response were identified that could be blocked with monoclonal antibodies. Daclizumab (Zenapax) and basiliximab (Simulect) are MAb directed against the α-chain of the IL-2-receptor (also known as CD-25). CD-25 is present in high concentrations on activated T-lymphocytes. By competitively blocking this site, IL2-dependent proliferation of T-cells is inhibited without the deleterious effects associated with T-cell depletion. Daclizumab was studied as an induction agent in two prospective randomized controlled multicenter trials of first-time recipients of cadaver-donor renal allografts. The incidence of biopsy-proven acute rejection at 6 months was reduced by 37% in the U.S. trial [97] and by 40% in the European study [74]. Daclizumab was administered on the day of transplant and at 14-day intervals thereafter for a total of five doses. Basiliximab is similarly efficacious, with pivotal trials demonstrating a reduction in the composite endpoint of death, and graft loss or acute rejection of 26% and 31%. The dosing regimen is easier to comply with because only two doses were administered: one on the day of transplantation and the other on the fourth postoperative day. Unlike the polyclonal preparation and OKT3, infusion of IL-2 receptor blockers is well tolerated by patients (the cytokine release syndrome does not occur). However, there have been reports of severe hypersensitivity reactions within 24 hours of the first dose. The most common adverse reactions of the IL-2 receptor blockers
22
2.
Current Immunosuppressive Drugs and Clinical Use
are nausea, fever, and headache. The incidence of PTLD and infection are similar to the other antibody preparations in clinical use.
Anti-CD-20 Anti-CD-20 (rituximab) is a humanized monoclonal antibody that has been utilized in several desensitization protocols for ABO-incompatible kidney transplants [96]. CD-20 is a common cell surface marker present on immature and mature B-cells. Historically, ABOincompatible kidney transplants have been performed after several preoperative plasmapheresis sessions with the hope of depleting the circulating anti-A or anti-B antibody levels to avoid hyperacute rejection. These desensitization protocols also employ antithymocyte globulin and other more conventional immunosuppressive agents in attempt to inhibit antibody-producing cells. Rituximab has recently been added to the desensitization armamentarium to try to deplete B-cells that are programmed to become part of the antibodyproducing population (i.e., plasma cells). Tyden et al. have recently used rituximab preemptively in combination with immunoadsorption to successfully transplant 11 ABO-incompatible kidney recipients [96]. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD-20 antigen found on the surface of normal and malignant B-cells. The monoclonal antibody is an IgG1 kappa immunoglobulin with light and heavy chains of murine origin and variable regions derived from human sources. The agent is well tolerated in the transplant population, but when used to treat B-cell malignancies it has been associated with life-threatening tumor lysis syndrome. As newer monoclonal antibodies are developed and a better understanding of antibody secreting cells evolves, plasma cells will be more specifically targeted and effectively destroyed. Plasma cells are protean, expressing different cell surface markers at different time points in their maturation. This selective regulation of cell surface markers makes it difficult to definitively target the plasma cell with a single agent.
Alemtuzumab Alemtuzumab (Campath-1H) is a recombinant DNAderived humanized monoclonal antibody directed against the 21–28 kD cell surface glycoprotein
CD-52 [41]. CD-52 is expressed on the surface of a variety of normal and malignant cell lines. B- and T-lymphocytes, natural killer cells, macrophages, some granulocytes, and some tissues of the male reproductive system possess the CD-52 cell surface marker at some time point in their maturation. The Campath antibody is 150 kD in size and is an IgG1 subtype. The mechanism of action of Campath-1H is antibody-dependent cell lysis [14]. The initial indication for Campath-1H was refractory chronic lymphocytic leukemia [41]. The toxicodynamic profile of Campath-1H is similar to that of the other monoclonal antibody preparations in that similar instances of infusion reactions, lymphopenia, myelosuppression, posttreatment malignancy, and infections have been reported [14]. Campath-1H has also been employed in an ex vivo fashion for the depletion of T-lymphocytes prior to bone marrow transplantation for the prevention of graftversus-host disease [41]. Within the last several years, interest in Campath-1H as an immunosuppressive agent for renal transplantation has surfaced. Preliminary data on this agent in combination with low-dose calcineurin inhibition have produced encouraging results. However, these data are limited to a small number of patients [14]. The cohort of patients involved in trials with Campath-1H consists of 31 renal allograft recipients with a mean follow-up of 21 months. The incidence of acute rejection was 20% [14]. More trials are needed to define the efficacy of Campath-H1 as an induction agent, as well as its potential benefit when used to combat acute rejection.
Co-stimulation Inhibitors Abatacept (CTLA4-Ig) is a novel fusion protein consisting of the extracellular domain of human CTLA4 (a T-cell membrane protein subserving an inhibitory function) fused to a fragment of the Fc portion of a human immunoglobulin (Ig) G1 antibody. By binding avidly to B7-1 (CD-80) and B7-2 (CD-86) on the surface of the antigen-presenting cell (APC), the interaction of the T-cell’s CD-28 molecule with the APC’s CD-80/86 is blocked and the second signal required for T-cell activation is not delivered. Abatacept has been shown to be effective in patients with psoriasis and rheumatoid arthritis [5, 35], but did not demonstrate substantial efficacy in a nonhuman primate renal transplant model [49].
23
Harrison S. Pollinger et al.
It was hypothesized that a more potent CTLA4-Ig protein could be developed by engineering a molecule with higher avidity for CD-80 and CD-86. Belatacept was derived from abatacept by a 2-amino-acid substitution, which led to a fourfold increase in avidity to CD-86 and a twofold increase in avidity to CD-80. In vitro belatacept demonstrated tenfold more potent inhibition of T-cell activation and was dramatically more effective than the parent compound in preclinical transplant models [55]. Recently, in a multicenter phase-2 study belatacept was compared to cyclosporine in patients receiving basiliximab, MMF, and steroids. Belatacept did not appear to be inferior to cyclosporine in preventing acute renal allograft rejection [98]. Importantly, belatacept was associated with an improved cardiovascular and metabolic risk profile and was not nephrotoxic. However, the incidence of infection and neoplasms as similar in the belatacept and cyclosporine groups. Thus, belatacept — despite its elegantly specific mechanism of action — still provides generalized immunosuppression and carries with it the attendant risks of such therapy.
Deoxyspergualin 15-deoxyspergualin (DSG) is a synthetic derivative of spergualin, an antibiotic produced by Bacillus laterosporous. The mechanism of action is unknown but it appears to differ from that of other available immunosuppressive agents. It binds to a member of the heat shock protein 70 family and does not compete with the immunophilins, cyclophilin, or FK binding protein [71]. DSG has been shown to inhibit several macrophage functions. It inhibits lysosomal enzyme release and superoxide production by macrophages, and blocks induction of ornithine decarboxylase activity, inhibition of which impairs macrophage function [27, 44]. This antimacrophage activity makes DSG a potentially important immunosuppressant for cell transplantation in general, and islet transplantation in particular. Macrophage proinflammatory mediators such as nitric oxide and oxygen-free radicals have been shown to be deleterious to beta cells, and macrophages have been associated with primary nonfunction of islet allografts [47]. Thus, an antimacrophage agent such as DSG (which is itself not diabetogenic) may be particularly useful as part of an immunosuppressive protocol to protect islet allografts [102]. A pilot study using
DSG in recipients of simultaneous islet/kidney allografts was successful, and further studies are underway [36]. However, the studies ongoing are of an exploratory nature and pivotal trials of this agent are still some years away.
Conclusions As a discipline, transplantation has entered an exciting time. In the last decade several novel classes of immunosuppressive agents from humanized monoclonal antibody preparations to the costimulatory inhibitors have been introduced. As always, a priority has been to maximize efficacy while simultaneously reducing toxicity. This fundamental philosophy is and will always be a daunting task for investigators striving for newer and better immunosuppressive agents. As the field of immunosuppression advances and the technologies that monitor the immune response become more complex — examining the molecular origins of immunity rather than surrogates of the immune response such as allograft function — the agents will evolve to become more specific and effective. As transplantation becomes less invasive with the advent of cellular transplantation, this will drive immunosuppression down a similar path of less toxic and more tolerable treatment regimens. Both of these disciplines will play vital roles in allowing transplantation to reach its full potential for the long-term replacement of organs and tissues.
24
REFERENCES 1. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321–1325; 1995. 2. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344:423–428; 1994. 3. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809–815; 1983. 4. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337–342; 1985. 5. Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., Weiner, R. S., Birkhofer, M. J., Warner, G. L., Berry, K. K., Linsley, P. S., Krueger, J. G.,
2.
6.
7.
8.
9.
10.
11. 12.
13.
14.
15.
16.
17.
18.
19.
Current Immunosuppressive Drugs and Clinical Use
Ochs, H. D., Kelley, S. L., Kang, S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243–1252; 1999. Allison, A. C., Almquist, S. J., Muller, C. D., Eugui, E. M. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 23:10–14; 1991. Allison, A. C., Hovi, T., Watts, R. W., Webster, A. D. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 2:1179–1183; 1975. Allison, A. C., Hovi, T., Watts, R. W., Webster, A. D. The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp pp 207–224; 1977. Altmann, D. M., Hogg, N., Trowsdale, J., Wilkinson, D. Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells. Nature 338:512–514; 1989. Barber, W. H., Mankin, J. A., Laskow, D. A., Deierhoi, M. H., Julian, B. A., Curtis, J. J., Diethelm, A. G. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51:70–75; 1991. Benjamin, R. J., Waldmann, H. Induction of tolerance by monoclonal antibody therapy. Nature 320:449–451; 1986. Bonnefoy-Berard, N., Vincent, C., Revillard, J. P. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51:669–673; 1991. Borel, J. F., Feurer, C., Gubler, H. U., Stahelin, H. Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 6:468–475; 1976. Calne, R., Moffatt, S. D., Friend, P. J., Jamieson, N. V., Bradley, J. A., Hale, G., Firth, J., Bradley, J., Smith, K. G., Waldmann, H. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68:1613–1616; 1999. Carey, G., Lisi, P. J., Schroeder, T. J. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation 60:151–158; 1995. Chatenoud, L., Legendre, C., Ferran, C., Bach, J. F., Kreis, H. Corticosteroid inhibition of the OKT3-induced cytokinerelated syndrome: Dosage and kinetics prerequisites. Transplantation 51:334–338; 1991. Clipstone, N. A., Crabtree, G. R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695–697; 1992. Colvin, R. B., Preffer, F. I. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies. Clin Lab Med 11:693–714; 1991. Cosimi, A. B., Burton, R. C., Colvin, R. B., Goldstein, G., Delmonico, F. L., LaQuaglia, M. P., Tolkoff-Rubin, N., Rubin, R. H., Herrin, J. T., Russell, P. S. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32:535–539; 1981.
25
20. Cosimi, A. B., Cho, S. I., Delmonico, F. L., Kaplan, M. M., Rohrer, R. J., Jenkins, R. L. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 43:91–95; 1987. 21. Cupps, T. R., Fauci, A. S. Corticosteroid-mediated immunoregulation in man. Immunol Rev 65:133–155; 1982. 22. Curtis, J. J. Hypertension following kidney transplantation. Am J Kidney Dis 23:471–475; 1994. 23. d’Apice, A. J., Becker, G. J., Kincaid-Smith, P., Mathew, T. H., Ng, J., Hardie, I. R., Petrie, J. J., Rigby, R. J., Dawborn, J., Heale, W. F., et al. A prospective randomized trial of low-dose versus high-dose steroids in cadaveric renal transplantation. Transplantation 37:373–377; 1984. 24. d’Apice, A. J., Mathews, J. D., Tait, B. D., Kincaid-Smith, P. Association of HLA antigens with glucose intolerance following renal transplantation. Tissue Antigens 11:423–426; 1978. 25. Davis, M., Williams, R., Chakraborty, J., English, J., Marks, V., Ideo, G., Tempini, S. Prednisone or prednisolone for the treatment of chronic active hepatitis?: A comparison of plasma availability. Br J Clin Pharmacol 5:501–505; 1978. 26. Delmonico, F. L. Antithymocyte globulin therapy after renal transplantation at the Massachusetts General Hospital. Transplant Proc 16:979–982; 1984. 27. Dickneite, G., Schorlemmer, H. U., Weinmann, E., Bartlett, R. R., Sedlacek, H. H. Skin transplantation in rats and monkeys: Evaluation of efficient treatment with 15-deoxyspergualin. Transplant Proc 19:4244–4247; 1987. 28. Dunkelberg, J., Trotter, J., Wachs, M., Bak, T. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 9:463–468; 2003. 29. Eason, E., Cosimi, A. Biologic immunosuppresive agents. In: Transplantation. Ed by Ginns, L., Cosimi, A. B., Morris, P., 1999. Blackwell Science, Malden, Massachusetts. 30. Eckhoff, D. E., McGuire, B. M., Frenette, L. R., Contreras, J. L., Hudson, S. L., Bynon, J. S. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 65:180–187; 1998. 31. Elion, G. The pharmacology of azathioprine. In: The George Hitchings and Gertrude Elion lecture, pp 400–407. Ann NY Acad Sci, 1993. 32. Findlay, J., Radics, L. On the chemistry and high field nuclear magnetic resonance spectroscopy of rapamycin. Can J Chem 58:579–584; 1980. 33. Freeman, D. J. Pharmacology and pharmacokinetics of cyclosporine. Clin Biochem 24:9–14; 1991. 34. Gaber, A. O., First, M. R., Tesi, R. J., Gaston, R. S., Mendez, R., Mulloy, L. L., Light, J. A., Gaber, L. W., Squiers, E., Taylor, R. J., Neylan, J. F., Steiner, R. W., Knechtle, S., Norman, D. J., Shihab, F., Basadonna, G., Brennan, D. C., Hodge, E. E., Kahan, B. D., Kahan, L., Steinberg, S., Woodle, E. S., Chan, L., Ham, J. M., Schroeder, T. J.,
Harrison S. Pollinger et al.
35.
36.
37.
38. 39.
40.
41.
42.
43. 44.
45.
46.
et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66:29–37; 1998. Genovese, M. C., Becker, J. C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., Li, T., Aranda, R., Hagerty, D. T., Dougados, M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123; 2005. Gores, P. F., Najarian, J. S., Stephanian, E., Lloveras, J. J., Kelley, S. L., Sutherland, D. E. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 341:19–21; 1993. Groth, C. G., Brattstrom, C., Claesson, K., Backman, L. New trails in transplantation: How to exploit the potential of sirolimus in clinical transplantation. Transplant Proc 30:4064–4065; 1998. Guilbeau, J. M. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 36:1391–1395; 2002. Gupta, S. K., Manfro, R. C., Tomlanovich, S. J., Gambertoglio, J. G., Garovoy, M. R., Benet, L. Z. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 30:643–653; 1990. Gutstein, N. L., Seaman, W. E., Scott, J. H., Wofsy, D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol 137:1127–1132; 1986. Hale, G., Jacobs, P., Wood, L., Fibbe, W. E., Barge, R., Novitzky, N., Toit, C., Abrahams, L., Thomas, V., Bunjes, D., Duncker, C., Wiesneth, M., Selleslag, D., Hidajat, M., Starobinski, M., Bird, P., Waldmann, H. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 26:69–76; 2000. Halloran, P., Mathew, T., Tomlanovich, S., Groth, C., Hooftman, L., Barker, C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63:39–47; 1997. Halloran, P. F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715–2729; 2004. Hibasami, H., Tsukada, T., Suzuki, R., Takano, K., Takaji, S., Takeuchi, T., Shirakawa, S., Murata, T., Nakashima, K. 15-Deoxyspergualin, an antiproliferative agent for human and mouse leukemia cells shows inhibitory effects on the synthetic pathway of polyamines. Anticancer Res 11:325–330; 1991. Horber, F. F., Casez, J. P., Steiger, U., Czerniak, A., Montandon, A., Jaeger, P. Changes in bone mass early after kidney transplantation. J Bone Miner Res 9:1–9; 1994. Jensik, S. C. Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the US multicenter, randomized,
26
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 30:1216–1218; 1998. Kaufman, D. B., Platt, J. L., Rabe, F. L., Dunn, D. L., Bach, F. H., Sutherland, D. E. Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts. J Exp Med 172:291–302; 1990. Keown, P. Pharmacokinetics, drug interactions and analytical measurements of cyclosporine. In: T-cell directed immunointervention, pp 51–76. Ed by Bach, J., Oxford, Blackwell Scientific, 1993. Kirk, A. D., Burkly, L. C., Batty, D. S., Baumgartner, R. E., Berning, J. D., Buchanan, K., Fechner, J. H. Jr., Germond, R. L., Kampen, R. L., Patterson, N. B., Swanson, S. J., Tadaki, D. K., TenHoor, C. N., White, L., Knechtle, S. J., Harlan, D. M. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 5:686–693; 1999. Kobashigawa, J., Miller, L., Renlund, D., Mentzer, R., Alderman, E., Bourge, R., Costanzo, M., Eisen, H., Dureau, G., Ratkovec, R., Hummel, M., Ipe, D., Johnson, J., Keogh, A., Mamelok, R., Mancini, D., Smart, F., Valantine, H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66:507–515; 1998. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497; 1975. Kolars, J. C., Awni, W. M., Merion, R. M., Watkins, P. B. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488–1490; 1991. Kovarik, J. M., Mueller, E. A., Richard, F., Niese, D., Halloran, P. F., Jeffery, J., Paul, L. C., Keown, P. A. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 62:759–763; 1996. Kronbach, T., Fischer, V., Meyer, U. A. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630–635; 1988. Larsen, C. P., Pearson, T. C., Adams, A. B., Tso, P., Shirasugi, N., Strobertm, E., Anderson, D., Cowan, S., Price, K., Naemura, J., Emswiler, J., Greene, J., Turk, L. A., Bajorath, J., Townsend, R., Hagerty, D., Linsley, P. S., Peach, R. J. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5:443–453; 2005. Lewis, G. P., Jusko, W. J., Graves, L., Burke, C. W. Prednisone side-effects and serum-protein levels: A collaborative study. Lancet 2:778–780; 1971. Lindholm, A., Henricsson, S. Intra- and interindividual variability in the free fraction of cyclosporine in plasma in
2.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Current Immunosuppressive Drugs and Clinical Use
recipients of renal transplants. Ther Drug Monit 11:623–630; 1989. Lindholm, A., Henricsson, S., Dahlqvist, R. The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol 29:541–548; 1990. Lombardi, G., Sidhu, S., Daly, M., Batchelor, J. R., Makgoba, W., Lechler, R. I. Are primary alloresponses truly primary? Int Immunol 2:9–13; 1990. Maki, T., Simpson, M., Monaco, A. P. Development of suppressor T cells by antilymphocyte serum treatment in mice. Transplantation 34:376–381; 1982. Martell, R., Heinrichs, D., Stiller, C. R., Jenner, M., Keown, P. A., Dupre, J. The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 104:660–661; 1986. Matas, A. J., Gillingham, K. J., Payne, W. D., Najarian, J. S. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57:857–859; 1994. Mayer, A. D., Dmitrewski, J., Squifflet, J. P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., Vanrenterghem, Y., Donck, J., van Hooff, J., Christiaans, M., Morales, J. M., Andres, A., Johnson, R. W., Short, C., Buchholz, B., Rehmert, N., Land, W., Schleibner, S., Forsythe, J. L., Talbot, D., Pohanka, E., et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64:436–443; 1997. Meier-Kriesche, H. U., Kaplan, B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with Sandimmune. Am J Transplant 2:100–104; 2002. Metcalfe, S. Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation. Transplantation 38:161–164; 1984. Mohacsi, P. J., Tuller, D., Hulliger, B., Wijngaard, P. L. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 16:484–492; 1997. Montalbano, M., Neff, G. W., Yamashiki, N., Meyer, D., Bettiol, M., Slapak-Green, G., Ruiz, P., Manten, E., Safdar, K., O’Brien, C., Tzakis, A. G. A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications. Transplantation 78:264–268; 2004. Morris, R. Rapamycin: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplantation Rev 6:39–87; 1992. Mueller, E. A., Kovarik, J. M., van Bree, J. B., Lison, A. E., Kutz, K. Pharmacokinetics and tolerability of a microemulsion
27
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
formulation of cyclosporine in renal allograft recipients: A concentration-controlled comparison with the commercial formulation. Transplantation 57:1178–1182; 1994. Murgia, M. G., Jordan, S., Kahan, B. D. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49:209–216; 1996. Nadler, S. G., Tepper, M. A., Schacter, B., Mazzucco, C. E. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258:484–486; 1992. Nandakumaran, M., Eldeen, A. S. Transfer of cyclosporine in the perfused human placenta. Dev Pharmacol Ther 15:101– 105; 1990. Naoumov, N. V., Tredger, J. M., Steward, C. M., O’Grady, J. G., Grevel, J., Niven, A., Whiting, B., Williams, R. Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. Gut 30:391–396; 1989. Nashan, B., Light, S., Hardie, I. R., Lin, A., Johnson, J. R. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 67:110–115; 1999. Neild, G. H., Rocchi, G., Imberti, L., Fumagalli, F., Brown, Z., Remuzzi, G., Williams, D. G. Effect of cyclosporin A on prostacyclin synthesis by vascular tissue. Thromb Res 32:373–379; 1983. Norman, D. J., Barry, J. M., Bennett, W. M., Leone, M., Henell, K., Funnell, B., Hubert, B. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 11:90–93; 1988. Norman, D. J., Kahana, L., Stuart, F. P. Jr., Thistlethwaite, J. R. Jr., Shield, C. F. III, Monaco, A., Dehlinger, J., Wu, S. C., Van Horn, A., Haverty, T. P. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55:44–50; 1993. O’Connell, P., d’Apice, A., Walker, R., Francis, D., Kincaid-Smith, P. Cessation of steroids in renal allograft recipients on combined cyclosporin A, azathioprine, and prednisolone. Transplant Proc 20:11–13; 1988. Ojo, A. O., Held, P. J., Port, F. K., Wolfe, R. A., Leichtman, A. B., Young, E. W., Arndorfer, J., Christensen, L., Merion, R. M. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:931–940; 2003. Otto, M. G., Mayer, A. D., Clavien, P. A., Cavallari, A., Gunawardena, K. A., Mueller, E. A. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. Transplantation 66:1632–1640; 1998. Ponticelli, C., Rivolta, E., Tarantino, A. Treatment of severe rejection of kidney transplants with Orthoclone OKT3. Clin Transplant 1:99–103; 1987.
Harrison S. Pollinger et al. 82. Remuzzi, G., Bertani, T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 13:261–272; 1989. 83. Remuzzi, G., Perico, N. Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int Suppl 52:S70–74; 1995. 84. Satterthwaite, R., Aswad, S., Sunga, V., Shidban, H., Bogaard, T., Asai, P., Khetan, U., Akra, I., Mendez, R. G., Mendez, R. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 65:446–449; 1998. 85. Sehgal, S., Baker, H., Vezina, C. Rapamycin (AY-22,989) a new antifungal antibiotic: II. Fermentation isolation, and characterization. J Antibiotic 28:727–732; 1975. 86. Shapiro, R., Jordan, M. L., Scantlebury, V. P., Vivas, C., Gritsch, H. A., Casavilla, F. A., McCauley, J., Johnston, J. R., Randhawa, P., Irish, W., Hakala, T. R., Fung, J. J., Starzl, T. E. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: First report. J Urol 160:1982–1985; discussion 1985–1986; 1998. 87. Simpson, M., Monaco, A. Clinical uses of polyclonal and monoclonal antilymphoid sera. In: Monoclonal antibodies in transplantation, p 1. Ed by Chatenoud, L., 1995. 88. Sollinger, H. W., Belzer, F. O., Deierhoi, M. H., Diethelm, A. G., Gonwa, T. A., Kauffman, R. S., Klintmalm, G. B., McDiarmid, S. V., Roberts, J., Rosenthal, J. T., et al. RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 216:513–518; discussion 518–519; 1992. 89. Sollinger, H. W., Deierhoi, M. H., Belzer, F. O., Diethelm, A. G., Kauffman, R. S. RS-61443: A phase I clinical trial and pilot rescue study. Transplantation 53:428–432; 1992. 90. Spencer, C. M., Goa, K. L., Gillis, J. C. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54:925–975; 1997. 91. Starzl, T. E. Heterologous antilymphocyte globulin. N Engl J Med 279:700–703; 1968. 92. Starzl, T. E., Abu-Elmagd, K., Tzakis, A., Fung, J. J., Porter, K. A., Todo, S. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of “forbidden organs,” side effects, mechanisms, and practical pharmacokinetics. Transplant Proc 23:914–919; 1991. 93. Tanaka, H., Kuroda, A., Marusawa, H., Hashimoto, M., Hatanaka, H., Kino, T., Goto, T., Okuhara, M.
28
94.
95.
96.
97.
98.
99.
100. 101.
102.
103. 104.
Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 19:11–16; 1987. Thistlethwaite, J. R. Jr., Gaber, A. O., Haag, B. W., Aronson, A. J., Broelsch, C. E., Stuart, J. K., Stuart, F. P. OKT3 treatment of steroid-resistant renal allograft rejection. Transplantation 43:176–184; 1987. Thomas, J. M., Carver, F. M., Foil, M. B., Hall, W. R., Adams, C., Fahrenbruch, G. B., Thomas, F. T. Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation 36:104–106; 1983. Tyden, G., Kumlien, G., Genberg, H., Sandberg, J., Lundgren, T., Fehrman, I. ABO incompatible kidney transplantations without splenectomy, using antigenspecific immunoadsorption and rituximab. Am J Transplant 5:145–148; 2005. Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., Backman, L., Burdick, J. Interleukin2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338:161–165; 1998. Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., Charpentier, B. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770–781; 2005. Williams, S. K., Wang, T. F., Castrillo, R., Jarrell, B. E. Liposuction-derived human fat used for vascular graft sodding contains endothelial cells and not mesothelial cells as the major cell type. J Vasc Surg 19:916–923; 1994. Winter, G., Milstein, C. Man-made antibodies. Nature 349:293–299; 1991. Woo, K. T., Junor, B. J., Vikraman, P., d’Apice, A. J., Kincaid-Smith, P. Serum-alkaline-phosphatase as predictor of avascular necrosis of bone in renal-transplant recipients. Lancet 1:620–621; 1979. Xenos, E. S., Casanova, D., Sutherland, D. E., Farney, A. C., Lloveras, J. J., Gores, P. F. The in vivo and in vitro effect of 15-deoxyspergualin on pancreatic islet function. Transplantation 56:144–147; 1993. Yee, G. C. Pharmacokinetic interactions between cyclosporine and other drugs. Transplant Proc 22:1203–1207; 1990. Zimmerman, J. J., Kahan, B. D. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 37:405–415; 1997.
3 Stem and Precursor Cells for Transplant Therapy Jingli Cai and Mahendra Rao National Institute on Aging, Triad Technology Center, Baltimore, Maryland
Introduction Cell replacement therapy as a potential treatment for previously intractable diseases is now being considered a more feasible and effective treatment than even just a decade ago. Preliminary success in corneal therapy, the availability of commercial cartilage and skin replacement products, new advances in islet cell replacement, commercialization of cord blood therapy, and the potential of obtaining large numbers of cells from adult, fetal, and embryonic sources has led to the hope that stem cells may serve as a viable treatment option for treatment of a wide range of disorders, including congestive cardiac failure, lysosomal storage disorders, and metastatic tumors [15, 78]. This potential of stem cells has led to renewed commercial and regulatory interest in the field. In this chapter, we use the central nervous systems (CNS) as an example to illustrate the advances made and obstacles that must be overcome. In the first section, we discuss the current research and compare the advantages and disadvantages of different cell sources. In the second half of the chapter, we highlight the problems that must be solved for cell therapy in repair.
Some Basic Facts The CNS consists of approximately 1012 cells, of which the largest majority by far are fully differentiated postmitotic cells. Approximately 10% of these cells are neurons, whereas the remaining cells are supporting cells. For example, astrocytes provide trophic support, whereas oligodendrocytes produce myelin and ensheath
Cellular Transplantation: From Laboratory to Clinic
axons to enhance communication among neurons. Neurons communicate with each other and act in concert to regulate bodily activities. Any single neuron may make tens of thousands of connections. These connections may be made in close proximity to the soma of the cell or at distances that could be even several feet away [47]. The brain in general does not repair itself by regenerating new neurons to any large extent in most regions. Cues to direct appropriate differentiation of neural stem cells (NSCs) do not exist in all but selected areas of persistent stem cell populations. These stem cell populations are present predominantly in more cranial regions of the brain, such as the subventricular zone (SVZ) around the lateral ventricle [31, 74]. These persistent NSC populations can differentiate into glia and a small number of neurons that are directed to the olfactory bulb and the hippocampus — small but critical regions of the brain [21]. Although some controversy exists as to the extent of new neurogenesis and the number of NSCs present, it is reasonable to state that the total number of NSCs present in the adult is small, they do not participate in the repair process in most areas of the brain, and the roles of NSCs in the adult appear to be limited to very specific regions [22, 60, 68]. One more aspect of repair in the brain that must be kept in mind is that in the adult brain distances from sites of injury to stem cell niches are very large and no direct pathways for cell migration exist [45]. Radial glia that direct neuronal migration in the early developmental stages are no longer present in the adult, and fiber tracts are oriented in directions that are not useful for directing cells to cortical gray matter [77]. Thus, damage to cortical regions may not be signaled
29
Copyright © 2007, Elsevier Inc. All rights of reproduction in any form reserved.
Jingli Cai and Mahendra Rao
to the periventricular regions. Even with correct signals, there are no significant numbers of cells to migrate to that region, and even if a small number did so no cues to direct their site- and region-specific differentiation would exist [10]. As experiments have been performed, it has become clearer that different areas of the brain are structurally different and perform different functions, and that types of neurons present differ in their properties. These functional and structural differences arise very early in development and appear to include the stem cells present in those regions [47]. Thus, NSCs present in the hippocampus (or the SVZ associated with this region) differ from the NSCs present in the anterior SVZ associated with the olfactory bulb. One more critical fact to keep in mind is that the brain is relatively insulated from the rest of the body, and it is difficult to reach specific areas of the brain without causing damage as cells are being harvested and routes of administration are considered. The stem cell niches are present deep inside the brain and cannot be accessed by direct injection with any ease. Possible routes include deposition of cells in the ventricles or cerebrospinal fluid (CSF) space and delivery via the circulatory system (arterial or venous injection) [4, 19, 86]. Overall, when cell replacement therapy is considered one must take into account these basic facts while evaluating the type of cell to use, the mechanism of action of that particular cell (Table 3.1), and how one will get acceptable numbers of such cells to the appropriate location and how appropriate cues to direct differentiation will be provided. Issues that need to be considered for a successful cell therapy are summarized in Table 3.2.
TABLE 3.1 Mechanisms by which cells may have a beneficial effect. Possible Mechanisms
Examples
Replacing damaged or dead cells Supplying growth factor/gene therapy Delivering a toxic agent Mobilizing the endogenous stem cell pool Repairing damaged regions Reconstructing neural circuit
PD, AD, HD, stroke, ALS, epilepsy AD, HD, lysosomal storage diseases, brain tumor Brain tumors Stroke
HD, brain ischemia Traumatic spinal or brain injury
Cell Source Issues NEURAL STEM CELLS Stem cells are a population of cells that self-renew and are multipotent. Stem cells are classified by the tissue and the developmental stage from which they are harvested, and in general most of the tissue-specific stem cells (TSC) undergo limited but not lifelong selfrenewal. TSC have the ability to divide either symmetrically or asymmetrically. By symmetric division, stem cells give rise to two progenies whose properties remain similar. In contrast, stem cells can produce two different daughter cells by asymmetric division, with one cell being similar to itself and the other being a differentiated cell. In general, TSC derived at embryonic stages appear to self-renew for longer periods and
TABLE 3.2 Issues that need to be considered for successful therapy. Cell Issues
Host Issues
Transplantation
Choice of cell source
Diagnosis and timing of therapy Age and medical history Delivery location Dose vs. severity, brain size Surgery techniques
Monitoring cell survival
Cell quantity Directed differentiation Cell purification
Immunosuppression
30
Tracing cell migration Quantifying cell proliferation Following cell differentiation Evaluating anatomical and functional integration Estimating side effects of transplantation
3.
Stem and Precursor Cells for Transplant Therapy
have shorter cycle times than TSC derived from later stages of development. In the CNS, NSCs have been isolated from different stages of development and different locations. These NSCs differ in their self-renewal capacity, position markers they express, and the proportions and phenotypes of cells they differentiate into [43, 48, 89, 90]. Both lineage-specific (positive and negative) and general stem cell markers have been identified to prospectively identify and locate stem cells in the nervous system [9, 74]. However, there is still no perfect marker (i.e., useful for all NSCs). Transplantation of NSCs has been tested in several pilot studies, and some positive and cautious conclusions can be made. For example, in Parkinson’s disease (PD) NSCs isolated from 7- to 8-weekold human embryos showed alleviation of symptoms and survival of transplanted dopaminergic neurons [17, 32]. Transplanting SVZ adult NSCs into stroke rat models significantly improved neurological function and reduced infarct size as assessed by magnetic resonance imaging (MRI) and histopathological analysis [95]. Dramatic improvement in experimental autoimmune encephalomyelitis (EAE) models has also been reported [62, 75]. However, these and other studies also identify areas of concern that need further research. Adult NSCs show a decreased capability to self-renew. In most studies, adult NSCs show shortened telomere length, longer cell cycle time, inadequate differentiation, and limited proliferation capability [6]. It also remains a problem to obtain sufficient cell numbers. In comparison, fetal cells grow better. However, it has been difficult to maintain a purified population of cells. In addition, some studies have suggested that cells change in their properties when maintained in culture, making the idea of a bank of cells difficult to implement. Delivery via arterial or venous circulation does not seem possible, and issues of homing and migration seem open to interpretation. Further, a major concern has been the inability to obtain robust differentiation after transplantation. Most reports of stem cell transplants have suggested poor survival and limited differentiation and/or limited migration [55]. Svendsen and colleagues, for example, reported that the only dopaminergic neurons they found were those that had been predifferentiated in culture [8]. It has also become clear that the brain is not an immune-privileged site, and as such nonautologous cells are likely to be rejected over time. Thus, although dramatic progress has been made in understanding the
biology of the cells, identifying methods of isolating and amplifying cells in culture, and following cells after transplantation it has been difficult to demonstrate substantial success in a clinical trial. However, current studies have identified problems and provided clues as to how such problems may be solved.
RESTRICTED PRECURSOR CELLS In contrast to the hematopoietic stem cell (HSC) model, in which the most primitive cell is the optimal cell for therapy, many researchers in the CNS field believe progenitor cells may be used for therapy as well. These restricted precursors are defined by limited self-renewal and the ability to give rise to a restricted set of mature progeny. Such restricted precursor cells (blast cells) have been identified in the CNS, and their properties have been studied carefully [57]. These include olfactory ensheathing glia, oligodendrocyte precursors, glial precursors, astrocyte precursors, and neuronal precursors [36, 50, 67, 79]. Although the restricted precursor cells do not have the same prolonged self-renewal as NSCs but have a more restricted differentiation capacity, they are nevertheless a possible cell source in many tissues and many diseases. We and others have reasoned that differentiated cells are not replaced in large numbers in many solid tissues and organs, and as such limited self-renewal may not be a limiting factor in providing long-term benefits. Furthermore, many diseases in solid tissue are diseases affecting a specific subpopulation. Given that no cues for directing differentiation of immature cells to a particular lineage exist, using selected cells may be more appropriate (i.e., glial cells for glial diseases and appropriate neuronal progenitors for neuronal diseases) [69]. In the CNS, it appears that glial proliferation after injury is robust and that cues are present in the brain to direct glial progenitors to mature, migrate, and respond after tissue damage. Thus, the possibility exists that transplanted cells can co-opt the same cues for efficient repairs. Glial progenitors have been shown to be effective in enhancing repair and remyelination in a variety of models of injury [5, 35, 42]. Neuronal progenitors have been shown to be effective in transplants in the hippocampus, and long-term reconstitution studies have shown that mature cells derived from transplanted progenitors can survive for months and years in rodent models [29, 34].
31
Jingli Cai and Mahendra Rao
Some investigators have reasoned that predifferentiating NSCs might be the best approach for therapy because it combines the prolonged self-renewal ability of NSCs with the ability of differentiated cells to respond to local cues. Indeed, forcing NSCs down a distinct lineage before transplantation into a rat model of spinal cord injury Hofstetter et al. [44] found more oligodendrocyte and neurons differentiated from Ngn2NSCs grafts, with better functional recovery and less neuropathic pain compared to naive NSCs. Although using progenitor cells has some undeniable advantages, several problems remain. There are no autologous sources of progenitor cells, with the exception of perhaps olfactory ensheathing glia. Amplifying sufficient numbers of glial cells from biopsy material such as that performed in temporal lobe epilepsy remains a challenge. The limited self-renewal restricts the number of cells available and shortens the time window between collection and transplantation. As with NSCs, using progenitor cells does not resolve the immune issues associated with nonautologous/ mismatched transplants. In addition, migration and integration issues that affect transplants in solid tissues remain. No data that progenitors can be delivered via arterial or venous circulation have been reported, and neuronal progenitors (unlike glial progenitors) do not migrate extensively. Although progenitor cell transplants offer some benefits in therapies for some diseases, they are not a panacea, and several issues that may be unique to progenitor cells need to be considered when evaluating these cells for therapy.
TRANSDIFFERENTIATED CELLS An alternative cell source that may resolve many of the problems associated with using NSCs or progenitor cells could be the idea of transdifferentiating autologous stem cells. Examples include HSCs and MSCs (bone marrow stromal cells) that are relatively abundant, easily collected, and may be delivered via the circulatory system [65]. One can harvest cells in sufficient numbers or obtain enough via limited amplification in culture. These cells by their very nature are migratory and survive in circulation. They have in previous studies been shown to circulate through various tissues in small but readily detectable numbers [39]. Moreover, a plethora of reports has suggested that these particular stem cells are plastic, respond to tissue damage, accumulate at sites of
injury, and can respond to local cues to differentiate in a site- and tissue-specific fashion [88]. HSCs accumulate in cardiac tissue after an infarct, and some cells transdifferentiate into cardiac muscle and others contribute to blood vessels, resulting in tissue reconstitution. Others studies have suggested similar benefits in lung, nervous system, liver, and other solid tissue [18, 38, 41]. Although controversy exists about transdifferentiation [56], we do not feel that this chapter needs to focus on the controversy. We simply want to emphasize that although the usage of transdifferentiated cells for therapy offers many potential advantages several questions and problems need to be solved. The frequency and heritability of the transdifferentiation process needs to be tested, and the persistence of the transdifferentiated cells in their new environment must be assessed over a long time period. The effect of the nontransdifferentiated population that does not respond to local cues must be considered, and more control on directing the process must be obtained. It is fair to state that it is unclear if transdifferentiated cells are better than tissuespecific stem cells or progenitor cells for all therapies and in all diseases. Rather, it will be important to weigh each of these potential cell sources carefully to determine which one will be the best cell choice for therapy. Further transdifferentiation of nonneuronal populations does not solve the problems of delivery and migration in a solid tissue organ either. Other cells that can be dedifferentiated or transdifferentiated have been described as well [84]. In the nervous system, for example, all major types of glial cells (including oligodendrocyte precursors, astrocytes, and radial glia cells) have been reported to transdifferentiate into mature neurons [13, 53, 87]. Even postmitotic neurons have been reported to reenter the cell cycle and give rise to dividing precursor cells [1, 7, 24]. The added advantage of such transdifferentiated populations compared to nonneuronal stem cell populations is that one can imagine directing surplus cells present in situ (at site of damage or close to it) to transdifferentiate into the appropriate cell type and thus circumvent the difficulties associated with delivering the right numbers of cells to the right place and at the right time. Indeed, Macklis and colleagues [14, 25] have shown that if the injury paradigm is designed correctly either stem cells present locally or transdifferentiated cells are activated to repair and regenerate damaged tissue. The results are quite spectacular, and the degree of appropriate connectivity seen is impressive. However, as with other
32
3.
Stem and Precursor Cells for Transplant Therapy
transdifferentiated cells it remains to be seen whether these cells will be more stable, whether the numbers will be sufficient, and whether one will be able to induce such transdifferentiation in all injury paradigms.
ESC-DERIVED CELLS Embryonic stem cells (ESCs) are pluripotent, with an unlimited self-renewal capability, and can be induced to differentiate into any cell type of an organism. Their relatively rapid cell cycle and ability to generate all cell types and tissues make ESCs promising candidates for therapeutic applications in which large-scale expansion of cells is important. Human ESC lines, derived from embryos generated in excess for in vitro fertilization [27], can be expanded in vitro with little or no change of properties over a long time period [12, 81]. Such expanded lines can be induced by appropriate exogenous signaling molecules to generate appropriate cell types [49, 76, 91]. A brief list of various methods used for neural differentiation is summarized in Table 3.3. Similar methods have been described for mesenchymal and endodermal derivatives as well. It is quite clear that ESCs can serve a virtually unlimited source of specific cell types. New ESC lines can be obtained in a relatively high frequency [58] (up to 30% efficiency has been reported), which provides the possibility of creating a bank of
ESC lines whereby one could obtain immunologically matched cell lines. This bank would not have to be extremely large because there are only a limited number of MHC class molecules. By choosing an immunologically matched line, one could perhaps avoid the problems of long-term immunosuppressive therapy. However, issues such as obtaining sufficient numbers of cells for therapy, donor cell survival, integration, migration, and delivery still have to be resolved. ESCs in addition may have some specific problems of their own. For example, the inability of immature ESCs to respond to environmental cues and their truly impressive selfrenewal capacity permit small numbers of ESCs to form teratomas after transplantation. This imposes a far more stringent requirement of purity on ESC samples than on any other stem cell population. Cell sorting may help to overcome this problem, but it requires developing sorting and selection protocols and identifying cell-typespecific markers that may not be available in some cases. Currently, the number of ESC lines available is small (http://stemcells.nih.gov/research/registry/ ), and immunological matching is not feasible. One possible resolving strategy is nuclear transfer, which has been successfully demonstrated in some pilot studies [46] but is highly restricted in most countries. Long-term propagation is currently an absolute requirement, and although reports have suggested stability we note that growing cells in culture imposes stresses and selection pressures and changes can and do occur. Mouse ESCs
TABLE 3.3 Neural differentiation methods used with human ESCs. Progeny Phenotype
Methods
Reference
99% NCAM+, 97% nestin+, and 90.5% A2B5+ neural progenitor cells Nestin+, NCAM+ neural precursor cells, and Tuj1+ neurons Neural-tube rosettes Neural cells and glial cells 39% and 52% NF-L+ neurons MAP2+ and NF+ neurons
Prolonged culture and mechanical selection
80
Treatment of ES cell aggregates with RA
11
ES cell aggregates Noggin treatment RA and NGF treatment EB culture in the presence of 50% conditioned medium from the human hepatocarcinoma cell line HepG2 (MedII) Co-culture with PA6 stromal cells
94 72 82 83
87% of hES colonies contained tyrosine hydroxylase (TH)-positive cells Up to 79% neurons express TH 40% of Tuj1+ neurons express TH
Co-culture with MS5, MS5-Wnt, or S2 stromal cells Co-culture with stromal cells
33
93 73 71
Jingli Cai and Mahendra Rao
show a decrease in the ability to contribute to the germ line after as few as twenty passages [2, 63]. Unlike adult NSCs, which may have incorrect positional information, ESC derived cells may lack appropriate positional information. Thus, ESC biologists may face similar issues in terms of the ability of the cells to survive and integrate in a tissue- and site-specific fashion. A substitute for ESCs is embryonic carcinoma (EC) cells, which show surprisingly similar characteristics. They have the ability of extensive self-renewal and can differentiate into committed precursors and terminal differentiated cells; for example, postmitotic neurons [59]. The differentiation of EC cells is accompanied by loss of tumorigenicity [66]. NTera2 (NT2) cells originate from testicular carcinoma, and one subclone NT2/D1 is used to get mature neurons through the treatment with RA. NT2-derived neurons are commercially available as LBS neurons (Layton BioScience, Sunnyvale, CA) and have been transplanted into patients [51, 52]. Neuropathological evaluation and immunohistochemical analysis of one patient showed survival of grafted LBS neurons 27 months after transplantation and no signs of neoplasm formation [64]. However, no detailed reports on cell integration or migration are available.
We note, however, that teratocarcinoma lines do not offer any specific benefit over ESC except for the fact that they may be easier to grow. We note as well that karyotyping of EC cells and their derivatives has been reported to be abnormal [20, 61]. We believe their utility should be relegated to using them as models for potentially safer cells. The relationship of different cell types in the CNS is illustrated in Figure 3.1. It is clear from the previous discussion that each cell type offers some unique advantages or disadvantages (Table 3.4), and thus it is unlikely that one will use a single well-characterized cell type for all diseases. Indeed, it is clear that the field is moving in that direction. For some disease for which proliferation and migration are critical, more undifferentiated cells will be transplanted early in the disease course. In other diseases, in which a single cell type may be required or be sufficient such as in PD, differentiated progenitor cell populations are being evaluated. Creative studies on utilizing the propensity of cell fusion and the transient survival of transdifferentiated cells are being initiated to harness the specific positive features of different stem cell populations. Cell types that have been used in different disease models are outlined in Table 3.5.
Figure 3.1. Major differentiation pathways in the CNS. NSCs — which can be isolated from different developmental stages, derived from ESCs, or transdifferentiated from other tissue cells — can give rise to all types of mature cells in the CNS.
34
TABLE 3.4 Comparison of different cell sources. Cell Type
Advantage
Disadvantage
Neural stem cells (adult and fetal)
High potential of self-renewal.
Lineage-restricted precursors
Useful for replacing a specific mature cell type. Great availability. No ethical problems. Ideal for autologous cell therapy. Great availability. Most capable of expanding.
Limited resources. Differentiation direction not totally understood yet. Fetal ones are not ethically acceptable. Limited self-renewal capability.
Transdifferentiated cells
Specialized cells
ES-derived cells
Olfactory nerve-ensheathing cells Neural crest stem cells Retinal stem cells
Remyelinating capability. Promoting axon growth. Multipotent and very plastic. Integrative plasticity and ability to differentiate into retinal neurons.
Transdifferentiation rate is very low.
Potential malignant transformation. Differentiation mechanism not clear yet. Ethical problem. Limited sources. Poor proliferation capability. Differentiation mechanisms not clear. Limited sources.
TABLE 3.5 Different cell types for therapy in different diseases. Diseases
Types of CNS Cells Affected
Most Commonly Used Cell Type in Treatment
Obstacles to Overcome
Alternative Cell Sources
Reference
PD
Dopaminergic neurons in the A9 region of the substantia nigra parsa compact Neuronal circuitry and supporting glial cells
Fetal mesencephalic neurons
Limited clinical benefits. Side effect as dyskinesias. Source and ethical problems. Potential tumorigenicity if contaminated with undifferentiated cells.
ES- or NSC-derived specific A9 dopaminergic neurons Hematopoietic stem cells
40 70 28
Low proliferation rate.
Forebrain-derived NSPCs
90
Noggin-expressing NPCs
85
Stroke
Spinal cord injury
HD AD Lysosomal storage diseases
Varied neurons and glia
Glutamate-induced neuron death Basal forebrain cholinergic neurons Abnormal morphology found in neurons
Human neuronal cells derived from NTera2/D1 teratocarcinoma cell line Spinal-cord-derived neural stem/ progenitor cells Neural precursor cells
Predominantly differentiated into astrocytes. Fetal striatum neurons Source and ethical problems. Fetal NSC-derived Source and ethical cholinergic neurons problems. Bone marrow cells with Limited delivery of the vector to the target and retrovirally transduced transient expression of lysosomal genes the gene.
33
ES or adult NSC-derived 37 neurons ES or adult NSC-derived 92 neurons Gene therapy using 23 NSCs for delivery
Jingli Cai and Mahendra Rao
Difficulties Researchers Face As we have discussed before, identifying the optimum cells for therapy and obtaining sufficient numbers of cells to perform such experiments is only part of the process of translating cell therapy to the clinic. Researchers face many challenges before such therapy can be widely used in clinical practice. There are huge differences in the CNS structure and function between animal models and human beings. Most of the disease models only reflect parts of the human diseases. The mechanisms of action of many of the cells touted for therapy remain unclear. Noninvasive measures to assess cell survival, integration, migration, and differentiation after transplantation remain limited. Many of the diseases for which cell therapy is being considered are not diagnosed early, and the window of opportunity for therapy may be lost. Unlike drugs, it is also unclear how long the follow-up after such therapy should be. The FDA (Food and Drug Administration), like all of us, is uncertain and remains reluctant to allow therapy or trials to proceed in the face of such uncertainty. These difficulties (discussed in material following) need to be resolved for any cell being considered for therapy in a particular disease model.
BASIC DEVELOPMENTAL BIOLOGY BACKGROUND IS UNCLEAR Understanding the relationship between the pathology of diseases and the development of a particular system is critical in designing effective and specific therapies for any disorder. In cell therapy, one needs to also understand how cells respond to and effect changes. Perhaps the single largest problem in translating potentially exciting results to the clinic has been a difficulty in obtaining a consensus on how stem cells exert a particular effect. MSCs have been reported to have measurable effects even though they do not survive in culture. Their benefits have been variously attributed to transdifferentiation, release of growth factor in the local environment, and modulation of the immune system [16]. Likewise, we understand little of how cells fuse, how transdifferentiation actually occurs, and how stem cells (which are normally restricted to a particular niche) can sense cues, steer themselves, and respond appropriately when endogenous stem cells fail to do so. Understanding such basic issues is critical. We do not need to understand them in detail before one moves
to the clinic, but we do need to understand them well enough so that we can manipulate the system and predict the effects with some reliability and reproducibility.
ANIMAL MODELS AND TESTS ARE DIFFERENT FROM WHAT IS APPLICABLE IN HUMANS Another major problem facing translational work has been the slow but clear realization that there are species differences between stem cells as well as difficulties in extrapolating from animal models to human disease. Differences could be mundane or critical, but it is often difficult to predict a priori whether the difference will be one or the other. These differences affect experimental design and assessment of results, and raise questions about appropriateness of animal models that should be used. Examples of these differences have been reviewed elsewhere [28]. The point we wish to make is that although these issues bedevil drug evaluations they effect cell transplanters to a greater extent. The reason is that cells themselves respond to the environment and their response changes over time. This is not true for drugs, at least in the context of testing them in an animal model. This dual interaction of host and transplant adds a huge layer of complexity, which makes translating cell therapy to the clinic a lot more difficult than any other drug or small-molecule agent.
NONINVASIVE MEASURES OF CELL SURVIVAL, INTEGRATION, MIGRATION, AND DIFFERENTIATION AFTER TRANSPLANTATION REMAIN LIMITED Another critical aspect of therapy, given the persistence of stem or progenitor populations, will be developing simple noninvasive measures to follow patients subjected to therapy. This has not been as much of a problem in the hematopoietic system because accessing this system has been relatively straightforward. However, in solid tissues one will nevertheless have to estimate what cells do and whether their behaviors remain appropriate. This requires developing methods to monitor cells and to delete them should something abnormal be identified. Unfortunately, to date only a few noninvasive methods that are sensitive enough exist.
36
3.
Stem and Precursor Cells for Transplant Therapy
In PD, it is possible to monitor dopamine release noninvasively [26, 54]. Lumbar puncture [3] to access CSF is often an inexpensive method of following factor levels in the CNS when cells are used as drug delivery vehicles. However, MRI and computerized axial tomographic (CT) scan — our mainstays in examining tissue — do not have sufficient resolution to look at small numbers of cells. MRI dyes such as the ferridox labeling technique enhance sensitivity but resolution is still at the level of hundreds of cells even with more powerful magnets. Likewise, no reliable method of eliminating cells has been developed. Engineering suicide genes, introducing regulatory/inducible promoters, identifying cell-type-specific toxins, and so on are all being attempted. It is fair to state that currently no off-the-shelf strategy to eliminate cells after they have been introduced exists.
PREDICTING THE BEHAVIOR OF CELLS IN A DISEASED ENVIRONMENT IS DIFFICULT An important concern related to therapy in general and stem cells in particular is that little information is available about the diseased and damaged environment and the response of stem cells or progenitors to such an environment. This is critical when translating cell therapy results in animal models to the clinic. We note that transplanting human embryonic dopamine neurons into the brains of PD patients also shows clear age-related effects, with some clinical benefit seen in younger but not in older patients [28]. Similarly, Olanow et al. showed that a significant therapy effect is observed in patients with mild PD but not in those severely affected [70]. Unfortunately, not many good models of aging and progressive damage are available. They require an extraordinarily long time to generate, often rodent models are not useful, and costs for primate models make them prohibitive. Often, the only model that seems appropriate is a human, but clinical studies prospective or retrospective are also expensive and time consuming. Further, it is difficult to imagine that anyone would consider it ethical or moral to perform experiments on humans without reasonable animal data. This potential catch-22 situation predicts that we will have failures translating promising therapy in an animal model to humans. Such failures are not unexpected, as these have been seen in medicine trials as well. The recent recalls of Tysabri and Vioxx after extensive animal studies are good examples.
We would emphasize that cell therapy supporters are concerned about the same issue and believe that the likelihood of failures remains high and may be higher in cell therapy studies when compared to drug trials. It is perhaps such valid concerns that have made the progress to the clinic slower than what patient advocates would like. Dramatic results with cell therapy have been reported in spinal cord injury models, after stroke, and in the treatment of lysosomal disorders. However, to date no clinical trial has been initiated and it is perhaps with good reason that the FDA has been slow in granting approvals. It is important to remember that the litany of problems and issues we have discussed do not amount to an insurmountable obstacle in the path of translational research. Indeed, the number of potential disease targets for therapy being considered is large, and the number of investigational new drug (INDs) applications filed has increased dramatically over the last few years. We would instead suggest to the reader that the criteria laid out in this chapter help to evaluate cells for therapy and identify problems that need to be addressed. As discussed in subsequent sections of this book, cell therapy is indeed moving toward the clinic. We would argue that, for example, based on the criteria we have outlined pancreatic islets are a good candidate for clinical therapy. The mechanism of action is known, the number of cells required is small, the cells themselves are not required to do anything other than their normal biological function, and methods of isolating, propagating (for a short time), and delivering cells have been clearly defined. Investigators have also developed adequate immunosuppressive protocols and methods of monitoring posttransplantation, and have resolved dosing, quality control, and manufacturing issues. Similarly, a reasonable case can be made for limbal stem cells for corneal injury, dopaminergic neurons for PD, MSC for mesenchymal abnormalities, and so on.
Future Prospects It is important to emphasize that since 2002 the landscape for stem cell therapy has changed. The major impetus for change has been the involvement of the FDA. The FDA has reasoned that cells need to be classified as a drug when cells are used as modified in any fashion in culture or are used in a manner that is akin to a new use or function of these cells. Because cells can change in as little as 48 hours in culture,
37
Jingli Cai and Mahendra Rao
the FDA has argued that even if cells were isolated from the same patient but would be implanted in the future, manipulated (minimal as this may be), exposed to animal protein, or infected with a reagent they should be considered a product. Likewise, if BMSC (bonemarrow-derived mesenchymal stem cells) were used to make neurons this would be a different use of these cells and subject to FDA purview. This has had both positive and negative effects on the industry. The process of review and time to submit an IND application need to be factored into the planning of any therapy. Likewise, scale-up, lot sizes, good manufacturing practice (GMP), and product manufacturing are all issues that need to be considered. These more rigorous criteria have prolonged the process of moving promising therapies to the clinic and have greatly increased the expense to initiate trials for studies that could previously have been performed under IRB approval. Further, the FDA itself is not clear as to what is feasible in this new and rapidly changing field, and because no cell therapy has been approved as a product under the new guidelines it is not clear to the industry and investors how to factor the risk and time involved in adhering to the new regulations. Uncertainty has led to reluctance to invest, as is evidenced by the lack of large corporation or pharmaceutical companies investing in this field. Nevertheless, we believe that the net effect of the FDA’s involvement in the field has been beneficial and has brought a much-needed rigor in a fragmented field. The GMP and manufacturing regulations now required have forced investigators to examine the compositions of their cell products in much greater detail. Comparison between samples from different investigators is now becoming possible. Results from one study can now be evaluated against those derived at another center, and improvements can now be tested in a more rational way. Greater attention is now being paid to devising surrogate measures of potency and efficacy, and dosing studies are becoming the norm. Issues of follow-up potential side effects and more quantitative measures of improvement are being devised, and more attention to appropriate animal models that better mimic the human disease target are being developed. The effect of these regulations in the long term cannot be predicted, but we think it is safe to say that overall most investigators have welcomed the oversight despite the associated regulatory burden. The FDA on its part has played a proactive role and has initiated several workshops and courses to educate academic
researchers on the new regulations, and the NIH has recognized the need to fund new GMP facilities. The NHLBI (National Heart, Lung, and Blood Institute), for example, has developed cord blood banking procedures and has provided templates for investigators who wish to obtain FDA approval. Production Assistance for Cellular Therapies (PACT) facilities is a publicly funded GMP service that will allow investigators to obtain GMPquality cells without investing huge amounts in infrastructure. The NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) has likewise worked in partnership with pancreatic islet groups to standardize protocols and studies to help the entire field move forward. The number of INDs filed has increased dramatically in the last year or so, and we feel that it is not long before a cell product will be licensed for therapy. Biotechnology investments have seen a rebound as the economic climate has changed, and a significant portion of the investment has been in stem cells, nanotechnology, and other cutting-edge therapies. Investors have recognized that although regulations and rules are a burden they do remove uncertainty, making risks and benefits easier to evaluate. We expect that once the extent of regulatory delay is known and can be factored in changes instituted in the past few years will make for a healthy investment climate. As one surveys the stem cell landscape, it becomes clear that some stem cells or progenitor cells are already in therapy, some cells are in early clinical studies, and some have great promise based on animal studies (summarized in Table 3.6). To date most of the reported benefits have come from HSC and HSC-related products. It appears to us that the next cell type that may prove of utility is the MSC where several companies and investigators have reported utility either as an adjuvant to HSC to improve homing, as a source of cells for replacing defective cells in osteogenesis imperfecta, or as a source of trophic molecules in a variety of injuries in a variety of tissues. NSCs and progenitor cells are being explored for use in lysosomal storage disorders and treatment of PD, spinal cord injury, and stroke. Stem Cell, Inc. and Geron are two companies with submitted INDs. Unfortunately, the promise of these preliminary results and the relative ease with which one can perform some of these experiments have led to a proliferation of offshore clinics that purport to use stem cells to treat any or all diseases. In our opinion, these clinics have little to recommend to the scientific community, as they remain
38
3.
Stem and Precursor Cells for Transplant Therapy TABLE 3.6 Current clinical trials of cell therapy.
Cell Type
Candidate Diseases
Clinical Trial Performed
Bone marrow stem cells
Heart failure Severe long bone nonunion fractures Acute lymphocytic leukemia Neoplasm metastasis renal cell carcinoma Metastatic or recurrent kidney cancer Recurrent testicular cancer Disorders of heart muscle Cornea disease Severe stress urinary incontinence Severe systemic sclerosis
Texas Heart Institute Aastrom Biosciences, Inc. Various places
Hematopoietic stem cells
Thigh muscle cells Cornea cells Muscle stem cell from patient arm T-cell depleted autologous peripheral stem cells Adult neural stem cells Chondrocyte cells Macrophages isolated from the patient’s own blood
Parkinson’s disease
Cedars-Sinai Medical Center, Los Angeles, CA Tigenix, Inc., Belgium Proneuron, Inc.
Damaged knee joint Spinal cord injury
unwilling to share their results, conduct appropriate double-blind trials, or subject their data to peer review. Although we do not deny that some people may obtain some benefit, we would remind all readers that purported magical remedies have been available throughout recorded history. Many never survived scientific scrutiny, and in some cases were shown to be harmful. Some that showed benefit, however, were co-opted by the scientific establishment, and those then could be improved upon, standardized, and used as a base for a further round of improvement or modification. It is this scientific method that is crucial to progress and widespread applicability, and any unwillingness to subject oneself to this scrutiny should raise a red flag of caution. Scientists themselves have not been immune to the hype, and many claims have been made about the “magical” properties of these cells — such as how they can identify sites of injury, steer themselves to that site, recognize the type of damage that exists, and begin to respond in a tissue- and site-specific manner. These claims have led to passionate counterclaims and discord within the community. We, however, believe that success for this field will come in measured paces following accepted scientific protocols and performing rigorous peer-reviewed experiments with no unseemly haste to rush to the clinic. The phrase “hasten slowly” seems appropriate here. Efficiency in experimental design and care in performing controls will reduce the number of times
Mount Sinai Hospital Osaka University Medical University of Innsbruck, Austria UPMC Cancer Centers
one rushes up a promising blind alley, and will allow one to achieve success quicker than leaping at every potentially exciting news item. There will be failures, but we will learn from them and we believe there is a high likelihood of success.
39
REFERENCES 1. Alexanian, A. R., Nornes, H. O. Proliferation and regeneration of retrogradely labeled adult rat corticospinal neurons in culture. Exp Neurol 170:277–282; 2001. 2. Auerbach, W., Dunmore, J. H., Fairchild-Huntress, V., Fang, Q., Auerbach, A. B., Huszar, D., Joyner, A. L. Establishment and chimera analysis of 129/SvEv- and C57BL/6-derived mouse embryonic stem cell lines. Biotechniques 29:1024–1028, 1030, 1032; 2000. 3. Bakshi, A., Hunter, C., Swanger, S., Lepore, A., Fischer, I. Minimally invasive delivery of stem cells for spinal cord injury: Advantages of the lumbar puncture technique. J Neurosurg Spine 1:330–337; 2004. 4. Begley, D. J. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol Ther 104:29–45; 2004. 5. Blakemore, W. F., Gilson, J. M., Crang, A. J. Transplanted glial cells migrate over a greater distance and remyelinate demyelinated lesions more rapidly than endogenous remyelinating cells. J Neurosci Res 61:288–294; 2000. 6. Brazel, C. Y., Rao, M. S. Aging and neuronal replacement. Ageing Res Rev 3:465–483; 2004.
Jingli Cai and Mahendra Rao 7. Brewer, G. J. Regeneration and proliferation of embryonic and adult rat hippocampal neurons in culture. Exp Neurol 159:237–247; 1999. 8. Burnstein, R. M., Foltynie, T., He, X., Menon, D. K., Svendsen, C. N., Caldwell, M. A. Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinson’s disease. Int J Biochem Cell Biol 36:702–713; 2004. 9. Cai, J., Limke, T. L., Ginis, I., Rao, M. S. Identifying and tracking neural stem cells. Blood Cells Mol Dis 31:18–27; 2003. 10. Cai, J., Rao, M. S. Stem cell and precursor cell therapy. Neuromolecular Med 2:233–249; 2002. 11. Carpenter, M. K., Inokuma, M. S., Denham, J., Mujtaba, T., Chiu, C. P., Rao, M. S. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol 172:383–397; 2001. 12. Carpenter, M. K., Rosler, E. S., Fisk, G. J., Brandenberger, R., Ares, X., Miura, T., Lucero, M., Rao, M. S. Properties of four human embryonic stem cell lines maintained in a feeder-free culture system. Dev Dyn 229:243–258; 2004. 13. Chanas-Sacre, G., Rogister, B., Moonen, G., Leprince, P. Radial glia phenotype: Origin, regulation, and transdifferentiation. J Neurosci Res 61:357–363; 2000. 14. Chen, J., Magavi, S. S., Macklis, J. D. Neurogenesis of corticospinal motor neurons extending spinal projections in adult mice. Proc Natl Acad Sci USA 101:16357–16362; 2004. 15. Chiu, A. Y., Rao, M. S. (eds): Human embryonic stem cells. Totowa, NJ, Humana Press, 2003. 16. Chopp, M., Li, Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 1:92–100; 2002. 17. Clarkson, E. D. Fetal tissue transplantation for patients with Parkinson’s disease: A database of published clinical results. Drugs Aging 18:773–785; 2001. 18. Cogle, C. R., Yachnis, A. T., Laywell, E. D., Zander, D. S., Wingard, J. R., Steindler, D. A., Scott, E. W. Bone marrow transdifferentiation in brain after transplantation: A retrospective study. Lancet 363:1432–1437; 2004. 19. Daley, G. Q., Goodell, M. A., Snyder, E. Y. Realistic prospects for stem cell therapeutics. Hematology (Am Soc Hematol Educ Program) 398–418; 2003. 20. Duran, C., Talley, P. J., Walsh, J., Pigott, C., Morton, I. E., Andrews, P. W. Hybrids of pluripotent and nullipotent human embryonal carcinoma cells: Partial retention of a pluripotent phenotype. Int J Cancer 93:324–332; 2001. 21. Eichenbaum, H., Fortin, N. J. Bridging the gap between brain and behavior: Cognitive and neural mechanisms of episodic memory. J Exp Anal Behav 84(3):619–29; 2005 Nov. 22. Emsley, J. G., Mitchell, B. D., Kempermann, G., Macklis, J. D. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog Neurobiol 75:321–341; 2005. 23. Eto, Y., Ohashi, T. Novel treatment for neuronopathic lysosomal storage diseases: Cell therapy/gene therapy. Curr Mol Med 2:83–89; 2002.
40
24. Evans, J., Sumners, C., Moore, J., Huentelman, M. J., Deng, J., Gelband, C. H., Shaw, G. Characterization of mitotic neurons derived from adult rat hypothalamus and brain stem. J Neurophysiol 87:1076–1085; 2002. 25. Eyding, D., Macklis, J. D., Neubacher, U., Funke, K., Worgotter, F. Selective elimination of corticogeniculate feedback abolishes the electroencephalogram dependence of primary visual cortical receptive fields and reduces their spatial specificity. J Neurosci 23:7021–7033; 2003. 26. Fischman, A. J. Role of [18F]-dopa-PET imaging in assessing movement disorders. Radiol Clin North Am 43:93–106; 2005. 27. Fishel, S. B., Edwards, R. G., Evans, C. J. Human chorionic gonadotropin secreted by preimplantation embryos cultured in vitro. Science 223:816–818; 1984. 28. Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W. Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., Eidelberg, D., Fahn, S. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 344:710–719; 2001. 29. Gage, F. H., Coates, P. W., Palmer, T. D., Kuhn, H. G., Fisher, L. J., Suhonen, J. O., Peterson, D. A., Suhr, S. T., Ray, J. Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain. Proc Natl Acad Sci USA 92:11879–11883; 1995. 30. Ginis, I., Rao, M. S. Toward cell replacement therapy: Promises and caveats. Exp Neurol 184:61–77; 2003. 31. Goldman, J. E. What are the characteristics of cycling cells in the adult central nervous system? J Cell Biochem 88:20–23; 2003. 32. Greene, P. E., Fahn, S. Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. Neurosurg Focus 13:e3; 2002. 33. Haas, S., Weidner, N., Winkler, J. Adult stem cell therapy in stroke. Curr Opin Neurol 18:59–64; 2005. 34. Han, S. S., Kang, D. Y., Mujtaba, T., Rao, M. S., Fischer, I. Grafted lineage-restricted precursors differentiate exclusively into neurons in the adult spinal cord. Exp Neurol 177:360–375; 2002. 35. Han, S. S., Liu, Y., Tyler-Polsz, C., Rao, M. S., Fischer, I. Transplantation of glial-restricted precursor cells into the adult spinal cord: Survival, glial-specific differentiation, and preferential migration in white matter. Glia 45:1–16; 2004. 36. Hartfuss, E., Galli, R., Heins, N., Gotz, M. Characterization of CNS precursor subtypes and radial glia. Dev Biol 229:15–30; 2001. 37. Hauser, R. A., Sandberg, P. R., Freeman, T. B., Stoessl, A. J. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology 58:1704; author reply 1704; 2002. 38. Heike, T., Nakahata, T. Stem cell plasticity in the hematopoietic system. Int J Hematol 79:7–14; 2004. 39. Hennessy, B., Korbling, M., Estrov, Z. Circulating stem cells and tissue repair. Panminerva Med 46:1–11; 2004. 40. Hermann, A., Gerlach, M., Schwarz, J., Storch, A. Neurorestoration in Parkinson’s disease by cell replacement and
3.
41. 42.
43.
44.
45.
46.
47. 48.
49.
50.
51.
52.
53.
Stem and Precursor Cells for Transplant Therapy
endogenous regeneration. Expert Opin Biol Ther 4:131–143; 2004. Herzog, E. L., Chai, L., Krause, D. S. Plasticity of marrowderived stem cells. Blood 102:3483–3493; 2003. Hill, C. E., Proschel, C., Noble, M., Mayer-Proschel, M., Gensel, J. C., Beattie, M. S., Bresnahan, J. C. Acute transplantation of glial-restricted precursor cells into spinal cord contusion injuries: Survival, differentiation, and effects on lesion environment and axonal regeneration. Exp Neurol 190:289–310; 2004. Hitoshi, S., Tropepe, V., Ekker, M., van der Kooy, D. Neural stem cell lineages are regionally specified, but not committed, within distinct compartments of the developing brain. Development 129:233–244; 2002. Hofstetter, C. P., Holmstrom, N. A., Lilja, J. A., Schweinhardt, P., Hao, J., Spenger, C., Wiesenfeld-Hallin, Z., Kurpad, S. N., Frisen, J., Olson, L. Allodynia limits the usefulness of intraspinal neural stem cell grafts: Directed differentiation improves outcome. Nat Neurosci 2005. Horner, P. J., Palmer, T. D. New roles for astrocytes: The nightlife of an astrocyte. La vida loca! Trends Neurosci 26:597–603; 2003. Hwang, W. S., Roh, S. I., Lee, B. C., Kang, S. K., Kwon, D. K., Kim, S., Kim, S. J., Park, S. W., Kwon, H. S., Lee, C. K., Lee, J. B., Kim, J. M., Ahn, C., Paek, S. H., Chang, S. S., Koo, J. J., Yoon, H. S., Hwang, J. H., Hwang, Y. Y., Park, Y. S., Oh, S. K., Kim, H. S., Park, J. H., Moon, S. Y., Schatten, G. Patient-specific embryonic stem cells derived from human SCNT blastocysts. Science 2005. Jacobson, M., Rao, M. S. Developmental neurobiology, 4th ed. New York, NY, Plenum Publishing Corporation, 2005. Jain, M., Armstrong, R. J., Tyers, P., Barker, R. A., Rosser, A. E. GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro. Exp Neurol 182:113–123; 2003. Kawaguchi, J., Mee, P. J., Smith, A. G. Osteogenic and chondrogenic differentiation of embryonic stem cells in response to specific growth factors. Bone 36:758–769; 2005. Keirstead, H. S., Ben-Hur, T., Rogister, B., O’Leary, M. T., Dubois-Dalcq, M., Blakemore, W. F. Polysialylated neural cell adhesion molecule-positive CNS precursors generate both oligodendrocytes and Schwann cells to remyelinate the CNS after transplantation. J Neurosci 19:7529–7536; 1999. Kondziolka, D., Wechsler, L., Gebel, J., DeCesare, S., Elder, E., Meltzer, C. C. Neuronal transplantation for motor stroke: From the laboratory to the clinic. Phys Med Rehabil Clin N Am 14:S153–160, xi; 2003. Kondziolka, D., Wechsler, L., Goldstein, S., Meltzer, C., Thulborn, K. R., Gebel, J., Jannetta, P., DeCesare, S., Elder, E. M., McGrogan, M., Reitman, M. A., Bynum, L. Transplantation of cultured human neuronal cells for patients with stroke. Neurology 55:565–569; 2000. Laywell, E. D., Rakic, P., Kukekov, V. G., Holland, E. C., Steindler, D. A. Identification of a multipotent astrocytic stem
41
54. 55.
56. 57. 58.
59.
60. 61.
62. 63.
64.
65.
66.
67.
68.
cell in the immature and adult mouse brain. Proc Natl Acad Sci USA 97:13883–13888; 2000. Leenders, K. L. Neuroimaging methods applied in Parkinson’s disease. J Neurol 251 Suppl 6:VI/7–12; 2004. Lepore, A. C., Han, S. S., Tyler-polsz, C. J., Cai, J., Rao, M. S., Fischer, I. Differential fate of multipotent and lineage-restricted neural precursors following transplantation into the adult CNS. Neuron Glia Biology 1–14; 2004. Liu, Y., Rao, M. S. Transdifferentiation: Fact or artifact. J Cell Biochem 88:29–40; 2003. Liu, Y., Rao, M. S. Glial progenitors in the CNS and possible lineage relationships among them. Biol Cell 96:279–290; 2004. Mitalipova, M., Calhoun, J., Shin, S., Wininger, D., Schulz, T., Noggle, S., Venable, A., Lyons, I., Robins, A., Stice, S. Human embryonic stem cell lines derived from discarded embryos. Stem Cells 21:521–526; 2003. Moasser, M. M., Reuter, V. E., Dmitrovsky, E. Overexpression of the retinoic acid receptor gamma directly induces terminal differentiation of human embryonal carcinoma cells. Oncogene 10:1537–1543; 1995. Morshead, C. M., van der Kooy, D. A new “spin” on neural stem cells? Curr Opin Neurobiol 11:59–65; 2001. Mostert, M. M., van de Pol, M., van Echten, J., Olde Weghuis, D., Geurts van Kessel, A., Oosterhuis, J. W., Looijenga, L. H. Fluorescence in situ hybridization-based approaches for detection of 12p overrepresentation, in particular i(12p), in cell lines of human testicular germ cell tumors of adults. Cancer Genet Cytogenet 87:95–102; 1996. Muraro, P. A., Cassiani-Ingoni, R., Martin, R. Using stem cells in multiple sclerosis therapies. Cytotherapy 6:615–620; 2004. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., Roder, J. C. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci USA 90:8424–8428; 1993. Nelson, P. T., Kondziolka, D., Wechsler, L., Goldstein, S., Gebel, J., DeCesare, S., Elder, E. M., Zhang, P. J., Jacobs, A., McGrogan, M., Lee, V. M., Trojanowski, J. Q. Clonal human (hNT) neuron grafts for stroke therapy: Neuropathology in a patient 27 months after implantation. Am J Pathol 160:1201–1206; 2002. Neuhuber, B., Timothy Himes, B., Shumsky, J. S., Gallo, G., Fischer, I. Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations. Brain Res 1035:73–85; 2005. Newman, M. B., Misiuta, I., Willing, A. E., Zigova, T., Karl, R. C., Borlongan, C. V., Sanberg, P. R. Tumorigenicity issues of embryonic carcinoma-derived stem cells: Relevance to surgical trials using NT2 and hNT neural cells. Stem Cells Dev 14:29–43; 2005. Nishiyama, A., Watanabe, M., Yang, Z., Bu, J. Identity, distribution, and development of polydendrocytes: NG2-expressing glial cells. J Neurocytol 31:437–455; 2002. Nunes, M. C., Roy, N. S., Keyoung, H. M., Goodman, R. R., McKhann, G., II, Jiang, L., Kang, J., Nedergaard, M.,
Jingli Cai and Mahendra Rao
69.
70.
71.
72. 73.
74. 75.
76.
77. 78. 79.
80.
81.
82.
Goldman, S. A. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 9:439–447; 2003. Ogawa, Y., Sawamoto, K., Miyata, T., Miyao, S., Watanabe, M., Nakamura, M., Bregman, B. S., Koike, M., Uchiyama, Y., Toyama, Y., Okano, H. Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. J Neurosci Res 69:925–933; 2002. Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., Freeman, T. B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 54:403–414; 2003. Park, C. H., Minn, Y. K., Lee, J. Y., Choi, D. H., Chang, M. Y., Shim, J. W., Ko, J. Y., Koh, H. C., Kang, M. J., Kang, J. S., Rhie, D. J., Lee, Y. S., Son, H., Moon, S. Y., Kim, K. S., Lee, S. H. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem 92:1265–1276; 2005. Pera, M. F. Human pluripotent stem cells: A progress report. Curr Opin Genet Dev 11:595–599; 2001. Perrier, A. L., Tabar, V., Barberi, T., Rubio, M. E., Bruses, J., Topf, N., Harrison, N. L., Studer, L. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA. 101:12543–12548; 2004. Pevny, L., Rao, M. S. The stem-cell menagerie. Trends Neurosci 26:351–359; 2003. Pluchino, S., Quattrini, A., Brambilla, E., Gritti, A., Salani, G., Dina, G., Galli, R., Del Carro, U., Amadio, S., Bergami, A., Furlan, R., Comi, G., Vescovi, A. L., Martino, G. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422:688–694; 2003. Pomp, O., Brokhman, I., Ben-Dor, I., Reubinoff, B. E., Goldstein, R. S. Generation of peripheral sensory and sympathetic neurons and neural crest cells from human embryonic stem cells. Stem Cells 2005. Rakic, P. Elusive radial glial cells: Historical and evolutionary perspective. Glia 43:19–32; 2003. Rao, M. S. (ed). Neural development and stem cells, 2nd ed. Totowa, NJ, Humana Press, 2005. Rao, M. S., Noble, M., Mayer-Proschel, M. A tripotential glial precursor cell is present in the developing spinal cord. Proc Natl Acad Sci USA 95:3996–4001; 1998. Reubinoff, B. E., Itsykson, P., Turetsky, T., Pera, M. F., Reinhartz, E., Itzik, A., Ben-Hur, T. Neural progenitors from human embryonic stem cells. Nat Biotechnol 19:1134–1140; 2001. Rosler, E. S., Fisk, G. J., Ares, X., Irving, J., Miura, T., Rao, M. S., Carpenter, M. K. Long-term culture of human embryonic stem cells in feeder-free conditions. Dev Dyn 229:259–274; 2004. Schuldiner, M., Eiges, R., Eden, A., Yanuka, O., ItskovitzEldor, J., Goldstein, R. S., Benvenisty, N. Induced neuronal
42
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
differentiation of human embryonic stem cells. Brain Res 913:201–205; 2001. Schulz, T. C., Palmarini, G. M., Noggle, S. A., Weiler, D. A., Mitalipova, M. M., Condie, B. G. Directed neuronal differentiation of human embryonic stem cells. BMC Neurosci 4:27; 2003. Seaberg, R. M., Smukler, S. R., Kieffer, T. J., Enikolopov, G., Asghar, Z., Wheeler, M. B., Korbutt, G., van der Kooy, D. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat Biotechnol 22:1115–1124; 2004. Setoguchi, T., Nakashima, K., Takizawa, T., Yanagisawa, M., Ochiai, W., Okabe, M., Yone, K., Komiya, S., Taga, T. Treatment of spinal cord injury by transplantation of fetal neural precursor cells engineered to express BMP inhibitor. Exp Neurol 189:33–44; 2004. Snyder, E. Y., Daley, G. Q., Goodell, M. Taking stock and planning for the next decade: Realistic prospects for stem cell therapies for the nervous system. J Neurosci Res 76:157–168; 2004. Steindler, D. A., Laywell, E. D. Astrocytes as stem cells: Nomenclature, phenotype, and translation. Glia 43:62–69; 2003. Tao, H., Ma, D. D. Evidence for transdifferentiation of human bone marrow-derived stem cells: Recent progress and controversies. Pathology 35:6–13; 2003. Walder, S., Ferretti, P. Distinct neural precursors in the developing human spinal cord. Int J Dev Biol 48:671–674; 2004. Watanabe, K., Nakamura, M., Iwanami, A., Fujita, Y., Kanemura, Y., Toyama, Y., Okano, H. Comparison between fetal spinal-cord- and forebrain-derived neural stem/progenitor cells as a source of transplantation for spinal cord injury. Dev Neurosci 26:275–287; 2004. Wobus, A. M., Boheler, K. R. Embryonic stem cells: Prospects for developmental biology and cell therapy. Physiol Rev 85:635–678; 2005. Wu, P., Tarasenko, Y. I., Gu, Y., Huang, L. Y., Coggeshall, R. E., Yu, Y. Region-specific generation of cholinergic neurons from fetal human neural stem cells grafted in adult rat. Nat Neurosci 5:1271–1278; 2002. Zeng, X., Cai, J., Chen, J., Luo, Y., You, Z. B., Fotter, E., Wang, Y., Harvey, B., Miura, T., Backman, C., Chen, G. J., Rao, M. S., Freed, W. J. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22:925–940; 2004. Zhang, S. C., Wernig, M., Duncan, I. D., Brustle, O., Thomson, J. A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 19:1129–1133; 2001. Zhang, Z. G., Jiang, Q., Zhang, R., Zhang, L., Wang, L., Arniego, P., Ho, K. L., Chopp, M. Magnetic resonance imaging and neurosphere therapy of stroke in rat. Ann Neurol 53:259–263; 2003.
4 Creating Animals for Cell Xenotransplantation David White Robarts Research Institute, University of Western Ontario Siebens Drake Centre, London, Ontario, Canada
The rapid advances made in molecular biology over the last two decades have opened the door to a wide range of therapeutic options that would have seemed fanciful science fiction not so very long ago. Nowhere has this advance been more spectacular or more controversial than in the genetic engineering of animals. The possibility now exists that animals can be “created” for specific therapeutic or agricultural applications. Public antagonism to genetically modified (GM) crops in certain countries has made the agricultural industry wary of pursuing use of genetically modified livestock as a component of the food chain. However, the use of genetically modified animals used for therapeutic purposes is, for the most part, considered acceptable. This chapter addresses the challenges of engineering animals — specifically the pig — as a source of cells for cell therapy in patients.
The Development of Microinjection The publication in 1982 by Palmiter and Brinster [55] of their transgenic “supermouse” and its appearance on the front cover of Nature announced the arrival of the new field of genetic engineering in the most dramatic fashion. As a matter of record, these were not the first transgenic animals (created almost by accident) produced by this group [14]. There were four different laboratories [22, 34, 83] that in 1980 demonstrated almost simultaneously that DNA injected into a mouse oocyte would become incorporated into the mouse genome. Chronologically, Gordon and colleagues were first. However, the construct used was cDNA and so was not expressed. In 1981, Costantini and Lacy and Wagner et al. [22, 83] both produced transgenic mice whose genome contained foreign globin genes, although Cellular Transplantation: From Laboratory to Clinic
neither group was able to demonstrate convincingly that the gene was indeed producing the protein in an appropriate manner. At that time, Palmiter — who was doing research into metallothioneines (MT) — had constructed a plasmid consisting of the MT promoter and the thymidine kinase gene from the herpes simplex virus [56]. This plasmid was sent to Ralph Brinster, who injected it into mouse oocytes (and fertilized eggs) and who upon inducing the promoter by exposure to cadmium was able to demonstrate an increase in thymidine kinase [14]. Brinster then took some of the injected eggs and transferred them to pseudopregnant surrogate mothers, thereby producing mice with much increased levels of thymidine kinase compared to controls. Next, the gene was incorporated into the genome in multiple copies and inherited by the offspring in a simple Mendelian fashion. The expression of thymidine kinase varied considerably between offspring [13, 56]. Thus, the technique of creating transgenic technology was firmly established. Brinster and Palmiter wanted to use this technique to cure a genetic disease. The model they settled on was the “little” mouse that lacked growth hormone and hence did not grow. Thus, a plasmid was constructed using the MT promoter and rat growth hormone. However, the experiment had to be delayed due to the time needed to build up a colony of little mice. It was during this delay that Brinster injected the growth hormone construct into the fertilized oocytes of normal mice and created the supermouse [55].
Embryonic Stem Cells and Knockouts Microinjection of DNA into fertilized oocytes provided the proof of principle that genes may be transferred successfully between species and continue to function.
43
Copyright © 2007, Elsevier Inc. All rights of reproduction in any form reserved.
David White
However, the technique has many limitations. The procedure itself is highly skilled, success rates are low (typically between 1 and 7% of eggs injected become transgenic animals), and results are extremely hit or miss. The location within the genome where the foreign gene becomes integrated is totally random, and for most constructs expression of the product is dependent on the site of integration. Thus, it is often the case that many transgenic animals must be produced before a founder with sufficient levels of expression can be identified. In addition, although microinjection provides a valuable methodology for adding a gene to an animal’s genome it does not provide a technology for removing a gene (termed a knockout) or replacing one gene with another (termed a knock-in). This state of affairs was at least partially rectified by the development of embryonic stem (ES) cell technology for mice. It has long been known that if the cells from the blastocysts of two different strains of mice were mixed the resultant offspring were chimeras between these two individuals. Termed allophenes or tetraparentals (because the offspring had four parents), such mice were often used to study developmental biology, tolerance, and reproductive development [6, 35]. Although most such chimeras were made between mouse strains, the technology has been applied to crossspecies chimeras [30, 62]. In 1981, Evans and Kaufman derived from mouse embryo cell lines termed ES cells, which under stringent culture conditions were immortal although remaining genetically normal. When mixed with cells of a blastocyst, these cells also produced chimeric mice. More importantly, the genetics of these ES cells could be passed on in the germ line of the chimera to produce offspring carrying the pure genetics of the ES cell line used [29]. The next challenge was to develop a technique for performing homologous recombination in these cell lines. Homologous recombination uses matching DNA sequences flanking the gene of interest to replace one gene with another. Because the new gene can be constructed to be nonfunctional, such technology allows genes to be silenced or knocked out. In 1987, two groups [28, 78] separately reported that they had successfully targeted genes in ES cells, with the latter describing new selection techniques that greatly improved the efficiency of homologous recombination. Production of transgenic mice using ES cell technology has produced many startling biological discoveries and has destroyed many cherished beliefs. However, despite several reports of
the discovery of ES cells in other species to date this technique for generating transgenics can only be applied to mice.
Dolly the Sheep and Other Animals The failure to develop ES cell technology for any species other than mice has meant that creating transgenics in larger species has been restricted to microinjection and the chance inherent in that technology. Some years ago we created pigs transgenic for a human complement regulatory protein hDAF by microinjection [24]. In total, 79 different founder transgenic animals were produced. Approximately half of these produced mRNA, and these were bred for one generation to allow a total analysis of tissue expression of the transgene. Variation in expression levels was vast both between pigs and between different cell types within the pig [23]. This inability to predict expression was both expensive and time consuming. In addition, there was no practical way of knocking out any genes from the pig. The arrival of Dolly the sheep in 1996 completely changed the situation [89]. Although the technique used for producing Dolly is generally referred to as cloning, a more accurate term would be nuclear transfer (NT). The methodology of nuclear transfer is remarkably simple in principle. The genetics desired are established in a primary cell culture (typically a fibroblast). In the case of Dolly, these were mammary cells taken from the udder of a six-year-old ewe. The mammary cells were cultured for several days and then fused with a sheep oocyte, from which the nucleus had been removed by micromanipulation. The oocyte with its new nucleus was then implanted into a foster mother. After 277 attempts, Dolly was born. Dolly’s existence challenged one of the fundamental tenets of developmental biology. Most scientists had thought cell differentiation was irreversible. After all, even over a 90-year lifespan a hepatocyte remains a hepatocyte, a nerve cell a nerve cell. The production of a live lamb from a cell taken from the udder of a 6-year-old sheep demonstrated that differentiated cells are not immutable. At the time of original publication, it was thought that the most likely explanation was that the cells used could by chance have been a mammary stem cell. It is now known that nuclear transfer can be successfully achieved from many different types of differentiated cells and in several different species. The birth of Dolly sparked a global interest
44
4.
Creating Animals for Cell Xenotransplantation
in nuclear reprogramming of somatic cells and animal cloning. Nuclear transfer technology is now widely used to produce animals from somatic cells. In the last few years, nuclear transfer has been used in a number of different mammalian species and has resulted in live births of cattle [41], goats [4], pigs [57, 61], horses [32], cats [93], and dogs [45]. In that pluripotent ES cells in domestic animals have not yet been developed, the technology of animal cloning provides an alternative methodology for gene targeting in these animals. Genetargeted animal clones have been successfully produced in sheep [49] and pigs [59] by homologous recombination in fetal fibroblast cells followed by nuclear transfer.
Making Pigs The technology for genetically altering pigs is now in place. Although efficiencies remain low, the level of success is sufficient that lines of pigs can be created with extra genes added or genes knocked out. The question that remains unanswered is which genes could allow pigs to be designed to provide cells for therapeutic transplantation. To begin to address this question, a basic understanding of the immunology of xenotransplantation is needed. To date, all pigs have been genetically engineered with the specific aim of generating either kidneys or hearts for xenotransplantation. The value of such pigs as donors for cell therapy is slowly being addressed. Thus, it is important to focus on the rejection process involved in vascularized xenograft rejection and extrapolate only those data that are relevant to cell therapy. Hyperacute rejection causes the rapid loss of function of a vascularized graft. Complement activation, usually mediated by antibody binding, leads to platelet aggregation, vasoconstriction, and loss of vascular integrity. The cardinal histological signs of hyperacute rejection are interstitial hemorrhage, edema, focal ischemia, and thrombosis. Activation of the complement cascade is of central importance in hyperacute rejection. The complement system consists of a triggered enzyme cascade of more than twenty serum proteins and five cell surface proteins. The primary function of the system is protection against invasive microorganisms. This is achieved by complement components alone, by a lytic mechanism involving cascade to the membrane attack complex, or by the recruitment of nonspecific effector mechanisms
such as phagocyte cells. The system consists principally of two activation pathways (there is a third called the mannose binding pathway), a single terminal pathway, regulatory proteins, and complement receptors. The function of the activation pathways is to generate C3 convertases. The classical pathway consists of C1, C4, C2, and C3, and is activated by antigen-antibody complexes. C1 binds to the Fc region of an antibody, and catalyzes the proteolytic cleavage of C4 and C2, generating the classical pathway C3 convertase, C4b2a. The alternative pathway functions in the absence of antibody. There are two possible mechanisms of initiation of the alternative pathway. One is by the spontaneous hydrolysis of the intramolecular thioester bond of C3. This hydrolyzed C3 reacts with serum factors B and D and forms an initial C3 convertase (C3bBb), which is able to split multiple C3 molecules to C3b. The other mechanism is that the thioester bond of C3 is directly attacked by a hydroxyl group available at a surface, resulting in binding of a C3b-like C3 to the surface and generation of C3bBb. In solution, the C3bBb convertase is unstable and factor B is readily displaced by factor H, to form a complex that is inactivated further by factor I. Similarly, if C3b or C3b-like C3 binds to a host surface regulatory mechanisms prevent further cascade. Foreign unprotected surfaces are able to stabilize the C3bBb enzyme in its active form and protect the C3b from factor H. Because the product of the alternative pathway C3 convertase is itself a subunit of the enzyme, an amplification loop is generated. The pathways are also interactive (see Figure 4.1). The C3b generated by the classical pathway C3 convertase complexes with factor B. The complement system cascades further by the cleavage of C5. C3b achieves this by serving as an attachment site for C5. C5 attaches to C3b and assumes a conformation that renders it susceptible to cleavage by neighboring classical and alternative pathway C3 convertases. C5b generated by the cleavage of C5 may remain loosely bound to C3b. Sequential attachment of C6 and C7 to C5b forms a complex with a transient membrane binding site. The membrane-associated complex is then joined by C8, yielding C5b678. C8 directs the insertion of up to 18 molecules of C9 in the lipid bilayer, yielding the annular membrane attack complex (MAC) consisting of C5b678 and poly C9. C5b678 is able to contribute to ion and water flux across a membrane, but the cell lysis is predominantly caused by the poly-C9 complex.
45
David White Classical pathway
iC4b C4 + C2
C1 + antibody MCP
C4b C3 convertase C4b2a DAF
C3b
C3
C5-C9 (MAC)
DAF C3 convertase C3bBb C3b MCP Alternative C3 + B pathway iC3b Figure 4.1. Activation pathways of the complement cascade, showing the sites of action of MCP and DAF.
Regulators of Complement Activation (RCA) Complement activation triggers powerful effector mechanisms against which host cells must be protected. Regulatory proteins of the complement system provide a means of preventing lysis of the organism’s own cells (autologous lysis). These regulatory proteins may be classified into two categories: • •
Inhibitors that down-regulate activation of complement in the fluid phase Regulators that control complement activation on target cells
A range of proteins fall into the second category of regulators. These include the following proteins. • • • • • •
C1 inhibitor Decay accelerating factor (DAF, CD55) Membrane cofactor protein (MCP, CD46), factor H, complement receptor 1 (CR1, CD35) Complement receptor 2 (CD21) C4 binding protein (C4bp) CD59
All of these proteins are involved in down-regulating complement action on host tissue. C1 inhibitor acts at the initial stage of the complement cascade, inhibiting C1 activation. CD59 functions by inhibiting the assembly of the MAC. The final common pathway of both the alternative and the classical complement pathway is the production of C3b, controlling both the alternative and classical pathways. DAF, MCP, and the other RCA molecules act at this critical stage of C3 activation. There is a degree of species specificity in the action of complement regulators. Indeed, complement regulatory molecules help separate self from non-self. Thus, pig RCA is not active against human complement and human regulators and is only partially active in nonhuman primates. Atkinson and colleagues have discussed these concepts in detail [2].
Inhibition of Complement Activation in Xenotransplantation There are three different approaches to the regulation of complement activation for xenografting.
46
•
Systemic inhibition of complement activation by the administration of a soluble complement
4.
•
•
Creating Animals for Cell Xenotransplantation
inhibitor (e.g., sCR1). This approach has the disadvantage of being systemic in that it blocks all complement activation. Thus, although such an approach could be acceptable in the short term, in the long term it carries with it a significant increased risk of infections, particularly in the immunosuppressed individual. Removal of recipient naturally occurring antispecies antibody or modification of the graft to remove antigenic targets (the knock-out pig). This approach does not down-regulate antibodyindependent (alternative pathway) complement activation, and is not likely therefore to completely prevent complement-mediated rejection of xenografts [40]. The specific inhibition of complement activation by expression of human regulators of complement activity on grafted tissue. This allows normal complement-dependent immunity in the host while inhibiting both classical and alternative pathways of complement activation locally on the xenograft.
It is postulated that the transgenic expression of human regulators of complement activity (RCA) on the tissues of pigs should prevent human complement activation, thus overcoming perhaps the most formidable hurdle to graft survival in pig-to-human xenotransplantation. It has been demonstrated that transfection of DAF and MCP protects animal cells from human-complementinduced lysis. DAF was more effective than MCP, and DAF/MCP transfectants were no more effective than DAF transfectants [25, 88]. DAF was therefore selected as a molecule that could potentially inhibit human complement activation on pig cells. The production of transgenic pigs expressing the human DAF molecule was undertaken with the primary purpose of establishing whether this could combat hyperacute rejection of pig organs in primate recipients. However, its value in protecting islet cells has also been evaluated.
Pigs Transgenic for Complement Regulatory Proteins It has been known for many years that inhibition of complement activation would inhibit xenograft hyperacute rejection. It was a widely held belief that porcine complement regulatory proteins were unable to regulate the activation of primate complement [2, 25]. Recent studies [15, 39] have suggested that failure of the
pig to express porcine CD55 in an appropriate fashion may be more significant than species incompatibility in complement-mediated xenograft destruction. Curiously, porcine CD55 is structurally different from other CD55 analogues and is more effective at inhibiting human complement than pig complement [58]. This is clearly an area that requires much more study. Although complement is the predominant player in hyperacute rejection, its role in vascular rejection and the relative importance of antibody and complement in the xenograft rejection process is less clear. There can be no doubt that anti-pig antibodies either elicited or “naturally occurring” are involved in the vascular rejection process [66]. However, the evidence of their ability to damage the graft in the absence of complement is based on in vitro models [7]. It is clear from recent studies with organs from Gal knockout pigs that complement in the absence of antibody binding will not cause hyperacute rejection. The role of complement in acute vascular rejection remains to be resolved. Whereas Wang and colleagues [84] were able to demonstrate that a rat heart xenograft was not rejected by a B-cell knockout mouse, Johnson and colleagues [40] demonstrated that rabbit hearts were hyperacutely rejected by neonatal pigs in the complete absence of antibody. Neither model seems of much relevance for testing pig-to-human transplants. Genetically engineered nonhuman primates with knockouts for B-cells or C3 would be needed to resolve this issue. Whatever the relative importance of antibody and complement in the xenograft rejection process, there is overwhelming evidence that expression of human complement regulatory proteins on pig cells protects them from human complement. The credit for first demonstrating this goes to a rarely quoted publication by Oglesby and colleagues [54]. Confirmation of these findings followed rapidly both in vitro [16, 25, 85] and in vivo using transgenic mice [17, 92] followed by transgenic pigs [24]. These studies used animals expressing a single complement regulatory transgene CD55, CD46, or CD59. A recent study by Loveland and colleagues [46] documented in detail the benefits of expressing complement regulatory proteins on porcine xenografts. They demonstrated that normal pig kidneys transplanted into non-immunosuppressed adult baboons were hyperacutely rejected in a median of 3.5 h, whereas CD46 transgenic grafts harvested at approximately 24-hour intervals posttransplant remained essentially undamaged for up to 68 h. The issue of how these results might apply to cell therapies has not yet
47
David White
been addressed. However, there have been some studies on islet xenotransplantation that have sought to address this issue.
Islet Xenotransplantation Since the 1970s, it has been demonstrated repeatedly in experimental animal models that islet allotransplantation could successfully be used to reverse diabetes [5, 65]. This advance has prompted research into developing methods for the isolation of human islets, which in turn has led to human islet transplantation into the liver via the portal vein of immunosuppressed patients with kidney transplants [67, 69, 74, 86]. Initial promising results of insulin independence in these patients proved short-lived, however, as it became apparent that most patients reverted back to hyperglycemia. Indeed, there is a striking anomaly when islet allotransplantation is compared to pancreas transplantation. Approximately 60% of the pancreas recipients remain insulin independent 3 years posttransplant [76], compared to only 7% at one year for islet recipients [48, 87]. The reason for such a stark difference in success rates remains obscure considering that the histocompatibility barrier, the immunosuppressive reagents employed, and the underlying autoimmune disease are the same in both types of transplant. However, it should be emphasized that islet autotransplantation for the treatment of surgically induced diabetes restores insulin independence in only 50% of cases [53, 68]. Although this demonstrates the functional capacity of islet transplantation per se, it also illustrates the problems associated with islet separation technology and the importance of islet integrity and islet cell mass to the restoration of carbohydrate control. This bleak picture of islet transplantation has, however, been transformed by the development of the Edmonton protocol [72]. The success of this protocol has been attributed to a number of factors. These include avoiding “diabetogenic” drugs, the use of freshly prepared islets, not performing transplants in kidney transplant recipients, and repeat transplantation. Although the long-term (5-year) results of the Edmonton protocol as measured by insulin independence on a relatively small number of patients have been disappointing, the overall benefit to restoration of carbohydrate control to the type 1 diabetic has been demonstrated by these allotransplants. However, as a potential cellular therapy for type 1 diabetes islet allotransplantation is never going to be a realistic option. There are approximately
8,000 type 1 diabetic patients per million people. Current organ donation rates are less than 30 per million of population. Given that the Edmonton protocol requires the islet yield from two and sometimes three pancreases, allotransplantation can at best treat 0.2% of the patient population in one year. Thus, an unlimited source of glucose-responsive cells is required as an essential component of the treatment of diabetes by cell transplantation. One such potential source could be appropriately genetically engineered pigs. Professor Carl Groth and colleagues have made a number of novel observations on the immune response elicited by adult pig islets when placed in contact with human (in vitro) or primate (in vivo) blood. Their insights have shed light on how to modify these pigs to provide islets suitable for transplantation into humans. It was believed at the outset of this study that unlike organ xenotransplants islet xenotransplants do not undergo hyperacute rejection [37]. The aim of the research was to establish if complement activation was in any way involved in the rejection of islet xenografts and if the use of islets from pigs transgenic for the human complement regulator hDAF described previously [24, 43] would benefit islet xenograft survival. In vitro analysis was performed using a loop of heparin-bonded PVC tube on a rocking device [50]. The tube contained 7 mls of whole human blood. When 5,000 porcine islets were introduced into these loops, they rapidly induced a cascade of undesirable events. These can be summarized briefly as induction of the clotting cascade with loss of platelets and WBC, activation of complement, and release of insulin (100,000 pmol/L), indicating islet cell death. This reaction has many of the pathological features of hyperacute rejection. Disappointingly, when islets from hDAF transgenic pigs whose organs were resistant to hyperacute rejection were introduced into these “loops” no difference was observed in the responses compared with that seen with nontransgenic islets. A FACS analysis of the islets from these transgenic pigs subsequently revealed that the transgene was not expressed on these islets [9]. An unexpected finding associated with this FACS analysis was that human islets (originally used as controls for the digestion process) also failed to express hDAF. Human islets expressed human CD59 well, but human MCP (CD46) was poorly expressed. In contrast, porcine islets expressed both porcine CD59 and porcine MCP at high levels (no reagent to detect porcine DAF was available). The expression levels of the major
48
4.
Creating Animals for Cell Xenotransplantation
xenogeneic epitope Gal were low or undetectable on API, whereas significant levels of Gal were present on fetal islet cells. Porcine and human endothelial cells subjected to the same digestion protocol as the islets expressed appropriate levels of DAF, MCP, and CD59. The observation that human islets do not express hDAF stimulated Groth and colleagues [10, 11] to introduce human islets into the loop with ABO-compatible human blood taken from healthy (i.e., not diabetic) volunteers. These human islets induced responses similar to those seen with adult pig islets. The clotting cascade was activated, platelets and white cells were lost, complement was activated, and insulin was released. In these experiments, however, the amount of insulin released was significantly less (33,600 pmols/l) than that seen with the pig islets. The majority of this insulin release occurred during the first 10 minutes of perifusion and could not be accounted for by the levels of glucose in the blood. In all of these in vitro experiments, both with human and porcine islets, the relationship between the observed events remains unclear. For example, does the complement activation initiate the clotting cascade or vice versa? Is complement activation directly responsible for the destruction of islets or are the released proinflammatory products (C3a and C5a) activating granulocytes and monocytes that subsequently damage the islets. In vivo studies were undertaken by transplanting adult pig islets intraportally into cynomolgus monkeys. Two groups of monkeys (n = 4 per group) were transplanted with 20,000 IE/kg API. One group had been pretreated with sCR1 to inhibit complement activation. Levels of
insulin in the blood were then monitored over the next hour. The results (see Figure 4.2) show that there is a significant insulin release (interpreted as a surrogate for islet destruction) in the untreated group. This insulin release is greatly reduced when complement activation is inhibited [50]. All of these data taken together strongly support the contention that adult pig islets exposed to human or primate blood suffer significant immediate posttransplant damage. This conclusion is supported by the studies of Contreras and colleagues [20, 21] using rhesus monkey serum and by Rayat et al. [64] using human serum, both of whom reported similar porcine islet cell destruction. In contrast, Mirenda and colleagues [51, 52] failed to achieve islet cell lysis when exposing pig islets to human serum that was diluted 50%. This suggests that destruction of porcine islets is highly concentration dependent (though of what is not known). It is also unclear as to what percentage of islets is rendered nonfunctional by this humorally mediated damage. Furthermore, if pig islets are damaged by humoral factors in primate and human serum why do they survive when transplanted into nude diabetic mice [26]? There are at least three possible explanations for this: (1) nude mice have inadequate complement activity [71], (2) antibody critical to the destruction of the islets is T-cell dependent [82], or (3) the site of transplantation (in this case, under the kidney capsule) confers some protection to the pig islets. In support of this last hypothesis, Brandhorst and colleagues [12] demonstrated that pig islet transplanted under the kidney capsule of nude diabetic rats could maintain reasonable carbohydrate control while
Insulin (pmol/L)
Islets (n = 4)
1800 1600 1400 1200 1000 800 600 400 200 0
Islets+TP10 (40 mg/kg i.v.; n = 4)
−10
0
10
20 30 Minutes
40
50
60
Figure 4.2. Intraportal transplantation of porcine islets into primates. Graph shows the effect of complement inhibition (TP 10 = sCR1) on posttransplant insulin levels [50].
49
David White Kidney capsule
500
Portal vein
Serum glucose (mg/dL)
450 400 350 300 250 200 150 100 50 0
2
4
6
8
10
12
14
16
Days posttransplant Figure 4.3. Adult porcine islet function in nude rats (intraportal versus subcapsular transplants). Adapted from [12].
transplantation via the portal vein to the liver resulted in failure (see Figure 4.3). These experiments give important pointers as to the ways in which pigs might be genetically engineered to reduce the immune responses described previously. The failure of the human transgene to be expressed on the islet b cells also highlights the importance of selecting the appropriate promoter when constructing animals specifically designed to provide therapeutic cells. At present, the only animals that have been genetically engineered with the specific aim of providing cells for xenotransplantation are tilapia (a fish) into which the human insulin gene has been introduced [60].
Clinical Islet Xenotransplantation Dr. Rafael Valdes at Hopital de Infantil de Mexico in Mexico City has performed a small controversial study of porcine to human islet transplantation in type 1 diabetic patients. Twelve patients with C-peptide negative type 1 diabetes were transplanted with neonatal pig islets (5,000/kg) and Sertoli cells (35 to 100/islet) derived from an SPF herd of pigs. The cells were inserted into neovascularized collagen tubes created by implanting a closed stainless steel mesh containing an inner Teflon stent subcutaneously 8 weeks prior to transplantation [80]. No immunosuppression was given. Of the 12 transplanted patients, 6 have functioning grafts as defined by reduction of exogenous insulin requirement HbA1c < 8% and production of porcine insulin
in response to IV glucose challenge. Biopsies of the grafts revealed the presence of insulin- and glucagonpositive cells, although the overall architecture of the islets was destroyed. Follow-up extends to more than 4 years, with two patients currently insulin independent. The presumption is that these cells survive in this subcutaneous environment because the Sertoli cells induce a T-cell deficit via Fas-Fas ligand interactions [8]. The ability of Sertoli cells to provide tropic and nutritive factors that stimulate germ cells and support islets in vitro [47, 75] must also be taken into account when interpreting the overall results of this study. However, it remains unclear how these islets can survive in the presence of both preexisting and elicited anti-pig antibody. It seems possible that the artificially created collagen chamber may provide a protective environment comparable to that of the kidney capsule in nude mice and rats. This chamber cannot, however, be considered an immunologically privileged site, nor can it be compared with encapsulation technology. Although the Sertoli cells may prevent T-cell-mediated rejection, there are clearly other factors that protect the islets from destruction by antibody and complement. There is a temptation to speculate that graft accommodation [1, 3] may be taking place. However, there is currently no evidence to support (or refute) this hypothesis. Curiously, in all of the reported studies in the literature involving the transplantation of porcine islets under the kidney capsule of nude mice not a single investigator has published an analysis of the antibody responses produced by these animals. Given the recent elegant studies of
50
4.
Creating Animals for Cell Xenotransplantation
de Vriens and colleagues [81, 82] on accommodation of hamster hearts in nude rats, this is clearly an area of research that needs to be further explored. Simeonovic and colleagues [73] published a detailed analysis of such antibody responses in immunocompetent mice and reported that the capacity of such hyperimmune sera to induce rejection of pig proislets (recently transplanted into CD4 T-cell-depleted recipients) after adoptive transfer was highly dependent on levels of IgG3. In contrast, Gourlay and colleagues [36] reported that adoptive transfer of hyperimmune anti-pig antibodies into nude mice bearing subcapsular porcine islets for more than 70 days failed to induce islet destruction. Transfer of immune T-cells did induce rejection, whereas naïve T-cells had no effect. In neither of these studies did the authors measure the complement competence in the recipients. These studies suggest that once revascularized islet xenotransplants become relatively insensitive to antibody destruction, particularly T-independent antibody. A detailed analysis of the elements involved in providing protection to these islets could well provide evidence for genetically engineering pigs that would give better survival in this interesting new approach to cell therapy.
Clinical Neural Xenotransplantation Another potential area for developing genetically engineered pigs is the supply of fetal neurons for the treatment of Parkinson’s disease and Huntington’s disease. The observation that human fetal neurons are able to survive and function when allografted into the adult brain without the use of immunosuppressive drugs suggests that cellular therapy is a promising approach to achieve neuronal replacement for treatment of diseases of the adult central nervous system (CNS). The use of human fetal tissue is limited by ethical, infectious, regulatory, and practical concerns. Pigs are a reasonable alternative source of fetal neuronal tissue because of their brain size, large litters, and the extensive experience in rearing them in captivity under controlled conditions. Fink and colleagues [31] have reported preliminary clinical studies of porcine fetal neural cells grafted unilaterally into Parkinson’s disease patients. Clinical improvement of 19% was reported in 10 patients assessed 12 months after unilateral striatal transplantation of 12 million fetal porcine ventral mesencephalic cells. In a single autopsied patient, some porcine cells were detected 7 months after transplantation [27]. Twelve Huntington’s disease
patients showed no change in total functional capacity score 1 year after unilateral striatal placement of up to 24 million fetal porcine striatal cells. Xenotransplantation of fetal porcine neurons is a promising approach to delivery of healthy neurons to the CNS. However, minimizing rejection remains a significant challenge in which genetic engineering of the donor species could play an important part.
Other Transgenic Pigs Generated for Xenotransplantation There have been a number of other genetically engineered pig lines developed for xenotransplantation. Although these have been produced primarily with organ transplantation as the goal, their potential in cell therapy should not be neglected. A brief summary of the current status of these pigs is included here.
KNOCKOUT PIGS The antibody response induced by pigs in humans is predominantly against the Gal epitope. For this reason several groups [38, 42, 44, 59, 63, 77] have knocked out the galactosyl transferase gene (Gal-KO), which controls its expression. The presumption that this would prevent vascular rejection was by no means certain because aggressive vascular rejection will occur between Gal-positive donors and recipients such as hamster to rat and pig to dog. There is a unanimous consensus that this manipulation prevents hyperacute rejection [19, 43, 91] even in porcine lungs [70]. This observation eliminates the concept that in pigto-primate transplantation hyperacute rejection could be induced by activation of the alternative pathway of complement. The most complete analysis of the effect of this knockout on graft survival has come from the Sachs group. Hearts from Gal-KO pigs transplanted heterotopically into baboons using an antiCD154 monoclonal antibody-based immunosuppressive regime regimen survived between 2 and 6 months, with a median of 78 days [43]. The predominant lesion associated with graft failure was a thrombotic microangiopathy, with resulting ischemic injury. Four baboons receiving either xeno-thymokidneys or vascularized thymic lobe plus kidney from Gal-KO pigs all survived longer than 2 months. Furthermore, none
51
David White
of these kidneys was lost to rejection [90, 91]. Studies by Chen et al. using Gal-KO kidneys have been less encouraging [19]. Recipients survived between 8 and 16 days, with 4 of 6 grafts failing due to severe acute humoral xenograft rejection. Circulating induced anti-non-Gal antibodies, which mediated strong complement-dependent cytotoxicity against GalT-KO porcine target cells, were markedly elevated at rejection. The immunosuppression used in these studies was different from that of the Sachs group in that it was not based on an anti-CD154 monoclonal antibody regime, nor was a thymokidney technique used. With several groups just starting to test Gal-KO organs in vivo, and with the development of Gal-KO hCD55 transgenic pigs [77], there is obvious potential for the advancement of xenotransplantation toward the clinic.
CONTROL OF THROMBOSIS Microthrombi formation and fibrin deposition are universal pathological findings in the acute vascular rejection of a xenograft. Several of the studies reviewed here and elsewhere have also reported systemic coagulopathys in recipients of xenografts. These observations have started to focus attention on whether it is possible to genetically engineer pigs to be phenotypically less pro-coagulant. Although these studies are still in their infancy, two deserve special mention here. Ghanekar and colleagues [33] cloned the porcine equivalent of fibrinogen-like protein 2 (fgl2), which is an inducible prothrombinase that plays an important role in the pathogenesis of fibrin deposition during viral hepatitis. Studies of pig-to-baboon kidney xenografts undergoing AVR in vivo revealed induction of pfgl2 expression on graft vascular endothelial cells that could account for the thrombosis characteristic of this form of rejection. In support of this, hearts transplanted heterotopically from fgl2 knockout mice into Lewis rats were devoid of thrombosis upon rejection, whereas transplants from wild-type mice developed AVR with intravascular thrombosis. One awaits the arrival of a pfgl2 knockout pig with interest. Chen and colleagues [18] have produced transgenic mice that express membrane-tethered fusion proteins based on human tissue factor pathway inhibitor or hirudin. Heterotopic hearts transplanted into non-immunosuppressed Lewis rats survived 6.7 and 7 days, respectively, whereas wildtype controls survived only 2.8 days. When recipient rats were immunosuppressed with Cyclosporin A wild-type
hearts, the hearts were rejected in 3 days, whereas hearts from both transgenic mice survived for more than 100 days showing normal histology. It can only be a matter of time before the production of pigs bearing these transgenes.
Conclusions and Future Directions The development of nuclear transfer techniques in the pig has given an impetus to genetically engineering of this species for the purpose of providing organs and tissues for clinical transplantation. It would seem that the extent of modifications should be limited only by imagination. Indeed, the number of research teams producing transgenic pigs has increased, as has the variety of transgenes and knockout options that can be applied. These include complement regulatory strategies, epitope elimination by knockouts, control of thrombosis, and even somewhat curiously the addition of HLA-D molecules [79]. Xenograft survival times continue to improve in the exacting and expensive pig-to-baboon model. However, these have yet to consistently achieve results comparable to current allograft survival. This limitation poses a serious dilemma for the future development of xenografting. Short- to medium-term allograft results are so successful that until they can at least be approximated by xenografts the application of xenotransplantation in the clinic will be problematic. Perhaps the most promising avenue for moving xenotransplantation to the clinic is in the deployment of cell therapies. Both islet and neural xenotransplants from pigs to patients are in current clinical practice. Both offer the advantage that there is no appropriate supply of human cells as an alternative source either because of donor shortage or ethical inhibitions. Both techniques avoid the use of immunosuppressive drugs, and perhaps using cells from specifically engineered porcine donors could in both cases enhance the results achieved.
52
REFERENCES 1. Andres, G., Yamaguchi, N., Brett, J., Caldwell, P. R., Godman, G., Stern, D. Cellular mechanisms of adaptation of grafts to antibody. Transpl Immunol 4:1–17; 1996. 2. Atkinson, J. P., Oglesby, T. J., White, D., Adams, E. A., Liszewski, M. K. Separation of self from non-self in the complement system: A role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 86 Suppl 1:27–30; 1991.
4.
Creating Animals for Cell Xenotransplantation
3. Bach, F. H., Ferran, C., Hechenleitner, P., Mark, W., Koyamada, N., Miyatake, T., Winkler, H., Badrichani, A., Candinas, D., Hancock, W. W. Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment. Nat Med 3:196–204; 1997. 4. Baguisi, A., Behboodi, E., Melican, D. T., Pollock, J. S., Destrempes, M. M., Cammuso, C., Williams, J. L., Nims, S. D., Porter, C. A., Midura, P., Palacios, M. J., Ayres, S. L., Denniston, R. S., Hayes, M. L., Ziomek, C. A., Meade, H. M., Godke, R. A., Gavin, W. G., Overstrom, E. W., Echelard, Y. Production of goats by somatic cell nuclear transfer. Nat Biotechnol 17:456–461; 1999. 5. Ballinger, W. F., Lacy, P. E. Transplantation of intact pancreatic islets in rats. Surgery 72:175–186; 1972. 6. Barnes, R. D., Tuffrey, M. Tolerance in ovum fusion derived tetraparental mouse chimaeras. Adv Exp Med Biol 29:427–434; 1973. 7. Baumann, B. C., Forte, P., Hawley, R. J., Rieben, R., Schneider, M. K., Seebach, J. D. Lack of galactose-alpha1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 172:6460–6467; 2004. 8. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., Duke, R. C. A role for CD95 ligand in preventing graft rejection. Nature 377:630–632; 1995. 9. Bennet, W., Bjorkland, A., Sundberg, B., Brandhorst, D., Brendel, M. D., Richards, A., White, D. J., Nilsson, B., Groth, C. G., Korsgren, O. A comparison between human islets and islets isolated from normal and hDAF transgenic pigs. In: Isolated islets of Langerhans trigger an instant blood mediated inflammatory reaction. Ed by Bennet, W. Stockholm, Carolinska Institute, 2000. 10. Bennet, W., Groth, C. G., Larsson, R., Nilsson, B., Korsgren, O. Isolated human islets trigger an instant blood mediated inflammatory reaction: Implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 105:125–133; 2000. 11. Bennet, W., Sundberg, B., Groth, C. G., Brendel, M. D., Brandhorst, D., Brandhorst, H., Bretzel, R. G., Elgue, G., Larsson, R., Nilsson, B., Korsgren, O. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation? Diabetes 48:1907–1914; 1999. 12. Brandhorst, D., Brandhorst, H., Zwolinski, A., Nahidi, F., Bretzel, R. G. Prevention of early islet graft failure by selective inducible nitric oxide synthase inhibitors after pig to nude rat intraportal islet transplantation. Transplantation 71:179–184; 2001. 13. Brinster, R. L., Chen, H. Y., Trumbauer, M., Senear, A. W., Warren, R., Palmiter, R. D. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 27:223–231; 1981. 14. Brinster, R. L., Chen, H. Y., Warren, R., Sarthy, A., Palmiter, R. D. Regulation of metallothionein–thymidine
53
15.
16.
17.
18.
19.
20.
21.
22. 23.
24. 25.
26.
27.
kinase fusion plasmids injected into mouse eggs. Nature 296:39–42; 1982. Capey, S., van den Berg, C. W. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: Consequences for xenotransplantation. Xenotransplantation 12:217–226; 2005. Carrington, C. A., Richards, A. C., Cozzi, E., Langford, G., Yannoutsos, N., White, D. J. Expression of human DAF and MCP on pig endothelial cells protects from human complement. Transplant Proc 27:321–323; 1995. Cary, N., Moody, J., Yannoutsos, N., Wallwork, J., White, D. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: A potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 25:400–401; 1993. Chen, D., Weber, M., McVey, J. H., Kemball-Cook, G., Tuddenham, E. G., Lechler, R. I., Dorling, A. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 4:1958–1963; 2004. Chen, S. H., Chang, F. M., Tsai, Y. C., Huang, K. F., Lin, M. T. Resuscitation from experimental heatstroke by transplantation of human umbilical cord blood cells. Crit Care Med 33: 1377–1383; 2005. Contreras, J. L., Bilbao, G., Smyth, C., Eckhoff, D. E., Xiang, X. L., Jenkins, S., Cartner, S., Curiel, D. T., Thomas, F. T., Thomas, J. M. Gene transfer of the Bcl-2 gene confers cytoprotection to isolated adult porcine pancreatic islets exposed to xenoreactive antibodies and complement. Surgery 130:166–174; 2001. Contreras, J. L., Eckhoff, D. E., Cartner, S., Bilbao, G., Ricordi, C., Neville, D. M. Jr., Thomas, F. T., Thomas, J. M. Long-term functional islet mass and metabolic function after xenoislet transplantation in primates. Transplantation 69:195–201; 2000. Costantini, F., Lacy, E. Introduction of a rabbit beta-globin gene into the mouse germ line. Nature 294:92–94; 1981. Cozzi, E., Tucker, A. W., Langford, G. A., Pino-Chavez, G., Wright, L., O’Connell, M. J., Young, V. J., Lancaster, R., McLaughlin, M., Hunt, K., Bordin, M. C., White, D. J. Characterization of pigs transgenic for human decay-accelerating factor. Transplantation 64:1383–1392; 1997. Cozzi, E., White, D. J. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1:964–966; 1995. Dalmasso, A. P., Platt, J. L., Bach, F. H. Reaction of complement with endothelial cells in a model of xenotransplantation. Clin Exp Immunol 86 Suppl 1:31–35; 1991. Davalli, A. M., Ogawa, Y., Scaglia, L., Wu, Y. J., Hollister, J., Bonner-Weir, S., Weir, G. C. Function, mass, and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 44:104–111; 1995. Deacon, T., Schumacher, J., Dinsmore, J., Thomas, C., Palmer, P., Kott, S., Edge, A., Penney, D., Kassissieh, S., Dempsey, P., Isacson, O. Histological evidence of fetal pig
David White
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
neural cell survival after transplantation into a patient with Parkinson’s disease. Nat Med 3:350–353; 1997. Doetschman, T., Gregg, R. G., Maeda, N., Hooper, M. L., Melton, D. W., Thompson, S., Smithies, O. Targeted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 330:576–578; 1987. Evans, M. J., Kaufman, M. H. Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154–156; 1981. Fehilly, C. B., Willadsen, S. M., Tucker, E. M. Interspecific chimaerism between sheep and goat. Nature 307:634–636; 1984. Fink, J. S., Schumacher, J. M., Ellias, S. L., Palmer, E. P., Saint-Hilaire, M., Shannon, K., Penn, R., Starr, P., VanHorne, C., Kott, H. S., Dempsey, P. K., Fischman, A. J., Raineri, R., Manhart, C., Dinsmore, J., Isacson, O. Porcine xenografts in Parkinson’s disease and Huntington’s disease patients: Preliminary results. Cell Transplant 9:273–278; 2000. Galli, C., Lagutina, I., Crotti, G., Colleoni, S., Turini, P., Ponderato, N., Duchi, R., Lazzari, G. Pregnancy: A cloned horse born to its dam twin. Nature 424:635; 2003. Ghanekar, A., Mendicino, M., Liu, H., He, W., Liu, M., Zhong, R., Phillips, M. J., Levy, G. A., Grant, D. R. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 172:5693–5701; 2004. Gordon, J. W., Scangos, G. A., Plotkin, D. J., Barbosa, J. A., Ruddle, F. H. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci USA 77:7380–7384; 1980. Gornish, M., Webster, M. P., Wegmann, T. G. Chimaerism in the immune system of tetraparental mice. Nat New Biol 237:249–251; 1972. Gourlay, W. A., O’Neil, J. J., Hancock, W. W., Monaco, A. P., Maki, T. Resistance of established porcine islet xenografts to humoral rejection by hyperimmune sera. Transplantation 68:888–893; 1999. Gray, D. W., McShane, P., Grant, A., Morris, P. J. A method for isolation of islets of Langerhans from the human pancreas. Diabetes 33:1055–1061; 1984. Harrison, S., Boquest, A., Grupen, C., Faast, R., Guildolin, A., Giannakis, C., Crocker, L., McIlfatrick, S., Ashman, R., Wengle, J., Lyons, I., Tolstoshev, P., Cowan, P., Robins, A., O’Connell, P., D’Apice, A. J., Nottle, M. An efficient method for producing alpha(1,3)-galactosyltransferase gene knockout pigs. Cloning Stem Cells 6:327–331; 2004. Harrower, T. P., Richards, A., Cruz, G., Copeman, L., Dunnett, S. B., Barker, R. A. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue. Xenotransplantation 11:60–71; 2004. Johnston, P. S., Wang, M. W., Lim, S. M., Wright, L. J., White, D. J. Discordant xenograft rejection in an antibody-free model. Transplantation 54:573–576; 1992.
54
41. Kato, Y., Tani, T., Sotomaru, Y., Kurokawa, K., Kato, J., Doguchi, H., Yasue, H., Tsunoda, Y. Eight calves cloned from somatic cells of a single adult. Science 282:2095–2098; 1998. 42. Kolber-Simonds, D., Lai, L., Watt, S. R., Denaro, M., Arn, S., Augenstein, M. L., Betthauser, J., Carter, D. B., Greenstein, J. L., Hao, Y., Im, G. S., Liu, Z., Mell, G. D., Murphy, C. N., Park, K. W., Rieke, A., Ryan, D. J., Sachs, D. H., Forsberg, E. J., Prather, R. S., Hawley, R. J. Production of alpha1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci USA 101:7335–7340; 2004. 43. Kuwaki, K., Tseng, Y. L., Dor, F. J., Shimizu, A., Houser, S. L., Sanderson, T. M., Lancos, C. J., Prabharasuth, D. D., Cheng, J., Moran, K., Hisashi, Y., Mueller, N., Yamada, K., Greenstein, J. L., Hawley, R. J., Patience, C., Awwad, M., Fishman, J. A., Robson, S. C., Schuurman, H. J., Sachs, D. H., Cooper, D. K. Heart transplantation in baboons using alpha1,3galactosyltransferase gene-knockout pigs as donors: Initial experience. Nat Med 11:29–31; 2005. 44. Lai, L., Kolber-Simonds, D., Park, K. W., Cheong, H. T., Greenstein, J. L., Im, G. S., Samuel, M., Bonk, A., Rieke, A., Day, B. N., Murphy, C. N., Carter, D. B., Hawley, R. J., Prather, R. S. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295: 1089–1092; 2002. 45. Lee, B. C., Kim, M. K., Jang, G., Oh, H. J., Yuda, F., Kim, H. J., Shamim, M. H., Kim, J. J., Kang, S. K., Schatten, G., Hwang, W. S. Dogs cloned from adult somatic cells. Nature 436:641; 2005. 46. Loveland, B. E., Milland, J., Kyriakou, P., Thorley, B. R., Christiansen, D., Lanteri, M. B., Regensburg, M., Duffield, M., French, A. J., Williams, L., Baker, L., Brandon, M. R., Xing, P. X., Kahn, D., McKenzie, I. F. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons. Xenotransplantation 11:171–183; 2004. 47. Luca, G., Calvitti, M., Neri, L. M., Becchetti, E., Capitani, S., Basta, G., Angeletti, G., Fanelli, C., Brunetti, P., Calafiore, R. Sertoli cell-induced reversal of adult rat pancreatic islet betacells into fetal-like status: Potential implications for islet transplantation in type I diabetes mellitus. J Investig Med 48:441–448; 2000. 48. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., Bates, G. P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493–506; 1996. 49. McCreath, K. J., Howcroft, J., Campbell, K. H., Colman, A., Schnieke, A. E., Kind, A. J. Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature 405:1066–1069; 2000. 50. McGregor, C. G., Teotia, S. S., Byrne, G. W., Michaels, M. G., Risdahl, J. M., Schirmer, J. M., Tazelaar, H. D., Walker, R. C.,
4.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
Creating Animals for Cell Xenotransplantation
Logan, J. S. Cardiac xenotransplantation: Progress toward the clinic. Transplantation 78:1569–1575; 2004. Mirenda, V., Le Mauff, B., Boeffard, F., Cassard, A., Jugeau, N., Soulillou, J. P., Anegon, I. Intact pancreatic islet function despite humoral xenorecognition in the pig-to-monkey combination. Transplantation 66:1485–1495; 1998. Mirenda, V., Le Mauff, B., Cassard, A., Huvelin, J. M., Boeffard, F., Faivre, A., Soulillou, J. P., Anegon, I. Intact pig pancreatic islet function in the presence of human xenoreactive natural antibody binding and complement activation. Transplantation 63:1452–1462; 1997. Morrison, C. P., Wemyss-Holden, S. A., Dennison, A. R., Maddern, G. J. Islet yield remains a problem in islet autotransplantation. Arch Surg 137:80–83; 2002. Oglesby, T. J., White, D., Tedja, I., Liszewski, K., Wright, L., Van den Bogarde, J., Atkinson, J. P. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor. Trans Assoc Am Physicians 104:164–172; 1991. Palmiter, R. D., Brinster, R. L., Hammer, R. E., Trumbauer, M. E., Rosenfeld, M. G., Birnberg, N. C., Evans, R. M. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 300:611–615; 1982. Palmiter, R. D., Chen, H. Y., Brinster, R. L. Differential regulation of metallothionein-thymidine kinase fusion genes in transgenic mice and their offspring. Cell 29:701–710; 1982. Park, K. W., Cheong, H. T., Lai, L., Im, G. S., Kuhholzer, B., Bonk, A., Samuel, M., Rieke, A., Day, B. N., Murphy, C. N., Carter, D. B., Prather, R. S. Production of nuclear transferderived swine that express the enhanced green fluorescent protein. Anim Biotechnol 12:173–181; 2001. Perez de la Lastra, J. M., Harris, C. L., Hinchliffe, S. J., Holt, D. S., Rushmere, N. K., Morgan, B. P. Pigs express multiple forms of decay-accelerating factor (CD55), all of which contain only three short consensus repeats. J Immunol 165:2563–2573; 2000. Phelps, C. J., Koike, C., Vaught, T. D., Boone, J., Wells, K. D., Chen, S. H., Ball, S., Specht, S. M., Polejaeva, I. A., Monahan, J. A., Jobst, P. M., Sharma, S. B., Lamborn, A. E., Garst, A. S., Moore, M., Demetris, A. J., Rudert, W. A., Bottino, R., Bertera, S., Trucco, M., Starzl, T. E., Dai, Y., Ayares, D. L. Production of alpha 1,3-galactosyltransferasedeficient pigs. Science 299:411–414; 2003. Pohajdak, B., Mansour, M., Hrytsenko, O., Conlon, J. M., Dymond, L. C., Wright, J. R. Jr. Production of transgenic tilapia with Brockmann bodies secreting [desThrB30] human insulin. Transgenic Res 13:313–323; 2004. Polejaeva, I. A., Chen, S. H., Vaught, T. D., Page, R. L., Mullins, J., Ball, S., Dai, Y., Boone, J., Walker, S., Ayares, D. L., Colman, A., Campbell, K. H. Cloned pigs produced by nuclear transfer from adult somatic cells. Nature 407:86–90; 2000. Polzin, V. J., Anderson, D. L., Anderson, G. B., BonDurant, R. H., Butler, J. E., Pashen, R. L., Penedo, M. C.,
55
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
Rowe, J. D. Production of sheep-goat chimeras by inner cell mass transplantation. J Anim Sci 65:325–330; 1987. Ramsoondar, J. J., Machaty, Z., Costa, C., Williams, B. L., Fodor, W. L., Bondioli, K. R. Production of alpha 1,3galactosyltransferase-knockout cloned pigs expressing human alpha 1,2-fucosylosyltransferase. Biol Reprod 69:437–445; 2003. Rayat, G. R., Rajotte, R. V., Elliott, J. F., Korbutt, G. S. Expression of Gal alpha(1,3)gal on neonatal porcine islet beta-cells and susceptibility to human antibody/complement lysis. Diabetes 47:1406–1411; 1998. Reckard, C. R., Barker, C. F. Transplantation of isolated pancreatic islets across strong and weak histocompatibility barriers. Transplant Proc 5:761–763; 1973. Richards, A. C., Davies, H. F., McLaughlin, M. L., Copeman, L. S., Holmes, B. J., Dos Santos Cruz, G., Bycroft, S., Chavez, G., White, D. J., Schuurman, H. J., Cozzi, E. Serum anti-pig antibodies as potential indicators of acute humoral xenograft rejection in pig-to-cynomolgus monkey kidney transplantation. Transplantation 73:881–889; 2002. Ricordi, C., Tzakis, A. G., Carroll, P. B., Zeng, Y. J., Rilo, H. L., Alejandro, R., Shapiro, A., Fung, J. J., Demetris, A. J., Mintz, D. H., et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 53:407–414; 1992. Robertson, G. S., Dennison, A. R., Johnson, P. R., London, N. J. A review of pancreatic islet autotransplantation. Hepatogastroenterology 45:226–235; 1998. Scharp, D. W., Lacy, P. E., Santiago, J. V., McCullough, C. S., Weide, L. G., Boyle, P. J., Falqui, L., Marchetti, P., Ricordi, C., Gingerich, R. L., et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 51:76–85; 1991. Schroeder, C., Allan, J. S., Nguyen, B. N., Wu, G., Zhang, T., Azimzadeh, A. M., Madsen, J. C., Schuurman, H. J., Sachs, D. H., Pierson, R. N. III. Hyperacute rejection is attenuated in GalT knockout swine lungs perfused ex vivo with human blood. Transplant Proc 37:512–513; 2005. Schulz, G., Staffileno, L. K., Reisfeld, R. A., Dennert, G. Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells. J Exp Med 161: 1315–1325; 1985. Shapiro, A. M., Lakey, J. R., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., Rajotte, R. V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238; 2000 Jul 27. Simeonovic, C. J., Townsend, M. J., Wilson, J. D., McKenzie, K. U., Ramsay, A. J., Matthaei, K. I., Mann, D. A., Young, I. G. Eosinophils are not required for the rejection of neovascularized fetal pig proislet xenografts in mice. J Immunol 158: 2490–2499; 1997. Socci, C., Falqui, L., Davalli, A. M., Ricordi, C., Braghi, S., Bertuzzi, F., Maffi, P., Secchi, A., Gavazzi, F., Freschi, M., et al. Fresh human islet transplantation to replace pancreatic
David White
75.
76. 77.
78.
79.
80.
81.
82.
83.
84.
endocrine function in type 1 diabetic patients: Report of six cases. Acta Diabetol 28:151–157; 1991. Suarez-Pinzon, W., Korbutt, G. S., Power, R., Hooton, J., Rajotte, R. V., Rabinovitch, A. Testicular sertoli cells protect islet beta-cells from autoimmune destruction in NOD mice by a transforming growth factor-beta1-dependent mechanism. Diabetes 49:1810–1818; 2000. Sutherland, D. E. International Pancreas Registry. Minneapolis, University of Minnesota, 1997. Takahagi, Y., Fujimura, T., Miyagawa, S., Nagashima, H., Shigehisa, T., Shirakura, R., Murakami, H. Production of alpha 1,3-galactosyltransferase gene knockout pigs expressing both human decay-accelerating factor and N-acetylglucosaminyltransferase III. Mol Reprod Dev 71: 331–338; 2005. Thomas, K. R., Capecchi, M. R. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51:503–512; 1987. Tu, C. F., Hsieh, S. L., Lee, J. M., Yang, L. L., Sato, T., Lee, K. H., Weng, C. N., Mao, S. J., Tsuji, K., Lee, C. J. Successful generation of transgenic pigs for human decay-accelerating factor and human leucocyte antigen DQ. Transplant Proc 32:913–915; 2000. Valdes, R., Martin, S., Cravioto, A., Tenopala, J. Biological encapsulation as a new model for preservation of islets of Langerhans. Transplant Proc 30:481; 1998. Vriens, P. W., Pollard, J. D., Hoyt, G., Morris, R. E., Scheringa, M., Bouwman, E., Robbins, R. C. Hamster cardiac xenografts are protected against antibody mediated damage, early after transplantation to Lewis rats. Xenotransplantation 8:239–246; 2001. Vriens, P. W., Stoot, J. H., Hoyt, G., Scheringa, M., Bouwman, E., Robbins, R. C. Pre-transplant blood transfusion induces tolerance to hamster cardiac xenografts in athymic nude rats. Xenotransplantation 8:247–257; 2001. Wagner, T. E., Hoppe, P. C., Jollick, J. D., Scholl, D. R., Hodinka, R. L., Gault, J. B. Microinjection of a rabbit betaglobin gene into zygotes and its subsequent expression in adult mice and their offspring. Proc Natl Acad Sci USA 78:6376–6380; 1981. Wang, H., DeVries, M. E., Deng, S., Khandaker, M. H., Pickering, J. G., Chow, L. H., Garcia, B., Kelvin, D. J., Zhong, R. The axis of interleukin 12 and gamma interferon
56
85.
86.
87.
88.
89.
90.
91.
92.
93.
regulates acute vascular xenogeneic rejection. Nat Med 6: 549–555; 2000. Wang, M. W., Wright, L. J., Sims, M. J., White, D. J. Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement. Scand J Immunol 34: 771–778; 1991. Warnock, G. L., Kneteman, N. M., Ryan, E. A., Rabinovitch, A., Rajotte, R. V. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35:89–95; 1992. Weir, G. C., Bonner-Weir, S. Scientific and political impediments to successful islet transplantation. Diabetes 46: 1247–1256; 1997. White, D. J., Oglesby, T., Liszewski, M. K., Tedja, I., Hourcade, D., Wang, M. W., Wright, L., Wallwork, J., Atkinson, J. P. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transpl Int 5 Suppl 1:S648–650; 1992. Wilmut, I., Schnieke, A. E., McWhir, J., Kind, A. J., Campbell, K. H. Viable offspring derived from fetal and adult mammalian cells. Nature 385:810–813; 1997. Yamada, K. Life-supporting pig-to-baboon renal transplantation using GalT knockout donors: Benefit of cotransplanting a vascularized donor thymic graft. Kidney Int 68:1971; 2005. Yamada, K., Yazawa, K., Shimizu, A., Iwanaga, T., Hisashi, Y., Nuhn, M., O’Malley, P., Nobori, S., Vagefi, P. A., Patience, C., Fishman, J., Cooper, D. K., Hawley, R. J., Greenstein, J., Schuurman, H. J., Awwad, M., Sykes, M., Sachs, D. H. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 11:32–34; 2005. Yannoutsos, N., Ijzermans, J. N., Harkes, C., Bonthuis, F., Zhou, C. Y., White, D., Marquet, R. L., Grosveld, F. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection. Genes Cells 1:409–419; 1996. Yin, X. J., Lee, H. S., Lee, Y. H., Seo, Y. I., Jeon, S. J., Choi, E. G., Cho, S. J., Cho, S. G., Min, W., Kang, S. K., Hwang, W. S., Kong, I. K. Cats cloned from fetal and adult somatic cells by nuclear transfer. Reproduction 129: 245–249; 2005.
B Cell Therapy for Peripheral Diseases and Reconstructive Applications
This page intentionally left blank
5 Islet Transplants for Diabetes: The Edmonton Protocol Peter A. Senior, BMedSci, MBBS, Ph.D., MRCP (UK) Assistant Professor, Department of Medicine, Clinical Islet Transplant Program, University of Alberta
A. M. James Shapiro, MBBS, Ph.D., FRCS, FRCPC Associate Professor, Department of Surgery, Clinical Islet Transplant Program, University of Alberta
Introduction Diabetes is a common condition whose prevalence is increasing rapidly worldwide [63]. Diabetes is characterized by hyperglycemia due to an absolute or relative deficiency of insulin. Chronic hyperglycemia is associated with a number of chronic complications that place a huge burden on affected individuals, their families, and health care systems. Chronic complications include microvascular disease; diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy; and macrovascular disease. Diabetic retinopathy is the most common cause of blindness in working-age adults. End-stage renal disease due to diabetic nephropathy is the leading indication for renal replacement therapy (renal dialysis) [5]. Macrovascular disease, predominantly coronary artery and cerebrovascular disease, is responsible for the majority of deaths in people with diabetes [69, 107]. Diabetes is associated with a twofold to fourfold increased risk of death [68] and a significant reduction in life expectancy. Insulin is a peptide hormone secreted by beta cells in response to blood glucose levels. Beta cells make up approximately 40% of cells in the islets of Langerhans. Islets are found in the pancreas, which is predominantly an exocrine gland. The islets make up the endocrine component that represents a tiny proportion of the pancreas. Insulin plays a key role in glucose homeostasis. Its major action is to lower blood glucose levels by promoting glucose uptake into fat, liver, and muscle, Cellular Transplantation: From Laboratory to Clinic
and by inhibiting glycogenolysis and gluconeogenesis. Insulin also has important effects on fat and protein metabolism. In clinical practice, insulin is administered subcutaneously by injections several times per day or continuously using a pump.
PATHOGENESIS OF DIABETES Type 1 diabetes results from an autoimmune process characterized by lymphocyte infiltration of the islets and “insulitis” [45, 86]. This leads to an absolute deficiency of insulin over a relatively short period. Males and females are affected equally, and there is a peak incidence during early teenage years and the disease usually presents before the age of 40. Insulin therapy is required in all cases in order to prevent metabolic decompensation. Formerly, the terms juvenile onset and insulin-dependent diabetes were used for this condition. The majority (> 85%) of diabetes worldwide is due to type 2 diabetes, formerly known as maturity onset or noninsulin-dependent diabetes. Hyperglycemia in type 2 diabetes is due to a relative deficiency of insulin. Defects in insulin action (insulin resistance) and of insulin action have both been described [34]. Type 2 diabetes is associated with obesity and physical inactivity, which are both associated with insulin resistance. Hyperinsulinemia as a compensatory response to insulin resistance, in a vain attempt to maintain euglycemia, is commonly seen in pre-diabetes and in the early stages of type 2 diabetes. Nevertheless, the natural history of type 2 diabetes is
59
Copyright © 2007, Elsevier Inc. All rights of reproduction in any form reserved.
P. A. Senior and A. M. James Shapiro
generally for insulin secretion to progressively decline over a number of years. Thus, although type 2 diabetes is usually treated by lifestyle changes and oral medication insulin therapy may be required with longer duration of diabetes.
run their blood sugars high deliberately in order to avoid hypoglycemia.
LIMITATIONS OF INSULIN THERAPY FOR DIABETES
A cure for type 1 diabetes is a highly attractive proposition and is the ultimate goal for many researchers and lay organizations (e.g., the Juvenile Diabetes Research Foundation is “dedicated to finding a cure”), as well as for affected individuals and their families. A number of strategies for restoration of endogenous insulin secretion have been considered and tested. Prevention of type 1 diabetes has thus far been unsuccessful [4, 44], although much has been learned about identifying individuals at risk. It is now possible to predict, with reasonable accuracy, the likelihood of developing diabetes in families at risk for type 1 diabetes [86]. Similarly, efforts to reverse type 1 diabetes in its early phases by manipulating the immune environment have shown little benefit [1, 21, 125]. Prevention of type 2 diabetes has been more successful, with lifestyle modification as well as pharmacological interventions proving effective [64, 65, 133]. Transplantation has been another strategy to restore functional beta cell mass. Whole-pancreas transplantation was pioneered in the late 1960s and is now well established as a treatment for selected cases of type 1 diabetes. Most commonly, pancreas transplantation is performed simultaneously with a kidney transplant [51]. Solitary pancreas-alone or pancreas after kidney transplants are, however, being performed more commonly than before [51]. Whole-pancreas transplantation as a treatment for type 1 diabetes is subject to a number of important limitations. The transplant involves a major and complex surgical procedure, with a substantial risk to the patient’s life. At one year, graft survival is > 80%, with patient survival being approximately 95% [51]. In addition, lifelong immunosuppression is required, further adding to the risks of pancreas transplantation. The very limited supply of suitable organs is a major obstacle limiting the availability of this treatment. Despite these limitations, successful pancreas transplantation can result in a robust and sustained restoration of euglycemia [105] superior to that achievable with insulin therapy and without the risk of hypoglycemia. Indeed, this success has been associated with the reversal of chronic diabetic complications [38].
The discovery of insulin and its introduction to clinical practice by Banting and Best, assisted by MacLeod and Collip, in 1921 was a major advance in diabetes care [17]. Prior to this, type 1 diabetes was associated with a dire prognosis and was universally fatal, usually within weeks or months. Although preventing these early deaths, the improved survival with insulin therapy was followed by a huge burden of complications and premature deaths from coronary artery disease and renal failure. Progress has been made over the years. Advances in insulin preparations, delivery devices, and technology for self-monitoring of blood glucose level have been helpful. Intensive insulin therapy can delay the development or progression of microvascular complications of diabetes [3], and the proportion of people developing microvascular complications appears to be declining [57]. However, these complications are not completely prevented, most likely because of an inability of insulin therapy to achieve euglycemia or normoglycemia. In contrast, the restoration of normoglycemia by successful whole-pancreas transplantation can lead to a resolution of the histological changes of diabetic nephropathy [38]. Thus, despite progress in insulin therapy diabetes continues to have a major impact on the lives of people with type 1 diabetes. Multiple daily injections, frequent selfmonitoring of blood glucose levels, careful attention to dietary carbohydrate intake, and exercise are required to achieve good glycemic control. This is associated with a reduced risk of, but is not a guarantee of freedom from, complications. Hypoglycemia is a major factor limiting the ability of insulin therapy to achieve normoglycemia. The intensive insulin therapy employed in the diabetes control and complications trial was associated with a threefold increase in hypoglycemia [3]. Hypoglycemia is a serious complication that can be associated with coma, seizure, or even death. Fear of hypoglycemia is a further difficulty, leading many individuals with type 1 diabetes to
ALTERNATIVE APPROACHES
60
5.
Islet Transplants for Diabetes: The Edmonton Protocol
Islet transplantation seeks to achieve the benefits of endogenous insulin secretion from the restoration of functional beta cells but with reduced risk. Major surgery is not required, and potential complications from multiple anastamoses and transplantation of the exocrine pancreas are avoided. The smaller amount of transplanted tissue may also represent a reduced alloantigen load.
Historical Perspectives on Islet Transplantation Islet transplantation is not a new idea. An attempt to transplant fragments of ovine pancreas into a child with diabetic ketoacidosis was reported in the nineteenth
century [137]. Interest waned following the discovery of insulin, but was rekindled as a result of the poor outcomes of early whole-pancreas transplants [129]. (See Figure 5.1.) The successful isolation of rat islets from the pancreas was pioneered at Washington University, St. Louis, under the direction of Dr. Paul Lacy in the 1960s [67]. Subsequently, transplantation of these islets was shown to reverse chemically induced diabetes in animal models [9]. Despite much enthusiasm and the initial success of islet transplantation in animal models, the transition to clinical practice proved difficult and frustrating. To further emphasize the slow pace of clinical islet transplantation, it was 1989 before insulin independence was achieved, albeit briefly, following islet transplantation in a type 1 diabetic subject with a previous kidney transplant [114].
Figure 5.1. Islet milestones.
61
P. A. Senior and A. M. James Shapiro
Improved outcomes in clinical islet transplantation were reported not long afterward. Insulin independence rates of more than 50% at one year were achieved in 10 patients receiving combined liver and islet allotransplants following upper abdominal exenteration (including pancreatectomy) for cancer [103]. However, insulin independence in this series of islet allotransplants was not achieved in any patients with preexisting diabetes. Interestingly, the immunosuppression received by the subjects receiving combined liver and islet transplants did not include steroids, in contrast to the regimen employed in diabetic subjects. Successful islet transplantation, predominantly in association with kidney transplantation, in type 1 diabetes was achieved by the European GRAGIL consortium (based in Geneva and Giessen) [12]. This improved success was attributed to advances both in peritransplant management and in immunosuppressive therapy. However, insulin independence rates at one year were only about 20%. Early experience in auto islet transplantation (which did not require immunosuppression) highlighted a
number of problems in using the islet preparations available at that stage. These preparations were impure, containing a large amount of exocrine tissue and other contaminants. Consequently, several serious complications were encountered: portal vein thrombosis, portal hypertension, and ultimately liver failure [134]. At this point, islet allotransplants were generally combined with another solid organ transplant that required and justified immunosuppression. Despite earlier optimism, serious complications and relatively disappointing insulin independence rates suggested that the benefits of islet-alone transplantation were outweighed by the risks. The future of islet-alone transplants seemed in doubt. The report in 2000 of insulin independence in all of seven type 1 diabetic subjects receiving islet-alone transplants at the University of Alberta in Edmonton [121] was followed by much interest in the medical and scientific communities as well as among the general public. Subsequently, there has been a huge expansion in clinical islet transplantation as well as basic and clinical research. (See Figure 5.2.)
Figure 5.2. Islet transplant activity (1999–2005).
62
5.
Islet Transplants for Diabetes: The Edmonton Protocol
Current Clinical Islet Transplantation PANCREAS SELECTION AND HARVESTING Human islets are isolated from pancreata harvested from brain dead donors. Donor selection is an important factor contributing to the likelihood of isolating a sufficient quantity of high-quality islets. The pancreas is a sensitive organ. Activation of the exocrine pancreas digestive enzymes leading to autodigestion is associated with damage to islets. Furthermore, islets are highly susceptible to ischemia because they are metabolically active and require excellent blood flow to maintain their health [20, 74]. Careful procurement of pancreata from stable donors with minimal periods of warm or cold ischemia is a key element for successful islet transplantation. The advent of the two-layer method using perfluorocarbon (thought to improve oxygen delivery to the islets) has been associated with improved islet yields [79, 100, 132]. It can be difficult to separate islets from exocrine tissue in younger donors, and islet mass also seems to be less in lean donors. Generally, pancreata from slightly older and heavier donors (> 45 years) are preferred because of improved islet yield [71, 84]. Care is taken to avoid potential donors who have known or undiagnosed diabetes. The optimal donor for islet transplantation is relatively distinct from that for whole-pancreas transplantation, where a young lean donor is optimal. This is fortunate because it avoids competition for organs between islet and whole-pancreas programs [104].
ISLET ISOLATION AND CULTURE Even though the pancreas is a sensitive organ, the process of islet isolation [102] requires the pancreas to be subjected to a hostile environment. The initial stage involves the cannulation of the pancreatic duct and controlled distension of the pancreas with collagenase [72]. Subsequently, the pancreas is cut into small pieces and placed in the Ricordi chamber, a stainless steel container, along with stainless steel marbles. The chamber is perfused with a blend of enzymes at 37◦ C and agitated. With this combination of chemical and mechanical dissociation, islets are freed from exocrine tissue. Digestion of the pancreas is generally complete within less than 30 minutes. Islets are separated from exocrine tissue over a series of density gradients using a COBE cell
separator. Generally, the final islet preparation consists of < 5 cc of tissue. The use of liberase as the digestive enzyme for islet isolation represented an advance over the commercially available collagenases used previously, which exhibited substantial variability in enzyme activity between batches [75]. Liberase is a purified blend of collagenase isoforms 1 and 11. Earlier reports suggested that there was good reproducibility between Liberase lots [70]. Nevertheless, substantial variation in islet yields persisted. More recently, evaluation of collagenase blended with a neutral protease at the time of use has yielded promising results [23]. Prior to release, islets are subject to a number of quality control tests, including a gram stain to rule out bacterial contamination and an assay to exclude significant amounts of endotoxin. Further assays of biological efficacy can also be employed, including measurement of insulin content, insulin secretion in response to low and high glucose (stimulation index), or bioassays such as transplantation into diabetic mice. The release criteria are outlined in Table 5.1. Previously, freshly isolated islets were suspended in transplant medium and infused immediately [121]. Long-term culture of islets is associated with a loss of endocrine cells [115]. However, it is clear that islets can be successfully cultured for several days prior to transplantation without significant loss of potency [56]. Indeed, the ability to culture islets prior to transplantation has a number of advantages. Safety is improved because transplants can be scheduled when the entire transplant team can be present. Time is also available to administer conditioning or other immunosuppressive therapy, avoiding exposure of islets to the cytokine release associated with many cell-depleting induction therapies. Logistically, patients no longer need to live close to the transplant center for indeterminate
63
TABLE 5.1 Release criteria for clinical islet transplantation. Parameter
Cut Point
Islet number Packed cell volume Islet viability Endotoxin content Gram stain
> 4,000 ie/kg < 10 cc > 70% < 5 EU/kg No bacteria seen
P. A. Senior and A. M. James Shapiro
periods of time. Indeed, islets can be successfully shipped from the isolation facility to distant transplant centers [48]. This opens up the potential for a small number of core islet isolation facilities, which would likely have economies of scale because islet isolation must be performed in a cGMP facility. Preliminary data from a multicenter trial of islet transplantation indicate superior outcomes from experienced centers and confirm the steep learning curve associated with islet isolation [120, 123]. Thus, the concentration of expertise in a small number of facilities seems sensible. Although there is generally some loss of islets during the culture period, there is an increase in islet purity because of more rapid loss of exocrine tissue. This increased purity, along with the associated reduction in the volume of tissue to be infused, has further safety advantages. Smaller and more pure preparations are associated with a reduced risk of portal hypertension and portal thrombosis. Thus, the ability to culture islets prior to transplant has a number of benefits both in terms of practicality and safety.
QUANTITY OF ISLETS NEEDED TO CURE DIABETES There is substantial heterogeneity between isolated islets, particularly in terms of their size but also in their shape. The ability to quantify islet number is important in order to compare clinical outcomes. The concept of an islet equivalent (IE) as the unit of enumeration of islets is a result of the variability in islet size. An IE attempts to combine islet size and number into one parameter. The reference value for an IE is a spherical islet with a diameter of 150 µm. Counts of islets in a small aliquot are performed in duplicate. After staining with dithizone, islets are counted manually under the microscope and a tally of islets of different sizes kept [10, 101]. From this an estimate of the number of IEs can be made. Counting islets is time consuming and there is substantial variation between observers in the estimates. This is exacerbated by the irregular, nonspherical nature of most islets. A number of strategies to automate counting islets and improve both the accuracy and precision of the count are being explored [47, 73]. Precise estimates of the number of islets in a human pancreas are difficult to find. It seems that under certain physiological conditions beta cell mass can expand;
for example, during pregnancy (which is a temporary state of insulin resistance) [14]. There is still debate as to whether this is the result of islet hyperplasia or islet hypertrophy (i.e., an increased number of islets or an increase in islet size), although animal data would favor the latter [18]. The most reliable technique for estimating islet number is using stereological principles [19]. This technique has been used to reliably estimate islet number and volume in animal models. Despite this uncertainty, it is clear that glucose tolerance can be maintained even despite significant reductions in total beta cell mass. Rates of diabetes following partial and subtotal pancreatectomy, particularly for neoplasia, provide the best data to support this. Diabetes is a universal complication after total or subtotal pancreatectomy, where more than 80% of the pancreas is removed. Removal of smaller proportions of the pancreas (40 to 80%) is associated with the development of diabetes in less than 50% of subjects [126]. There seems to be a relationship between glucose tolerance and the amount of pancreas removed [124]. The same phenomenon seems to apply in diabetes. Although difficult to study directly, it is estimated that despite the progressive loss of beta cells in type 1 diabetes euglycemia can be maintained until approximately 90% of the beta cell mass is lost [135]. Thus, it would be expected that replacement of only a small proportion of a normal total complement of islets would be required to restore insulin independence following islet transplantation. Insulin independence in the original series of seven patients from the University of Alberta was achieved after infusion of approximately 11,000 IE/kg in two (or more) islet infusions [121]. In a follow-up report, infusion of > 9,000 IE/kg (approximately 857,000 islets per recipient) was necessary for insulin independence to be achieved [108]. Although this total represented approximately 85% of the approximate one million islets in a normal pancreas, and although insulin independence was achieved, the ability of the transplanted islets to secrete insulin fell well short of that in normal control subjects. During the intravenous glucose tolerance test, the acute insulin response to glucose was 19% and the area under the curve for insulin was 36% compared with controls [108]. These data support suggestions that a significant proportion of islets are lost during the transplant procedure or fail to engraft [16]. More recent data indicate, however, that insulin independence can be achieved with a smaller number of
64
5.
Islet Transplants for Diabetes: The Edmonton Protocol
islets (7,271 IE/kg), and indeed from a single donor [55]. In the 5-year follow-up data from 69 patients transplanted at the University of Alberta there is no longer any clear relationship between insulin independence and number of islets infused [109]. A further area of uncertainty in relationship to the number of islets infused is whether a greater islet mass will give more robust, sustained insulin independence. The natural history of type 2 diabetes seems to suggest that after a period of initially successful compensation for insulin resistance there is a steady decline in beta cell mass with time [136]. The concept of islet stress and islet rest (to preserve and sustain beta cells) would support the hypothesis that a larger islet mass would be more likely to provide longer-term insulin independence. Although the notional number of islets infused in islet transplantation approaches the number in a normal pancreas, the number of islets successfully engrafting is almost certainly a fairly marginal islet mass. Sustained (> 5 years) insulin independence is unusual after islet transplantation [109] but much more common after successful whole-pancreas transplantation, where a full complement of islets is transplanted within a well-vascularized graft with an intact microvascular structure.
program have often led to the acceptance of organs from marginal donors that previously would have been declined. Consequently, the proportion of isolation procedures yielding preparations suitable for clinical use has remained static, or perhaps even declined in some well-established centers. The inefficiency of the isolation procedure contributes to the need for more than one islet infusion to attain insulin independence. Thus, currently the ratio of pancreata to insulin independence is probably greater than 4. Even if this ratio were improved to 1 or even 0.5 (one pancreas treating two patients), the current supply of pancreata means that islet transplantation would remain a very specialized treatment for a highly selected minority of type 1 diabetic patients. Single-donor success is an important goal if islet transplantation is to be used more widely. It is achievable but probably relies, in part at least, on very strict selection of donor and recipient selection, and on strict criteria for islet preparations (in terms of islet number and purity) [122]. Insulin independence is much more likely in small insulin-sensitive individuals.
Clinical Islet Transplantation RECIPIENT SELECTION
Inefficiency of Islet Isolation and Transplantation High-quality pure islet preparations have been a key development contributing to recent advances and success in clinical islet transplantation. Unfortunately, it is not possible to reliably achieve an islet preparation suitable for transplantation from every pancreas that undergoes processing. Generally, about half of attempted isolation procedures yield an islet preparation of sufficient quantity or quality to be transplanted. The remainder are utilized for research — if consent for such use has been given. This inefficiency is a major hurdle. Limited organ supply is the rate-limiting step facing most solid organ transplant programs. Islet transplantation faces the same issue. This limited supply further highlights the inefficiency of the islet isolation procedure. Recently, the expansion in the number of islet transplant centers has been associated with a decline in the number of organs being offered to any individual center. A reduced number of donor organs coinciding with a desire to expand the clinical
Clinical islet allotransplantation is associated with a number of short-term procedural risks, particularly from bleeding or portal vein thrombosis. In the longer term, the major risk is from the lifelong immunosuppression required to prevent rejection. Consequently, much effort is made in assessing potential islet transplant recipients. The aim of the assessment process is first to identify individuals in whom the benefits of islet transplantation outweigh the risks, and second to ensure that the risks are fully understood by the applicant. Thus, islet transplantation has tended to be restricted to those individuals most severely affected by diabetes. In particular, individuals at high short-term risk from their diabetes — often because of frequent, severe, and recurrent hypoglycemia — are often suitable candidates for islet transplantation. Unstable blood glucose control (despite an optimized insulin regimen) and progressive secondary complications of diabetes have also been identified as potential indications for islet transplantation. In our center, advanced microvascular complications are a caution because approximately 10% have required laser photocoagulation for diabetic retinopathy
65
P. A. Senior and A. M. James Shapiro
following transplant [109], whereas progression of albuminuria has been noted in 40% of subjects [118]. Early after transplant, there was a clear decline in renal function in a small number of subjects with preexisting renal impairment [108]. Heavy proteinuria, apparently associated with sirolimus, has also been noted in three cases [116]. Other functions of assessment are to exclude any alternative approach that could be used to address the difficulties for which islet transplantation may be indicated or the presence of other co-morbidities. Such co-morbidities could increase the risk of the procedure (e.g., underlying coronary artery disease, hepatic hemangiomata, and thrombophilia) or the risk of side effects of immunosuppression (e.g., gastroparesis and anemia). The wait for islet transplantation can be lengthy. Currently, the wait in Edmonton is approximately 2 years. Consequently, our practice is to review listed candidates on an annual basis to ensure that they still have indications for islet transplantation and have not developed any contraindications, and to provide an update on the latest clinical outcomes.
CROSS-MATCHING, TISSUE TYPING, AND IMMUNOSUPPRESSION Similar to liver transplantation, islet grafts have been assigned to ABO-compatible recipients and have not been matched for HLA type. Earlier, a cross match between donor spleen cells and recipient blood was routinely performed retrospectively for first transplants. Prospective cross matches are performed for individuals with high PRA (panel reactive antibody) or prior to second, or subsequent, islet infusions. There has been a transition from the earlier hemagglutination-based techniques for measuring PRA and performing the cross match to a flow-cytometrybased technique. It has become apparent that the new flow method is much more sensitive than the older assays. Preliminary retrospective analysis by the flowbased method of the “negative” (by the old method) cross matches in cases with early graft loss has suggested that alloimmunity and HLA mismatch may have played a significant role in the loss. Previously, the loss of these grafts had been postulated to be mediated mainly by recurrent autoimmunity.
SELECTING A RECIPIENT FOR AN ISLET PREPARATION
TRANSPLANTATION IN INDIVIDUALS WITH HIGH PRA
When an islet preparation of sufficient quality becomes available, a suitable recipient must be identified and called to the transplant center. Because islet transplants can be successfully scheduled, listed recipients no longer have to reside in Edmonton. Nevertheless, they must be prepared to travel to Edmonton at short notice. Key factors influencing recipient selection include ABO blood type, body weight, and the number of islets in the preparation. Preparations containing larger numbers of islets will preferentially be given to a larger individual. If small numbers of islets are given to a large recipient, it is likely that multiple procedures would be required to achieve insulin independence. This should be avoided because there are operative risks with each procedure. In addition, multiple procedures are associated with a sequential rise in portal pressure [27] and with an increased risk of bleeding (Villiger, in preparation). Patients who require a further transplant because they have not yet attained insulin independence are transplanted in preference to those who have not yet received any islet infusion.
Because the current flow-based assay for PRA is more sensitive, there has been an increase in the number of cases with positive PRA. This has necessitated the development of procedures to facilitate the identification of suitable islet preparations for recipients with high PRA. One aim has been to avoid the need to call a patient from a distant location to the transplant center only to find that the prospective cross matching is positive. This involves several steps.
66
•
•
The specificities of the antibodies causing the positive PRA (i.e., the HLA types the recipient has antibodies against) are identified. When the tissue typing of the donor is known, this can be used to rule out recipients with specific antibodies to that donor’s tissue type. Blood from recipients with high PRA is sent to the HLA lab each month and stored. If a recipient does not have specific antibodies against a donor, these samples can be used to perform a preliminary cross match against donor spleen cells. Where this is
5.
•
Islet Transplants for Diabetes: The Edmonton Protocol
negative, the patient can be called to the transplant center. A final cross match is performed at the time of transplant.
The process for identifying a suitable candidate is thus significantly more complex and involved than when the current clinical islet transplant program was initiated.
IMMUNOSUPPRESSION Successful islet transplantation for type 1 diabetes requires immunosuppression that can effectively control alloimmunity but can also control the autoimmune process that caused diabetes in the first place. A further challenge is to avoid the use of agents that are known to be toxic to islets — particularly corticosteroids, which have been the mainstay of immunosuppression since successful allotransplantation was first developed. The avoidance of steroids in islet transplantation seems to have been a key step in the recent advances in successful islet transplantation. In place of steroids, daclizumab (a humanized antibody to the interleukin 2 receptor) is administered intravenously immediately prior to transplantation at a dose of 1 mg/kg. This was repeated every 2 weeks for 5 doses in our initial transplants. Currently, our standard immunosuppressive regimen repeats the dose of daclizumab only once. Maintenance immunosuppression was achieved using sirolimus and a low dose of tacrolimus. Sirolimus is a novel agent that appears to be associated with less nephrotoxicity and diabetogenicity than calcineurin inhibitors (such as cyclosporine and tacrolimus). A loading dose of sirolimus (0.2 mg/kg) is given prior to transplant, followed by 0.15 mg/kg. The dose is then adjusted subsequently to achieve trough levels between 12 and 15 ng/ml for the first 3 months and between 7 and 10 ng/ml subsequently. A low dose of tacrolimus was used and adjusted to maintain trough levels between 3 and 6 ng/ml. The success of this regimen described initially at the University of Alberta has been replicated at other centers as part of a multicenter trial [120, 123]. Success has been reported with other regimens using antithymocyte globulin combined with etanercept (a monoclonal antibody that binds to tumor necrosis factor alpha) for induction and a combination of sirolimus and mycophenolate mofetil ± very-low-dose tacrolimus for maintenance [55].
Other immunosuppressive agents have been used in some cases because of drug intolerance or other side effects. Most of our experience is with a combination of tacrolimus, using higher doses with target trough levels between 8 and 10 ng/ml, and mycophenolate mofetil (up to 2 g/day as tolerated). This combination is better tolerated in individuals who are sirolimus intolerant and seems to be reasonably efficacious in terms of preserving islet function. In a small number of cases, the use of these higher doses of tacrolimus was accompanied by predictable nephrotoxicity. We are less confident in the ability of sirolimus combined with mycophenolate mofetil to provide adequate immunosuppression. The use of this combination is further limited by the side-effect profile of these drugs, which both affect the GI tract. A number of new immunosuppressive protocols are being developed and evaluated. Some of the strategies being tested include the use of antibodies to deplete the lymphocyte pool [120]. One hope is that as the immune system is reconstituted this approach may facilitate the development of tolerance. Tolerance is a major focus of much basic research because this would permit the minimization or even the avoidance of long-term immunosuppression.
THE TRANSPLANT PROCEDURE Islets are removed from culture media, recounted, and resuspended in approximately 100 ml of transplant media in a closed infusion bag system. Islets are then infused, aseptically, into the main portal vein under gravity, with regular monitoring of portal venous pressure before, during, and after the infusion. Access to the portal vein is achieved by a transcutaneous transhepatic approach using a combination of ultrasound and fluoroscopy to guide the radiologist. The procedure is performed using local anesthesia, combined with opiate analgesia and hypnotics given as premedication. Initially, a branch of the right portal vein is cannulated using a 22-gauge Chiba needle and a guide wire advanced into the main portal vein. A catheter is advanced over the guide wire and positioned proximal to the confluence of the portal vein. A portal venogram is performed routinely to confirm the position of the catheter. A description of the procedure has been published [89]. Portal venous pressure is measured by an indirect pressure transducer. Islet infusion did not proceed if
67
P. A. Senior and A. M. James Shapiro
initial pressure was > 20 mmHg or if portal pressure rose to > 22 mmHg or more than twice the baseline value [89]. Unfractionated heparin (35 units per kg per 5 cc of islet tissue) is mixed with the islet preparation immediately prior to infusion to reduce the risk of portal vein thrombosis. Some centers have advocated the use of intravenous heparin to provide full anticoagulation. The disadvantage of such anticoagulation in islet allotransplantation where a transhepatic puncture provides access to the portal vein is the increased risk of bleeding. Full heparinization is required in islet autotransplantation where large volumes of unpurified islet tissue (with an even greater potential to promote thrombosis) are infused. In autotransplantation, islets are infused into the portal vein under direct vision during the laparotomy and any bleeding can be controlled directly. Upon completion of the islet infusion, the catheter is withdrawn. A number of modifications have been made to this part of the procedure, largely to reduce the frequency of bleeding from the hepatic puncture. Earlier, gelatin sponge (gelfoam) was used to embolize the catheter tract. Subsequently, metal coils in combination with a fibrin “tissue glue” (Tisseel, Baxter) were used. Currently, a microfibrillary collagen (Avitene, Davol) is being employed without the use of metal coils. This compound can be mixed with contrast to permit visualization of its placement, reducing the risk of embolization into the portal vein. The avoidance of coils is advantageous for future imaging because the metal coils produce artifacts on MR images and cast acoustic shadows on ultrasound studies of the liver. Patients are instructed to lie on their right-hand side for 4 hours following the procedure. An ultrasound examination is performed the following day to rule out any free fluid in the abdomen and to confirm that the portal vein is patent and has normal flow. The ultrasound is repeated at one week to exclude any late portal vein thrombosis.
INTRAHEPATIC ISLET ENGRAFTMENT Although islets represent a tiny proportion of the total pancreas (1%), they receive a disproportionate share of the pancreas’ blood supply (15%) [20, 58]. This reflects the fact that islets are metabolically active. Islets are accustomed to an abundant oxygen supply. Hypoxia is therefore a major metabolic challenge to isolated islets whose microvasculature has been disrupted. Isolated
islets are now reliant on passive diffusion of oxygen. Larger islets may be even more affected because of the greater distance over which oxygen has to diffuse. The situation may not be improved following islet infusion. Islets embolize into distal branches of the portal vein, where they lodge in presinusoidal capillaries [134]. The oxygen tension within islets (pO2 8 to 10 mmHg) is lower than in the portal vein (10 to 15 mmHg), both of which are significantly lower than the oxygen tension seen in the intact pancreas (40 mmHg) [25, 96, 119]. Engraftment refers to the process whereby islets become revascularized. Although infused into the portal vein, it would seem that engrafted islets derive their blood supply from the arterial circulation [8]. Generally, revascularization is believed to take about two weeks. Nevertheless, the vascular density observed in transplanted rodent islets at one month is only half that seen in the native pancreas, suggesting that the blood supply of transplanted islets may always be suboptimal [26]. Hypoxia is likely a key factor responsible for the very marked early loss of transplanted islets. The process leading to cell death has already begun even before transplantation. Some 30% of cells within islets can be seen to be undergoing apoptosis, with beta cells particularly affected, immediately following isolation [90]. After transplantation there is further loss of cells mediated by nonimmune factors. Some studies in immunodeficient mice have demonstrated that 70% of beta cells in transplanted islets are lost in the first month [32]. This loss does not seem to be related to the transplant site (islet grafts in rodents are often placed under the kidney capsule or in the spleen as well as intraportally) [25]. Experience in clinical islet transplantation would tend to be consistent with perhaps only one-third of islets engrafting successfully [99]. Islets that successfully survive this hypoxic stress face further challenges. One of these is an inflammatory response due to activation of the clotting cascade and platelets immediately after islets come into contact with blood [13]. This response has been termed the instant blood-mediated inflammatory reaction (IBMIR). Islets constitutively express tissue factor, a potent activator of the clotting cascade, causing the IBMIR [81]. The thrombosis resulting from IBMIR is associated with the formation of a fibrin capsule around newly implanted islets and disrupted islet morphology [13, 81], and may be associated with a negative outcome in clinical islet transplantation [59]. This early inflammatory process may represent a key initiating event leading to
68
5.
Islet Transplants for Diabetes: The Edmonton Protocol
macrophage infiltration and perhaps ultimately to activation of alloimmune responses. Conversely, platelet activation may be an important precursor to the establishment of a vascular supply to these newly engrafted islets [22].
Why the Liver? Insulin secretion from beta cells within native islets is relatively complex. Although it is clear that insulin is secreted in response to increases in blood glucose levels, other secretagogues (e.g., arginine) also stimulate insulin secretion. The arrangement of alpha, beta, and delta cells within islets is not random [88]. Somatostatin secreted from delta cells has paracrine actions modulating insulin secretion [50]. The autonomic nervous system represents a further influence on insulin secretion and may influence pancreas regeneration [62]. Variations in pulse frequency and amplitude are seen to occur as insulin secretion changes in different physiologic states [61]. In the native pancreas, islets receive their blood supply from the systemic circulation while insulin secreted by islets drains into the portal vein and thence to the liver. The liver extracts much of the insulin during the first pass. Consequently, in the postprandial state the concentration of insulin in the systemic circulation is significantly lower than in the portal vein. Circulating insulin levels are significantly lower in whole-pancreas transplant recipients where the venous drainage of the graft is into the portal rather than the systemic circulation [95]. First-pass metabolism in the liver affects other substances relevant to intraportal islet transplantation, including drugs and nutrients. Intraportal infusion of islets may permit delivery of pancreatic hormones, particularly insulin, directly to the liver. The ability to deliver insulin and glucagon directly to the liver is attractive from a physiological perspective. The liver is a key site of insulin action. Insulin promotes glycogen synthesis and turns off both glycogenolysis and gluconeogenesis. Glucagon has the opposite effects to insulin on glycogenolysis and gluconeogenesis, raising blood glucose levels. Glucagon plays an important role in preventing hypoglycemia. (In addition to the loss of insulin secretion, normal glucagon secretion is lost in type 1 diabetes and contributes to the susceptibility to hypoglycemia seen in some patients [46].) The secretion of insulin from intrahepatic islets may not be exactly equivalent to portal delivery of insulin
from the native pancreas. Normally, insulin secretion will result in uniform concentration of insulin being delivered throughout the liver. With intrahepatic islet transplants, there may be areas of the liver surrounding engrafted islets that have relative hyperinsulinemia. This localized hyperinsulinemia may explain the patchy focal steatosis observed in some patients after clinical islet transplantation [15]. The intrahepatic location of transplanted islets has a number of potential advantages and disadvantages. The concentration of orally administered immunosuppressant drugs in the portal circulation is significantly higher than in the systemic circulation because of hepatic first-pass metabolism [35]. Potentially this could be advantageous, in that islets and the liver could be exposed to effective concentrations of drugs using lower doses with reduced potential for systemic toxicity. In fact, monitoring venous trough levels assesses dosing of most immunosuppressive drugs. The current recommended levels are relatively high in comparison to solid organ transplants. Peak drug levels in the portal system are likely very high and potentially may be toxic to islets in the longer term [11]. Another potential disadvantage is the exposure of islets to high concentrations of nutrients in the portal vein, not yet subject to the first-pass metabolism in the liver. Potentially, this may be associated with supramaximal stimulation of islets in the postabsorptive state, which may have deleterious effects on long-term islet function.
Peritransplant Glucose Management Careful blood glucose control around the time of transplant is important. Immunosuppressive induction regimens are often accompanied by a number of side effects. Nausea and vomiting are particularly common. This together with the need to fast prior to the procedure increases the risk of hypoglycemia, which after all is the leading indication for islet transplantation. Frequent measurements of capillary blood glucose are recommended and appropriate adjustments made to insulin doses in order to avoid hypoglycemia. Generally, intravenous infusions of insulin and dextrose are started prior to the transplant procedure in order to maintain euglycemia during the transplant. Some animal data imply superior outcomes if islets are transplanted into a euglycemic rather than a hyperglycemic environment [16], although the levels of hyperglycemia
69
P. A. Senior and A. M. James Shapiro
were far higher than would be expected in clinical practice. Immediately following the islet infusion, the insulin and dextrose infusions can be stopped. The blood glucose should continue to be monitored. Hypoglycemia is not uncommon in the first 12 hours after the infusion. This likely represents unregulated insulin release from transplanted beta cells, perhaps because of injury or even death of islets. In some cases, moderate doses of intravenous dextrose (5 to 10 g per hour) are required to maintain euglycemia. In some experimental protocols intravenous insulin (1 unit per hour) has been continued after the islet infusion, along with a variable-rate glucose infusion adjusted to maintain euglycemia. This approach has been advocated by centers reporting single-donor success [55]. As well as maintaining strict euglycemia, the insulin infusion is postulated to have an antiinflammatory action. Although maintaining euglycemia in order to avoid an additional metabolic stress to newly transplanted islets seems intuitively sensible, there is no clear human data indicating the superiority of intravenous insulin over the initial approach in Edmonton of recommencing subcutaneous insulin if capillary blood glucose levels rose above 8 mmol/l (144 mg/dl) premeal or above 10 mmol/l (180 mg/dl) 2 hours following a meal. In terms of diet, patients are advised to continue to follow a healthy diet as recommended by national diabetes associations. Three regular meals per day are preferred. Additional snacks, required prior to transplant to avoid hypoglycemia, are generally no longer required even if the individual has not attained complete insulin independence. Patients are encouraged to take regular exercise, as this will facilitate good blood glucose control.
Posttransplant Monitoring After transplant, regular and careful monitoring of immunosuppressant levels is required, both to ensure that effective levels are rapidly achieved and maintained and to ensure that levels do not overshoot the target, leading to toxicity. Meticulous self-monitoring of blood glucose level is recommended to guide dosing of supplementary insulin in those who are not yet insulin independent. Insulin requirements tend to increase over the first two weeks, usually reflecting improved appetite that is generally impaired after starting immunosuppressants.
Over the subsequent few weeks, insulin requirements are reduced, presumably reflecting improvements in islet function accompanying engraftment. A decision regarding the need for a further islet infusion is generally made after one month. By this point, further improvements in islet function are unlikely to be significant and the very common elevations of hepatic enzymes will usually have resolved [98].
Assessment of Islet Function Graft function can be assessed in a number of ways; for example, using a range of metabolic tests. The interpretation of the results is not always clear. It is unusual for these data to influence clinical care significantly, unless the test indicates complete graft loss, when a decision to discontinue immunosuppression is clarified. It is likely that in this situation the test will likely be merely to confirm and document the clinical impression. Frequent severe hypoglycemia, erratic blood glucose levels, and increased insulin requirements to pretransplant levels all suggest graft dysfunction or failure. The simplest estimates of graft function can be derived from records of self-monitoring of blood glucose and daily insulin requirements. These are not completely precise because they can be influenced by factors other than graft function, such as diet and exercise. Some patients’ dietary restrictions and excessive exercise, resulting from a desire to maintain euglycemia, have resulted in an unhealthy amount of weight loss. Fasting and postprandial estimates of blood glucose and C-peptide levels can give some impression of graft function. The interpretation of C-peptide levels can be difficult, particularly in individuals who are using insulin. C-peptide levels will vary depending on blood glucose levels that are variable. Fasting C-peptide levels, for example, could be low, even below the level of detection by the assay, but would not necessarily reflect graft dysfunction if the fasting glucose were also low. In contrast, undetectable C-peptide levels in the face of hyperglycemia would indicate significant graft dysfunction. The slow turnover of glycated hemoglobin A1c , used to monitor long-term glycemic control in diabetes, means it is not useful as an early marker of graft dysfunction. Other standardized tests include a mixed-meal test or a standard 75-g oral glucose tolerance test. A disadvantage of these tests is that they cause hyperglycemia, which indeed is the stimulus for islets in these tests.
70
5.
Islet Transplants for Diabetes: The Edmonton Protocol
Intravenous arginine will also stimulate insulin secretion from islets but by a glucose-independent mechanism, thus avoiding hyperglycemia. Again, the interpretation of these data is not always straightforward because within an individual there can be discordance between the results of oral mixed-meal and intravenous arginine tests. More specialized tests seek to tease out more detailed information about the ability of transplanted islets to secrete insulin. The intravenous glucose tolerance test permits the estimation of a number of parameters, including the acute insulin response to glucose as well as the area under the insulin curve and calculation of a disposition index. The glucose-potentiated arginine test relies on the fact that insulin secretion in response to arginine is markedly augmented by prior infusion of glucose. This is thought to indicate the maximum capacity of the islets to secrete insulin and has been proposed as a marker of functional beta cell mass [131]. Data from islet transplant recipients show a weak relationship between glucose-potentiated arginine insulin secretion and the number of transplanted islets [92]. Better tools to assess functional engrafted beta cell mass are still required. Other aspects of islet function have been assessed following islet transplantation, including glucagon secretion. Human studies of islet transplantation have demonstrated that the glucagon response to hypoglycemia is not restored to normal [94]. This absence of glucagon secretion is in contrast to studies in dogs receiving intraperitoneal islet transplants, which did secrete glucagon in response to hypoglycemia [53]. It also contrasts with whole-pancreas transplantation where alpha cells appear to function normally [93].
Outcomes Recent advances in islet transplantation using highly purified preparations with steroid-free immunosuppression have been associated with substantially improved outcomes. Definitions of success in islet transplantation have, of recent times at least, focused on insulin independence. Previously, when islet transplantation was less successful the presence of detectible c-peptide was the mark of success. Although insulin independence would seem to be a clearly defined, objective, and categorical variable it can contain a spectrum of success that may only be partial. Insulin independence, for example, might
rely on excessively strict dietary or exercise regimens. Similarly, individuals can be insulin independent and yet continue to have blood glucose values in the diabetic range in response to an oral glucose tolerance test — a situation not dissimilar to people with diet-controlled type 2 diabetes. Thus, insulin independence can be a relatively arbitrary state because there are no agreed levels at which insulin should either be discontinued after transplant or reinitiated with a failing graft. Insulin independence is nonetheless a very visible mark of success. The appetite for a cure for diabetes, with freedom from insulin injections as a badge of success, is huge in the medical and surgical communities as well as among patients and the general population. Some steps toward developing tools quantifying success in islet transplantation as more than just a dichotomous phenomenon have been made. The potential benefits of such a tool could be the ability to decipher incremental improvements in outcomes of different islet transplant protocols. To view anything short of insulin independence as a failure would be to underestimate the significant benefits of endogenous insulin secretion in terms of hypoglycemia avoidance and stable glycemia. There are also suggestions that such “partial success” may have benefits in terms of diabetes complications [39, 40]. The beta score is such a tool developed in Edmonton [110]. This tool gives a score for each of four parameters: fasting glucose, HbA1c , insulin independence, and stimulated c-peptide (with a maximum score of two for each parameter). The score correlates well with blood glucose levels 90 minutes after a mixed-meal test.
Insulin Independence Following initial reports of insulin independence from Edmonton there has been a rapid expansion in islet transplantation. It is estimated that approaching 500 individuals with type 1 diabetes have now received islet transplants at more than 40 institutions worldwide [120]. Edmonton’s initial success has been replicated at other centers. Insulin independence rates at one year continue to be substantial. Combined data from Edmonton, Miami, and Minneapolis indicated a one-year insulin independence rate of 82% [120, 122]. Nevertheless, the preliminary findings of the Immune Tolerance Network sponsored multicenter trial found that success rates at the three most experienced sites (> 80%) were much higher and less variable than in newly established sites (0 to 63%) [123].
71
P. A. Senior and A. M. James Shapiro
Longer-term insulin independence rates are perhaps less impressive. Of the first 69 patients transplanted in Edmonton, survival analysis indicates insulin independence rates of only 10% at 5 years [109]. Nevertheless, graft survival at 5 years as indicated by ongoing c-peptide production was 80%. Insulin independence was achieved following a single islet infusion in six subjects, after two infusions in 34, and after three infusions in 8. Three subjects did not achieve insulin independence despite receiving more than 18,000 IE/kg. Thus, insulin independence for more than one month was achieved in 48 completed transplants. The median follow-up in completed transplants was 34.9 months (range 4.1 to 67.8). Insulin independence was maintained for a median of 17 months (interquartile range 6.2 to 26.2). C-peptide persisted longer: median 27 months (range 17.9 to 36.9) [109]. (See Figure 5.3.)
Insulin Secretion and Blood Glucose Control C-peptide secretion and glucose tolerance in response to a mixed-meal test were superior in insulin-independent individuals compared with those with ongoing c-peptide production but who had resumed insulin therapy [109]. A decline in the c-peptide increment following the mixed-meal test seemed to precede the resumption of insulin therapy [109]. There was no evidence to suggest that insulin resistance contributed to the need to resume insulin therapy [109]. Blood glucose control was best in insulin-independent subjects (HbA1c 6.2%; IQ range 5.9 to 6.3), although not
Figure 5.3. Five year islet function–University of Alberta.
strictly normal (< 6.1%); intermediate in those resuming insulin therapy (6.8%; IQ range 6.5 to 7.0); and worst in subjects who had lost graft function (8.1%; IQ range 7.0 to 8.8) [109]. (See Figure 5.4.)
Hypoglycemia and Glycemic Lability Although insulin independence following islet transplantation is almost synonymous with success, there are other worthwhile outcomes that indicate clinical success. Prevention of severe hypoglycemia and stable, predictable blood glucose controls are important clinical outcomes because these are the main indications for islet
Figure 5.4. HbA1C insulin independent.
72
5.
Islet Transplants for Diabetes: The Edmonton Protocol
transplantation. These improvements are highly valued by patients, their families, and their doctors. Scores to objectively quantify both hypoglycemia (HYPO score) and glycemic lability (lability index) have been developed [112]. Both scores correlate well with the clinical impression of experienced diabetologists. Islet transplant candidates have scores that are significantly higher than typical type 1 diabetic controls. Successful islet transplantation has led to normalization of both the HYPO score and lability index [112]. These objective improvements would confirm the clinical impression. Furthermore, the reductions in hypoglycemia and increased stability are attributable to graft function, rather than improved self-care, in that the loss of graft function has been associated with a deterioration in both of these scores to pretransplant levels [112]. The improvements in HYPO and LI seem to be maintained with ongoing graft function, even if insulin therapy is resumed. This partly reflects the smaller insulin doses required in those with persistent graft function who require supplemental exogenous insulin. It also reflects the buffering role played by functional islets because they secrete insulin in a glucose-dependent manner. Thus, on occasions when insulin requirements are lower than usual (perhaps because of increased physical activity or lower carbohydrate intake) even if the supplemental insulin dose was not reduced insulin secretion from engrafted islets would decrease as glucose levels fell, reducing the risk of hypoglycemia.
Microvascular Complications Amputations, blindness, and kidney failure are complications of diabetes that are greatly feared by patients. Although the risks of complications can be reduced by tight glycemic control, they are not abolished. Furthermore, most patients with type 1 diabetes are unable to achieve the strict targets for glycemic control recommended by their doctors. As indicated earlier, hypoglycemia is a major factor that limits the ability to achieve glycemic targets with insulin therapy. It is often hoped that islet transplantation will enable people with diabetes to achieve superior glycemic control and thus prevent microvascular complications. While this seems a reasonable premise, it will likely take some time to accumulate sufficient data to confirm this unambiguously. Furthermore, there are some data that would suggest this view may be overly optimistic.
There are data examining the ability of islet or pancreas transplants to prevent complications in animal models of diabetes. A consistent finding in these studies is that reversal or prevention of complications is much more likely when transplantation (and presumably normalization of glycemia) takes place soon after the onset of diabetes [80, 97]. Another theme that emerges is the importance of achieving euglycemia. In a direct comparison between islet and pancreas transplantation in diabetic rats, superior glycemic control was achieved after pancreas transplantation, and only pancreas transplantation was able to prevent glomerulopathy (the early stage of diabetic nephropathy) [127]. In human studies of whole-pancreas transplantation, there is data to suggest a beneficial effect on microvascular complications. For example, reduced proteinuria at one year has been observed [31]. However, sustained normoglycemia over 10 years is required before regression of the histological changes of diabetic nephropathy can be observed [38]. Simultaneous pancreas and kidney (SPK) transplantation is associated with a reduced need for laser therapy for diabetic retinopathy compared with kidney transplantation alone [66]. However, more than 30% of SPK recipients required laser within 3 years following transplantation [66]. This raises the possibility that there may be perpetuating factors other than hyperglycemia in operation in the context of established complications. Advanced glycated end (AGE) products, for example, turn over slowly and are prosclerotic. Thus, AGEs could promote ongoing fibrosis that is typically seen in diabetic nephropathy. The strongest evidence for an effective means of preventing microvascular complications in humans is from the diabetes control and complications trial [3]. This trial examined the ability of intensive insulin therapy to prevent (primary prevention) and delay the progression (secondary prevention) of microvascular complications (predominantly retinopathy). Two points are worth noting before this data is extrapolated to the islet transplant setting. First, complications in the secondary prevention arm were at a relatively early stage. Second, rates of nephropathy in the intensively treated secondary prevention arm were the same as in the conventionally treated primary prevention arm, suggesting that it was more difficult to prevent nephropathy in those with established microvascular complications. Currently, most patients receiving clinical islet transplants have a long duration of diabetes and many have established complications. The animal and human
73
P. A. Senior and A. M. James Shapiro
data would suggest that although islet transplantation could reasonably be assumed to slow the progression of microvascular complications in many people it will be difficult to prevent them completely. The ability to reliably regress long-established complications will likely require sustained, robust euglycemia. Whether islet transplantation can reliably deliver the same degree of euglycemia as whole-pancreas transplantation remains to be demonstrated. In the last 5 years in Edmonton, laser photocoagulation has been required in 14% of patients receiving islet transplants [109]. In many cases this was after a relatively short period following islet transplantation. This is probably to be expected because although ultimately beneficial improved glycemic control is associated with a short-term worsening of diabetic retinopathy [2]. Concern regarding the impact of islet transplantation on renal function was raised in early reports from Edmonton [108, 121]. A decline in glomerular function rate was observed in two patients with preexisting renal dysfunction [108]. However, it is most likely that this decline was due to the hemodynamic effects of tacrolimus rather than the progression of diabetic nephropathy. Nevertheless, subsequent data from Edmonton indicate that development or progression of albuminuria (a typical feature of diabetic nephropathy) is seen in a significant proportion (40%) of islet transplant recipients [118]. The relative contributions of the transplant itself, and the direct and indirect effects of the immunosuppressant drugs, remain to be clarified. Immunosuppressants could have a direct impact on renal function because they are nephrotoxic. These drugs also increase blood pressure that accelerates diabetic nephropathy. Sirolimus is associated with hypertension, but has been thought to be free of direct nephrotoxic side effects. This assumption has been questioned recently with several reports of heavy proteinuria developing after renal transplantation [36] and now after islet transplantation [116]. Other data suggest that ongoing islet graft function, albeit short of insulin independence, may be associated with superior renal function in the context of kidney plus islet transplantation [41]. Fiorina et al. demonstrated reduced albuminuria and improved renal graft survival in those with continued c-peptide production compared with those who had lost islet graft function. There was no difference in GFR, however, and the differences in albuminuria could be attributed to superior blood pressure control. The improved survival of kidney grafts in those with surviving islet grafts arguably has more to do
with immunological matching of the grafts than with a protective effect of endogenous insulin secretion. Although earlier reports in pancreas transplantation have suggested a beneficial effect on diabetic neuropathy, we have not seen any clear positive or negative effect of islet transplantation at this stage.
Cardiovascular Disease Cardiovascular disease is the leading cause of death in people with diabetes. It is not surprising that there has been interest in the impact of islet transplantation on cardiovascular disease and cardiovascular risk factors. It is clear that hyperglycemia is a risk factor for cardiovascular disease, even into the so-called normal range. Changes to the diagnostic criteria for diabetes have reflected this [6]. The new condition of prediabetes (impaired fasting glucose and impaired glucose tolerance) is associated with increased risk not only for diabetes but for cardiovascular disease [6]. Despite the clear associations between hyperglycemia and cardiovascular disease, to date there are no clinical trials that have demonstrated the ability for improved glycemic control to reduce cardiovascular events. Nevertheless, preliminary data from long-term follow-up of the DCCT cohort are promising. Six and a half years of tight glycemic control was associated, some 10 years later, with a 57% reduction in risk of cardiovascular end points (heart attack and stroke) (Nathan et al. ADA, 2005). Although relatively young, and with low cholesterol levels and little hypertension, coronary artery disease is common (43% of asymptomatic applicants) in prospective islet transplant recipients [117]. Following transplantation, there is an increase in the proportion of individuals receiving antihypertensive and lipid-lowering therapies [109]. Although hypertension and dyslipidemia (recognized adverse effects of sirolimus) are more common, we have not seen as yet any evidence of progression of cardiovascular disease either clinically or on annual myocardial perfusion imaging following islet transplantation. Other groups have demonstrated improvements in surrogate markers of cardiovascular disease and endothelial function following islet transplantation. Again, in the context of islet plus kidney transplant individuals with persistent c-peptide production had improved endothelial function, reduced progression in intima-medial
74
5.
Islet Transplants for Diabetes: The Edmonton Protocol
thickness (a marker of atherosclerosis), and the suggestion of fewer cardiovascular deaths [40].
Risks of Islet Transplantation The risks of islet transplantation can be divided broadly into four categories. • • • •
Procedural risks Side effects of immunosuppressant drugs Risks of long-term immunosuppression As yet “unknown” risks of this novel treatment.
These have been described in detail previously [111], but a brief summary here is helpful. The major procedural risks of islet transplantation via a transcutaneous approach to the portal vein are bleeding from the hepatic puncture. One case of upper GI bleeding immediately following islet transplantation suggested the formation of a fistula between a hepatic vessel and the biliary tree. In a small number of cases, bleeding has been associated with cardiovascular instability and necessitated blood transfusion. Bleeding and biliary punctures have been associated with abdominal pain, which although requiring opiate analgesia in some have been self-limiting and have not required specific therapy. Portal venous thrombosis has, fortunately, been an uncommon complication. There have been a small number of branch portal vein thromboses (< 4% of procedures), but none affecting the main portal vein. These have resolved after a period of anticoagulation. There is a rise in liver enzymes in almost all subjects following clinical islet transplantation. In some cases, these have been to levels greater than ten times the upper limit of normal [98]. The very marked elevations noted in a few patients are thought to be due to a specific batch of enzymes used in the preparation of the islets. The more modest elevations seen routinely are thought to reflect the inflammatory response to the graft and the islet transplant procedure itself. Generally, these elevations are asymptomatic and resolve spontaneously within 4 to 6 weeks [98]. There have been no procedural deaths. There was one postoperative myocardial infarct following severe vomiting and inadequate beta blockade (due to omission of regular betablockers because of immunosuppressant related nausea) in a patient with preexisting coronary disease.
The immunosuppressants used in islet transplantation have a number of side effects. Side effects of sirolimus and tacrolimus include nausea, oral ulceration, GI upset (either diarrhea or constipation), fatigue, anemia, neutropenia, edema, tremor, acne, hypertension, and dyslipidemia. Of the two, tacrolimus is better tolerated, but tacrolimus is used at lower doses when combined with sirolimus in islet transplantation. More side effects of tacrolimus (nephrotoxicity, tremor, and anxiety) are seen when higher doses of tacrolimus are used. Increased doses of tacrolimus are used when sirolimus is not tolerated and mycophenolate mofetil is substituted for sirolimus. Mycophenolate is associated with gastrointestinal side effects; mainly diarrhea, which usually improves with dose reductions. Long-term immunosuppression is associated with risks of infection, particularly with atypical organisms. Cytomegalovirus (CMV) can be transmitted from donor to recipient. CMV disease can pose a risk to the graft and to the recipient. Rates of CMV transmission seem to be lower in islet transplantation than in solid organ transplantation, perhaps reflecting the small amount of highly purified and lymphocyte free tissue that is transplanted. In Edmonton, two cases of possible seroconversion have been observed following transplantation but no cases of CMV disease. One case of late CMV seroconversion, perhaps indicating subclinical CMV disease, has been reported in another islet transplant center [43]. Neoplasia is another risk, with posttransplant lymphoproliferative disease (PTLD) a serious malignancy associated with immunosuppression in solid organ as well as bone marrow transplantation [130]. Currently, no cases of PTLD have been reported after clinical islet transplantation. The long-term consequences of intraportal islet transplantation and intrahepatic insulin secretion remain unknown. The secretion of insulin is not entirely physiological and glucagon secretion appears abnormal [94]. Hepatic steatosis, observed on ultrasound and MRI after islet transplantation, is likely associated with intrahepatic insulin secretion [15, 77]. Frequently, the steatosis is patchy, presumably reflecting the fact that islets are scattered throughout the liver. There is the suggestion that steatosis may indicate graft stress, rather than health [15]. A uniform homogeneous pattern of hepatic steatosis is generally seen in association with the hyperinsulinemia seen in insulin resistant states, such as type 2 diabetes. Hyperinsulinemia seems to be a key underlying feature in nonalcoholic steatohepatitis (NASH), which is improved by interventions that reduce insulin
75
P. A. Senior and A. M. James Shapiro
resistance [33]. A proportion of subjects with NASH seem to be at risk for liver cirrhosis and liver cancer. The steatosis seen after islet transplantation thus warrants careful observation. Other, as yet unknown, risks may become apparent with long-term follow-up of islet transplant recipients.
Summary Over time, as the number of islet transplant procedures and the duration of follow-up increase the effectiveness and benefits, as well as the limitations, of islet transplantation become clearer. Recent developments in islet transplantation undoubtedly represent a very significant step forward in terms of insulin independence and graft survival rates compared with historical data. Furthermore, the procedure seems to be safe, particularly in contrast to whole-pancreas transplantation that continues to have finite perioperative mortality. Nevertheless, questions remain about the degree of glycemic control achieved by islet transplantation, its longevity, and the ability of islet transplantation to have a clear beneficial impact on micro- and macrovascular complications. It does seem clear, however, that islet transplantation is effective for reducing hypoglycemia and stabilizing glycemic control [113]. Successful islet transplantation also reduces the fear of hypoglycemia [60] and anecdotally has a hugely positive impact on the quality of life of selected patients with type 1 diabetes who have the most difficult problems with hypoglycemia and lability. Although encouraging, it is clear that there are a number of challenges that must be overcome. One of the challenges is the apparent decline in graft function over time. The reasons for declining graft function over time are unclear. Consequently, it is difficult to know in which way efforts to intervene should be directed. There are currently no markers for rejection. Nor is it possible to reliably biopsy transplanted islets. (A small number of liver biopsies, performed for various reasons, have incidentally noted the presence of functional islets on some occasions, but not in all cases.) Such graft dysfunction could be due to rejection caused by alloimmunity, which in other transplant settings would be treated by increased immunosuppression. However, there is the suspicion that some late graft dysfunction may reflect immunosuppressant toxicity. For example, the antiproliferative effects of sirolimus may prevent islet proliferation or neogenesis. Additionally, autoimmunity is an additional
immune challenge in islet transplantation that could lead to graft dysfunction. Thus, currently islet transplantation is a specialized treatment that can be a life-altering treatment for a highly selected group of type 1 diabetic patients. It is clear that there is scope for significant improvements that hopefully will permit the full potential of this treatment to be realized and the availability of this treatment can be expanded to a broader audience.
Other Transplant Settings AUTOISLET TRANSPLANTATION So far the discussion of islet transplantation has been confined to islet-alone allotransplantation for type 1 diabetes. Autotransplantation of islets following pancreatectomy has been used for many years, albeit in relatively small numbers of cases. Many of the concerns and cautions surrounding clinical islet allotransplantation do not apply to autotransplantation. There is neither allo- nor autoimmunity to be concerned about, nor is there any need for long-term immunosuppression. Nevertheless, the risks of portal vein thrombosis have been considerable, particularly because large impure preparations of islets have tended to be used. The expertise of the islet isolation lab in Edmonton has facilitated islet autotransplantation locally. Isolating islets from these diseased pancreata, which are often fibrotic due to chronic pancreatitis, is not always easy. Nevertheless, the avoidance of the cytokine storm seen in brain-dead donors and minimized cold ischemia time mitigates this difficulty [29].
ALLOTRANSPLANTATION FOR SECONDARY DIABETES Islet allotransplantation has been restricted to patients with type 1 diabetes, not least because they are insulin deficient and insulin sensitive. As such, the likelihood that islet transplantation could have a beneficial effect is maximized. In particular, the ability to achieve insulin independence is enhanced. Individuals with secondary diabetes, due to pancreatic disease or following pancreatic surgery, could, however, be considered for islet allotransplantation because such patients may experience the same difficulties with hypoglycemia and glycemic lability as the type 1 patients currently considered for
76
5.
Islet Transplants for Diabetes: The Edmonton Protocol
clinical islet transplantation. One important exclusion would be those with diabetes secondary to pancreatectomy for cancer.
ISLET ALLOTRANSPLANTATION FOR TYPE 2 DIABETES Some have raised the question of islet allotransplantation for type 2 diabetes. Generally, type 2 diabetes is associated with insulin resistance rather than with insulin deficiency. Most affected patients are heavier than type 1 subjects, and many are overweight or obese. Although in long-standing type 2 diabetes insulin deficiency can develop [135], the majority of subjects continue to have ongoing endogenous islet function. The increased demand placed on transplanted islets because of insulin resistance and greater body weight means that insulin independence would be difficult to achieve. Whether a reduction of insulin requirements by 40 or 50 units of insulin per day is worthwhile in an individual taking 140 units per day is unclear. It is therefore uncertain how beneficial islet transplantation would be in type 2 diabetes and whether these benefits would justify the risks. Particularly in that currently the organ supply is so limited the consensus seems to be to exclude type 2 diabetic patients from islet transplant programs.
OPTIMIZING ENGRAFTMENT The loss of islets during and immediately after transplantation is a major challenge. Developments in the use of agents to prevent the IBMIR [49, 82], the overexpression of antiapoptotic genes [37], and the avoidance of immunosuppressive agents that prevent islet regeneration will hopefully enhance islet engraftment. The ability to expand the number of beta cells either prior or subsequent to islet transplantation would be hugely beneficial. The ability of a number of growth factors to perform in this manner is being explored, including GLP-1, exendin-4, EGF, gastrin, INGAP, and hepatocyte growth factor [24, 76, 85, 87, 106, 128].
SINGLE-DONOR TRANSPLANTATION Optimization of islet isolation and engraftment, and developments in the ability to expand the beta cell mass, will play a role in facilitating reliable single-donor transplant success. Currently, single-donor success has been reported by the Minnesota group [55]. It is not clear whether developments in islet isolation or transplantation procedures, immunosuppression, or careful selection of donors and recipients are the most important factors leading to this success [122]. Nevertheless, single-donor success is an important milestone in the progress of islet transplantation.
Future Directions Despite rapid progress, much remains to be done before the dream of a cure for diabetes will be realized. Research focused in a number of areas holds promise for the future — some in the nearer term, others further into the future.
OPTIMIZATION OF ISLET ISOLATION Currently, islet isolation remains inefficient and unpredictable. Ultimately, the aim would be to develop the ability to reliably isolate sufficient islets from a single-donor pancreas to treat one or more diabetic recipients. The complexity of the islet isolation process means that there are a large number of variables that must be considered in order to optimize the yield of transplantable preparations. Improvements in organ procurement, transportation, and islet culture (as well as a reliable supply of enzymes with predictable performance) will all be helpful.
LIVING DONOR ISLET TRANSPLANTATION The first successful living donor islet transplant was reported recently by a group from Japan [78]. Achieving insulin independence following the infusion of islets isolated from a distal pancreatectomy (i.e., half a pancreas) underscores the major insults (cold ischemia and the proinflammatory cytokines associated with brain injury [29]) to which islets are exposed when isolated from cadaveric donors. Living donor transplantation could help overcome some of the difficulties of organ supply and may improve tissue matching. Making islet transplantation an elective procedure has benefits in terms of the conditioning treatments that can be given to the recipient even prior to islet isolation, let alone prior to islet infusion. Nevertheless, there are finite risks for the donor, from the procedure itself in the short term and of developing diabetes in the longer term [52, 129]. The use of a laparoscopic approach to distal pancreatectomy in
77
P. A. Senior and A. M. James Shapiro
the donor and careful selection of lean donors with good beta cell reserve should minimize these risks. Expectations of the isolation lab’s performance will be heightened because processing the pancreas from a living donor raises the stakes compared to a cadaveric donor pancreas. Living donation may be an attractive option for children with diabetes. A smaller number of islets may be required for insulin independence in view of their smaller size. Current immunosuppression may make this scenario less attractive because of the risks of long-term immunosuppression and the requirement for beta cell mass to expand to meet the increased insulin secretory demands associated with growth and puberty.
MINIMAL IMMUNOSUPPRESSION AND TOLERANCE Although sirolimus and tacrolimus have played a key role in the success of the “Edmonton protocol,” these drugs have side effects (some serious) that limit their tolerability. Further developments of novel immunosuppressant therapies that are more “islet friendly” with fewer nonimmune side effects would likely be associated with improved outcomes [120]. Together, these improvements would have a synergistic effect improving the risk/benefit ratio for islet transplantation. Some of these “islet friendly” approaches may have the potential to induce tolerance in animal models [120]. Tolerance refers to the concept of retraining the immune system such that it can accept an allotransplant as self. This would obviate the need for immunosuppression. Although full tolerance may be a distant possibility, interim steps might permit minimization of the immunosuppression required following transplantation. Clinical trials of such strategies are being designed.
ALTERNATIVE SOURCES OF ISLETS The limited organ supply is a major barrier to more widespread application of islet transplantation. Even with successful single donor protocols, the number of available organs is far outstripped by the number of people with diabetes who potentially could benefit from islet transplantation. A great deal of research is focused on the identification of alternative sources of islets or insulin-secreting cells. Xenotransplantation of porcine islets is being actively explored. Pork insulin can effectively control diabetes
in humans and was a standard therapy until the advent of recombinant human insulin. Porcine pancreata represent a potentially unlimited supply of organs from which islets can be isolated. Nevertheless, xenotransplantation poses a number of substantial challenges, not least the hyperacute rejection mediated by alpha Gal and other xenoantigens [30]. Ensuring the safety of xenotransplantation, particularly because of the potential for zoonoses, and the risks of porcine endogenous retrovirus (PERV) infections are further challenges [42]. Stem cell research and attempts to promote transdifferentiation of progenitor and ductal cells into insulinsecreting cells are another focus [54, 91]. Other groups are attempting to enable differentiated cells, including hepatocytes and myocytes, to secrete insulin in a glucose-dependent manner by a number of different approaches [7, 28, 83, 138].
Conclusions Some of the initial enthusiasm surrounding the initial reports of insulin independence after islet transplantation from Edmonton has been tempered by the realization that we are still a long way from the cure for diabetes we continue to pursue. Nevertheless, the Edmonton protocol has been an important step in this ongoing journey. It has helped raise the profile of islet transplantation among the general public as well as people with diabetes. Furthermore, it has provided a major impetus for further research as well as attracting increased commitment to research funding. The decline in insulin independence rates despite ongoing graft function raises important questions about the biology of transplanted islets and represents a challenge to be overcome. Islet transplantation as a clinical treatment for people with type 1 diabetes is now a reality, which is making a positive impact on the lives of individuals previously blighted by diabetes. The challenges that lie ahead are undoubtedly substantial, but the goal of a cure for diabetes remains incredibly worthwhile.
78
REFERENCES 1. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37:1574–1582; 1988.
5.
Islet Transplants for Diabetes: The Edmonton Protocol
2. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial Research Group. Arch Ophthalmol 116:874–886; 1998. 3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986; 1993. 4. Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685–1691; 2002. 5. United States Renal Data System. Incidence and prevalence of ESRD. Am J Kidney Dis 30:S40–53; 1997. 6. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26:5S–20; 2003. 7. Alam, T., Sollinger, H. W. Glucose-regulated insulin production in hepatocytes. Transplantation 74:1781–1787; 2002. 8. Andersson, A., Korsgren, O., Jansson, L. Intraportally transplanted pancreatic islets revascularized from hepatic arterial system. Diabetes 38 Suppl 1:192–195; 1989. 9. Ballinger, W. F., Lacy, P. E. Transplantation of intact pancreatic islets in rats. Surgery 72:175–186; 1972. 10. Barnett, M. J., McGhee-Wilson, D., Shapiro, A. M., Lakey, J. R. Variation in human islet viability based on different membrane integrity stains. Cell Transplant 13:481–488; 2004. 11. Bell, E., Cao, X., Moibi, J. A., Greene, S. R., Young, R., Trucco, M., Gao, Z., Matschinsky, F. M., Deng, S., Markman, J. F., Naji, A., Wolf, B. A. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52:2731–2739; 2003. 12. Benhamou, P. Y., Oberholzer, J., Toso, C., Kessler, L., Penfornis, A., Bayle, F., Thivolet, C., Martin, X., Ris, F., Badet, L., Colin, C., Morel, P. Human islet transplantation network for the treatment of type I diabetes: First data from the Swiss-French GRAGIL consortium (1999–2000). Groupe de Recherche Rhin Rhjne Alpes Geneve pour la transplantation d’Ilots de Langerhans. Diabetologia 44:859–864; 2001. 13. Bennet, W., Sundberg, B., Groth, C. G., Brendel, M. D., Brandhorst, D., Brandhorst, H., Bretzel, R. G., Elgue, G., Larsson, R., Nilsson, B., Korsgren, O. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation? Diabetes 48:1907–1914; 1999. 14. Bernard-Kargar, C., Ktorza, A. Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 50 Suppl 1:S30–35; 2001. 15. Bhargava, R., Senior, P. A., Ackerman, T. E., Ryan, E. A., Paty, B. W., Lakey, J. R., Shapiro, A. M. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 53:1311–1317; 2004. 16. Biarnes, M., Montolio, M., Nacher, V., Raurell, M., Soler, J., Montanya, E. Beta-cell death and mass in syngeneically
79
17. 18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 51:66–72; 2002. Bliss, M.: The Discovery of Insulin. Toronto, University of Toronto Press, 2000. Bock, T., Pakkenberg, B., Buschard, K. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52:1716–1722; 2003. Bock, T., Svenstrup, K., Pakkenberg, B., Buschard, K. Unbiased estimation of total beta-cell number and mean beta-cell volume in rodent pancreas. Apmis 107:791–799; 1999. Bonner-Weir, S., Orci, L. New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 31:883–889; 1982. Bougneres, P. F., Carel, J. C., Castano, L., Boitard, C., Gardin, J. P., Landais, P., Hors, J., Mihatsch, M. J., Paillard, M., Chaussain, J. L., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318:663–670; 1988. Brill, A., Dashevsky, O., Rivo, J., Gozal, Y., Varon, D. Plateletderived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 67:30–38; 2005. Bucher, P., Mathe, Z., Morel, P., Bosco, D., Andres, A., Kurfuest, M., Friedrich, O., Raemsch-Guenther, N., Buhler, L. H., Berney, T. Assessment of a novel twocomponent enzyme preparation for human islet isolation and transplantation. Transplantation 79:91–97; 2005. Bulotta, A., Farilla, L., Hui, H., Perfetti, R. The role of GLP-1 in the regulation of islet cell mass. Cell Biochem Biophys 40: 65–78; 2004. Carlsson, P. O., Palm, F., Andersson, A., Liss, P. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 50:489–495; 2001. Carlsson, P. O., Palm, F., Mattsson, G. Low revascularization of experimentally transplanted human pancreatic islets. J Clin Endocrinol Metab 87:5418–5423; 2002. Casey, J. J., Lakey, J. R., Ryan, E. A., Paty, B. W., Owen, R., O’Kelly, K., Nanji, S., Rajotte, R. V., Korbutt, G. S., Bigam, D., Kneteman, N. N., Shapiro, A. M. Portal venous pressure changes after sequential clinical islet transplantation. Transplantation 74:913–915; 2002. Chen, N. K., Sivalingam, J., Tan, S. Y., Kon, O. L. Plasmid-electroporated primary hepatocytes acquire quasiphysiological secretion of human insulin and restore euglycemia in diabetic mice. Gene Ther 12:655–667; 2005. Contreras, J. L., Eckstein, C., Smyth, C. A., Sellers, M. T., Vilatoba, M., Bilbao, G., Rahemtulla, F. G., Young, C. J., Thompson, J. A., Chaudry, I. H., Eckhoff, D. E. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes 52:2935–2942; 2003. Cooper, D. K., Gollackner, B., Knosalla, C., Teranishi, K. Xenotransplantation: How far have we come? Transpl Immunol 9:251–256; 2002.
P. A. Senior and A. M. James Shapiro 31. Coppelli, A., Giannarelli, R., Vistoli, F., Del Prato, S., Rizzo, G., Mosca, F., Boggi, U., Marchetti, P. The beneficial effects of pancreas transplant alone on diabetic nephropathy. Diabetes Care 28:1366–1370; 2005. 32. Davalli, A. M., Ogawa, Y., Ricordi, C., Scharp, D. W., Bonner-Weir, S., Weir, G. C. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 59:817–820; 1995. 33. Day, C. P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16:663–678; 2002. 34. DeFronzo, R. A. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview. Diabetologia 35:389–397; 1992. 35. Desai, N. M., Goss, J. A., Deng, S., Wolf, B. A., Markmann, E., Palanjian, M., Shock, A. P., Feliciano, S., Brunicardi, F. C., Barker, C. F., Naji, A., Markmann, J. F. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: Local immunosuppression or islet toxicity? Transplantation 76:1623–1625; 2003. 36. Dittrich, E., Schmaldienst, S., Soleiman, A., Horl, W. H., Pohanka, E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 17:215–220; 2004. 37. Emamaullee, J., Liston, P., Korneluk, R. G., Shapiro, A. M., Elliott, J. F. XIAP overexpression in islet beta-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant 5:1297–1305; 2005. 38. Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C., Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69–75; 1998. 39. Fiorina, P., Folli, F., Bertuzzi, F., Maffi, P., Finzi, G., Venturini, M., Socci, C., Davalli, A., Orsenigo, E., Monti, L., Falqui, L., Uccella, S., La Rosa, S., Usellini, L., Properzi, G., Di Carlo, V., Del Maschio, A., Capella, C., Secchi, A. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidneytransplanted patients. Diabetes Care 26:1129–1136; 2003. 40. Fiorina, P., Folli, F., Maffi, P., Placidi, C., Venturini, M., Finzi, G., Bertuzzi, F., Davalli, A., D’Angelo, A., Socci, C., Gremizzi, C., Orsenigo, E., La Rosa, S., Ponzoni, M., Cardillo, M., Scalamogna, M., Del Maschio, A., Capella, C., Di Carlo, V., Secchi, A. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: A comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 75:1296–1301; 2003. 41. Fiorina, P., Folli, F., Zerbini, G., Maffi, P., Gremizzi, C., Di Carlo, V., Socci, C., Bertuzzi, F., Kashgarian, M., Secchi, A. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 14:2150–2158; 2003. 42. Fishman, J. A., Patience, C. Xenotransplantation: Infectious risk revisited. Am J Transplant 4:1383–1390; 2004.
80
43. Froud, T., Ricordi, C., Baidal, D. A., Hafiz, M. M., Ponte, G., Cure, P., Pileggi, A., Poggioli, R., Ichii, H., Khan, A., Ferreira, J. V., Pugliese, A., Esquenazi, V. V., Kenyon, N. S., Alejandro, R. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 5:2037–2046; 2005. 44. Gale, E. A., Bingley, P. J., Emmett, C. L., Collier, T. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363:925–931; 2004. 45. Gepts, W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:619–633; 1965. 46. Gerich, J. E. Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37:1608–1617; 1988. 47. Girman, P., Kriz, J., Friedmansky, J., Saudek, F. Digital imaging as a possible approach in evaluation of islet yield. Cell Transplant 12:129–133; 2003. 48. Goss, J. A., Schock, A. P., Brunicardi, F. C., Goodpastor, S. E., Garber, A. J., Soltes, G., Barth, M., Froud, T., Alejandro, R., Ricordi, C. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 74:1761–1766; 2002. 49. Goto, M., Johansson, H., Maeda, A., Elgue, G., Korsgren, O., Nilsson, B. Low-molecular weight dextran sulfate abrogates the instant blood-mediated inflammatory reaction induced by adult porcine islets both in vitro and in vivo. Transplant Proc 36:1186–1187; 2004. 50. Grube, D., Bohn, R. The microanatomy of human islets of Langerhans, with special reference to somatostatin (D-) cells. Arch Histol Jpn 46:327–353; 1983. 51. Gruessner, A. C., Sutherland, D. E. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of May 2003. Clin Transpl :21–51; 2003. 52. Gruessner, R. W., Sutherland, D. E., Drangstveit, M. B., Bland, B. J., Gruessner, A. C. Pancreas transplants from living donors: Short- and long-term outcome. Transplant Proc 33:819–820; 2001. 53. Gupta, V., Wahoff, D. C., Rooney, D. P., Poitout, V., Sutherland, D. E., Kendall, D. M., Robertson, R. P. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation sitedetermined. Diabetes 46:28–33; 1997. 54. Halban, P. A. Cellular sources of new pancreatic beta cells and therapeutic implications for regenerative medicine. Nat Cell Biol 6:1021–1025; 2004. 55. Hering, B. J., Kandaswamy, R., Ansite, J. D., Eckman, P. M., Nakano, M., Sawada, T., Matsumoto, I., Ihm, S. H., Zhang, H. J., Parkey, J., Hunter, D. W., Sutherland, D. E. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. Jama 293:830–835; 2005.
5.
Islet Transplants for Diabetes: The Edmonton Protocol
56. Hering, B. J., Kandaswamy, R., Harmon, J. V., Ansite, J. D., Clemmings, S. M., Sakai, T., Paraskevas, S., Eckman, P. M., Sageshima, J., Nakano, M., Sawada, T., Matsumoto, I., Zhang, H. J., Sutherland, D. E., Bluestone, J. A. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 4:390–401; 2004. 57. Hovind, P., Tarnow, L., Rossing, K., Rossing, P., Eising, S., Larsen, N., Binder, C., Parving, H. H. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26:1258–1264; 2003. 58. Jansson, L., Hellerstrom, C. Stimulation by glucose of the blood flow to the pancreatic islets of the rat. Diabetologia 25:45–50; 1983. 59. Johansson, H., Lukinius, A., Moberg, L., Lundgren, T., Berne, C., Foss, A., Felldin, M., Kallen, R., Salmela, K., Tibell, A., Tufveson, G., Ekdahl, K. N., Elgue, G., Korsgren, O., Nilsson, B. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 54:1755–1762; 2005. 60. Johnson, J. A., Kotovych, M., Ryan, E. A., Shapiro, A. M. Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care 27:624–625; 2004. 61. Juhl, C., Grofte, T., Butler, P. C., Veldhuis, J. D., Schmitz, O., Porksen, N. Effects of fasting on physiologically pulsatile insulin release in healthy humans. Diabetes 51 Suppl 1:S255–257; 2002. 62. Kiba, T. Relationships between the autonomic nervous system and the pancreas including regulation of regeneration and apoptosis: Recent developments. Pancreas 29:e51–58; 2004. 63. King, H., Aubert, R. E., Herman, W. H. Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431; 1998. 64. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403; 2002. 65. Knowler, W. C., Hamman, R. F., Edelstein, S. L., Barrett-Connor, E., Ehrmann, D. A., Walker, E. A., Fowler, S. E., Nathan, D. M., Kahn, S. E. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150–1156; 2005. 66. Koznarova, R., Saudek, F., Sosna, T., Adamec, M., Jedinakova, T., Boucek, P., Bartos, V., Lanska, V. Beneficial effect of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant 9:903–908; 2000. 67. Lacy, P. E., Kostianovsky, M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39; 1967. 68. Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W., Hill, R. D., Bingley, P. J., Patterson, C. C., Qiao, Z., Keen, H. The British Diabetic Association Cohort Study, I: All-cause mortality in
81
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
patients with insulin-treated diabetes mellitus. Diabet Med 16:459–465; 1999. Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W., Hill, R. D., Bingley, P. J., Patterson, C. C., Qiao, Z., Keen, H. The British Diabetic Association Cohort Study, II: Cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16:466–471; 1999. Lakey, J. R., Cavanagh, T. J., Zieger, M. A., Wright, M. Evaluation of a purified enzyme blend for the recovery and function of canine pancreatic islets. Cell Transplant 7:365–372; 1998. Lakey, J. R., Warnock, G. L., Rajotte, R. V., SuarezAlamazor, M. E., Ao, Z., Shapiro, A. M., Kneteman, N. M. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 61:1047–1053; 1996. Lakey, J. R., Warnock, G. L., Shapiro, A. M., Korbutt, G. S., Ao, Z., Kneteman, N. M., Rajotte, R. V. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 8:285–292; 1999. Lembert, N., Wesche, J., Petersen, P., Doser, M., Becker, H. D., Ammon, H. P. Areal density measurement is a convenient method for the determination of porcine islet equivalents without counting and sizing individual islets. Cell Transplant 12:33–41; 2003. Lifson, N., Kramlinger, K. G., Mayrand, R. R., Lender, E. J. Blood flow to the rabbit pancreas with special reference to the islets of Langerhans. Gastroenterology 79:466–473; 1980. Linetsky, E., Bottino, R., Lehmann, R., Alejandro, R., Inverardi, L., Ricordi, C. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 46:1120–1123; 1997. Lopez-Talavera, J. C., Garcia-Ocana, A., Sipula, I., Takane, K. K., Cozar-Castellano, I., Stewart, A. F. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: Reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 145:467–474; 2004. Markmann, J. F., Rosen, M., Siegelman, E. S., Soulen, M. C., Deng, S., Barker, C. F., Naji, A. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: A functional footprint of islet graft survival? Diabetes 52:1591–1594; 2003. Matsumoto, S., Okitsu, T., Iwanaga, Y., Noguchi, H., Nagata, H., Yonekawa, Y., Yamada, Y., Fukuda, K., Tsukiyama, K., Suzuki, H., Kawasaki, Y., Shimodaira, M., Matsuoka, K., Shibata, T., Kasai, Y., Maekawa, T., Shapiro, J., Tanaka, K. Insulin independence after livingdonor distal pancreatectomy and islet allotransplantation. Lancet 365:1642–1644; 2005. Matsumoto, S., Rigley, T. H., Qualley, S. A., Kuroda, Y., Reems, J. A., Stevens, R. B. Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant 11:769–777; 2002.
P. A. Senior and A. M. James Shapiro 80. Miao, G., Ito, T., Uchikoshi, F., Kamei, M., Akamaru, Y., Kiyomoto, T., Komoda, H., Nozawa, M., Matsuda, H. Stage-dependent effect of pancreatic transplantation on diabetic ocular complications in the spontaneously diabetic Torii rat. Transplantation 77:658–663; 2004. 81. Moberg, L., Johansson, H., Lukinius, A., Berne, C., Foss, A., Kallen, R., Ostraat, O., Salmela, K., Tibell, A., Tufveson, G., Elgue, G., Nilsson Ekdahl, K., Korsgren, O., Nilsson, B. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 360:2039–2045; 2002. 82. Moberg, L., Olsson, A., Berne, C., Felldin, M., Foss, A., Kallen, R., Salmela, K., Tibell, A., Tufveson, G., Nilsson, B., Korsgren, O. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: Implications for clinical islet transplantation. Transplantation 76:1285–1288; 2003. 83. Nakajima-Nagata, N., Sakurai, T., Mitaka, T., Katakai, T., Yamato, E., Miyazaki, J., Tabata, Y., Sugai, M., Shimizu, A. In vitro induction of adult hepatic progenitor cells into insulin-producing cells. Biochem Biophys Res Commun 318:625–630; 2004. 84. Nano, R., Clissi, B., Melzi, R., Calori, G., Maffi, P., Antonioli, B., Marzorati, S., Aldrighetti, L., Freschi, M., Grochowiecki, T., Socci, C., Secchi, A., Di Carlo, V., Bonifacio, E., Bertuzzi, F. Islet isolation for allotransplantation: Variables associated with successful islet yield and graft function. Diabetologia 48:906–912; 2005. 85. Nathan, D. M., Cleary, P. A., Backlund, J. Y., Genuth, S. M., Lachin, J. M., Orchard, T. J., Raskin, P., Zinman, B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653; 2005. 86. Nielsen, J. H., Svensson, C., Galsgaard, E. D., Moldrup, A., Billestrup, N. Beta cell proliferation and growth factors. J Mol Med 77:62–66; 1999. 87. Notkins, A. L., Lernmark, A. Autoimmune type 1 diabetes: Resolved and unresolved issues. J Clin Invest 108:1247–1252; 2001. 88. Ogawa, N., List, J. F., Habener, J. F., Maki, T. Cure of overt diabetes in NOD mice by transient treatment with antilymphocyte serum and exendin-4. Diabetes 53:1700–1705; 2004. 89. Orci, L., Unger, R. H. Functional subdivision of islets of Langerhans and possible role of D cells. Lancet 2:1243–1244; 1975. 90. Owen, R. J., Ryan, E. A., O’Kelly, K., Lakey, J. R., McCarthy, M. C., Paty, B. W., Bigam, D. L., Kneteman, N. M., Korbutt, G. S., Rajotte, R. V., Shapiro, A. M. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: Radiologic aspects. Radiology 229: 165–170; 2003. 91. Paraskevas, S., Maysinger, D., Wang, R., Duguid, T. P., Rosenberg, L. Cell loss in isolated human islets occurs by apoptosis. Pancreas 20:270–276; 2000.
82
92. Paris, M., Tourrel-Cuzin, C., Plachot, C., Ktorza, A. Review: Pancreatic beta-cell neogenesis revisited. Exp Diabesity Res 5:111–121; 2004. 93. Paty, B. W., Imes, S., Ryan, E. A., Senior, P. A., Robertson, R. P., Shapiro, A. M. J. Insulin secretory reserve as a measure of functional islet mass following islet allotransplantation in type 1 diabetes. Diabetes 53:A35–36; 2004. 94. Paty, B. W., Lanz, K., Kendall, D. M., Sutherland, D. E., Robertson, R. P. Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 72:1103–1107; 2001. 95. Paty, B. W., Ryan, E. A., Shapiro, A. M., Lakey, J. R., Robertson, R. P. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes 51:3428–3434; 2002. 96. Petruzzo, P., Laville, M., Badet, L., Lefrancois, N., Bin-Dorel, S., Chapuis, F., Andreelli, F., Martin, X. Effect of venous drainage site on insulin action after simultaneous pancreas-kidney transplantation. Transplantation 77:1875–1879; 2004. 97. Pileggi, A., Ricordi, C., Alessiani, M., Inverardi, L. Factors influencing islet of Langerhans graft function and monitoring. Clin Chim Acta 310:3–16; 2001. 98. Pugliese, G., Pricci, F., Pesce, C., Romeo, G., Lenti, E., Caltabiano, V., Vetri, M., Purrello, F., Di Mario, U. Early, but not advanced, glomerulopathy is reversed by pancreatic islet transplants in experimental diabetic rats: Correlation with glomerular extracellular matrix mRNA levels. Diabetes 46:1198–1206; 1997. 99. Rafael, E., Ryan, E. A., Paty, B. W., Oberholzer, J., Imes, S., Senior, P., McDonald, C., Lakey, J. R., Shapiro, A. M. Changes in liver enzymes after clinical islet transplantation. Transplantation 76:1280–1284; 2003. 100. Rickels, M. R., Schutta, M. H., Markmann, J. F., Barker, C. F., Naji, A., Teff, K. L. {beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes 54:100–106; 2005. 101. Ricordi, C., Fraker, C., Szust, J., Al-Abdullah, I., Poggioli, R., Kirlew, T., Khan, A., Alejandro, R. Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation 75:1524–1527; 2003. 102. Ricordi, C., Gray, D. W., Hering, B. J., Kaufman, D. B., Warnock, G. L., Kneteman, N. M., Lake, S. P., London, N. J., Socci, C., Alejandro, R., et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 27:185–195; 1990. 103. Ricordi, C., Lacy, P. E., Finke, E. H., Olack, B. J., Scharp, D. W. Automated method for isolation of human pancreatic islets. Diabetes 37:413–420; 1988. 104. Ricordi, C., Tzakis, A. G., Carroll, P. B., Zeng, Y. J., Rilo, H. L., Alejandro, R., Shapiro, A., Fung, J. J.,
5.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
Islet Transplants for Diabetes: The Edmonton Protocol
Demetris, A. J., Mintz, D. H., et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 53:407–414; 1992. Ris, F., Toso, C., Veith, F. U., Majno, P., Morel, P., Oberholzer, J. Are criteria for islet and pancreas donors sufficiently different to minimize competition? Am J Transplant 4:763–766; 2004. Robertson, R. P. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes 53:633–644; 2004. Rooman, I., Bouwens, L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia 47:259–265; 2004. Roper, N. A., Bilous, R. W., Kelly, W. F., Unwin, N. C., Connolly, V. M. Cause-specific mortality in a population with diabetes: South Tees diabetes mortality study. Diabetes Care 25:43–48; 2002. Ryan, E. A., Lakey, J. R., Rajotte, R. V., Korbutt, G. S., Kin, T., Imes, S., Rabinovitch, A., Elliott, J. F., Bigam, D., Kneteman, N. M., Warnock, G. L., Larsen, I., Shapiro, A. M. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710–719; 2001. Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R. T., Shapiro, A. M. J. Fiveyear follow-up after clinical islet transplantation. Diabetes 54:2060–2069; 2005. Ryan, E. A., Paty, B. W., Senior, P. A., Lakey, J. R., Bigam, D., Shapiro, A. M. Beta-score: An assessment of beta-cell function after islet transplantation. Diabetes Care 28:343–347; 2005. Ryan, E. A., Paty, B. W., Senior, P. A., Shapiro, A. M. Risks and side effects of islet transplantation. Curr Diab Rep 4: 304–309; 2004. Ryan, E. A., Shandro, T., Green, K., Paty, B. W., Senior, P. A., Bigam, D., Shapiro, A. M., Vantyghem, M. C. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53:955–962; 2004. Ryan, E. A., Shandro, T., Green, K., Paty, B. W., Senior, P. A., Bigam, D., Shapiro, A. M., Vantyghem, M. C. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53:955–962; 2004. Scharp, D. W., Lacy, P. E., Santiago, J. V., McCullough, C. S., Weide, L. G., Falqui, L., Marchetti, P., Gingerich, R. L., Jaffe, A. S., Cryer, P. E., et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 39:515–518; 1990. Schmied, B. M., Ulrich, A., Matsuzaki, H., Ding, X., Ricordi, C., Moyer, M. P., Batra, S. K., Adrian, T. E., Pour, P. M. Maintenance of human islets in long-term culture. Differentiation 66:173–180; 2000.
83
117. Senior, P. A., Paty, B. W., Cockfield, S. M., Ryan, E. A., Shapiro, A. M. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5:2318–2323; 2005. 118. Senior, P. A., Welsh, R. C., McDonald, C. G., Paty, B. W., Shapiro, A. M., Ryan, E. A. Coronary artery disease is common in nonuremic, asymptomatic type 1 diabetic islet transplant candidates. Diabetes Care 28:866–872; 2005. 119. Senior, P. A., Zeman, M., Paty, B. W., Shapiro, A. M., Ryan, E. A. Renal outcomes after clinical islet allotransplantation at the University of Alberta: 4-year follow-up. Diabetes 53:A69; 2004. 120. Sezai, S., Sakurabayashi, S., Yamamoto, Y., Morita, T., Hirano, M., Oka, H. Hepatic arterial and portal venous oxygen content and extraction in liver cirrhosis. Liver 13:31–35; 1993. 121. Shapiro, A. M., Lakey, J. R., Paty, B. W., Senior, P. A., Bigam, D. L., Ryan, E. A. Strategic opportunities in clinical islet transplantation. Transplantation 79:1304–1307; 2005. 122. Shapiro, A. M., Lakey, J. R., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., Rajotte, R. V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238; 2000. 123. Shapiro, A. M., Ricordi, C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant 4:295–298; 2004. 124. Shapiro, A. M., Ricordi, C., Hering, B. Edmonton’s islet success has indeed been replicated elsewhere. Lancet 362:1242; 2003. 125. Shibata, S., Sato, T., Andoh, H., Yasui, O., Yoshioka, M., Kurokawa, T., Watanabe, G., Ise, N., Kotanagi, H., Asanuma, Y., Koyama, K. Outcomes and indications of segmental pancreatectomy. Comparison with distal pancreatectomy. Dig Surg 21:48–53; 2004. 126. Skyler, J. S. Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes Metab Rev 3:1017–1035; 1987. 127. Slezak, L. A., Andersen, D. K. Pancreatic resection: Effects on glucose metabolism. World J Surg 25:452–460; 2001. 128. Spadella, C. T., Schellini, S. A., Bacchi, C. E. Pancreas transplantation versus islet transplantation versus insulin therapy in the prevention of nephropathy in alloxan-induced diabetic rats. Transplant Proc 30:327–329; 1998. 129. Suarez-Pinzon, W. L., Lakey, J. R., Brand, S. J., Rabinovitch, A. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}cells from pancreatic duct cells and an increase in functional {beta}-cell mass. J Clin Endocrinol Metab 90:3401–3409; 2005. 130. Sutherland, D. E., Gruessner, R. W., Dunn, D. L., Matas, A. J., Humar, A., Kandaswamy, R., Mauer, S. M., Kennedy, W. R., Goetz, F. C., Robertson, R. P., Gruessner, A. C., Najarian, J. S. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 233:463–501; 2001.
P. A. Senior and A. M. James Shapiro 131. Taylor, A. L., Marcus, R., Bradley, J. A. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol; 2005. 132. Teuscher, A. U., Kendall, D. M., Smets, Y. F., Leone, J. P., Sutherland, D. E., Robertson, R. P. Successful islet autotransplantation in humans: Functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 47:324–330; 1998. 133. Tsujimura, T., Kuroda, Y., Avila, J. G., Kin, T., Oberholzer, J., Shapiro, A. M., Lakey, J. R. Influence of pancreas preservation on human islet isolation outcomes: Impact of the two-layer method. Transplantation 78:96–100; 2004. 134. Tuomilehto, J., Lindstrom, J., Eriksson, J. G., Valle, T. T., Hamalainen, H., Ilanne-Parikka, P., Keinanen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., Salminen, V., Uusitupa, M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with
84
135.
136.
137.
138. 139.
impaired glucose tolerance. N Engl J Med 344:1343–1350; 2001. Walsh, T. J., Eggleston, J. C., Cameron, J. L. Portal hypertension, hepatic infarction, and liver failure complicating pancreatic islet autotransplantation. Surgery 91:485–487; 1982. Weir, G. C., Bonner-Weir, S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53 Suppl 3:S16–21; 2004. Weir, G. C., Bonner-Weir, S. Five stages of evolving betacell dysfunction during progression to diabetes. Diabetes 53:S16–21; 2004. Williams, P. Notes on diabetes treated with extract and by grafts of sheep’s pancreas. Bmj 2:1303–1304; 1894. Wilson, M. O., Scougall, K. T., Ratanamart, J., McIntyre, E. A., Shaw, J. A. Tetracycline-regulated secretion of human (pro)insulin following plasmid-mediated transfection of human muscle. J Mol Endocrinol 34:391–403; 2005.
6 Characterization of Islet Preparations Clark K. Colton (1), Klearchos K. Papas (1 and 3), Anna Pisania (1), Michael J. Rappel (1), Daryl E. Powers (1), John J. O’Neil (2 and 4), Abdulkadir Omer (2), Gordon Weir (2), and Susan Bonner-Weir (2) (1) Department of Chemical Engineering, Massachusetts Institute of Technology Cambridge, Massachusetts (2) Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts (3) Diabetes Institute, University of Minnesota, Minneapolis, Minnesota (4) Lifescan, Inc., Johnson and Johnson, Skillman, New Jersey
Introduction
•
Following the initial report in 2000 from Edmonton of insulin independence in the first seven patients treated with a new protocol [171], nearly 500 patients with type 1 diabetes received islet transplants at 43 institutions worldwide as of mid 2005, and high rates of insulin independence were observed at 1 year in the leading transplant centers [170]. Despite these very promising results, various problems currently remain to be solved, including the following. •
•
•
Initial insulin independence usually requires an average of 12,000 islets/kg body weight, or about 850,000 islets for a 70-kg human, which corresponds to the islet yield from two or more human cadavers [150, 160]. For islet transplantation to be a widely accepted treatment modality, it is essential that the donor/recipient ratio be brought down to 1:1 [90]. Although several centers report insulin independence with some single donors [90, 152, 160], success with single donors is limited by the quality of the islet preparation, which is related in part to the quality of the donor pancreata [70, 152]. Even experienced centers can obtain clinical-grade preparations in no more than about 50% of islet isolations [175]. Patients typically have glucose intolerance. It has been suggested that functional capacity for insulin secretion is only about 20 to 40% of that in nondiabetic patients [158, 159].
Cellular Transplantation: From Laboratory to Clinic
There is a progressive loss of insulin independence over time, leaving only about 50% of patients still insulin free at 2 years and 10% at 5 years [160].
The entire process (from brain death of the donor and organ removal to the posttransplant period) can last several days, during which a variety of factors and sequential insults can lead to a substantial loss in islet mass and viability [152]. The quality of the original islets of the donor, itself an important factor, can only decrease. Donor brain death could exert a negative influence on islets by evoking release of inflammatory cytokines [31, 34, 44, 95], but this postulate is based only on experiments in rodents with extreme brain destruction. Hypoxia, or even anoxia, occurs to varying degrees during pancreas retrieval, storage, and islet isolation. Mechanical and enzymatic disruption adds stresses during islet isolation. Hypoxia likely occurs during most conventional islet culture conditions and may be severe during islet shipment. These stresses, in turn, lead to mitochondrial dysfunction—including excessive levels of reactive oxygen species (among other possible sources of ROS), intracellular redox imbalance, accumulation of reduced pyridine nucleotides, mitochondrial membrane depolarization, cytochrome c release, and change in energy state resulting from insufficient ATP generation. All of these are associated with activation (as cause and/or effect) of apoptotic and necrotic pathways [23, 113]. Last, following transplantation islets are exposed to hypoxia until vascularization occurs and to presumed stress
85
Copyright © 2007, Elsevier Inc. All rights of reproduction in any form reserved.
Colton et al.
from the immune system. It has been hypothesized that islets are further damaged by instant blood-mediated inflammatory reaction, which may be induced by inflammatory mediators such as tissue factor and MCP-1 following contact of the islets with ABO-compatible blood [90]. To move forward in development of improved methods, it is essential to have assays to assess meaningful characteristics of islet preparations. Unfortunately, the tools in clinical use today are rather blunt instruments. Currently used parameters are not capable of quantifying the “dose” of islets transplanted and are not predictive of transplantation outcome [42, 46, 156]. Development of improved methods will have a number of benefits in terms of facilitating the ability of practitioners to (1) predict transplantation outcome, (2) improve islet isolation procedures, (3) make more efficient use of islets, (4) standardize test conditions in research, and (5) facilitate FDA licensing [47, 191] and insurance coverage. In this chapter we examine methods for in vitro characterization of islet preparations. After a description of islet isolation processes, and consideration of the information we need, we divide methods into three groups: (1) islet purity and composition, (2) quantity of islets, and (3) viability of islets. We also review assays currently in use, as well as new methods under study at various laboratories with special attention to our own efforts. In examining these methods, we give attention to utility in terms of adequacy for the intended purpose,
accuracy and precision, time required to perform the assay and obtain a result, and cost in terms of materials and equipment.
Islet Isolation HUMAN ISLETS The pancreas is surgically removed from the donor by a surgical team, stored in University of Wisconsin (UW) preservation solution [73] on ice and shipped to the processing facility. The pancreas may be stored by the so-called two-layer method, in which the pancreas floats at the interface between UW solution and oxygenated perfluorocarbon (PFC)—an oxygen carrier— in order to reduce oxygen limitations and ischemia. Extensive studies have been performed on the purported advantages provided by the two-layer method [53, 71, 93, 96, 109, 185], but recent measurements suggest that the current technique provides little, if any, amelioration of oxygen supply limitations in the tissue [120]. In the islet isolation process (Figure 6.1), the pancreas is digested enzymatically with mechanical agitation by automatic means or hand shaking. It was first described by the laboratory of Lacy [155] in 1988, and since then several improvements have been reported. Briefly, the pancreas is dissected from the duodenum, and the
Distension with Collagenase/Protease Solution Ricordi Chamber (Shaker) Density Gradient Centrifugation
Ischemic Conditions
Exocrine Tissue
Islet Preparation
150 µm
1-2% original pancreas volume
Figure 6.1. Schematic diagram of human islet isolation. The pancreas is distended with an enzyme blend and placed in the Ricordi chamber. Through enzymatic digestion and mechanical disruption, islets are liberated from the pancreas and purified with a density gradient centrifugation.
86
6.
Characterization of Islet Preparations
main and accessory ducts are clamped and divided. An enzyme blend that includes collagenase is injected through a cannula placed at the pancreatic duct to allow the organ to distend. Collagenase was originally used as the dissociation enzyme but has been substituted in most centers by Liberase, a standardized mixture of purified enzymes (primarily two types of collagenase) from Roche Applied Sciences, because of improved islet yields from human pancreata [98–100]. After distension, the pancreas is cut into a number (typically 8 to 10) of small pieces that are placed in the dissociation chamber, which is called a Ricordi chamber. The chamber consists of an upper conical part that is separated by a mesh from the lower cylindrical part, in which stainless steel spheres and the pancreatic pieces are placed. The lower part has two inlets at its base, whereas the conical part has an outlet at its top. The pancreatic tissue is digested by a combination of enzymatic digestion at 37◦ C and mechanical agitation of the spheres provided by manual or motorized shaking of the chamber. The enzyme is circulated by a peristaltic pump through the chamber and heating system, which allows the enzyme to be activated in the chamber. Continuous flow allows the islets to be collected, when desired, from the top of the conical part of the chamber after they are released. Cooling and dilution prior to collection of the islets protect them from further enzymatic action. The outlet of the chamber where islets are collected is periodically sampled to monitor the dissociation process and to decide when to stop the enzymatic digestion. At the end of the dissociation process, the cell aggregates are collected in separate containers, and the pancreatic ducts and vessels are retained in the cylindrical part of the chamber by the mesh. In the final purification step, density gradient centrifugation is used to separate the small islet fraction from the non-islet fraction (exocrine: duct, acinar), usually using a specialized cell processor (COBE 2991 Cell Processor). The gradient medium used for human islet isolations is Ficoll, and the density gradients are continuous (between 1 and 1.11 g/ml). At the end of the purification step, the upper layers usually contain highly purified islets at a density of about 1.08 g/ml, whereas less pure and embedded islets are found within more dense layers. The tissue is emptied into about 14 tubes or flasks, and tubes 4 through 9 (in order of elution) contain most of the islet population. The content of individual tubes is accessible for assays and experiments. Usually, all fractions containing significant
numbers of islets are combined in clinical preparations for transplantation.
RAT AND PORCINE ISLETS Isolation of rat pancreatic islets was first successfully performed and described by Lacy and Kostianovsky, and current procedures are based on their method—a two-step process involving digestion with collagenase followed by sedimentation [94]. This method was later modified to include discontinuous Ficoll gradient purification [167]. Some centers use different gradient media, such as Histopaque. The pancreas is distended with chilled Hanks’ Balanced Salt Solution (HBSS) supplemented with glucose and antibiotics or UW solution. The pancreas is dissected from the surrounding tissue and stored in supplemented HBSS or UW solution. The pancreas is distended in a similar way as for the human islet isolation, placed in a 50-ml tube, and then digested with crude collagenase or the more well-defined collagenase preparation known as LiberaseRI in a static incubation for about 20 minutes in a water bath at 37◦ C. After the digestion, cold medium supplemented with serum is added to stop the digestion. The tissue is washed in fresh medium and passed through a mesh (about 400 mm) to remove large fibrous pieces. The collected tissue is centrifuged, washed, and resuspended in the density gradient medium with culture medium on top. Islets are collected from the interface at a density about 1.077 g/ml. Islets are washed in fresh medium two to three times and purified further with sedimentation. Porcine islets are isolated in a manner similar to that of human islets [19, 115, 157, 197]. Pancreata are distended with a collagenase solution and digested using a modified semiautomated method. The digestion takes place also at 37◦ C and lasts 40 to 60 minutes. The purification step also takes place with a Ficoll gradient in a COBE 2991 Cell Processor using layers with densities of 1.11, 1.096, and 1.06 g/ml, and most of the islets are collected between 1.11 and 1.096 g/ml. Some centers follow different protocols for porcine islets, with a static incubation in a chamber similar to the Ricordi chamber. Islets isolated from rat and porcine pancreata usually contain very little contamination by other pancreatic cells. By contrast, human islet preparations that are transplanted typically consist of about 50% non-islet components on average, largely acinar and duct cells [60, 86, 116, 169, 177].
87
Colton et al.
What Do We Want to Know? The general areas used to characterize islet preparations prior to transplantation include (1) safety, (2) identity, (3) quantity, (4) viability, (5) potency, and (6) other. The information needed reflects the answers to the following questions.
transplantation outcome and for testing in vitro islet quality assays. Development of meaningful assays of islet preparations has proven to be a challenge and is under study in several laboratories. Why are islet preparations so difficult to characterize? There are several reasons. •
•
•
•
•
•
•
Safety: Is the preparation sterile? Is it free from microbial cells, mycoplasma, endotoxins, and other adventitious agents? Purity and composition: What fraction of the preparations is islet (endocrine) and non-islet (exocrine) tissue? What is the cell composition (i.e., what fraction is b cells, non-b islet (a, d, PP) cells, duct, and acinar cells)? Quantity: How much total tissue is present? What is the tissue volume? What is the number of cells? What is the volume and number of cells of islet and non-islet tissue? What is the volume and number fraction of the individual component cells, especially b cells? Viability: For the total tissue and for the islet tissue, how much is viable? What fraction of the tissue is viable? How, indeed, do we define viability? How do we determine what is alive now? How do we deal with cells that are alive now but destined to be dead later because of irreversible commitment to the cell death process? Potency and function: What is the insulin secretory capacity in terms of glucose-stimulated insulin secretion? Do the islets cure diabetes when transplanted in a laboratory animal? Other: Can anything be learned from gene expression profiling? Are there other parameters of interest?
In this chapter, we focus on the second through fourth of these areas. The fifth area, potency and function, is also of interest but is not covered here. Glucosestimulated insulin secretion measured with freshly isolated islet preparations does not appear to correlate with transplantation outcome [177]. Transplantation of varying quantities of islets into the renal capsule of an immunodeficient mouse has arguably been the standard for more than 15 years [150, 155] for predicting clinical success, but the results are apparent only after a number of days and are therefore of retrospective value. Nonetheless, it is a potentially useful assay for correlating potency or dose to
•
•
•
Islets are cellular aggregates with a variety of nonsymmetric shapes and wide size distributions that are difficult to quantify accurately. Visual size estimation is prone to error, is operator dependent, and has large intrinsic uncertainty. Human preparations have varying amounts of impurities. Distinguishing between the properties of islet and exocrine tissue is difficult. The islet is a moving target. Islet volume decreases with time after isolation. Stress repeatedly occurs during pancreas retrieval, storage, islet isolation, culture, and shipment. Some cells are lost to apoptosis and necrosis. Recovered cells are likely not representative of the original islet. Many techniques suitable for cells are inapplicable to islets because of their 3D structure. Unfortunately, the islets cannot be usefully dissociated into dispersed cells by agitation and incubation with serine proteases such as trypsin because from 30 to 50% of the cells are lost during dissociation [140, 141, 193]. Cell damage may result from initiation of apoptosis arising from separation of the cell membrane from the extracellular matrix [55, 186], as has been demonstrated in trypsin dissociation of epithelial cells such as hepatocytes [172]. Thus, cells recovered from the dissociation process may not be representative of cells in the original islet.
Islet Purity and Cell Composition Light microscopic observation following staining with dithizone (diphenylthiocarbazone, DTZ) is the commonly accepted technique employed currently to assess the purity of islet preparations. Because of its inadequacies, a variety of new techniques have been examined over the past few years, as summarized in Table 6.1. In this section, each method is briefly summarized, including discussion of its strengths and weaknesses. There follows an in-depth discussion of recent studies examining morphological analysis by electron and light
88
6.
Characterization of Islet Preparations
TABLE 6.1 Measurements of islet purity and cell composition. Tissue Assayed
Parameter Measured
Method
Instrumentation
Intact Islet Preparation
Volume Fraction of Islets
DTZ Staining
Light Microscope
Tissue Morphology
Light Microscope
Volume Fraction of Cell Types
Immunohistochemistry
Laser Scanning Confocal Microscope
Number Fraction of Cell Types
Ultrastructural Analysis
Electron Microscope
Number Fraction of Cell Types
Immunohistochemistry
Fluorescence Microscope
Dispersed Single Cells
Laser Scanning Cytometer
microscopy and a comparison of cell composition data from these and other studies in the literature.
DTZ STAINING DTZ, a zinc-specific binding dye, is used to obtain an estimate of the volume fraction of islets in a sample [30]. Zinc is specific to islets and therefore islets stained with DTZ have a red color and can be visually differentiated from exocrine tissue. DTZ is usually dissolved in dimethylsulfoxide (DMSO) and diluted with HBSS to form a working solution. Aliquots from the islet preparation are incubated with DTZ, and the fraction of islets is estimated visually under a microscope as the volume fraction of cells stained red. Purity assessments by DTZ are rough visual estimates, and they usually grossly overestimate islet purity, as has been previously reported [116, 177].
MORPHOLOGICAL ANALYSIS Morphological analysis is usually carried out by electron or light microscopy. Aliquots from the islet preparation are processed using a standard procedure [116], during which they are fixed, dehydrated, cleared, embedded, cured, and trimmed to produce 1-mm sections in epoxy resin. This process takes about 3 days for light and 4 for electron microscopy. Frozen sections can be prepared in less than an hour.
ELECTRON MICROSCOPY (EM) ANALYSIS For ultrastructural determinations, ultrathin sections of islets are cut and stained with lead citrate and uranyl acetate and viewed on an electron microscope. Images from each block are collected with systematic sampling and examined on photographic prints. For the studies done by our group that are described in this chapter, between 500 and 800 cells are classified into cell types by their ultrastructure and granule morphology. Secretory granules of islet endocrine cells are too small to be seen with light microscopy, but zymogen granules of acinar cells are evident, which allows acinar contamination to be easily identified on the 1-mm thin plastic sections used as a preliminary assessment for sections to be taken for EM. At the EM level, cell boundaries are identified. Then each cell is assigned to a category of islet [I] cells, including b and non-b endocrine cells (a, d, PP), and non-islet (NI) cells including acinar and ductal cells. b cells have distinctive granules with an electron-dense core containing insulin crystals surrounded by a lighter halo. In addition, human b cells have characteristic lipid inclusions. Non-b cells (a, d, and PP) have more homogeneous granules without the crystalline structure and without the halos of b cells. Although these three non-b islet cells can be distinguished from one another by granule morphology, for quantitation purposes they can be classified together as non-b islet cells. Acinar cells have easily identifiable large electron-dense zymogen granules and stacks of endoplasmic reticulum. Duct cells can be identified by their size, shape, little endoplasmic
89
Colton et al.
reticulum, and lack of granules. Occasional dead cells or endothelial cells are categorized as “other.” The resulting cell composition is based on number, not volume, of cells and yields the number fraction fi of each cell type defined as the number ni of cells of type i divided by the total number of cells, nTC . LIGHT MICROSCOPY (LM) ANALYSIS For LM determinations, 1-mm sections are analyzed at 420x by stereological point counting [192] in which islet and non-islet tissue are distinguished (as described in the caption to Figure 6.2) at positions defined by a grid of points covering adjacent, non-overlapping fields. The points that lie in the islet and non-islet tissue are counted to obtain the volume fraction of islet tissue (not cell number). An example is shown in Figure 6.2. Islets are highly vascularized tissue, and freshly isolated islets have large dilated vascular spaces, the size of which decreases with time. Although the vascular space can be included within the domain of the islet, we have chosen to keep track of it separately. Assuming that the photomicrograph represents a plane through the tissue, the probability of a random point falling into a certain type of tissue is proportional to the volume fraction of that tissue [192]. The number of points falling on islet tissue (PI ), non-islet tissue (PNI ), and vascular space (PV ) is determined, and the volume fraction of islets I is
calculated from I =
PI + PV , PI + PV + PNI
(6.1)
where the numerator is the number of points falling within the domain of islets and the denominator is the total number of points. An entirely equivalent procedure is to first ignore the vascular space and calculate IXV =
PI , PI + PNI
(6.2)
where IXV is the islet volume fraction exclusive of islet vascular spaces. The tissue is reanalyzed at higher magnification (830x) to obtain the vascular void fraction VI in the islets from VI =
PV . PV + PI
(6.3)
By rearranging Equation 6.1 and substituting Equations 6.2 and 6.3, the islet volume fraction is then calculated from
I =
IXV 1 − VI IXV + (1 − IXV ) 1 − VI
.
(6.4)
Islet
Vascular Space
NonIslet
Figure 6.2. Sample field of view of a slide analyzed by light microscopy using an 830x magnification in an Olympus BH2 microscope. Intercepts of tissue with a 90-point grid are counted as islet, non-islet, or vascular space. Islet tissue is distinguished from non-islet tissue (exocrine or ganglia) by its cordlike pattern of cells (often around vascular spaces), lack of visible granulation, and occasional visible small lipid droplets, whereas the exocrine tissue is in the form of either large duct sheets or folded sheets of polarized columnar epithelia or clumps of small duct and acinar tissue. The acinar tissue is initially granulated with large stained granules, although after several days of culture these are less pronounced, and the small ducts are only faintly stained and surrounded by acinar tissue.
90
6.
Characterization of Islet Preparations
The vascular volume correction in Equation 6.4 puts the entire expression on a basis of total volume (including vascular volume). Equation 6.4 is equivalent to Equation 6.1, as can be verified by substituting Equations 6.2 and 6.3 into 6.4. In the analysis of samples reported in this chapter, we use the procedure that employs Equations 6.2 to 6.4 because separate estimation of vascular void fraction VI at higher magnification provides a more accurate and precise result. With islet preparations that average about 50% islet volume fraction, use of a total of 500 to 800 counted points yields a standard error equal to 3 to 5% of the mean value [192]. EM offers capability for identifying individual cell composition, whereas LM provides only islet volume fraction. The LM assessment method described is less time consuming than EM but still suffers from the time required to process the tissue. An appealing prospect is to use frozen sections, which can use the same LM approach. The time for tissue preparation and analysis should only take a few hours, which is fast enough to be valuable for evaluation of clinical samples prior to transplantation.
OTHER APPROACHES USING IMMUNOHISTOCHEMICAL ANALYSIS Immunohistochemistry can be applied to blocks of tissue or single cells from dissociated islets. Blocks of pancreatic tissue or islets are processed with a standard procedure of fixation, dehydration, and embedding [89, 138, 140, 177] to produce sections (paraffin 5 to 7 mm thick, frozen 8 to 15 mm). The sections are then incubated overnight with the primary antibodies (to insulin, glucagon, somatostatin, and pancreatic polypeptide), washed, and then incubated with the secondary antibody to which a fluorochrome is bound. The sections can be analyzed either by fluorescence or laser scanning confocal microscopy. Preparations of paraffin sections also require several days, making these measurements useful retrospectively. Single cells can be analyzed by a laser scanning cytometer, which is slide based and is a cross between a flow cytometer and a static image cytometer. STANDARD FLUORESCENCE MICROSCOPY The fraction of cells specific to each antibody is determined by examination under a fluorescence microscope, and results can reflect number fraction or volume fraction, depending on how the analysis is carried out.
Problems with immunohistochemical staining include the possibility of overlapping cells on paraffin sections and nonspecific staining. LASER SCANNING MICROSCOPY Cell composition estimation with immunohistochemistry has recently been performed with laser scanning confocal microscopy [22, 25] or laser scanning cytometry [75, 76] to analyze cell composition. Unlike conventional fluorescence microcopy, light is collected from a single focal plane in laser scanning confocal microscopy. The specimen (islet or pancreatic tissue) is scanned point by point and line by line, and a single image is created. Evenly spaced optical sections obtained by moving the focal plane in the axial direction can assemble a 3D image. These images can be analyzed by image analysis software to determine the number or volume fraction of different cell types. Samples analyzed to date include pancreatic blocks [25], wholemount islets [22], and dispersed cells [75]. The procedure employed with dispersed cells is summarized later in this chapter in Figure 6.18 in connection with cell viability measurements. Dispersed cells do not require the confocal feature and can be prepared in a few hours, but their use entails the problems identified with islet dissociation. If cell composition is based on counting the number of cells stained with a specific antibody, the number fraction is estimated [75]. If the normalization is based on a volume basis using a 3D reconstruction or other technique, the volume fraction is estimated [23]. A problem with current laser scanning microscopes is their very high cost, which makes them available in only a limited number of centers.
COMPARISON OF EM AND LM MORPHOLOGICAL ANALYSIS In a recent study [116], we carried out morphological analysis of 33 individual freshly isolated clinical islet preparations by EM and found it to be a valuable tool for assessing cellular composition. In a subsequent study [142], we examined the 1-mm sections from 27 of these blocks by LM to assess the purity of the preparations. Results of these two studies are summarized and compared between themselves in this section and with results using other techniques in the next section. Because results of these various studies are expressed on the basis of either number (in our case EM) or volume (LM) fraction, and the distinction is often blurred,
91
Colton et al. TABLE 6.2 Estimated volume (mm3 ) of pancreatic cells. Symbol
Native Pancreas
Freshly Isolated
νb νNb
1,000 400
950 400
νA νD νO
1,550 200 200
1,200 200 200
Islet Beta Non-Beta (Mainly Non-Islet Acinar Duct Other
a)
we also address the mathematical equations needed to convert between number and volume bases. This conversion is also required for calculating various quantities of interest. The cell volume estimates used in carrying out calculations are summarized in Table 6.2. Values for b and non-b cells (assumed to have properties of a cells) are taken from measurements with freshly isolated and purified rat islets [137, 141]. The b-cell volume for freshly isolated islets reflects an estimated 5% loss from the commonly accepted value of about 1,000 mm3 for the native pancreas [18, 32], which is consistent with a partial degranulation during isolation and dispersion. Acinar volume in the mature pancreas on average is within the 1,300- to 1,800-mm3 range reported for the adult rat [4, 5, 164], and it is assumed that about 20 to 25% of the volume in freshly isolated preparations is lost from degranulation. Values for duct and other cells are from our observations [17]. After several days in culture, surviving b cells regranulate. Acinar cells are more prone to death when cultured and not as well studied. Data from 27 freshly isolated clinical islet preparations are summarized in Table 6.3. Columns 2, 3, and 5 through 7 contain the number fraction of individual islet and non-islet cell types from EM ultrastructural analysis. Column 4 contains the number fraction of all islet cells (fIC ). The number fraction of non-islet cells (fNIC ) is simply fNIC = 1 − fIC . Columns 8, 9, and 10 contain the volume fraction quantities defined by Equations 6.2 through 6.4, respectively, from LM morphological analysis. The latter quantity, (I )LM , is the purity (i.e., the volume fraction of islets by LM morphology analysis). The average number fraction of b cells in the entire
preparation is 35.8%, and the average number fraction of islet cells in the preparation is 48.4%. The latter value is about 8% smaller than the average volume fraction of islets by LM, which is 52.3%. Although the precision of the mean values as expressed by SD or SEM (Table 6.3) is respectable because of the large number of preparations examined, values for individual samples vary widely, largely because of differences in purity between preparations. An objective of further analysis is to use the EM number fraction data (Table 6.3) together with the volume of each cell (Table 6.2) to estimate the volume fraction of islets so as to enable proper comparison with the value from LM analysis and to provide the basis for comparison with values in the literature. The results of these calculations, summarized in Table 6.4, make use of the basic number-volume relationships for cells summarized in Table 6.5. Equations 6.5 through 6.9 (Table 6.5) show how the numbers of individual cell types can be summed to determine the number fractions fIC and fNIC . Recognizing that the volume of each cell type is the product of the number of cells and the volume per cell of that type, Equations 6.10 through 6.14 (Table 6.5) lead to definitions of volume fractions fIC and fNIC for islet and non-islet cells, respectively, as the total volume of each cell type divided by the total volume of all cells. Next, the average cell volume for islet (ν IC ) and non-islet (ν NIC ) cells and for the total of all cells (ν TC ) is evaluated as the volume of cells of a particular type divided by the number of cells of that type. These relations reduce to Equations 6.15 through 6.17 (Table 6.5), respectively, in terms of number fractions and volume per cell of individual cell types. Equation 6.18 (Table 6.5) is especially important because it relates the volume fraction of islet cells (fIC ) to the number fraction (fIC ) by the ratio ν IC ν TC . If that ratio is unity, meaning all islet cells have the same average volume as all non-islet cells, then fIC = fIC . Last, the number fraction fbIC and volume fraction fbIC of b cells among all islet cells are given by Equations 6.19 and 6.20 (Table 6.5). Columns 12, 13, and 14 of Table 6.4 contain the estimated average cell volume for different cell combinations. The average for islet cells over all preparations 3 is 806 ± 9 mm . The ratio ν IC ν TC in column 15 averages 1.09 ± 0.02, and 22 of 27 samples fall between 1.0 and 1.15. This means that the volume correction associated with different cell sizes is usually small, and to a rough approximation the volume fraction of all cells
92
6.
Characterization of Islet Preparations
TABLE 6.3 Data from EM and LM morphological analysis and DTZ staining. Number Fraction Cells by EM
Volume Fraction by LM
Non-islet
DTZ
Beta
Islet NonBeta
Total
Acinar
Duct
Other
Islet Tissue w/o Vascular Void
Sample
fb
fNb
fIC
fA
fD
fO
(IXV )LM
VI
(I )LM
(I )DTZ
1
2
3
4
5
6
7
8
9
10
11
1–16 2–06 2–08 2–17 2–19 2–20 2–21 2–22 2–24 2–25 3–06 3–10 3–13 3–16 3–19 3–21 3–23 3–25 3–28 4–01 4–06 4–07 4–10 4–11 4–15 4–23 4–24
0.220 0.186 0.322 0.291 0.308 0.490 0.176 0.529 0.267 0.398 0.287 0.354 0.330 0.525 0.343 0.507 0.637 0.532 0.162 0.362 0.378 0.489 0.323 0.452 0.358 0.131 0.303
0.126 0.036 0.131 0.136 0.060 0.160 0.154 0.179 0.120 0.114 0.149 0.092 0.102 0.128 0.077 0.056 0.216 0.162 0.088 0.149 0.079 0.191 0.170 0.163 0.269 0.036 0.058
0.346 0.222 0.453 0.427 0.368 0.650 0.330 0.708 0.387 0.512 0.436 0.446 0.432 0.653 0.420 0.563 0.853 0.694 0.250 0.511 0.457 0.680 0.493 0.615 0.627 0.167 0.361
0.338 0.416 0.301 0.288 0.387 0.194 0.355 0.161 0.305 0.200 0.281 0.130 0.326 0.157 0.224 0.287 0.054 0.115 0.414 0.191 0.340 0.099 0.199 0.170 0.089 0.407 0.349
0.307 0.330 0.228 0.270 0.201 0.129 0.285 0.092 0.300 0.284 0.242 0.383 0.231 0.185 0.321 0.109 0.016 0.150 0.303 0.262 0.172 0.149 0.190 0.179 0.243 0.384 0.247
0.009 0.032 0.018 0.015 0.044 0.027 0.030 0.039 0.008 0.004 0.041 0.041 0.011 0.005 0.035 0.041 0.077 0.041 0.033 0.036 0.031 0.072 0.118 0.036 0.041 0.042 0.043
0.332 0.087 0.469 0.435 0.356 0.653 0.285 0.690 0.432 0.535 0.467 0.540 0.407 0.692 0.441 0.624 0.857 0.716 0.179 0.546 0.456 0.702 0.509 0.674 0.695 0.105 0.385
0.142 0.045 0.146 0.147 0.139 0.117 0.131 0.115 0.137 0.162 0.178 0.059 0.197 0.077 0.125 0.140 0.203 0.177 0.135 0.162 0.083 0.173 0.096 0.114 0.214 0.170 0.148
0.367 0.091 0.508 0.474 0.391 0.681 0.314 0.716 0.468 0.579 0.516 0.555 0.461 0.709 0.474 0.659 0.883 0.754 0.201 0.589 0.478 0.740 0.534 0.700 0.744 0.124 0.424
0.58 0.30 0.55 0.70 0.60 0.80 0.50 0.75 0.35 0.50 0.75 0.80 0.70 0.70 0.70 0.85 0.90 0.95 0.30 0.75 0.60 0.80 0.90 0.90 0.90 0.37 0.77
Mean SD COV SEM
0.358 0.129 0.36 0.025
0.126 0.056 0.44 0.011
0.484 0.163 0.34 0.031
0.251 0.108 0.43 0.021
0.229 0.089 0.39 0.017
0.036 0.024 0.67 0.005
0.491 0.192 0.39 0.037
0.138 0.042 0.30 0.008
0.523 0.195 0.37 0.038
0.68 0.19 0.28 0.04
that are islet cells is approximately 10% larger than the number fraction that are islet cells. Next, we must account for the extracellular volumes VIEC and VNIEC within the islet and non-islet domains, retrospectively. Volume definitions and relationships are shown in Figure 6.3. In each tissue, the
Vascular Void
Whole Islet
Volume Fraction Islet
total volumes VI and VNI in the islet and non-islet domains, respectively, are the corresponding sums of the extracellular volume and the cell volume, Equations 6.21 and 6.24 (Figure 6.3). The definitions of corresponding volume fractions for islet cells IC and islet extracellular space IEC , Equations 6.27
93
Colton et al. TABLE 6.4 Calculated quantities from EM and LM morphological analysis. Average Cell Volume (mm3 )
b Cells in Islets Number Fraction
Volume Fraction by EM
Islet Equivalent
Cell Volume Fraction
Islet Volume Fraction
Whole Islet Cells Islet
Number of cells Total b
Islet
Non-islet
Total
Size Ratio
Sample
ν IC
ν NIC
ν TC
ν IC /ν TC fbIC
fbIC
bI
(fIC )EM (I )EM
nIE
1
12
13
14
15
16
17
18
19
20
21
22
1–16 2–06 2–08 2–17 2–19 2–20 2–21 2–22 2–24 2–25 3–06 3–10 3–13 3–16 3–19 3–21 3–23 3–25 3–28 4–01 4–06 4–07 4–10 4–11 4–15 4–23 4–24
750 861 791 775 860 815 693 811 779 828 762 837 820 842 849 895 811 822 756 790 855 796 760 804 714 831 862
717 735 750 703 812 754 730 751 698 610 698 435 774 652 586 857 567 576 752 591 826 509 593 642 439 689 746
728 763 769 733 830 794 718 794 729 721 726 614 794 776 697 878 775 746 753 692 839 704 675 742 611 712 788
1.03 1.13 1.03 1.06 1.04 1.03 0.97 1.02 1.07 1.15 1.05 1.36 1.03 1.08 1.22 1.02 1.05 1.10 1.00 1.14 1.02 1.13 1.13 1.08 1.17 1.17 1.09
0.636 0.838 0.711 0.681 0.837 0.754 0.533 0.747 0.690 0.777 0.658 0.794 0.764 0.804 0.817 0.901 0.747 0.767 0.648 0.708 0.827 0.719 0.655 0.735 0.571 0.784 0.839
0.806 0.925 0.854 0.874 0.886 0.635 0.888 0.836 0.924 0.879 0.731 0.875 0.841 0.892 0.821 0.901 0.885 0.907 0.914 0.936 0.956 0.875 0.886 0.814 0.852 0.893 0.919
0.570 0.654 0.604 0.618 0.627 0.449 0.628 0.591 0.654 0.622 0.517 0.619 0.595 0.631 0.581 0.638 0.626 0.642 0.646 0.663 0.676 0.619 0.627 0.576 0.603 0.632 0.650
0.356 0.251 0.466 0.451 0.381 0.667 0.319 0.724 0.414 0.587 0.458 0.608 0.446 0.708 0.512 0.574 0.892 0.764 0.251 0.583 0.466 0.768 0.555 0.667 0.732 0.195 0.395
0.386 0.276 0.498 0.483 0.412 0.695 0.347 0.749 0.445 0.618 0.490 0.638 0.478 0.734 0.544 0.605 0.904 0.786 0.276 0.614 0.498 0.791 0.587 0.695 0.757 0.216 0.426
1670 1455 1583 1616 1456 1537 1806 1544 1607 1513 1643 1497 1527 1487 1475 1399 1545 1524 1656 1586 1465 1574 1647 1557 1754 1506 1453
1062 1219 1125 1101 1218 1159 963 1154 1108 1176 1082 1188 1166 1195 1204 1260 1153 1168 1073 1123 1212 1132 1079 1144 1001 1181 1220
Mean SD COV SEM
806 47 0.06 9
674 110 0.16 21
745 61 0.08 12
1.09 0.08 0.08 0.02
0.739 0.086 0.12 0.017
0.867 0.066 0.08 0.013
0.613 0.047 0.08 0.009
0.526 0.179 0.34 0.034
0.554 0.177 0.32 0.034
1560 95 0.06 18
1140 69 0.06 13
and 6.26 (Figure 6.3), respectively, are based on total islet volume. The volume fractions of non-islet cells NIC and non-islet extracellular space NIEC , Equations 6.23 and 6.22 (Figure 6.3), respectively, are based on the total non-islet volume. Capital letters are used to distinguish the volume fractions in Figure 6.3, which are based on total islet or non-islet
nbIE
tissue volume (including extracellular volume), from the volume fractions in Table 6.5 designated by lowercase letters, which are based on total cell volume (Equations 6.13 and 6.14) or total islet cell volume (Equation 6.20). Available data for estimating IEC and NIEC are limited. The extracellular spaces in islet and non-islet tissue
94
6.
Characterization of Islet Preparations
TABLE 6.5 Basic number-volume relationships for cells in islet preparations. All Cells in Preparation Number
nIC = nb + nNb nNIC = nA + nD + nO nTC = nIC + nNIC
(6.5) (6.6) (6.7)
Number Fraction
Volume
Cells
VIC = Vb + VNb = nb νb + nNb νNb (6.10) VNIC = VA + VD + VO = nA νA + nD νD + nO νO (6.11) VTC = VIC + VNIC (6.12)
Islet Non-islet Total
Volume Fraction
nIC nTC nNIC = = 1 − fIC nTC
VIC VTC VNIC = = 1 − fIC VTC
fIC =
(6.8)
fIC =
(6.13)
Islet
fNIC
(6.9)
fNIC
(6.14)
Non-islet
(6.15)
Islet
(6.16)
Non-islet
(6.17)
Total
(6.18)
Islet
Average Cell Volume
nb νb + nNb νNb 1 VIC nTC nb νb + nNb νNb = = = fb νb + fNb νNb nIC nIC nIC nTC fIC VNIC 1 ν NIC = = (fA νA + fD νD + fO νO ) nNIC fIC VTC ν TC = = fb νb + fNb νNb + fA νA + fD νD + fO νO nTC ν IC =
Cell Number Fraction/Volume Fraction Conversion
fIC =
VIC nIC ν IC ν IC = = fIC VTC nTC ν TC ν TC Islet Cells
β Cell Number Fraction fbIC =
nb nIC
=
nTC nb nIC nTC
=
fb
(6.19)
fIC
β Cell Volume Fraction fbIC =
Vb VIC
=
nb νb nIC ν IC
=
fb νb
(6.20)
fIC ν IC
of the mouse in vivo are 39 and 26% of tissue water, respectively, based on an estimated tissue water content of 75% [107]. Thus, IEC = 0.29 and NIEC = 0.19 when based on total tissue volume. This in vivo value for islets is comparable to an in vitro measurement in toad fish islets [31]. For islets, we keep separate track of the vascular volume fraction VI , defined by Equation 6.25 (Table 6.3), the mean value (Table 6.3, column 9) of
which is about 14% from LM data. Thus, the interstitial volume fraction is about 0.29 − 0.14 = 0.15. If the same value applies to non-islet tissue, its vascular volume fraction is about 0.19 − 0.15 = 0.04. The vascular volume fraction is similar for freshly isolated rat islets [15]. After 24 hours in culture, the vascular volume collapses completely, leading to a substantial reduction in rat islet volume [16], whereas the collapse is substantial
95
Colton et al.
Islet
Non Islet Vascular + Interstitial
VNIEC
Extracellular
Vascular VVI
VIEC
Interstitial VINT
VIXV
Acinar Cells
VNI
VNIC
Cellular
β Cells
VIC
Duct Cells Non β Cells
Other Cells
VNI = VNIEC + VNIC
Volume
VI = VVI + VIXV = VIEC + VIC
(6.21)
VVI VI V ΦIEC = IEC VI ΦVI =
Volume Fraction
ΦNIEC =
VNIEC VNI
ΦNIC = 1−ΦNIEC = Overall Purity
ΦI =
VI VI + VNI
VI
(6.22)
VNIC VNI
ΦIC = 1−ΦIEC =
(6.23)
(6.24) (6.25) (6.26)
VIC VI
VIC VIC VTC φIC 1−ΦIEC 1−ΦIEC 1−ΦIEC = = = φIC VIC VNIC VIC VTC VNIC VTC 1−ΦIC + + + 1−ΦIEC 1−ΦNIEC 1−ΦNIEC 1−ΦIEC 1−ΦIEC 1−ΦNIEC
(6.27)
(6.28)
Figure 6.3. Volume definitions and relationships in islet preparations.
but not complete after several days in culture of human islets. Returning to Figure 6.3, Equation 6.28 (Figure 6.3) for the volume fraction islets I is the key relationship, and its derivation is given in sequential detail. The first step involves use of Equations 6.23 and 6.27 (Figure 6.3) for expressing VNI and VI , respectively. All terms are then divided by the total cell volume VTC so that use can be made of volume fraction fIC from Equation 6.13 (Table 6.5), which in turn is related to number fraction fIC from Equation 6.18 (Table 6.5). Equation 6.28 (Figure 6.3) thus provides the bridge-relating number fraction to volume fraction data. Using Equation 6.28 (Figure 6.3), the average value of islet volume fraction (I )EM computed from EM cell number fraction data is 0.554 (Table 6.4, column 20), which compares well with the value measured directly by LM, (I )LM = 0.523 (Table 6.3, column 10). There
is exceptional agreement for volume fractions above 0.3. This agreement validates the use of LM point counting for determining islet purity. Several other quantities in Table 6.4 are of interest. An islet equivalent (IE), a sphere of diameter 150 mm, has a volume VIE = 1.77 × 106 mm3 . The volume of cells in an IE is given by the product of (1 − IEC ) and VIE , and thus the number of cells nIE in an IE is nIE =
(1 − IEC ) VIE ν IC
(6.29)
and the number of beta cells in an IE is nbIE = fb nIE .
(6.30)
The averages for all preparations (from columns 21 and 22 of Table 6.4, respectively) are nIE = 1,560 islet cells and nbIE = 1,140 b cells per IE.
96
6.
Characterization of Islet Preparations
Other b cell quantities calculated from EM data are shown in columns 16 through 18 of Table 6.4. The number fraction of b cells among all islet cells fbIC = 0.739 becomes fbIC = 0.867 on a cell volume basis. The volume fraction of the entire islet that is b cells bI is calculated from bI = (1 − IEC ) fbIC .
(6.31)
The average volume fraction of b cells in whole islets is bI = 0.613. Coefficients of variation for these last two quantities are 8%, thereby demonstrating that the volume fraction of b cells relative to all islet cells is highly reproducible from sample to sample. Whereas the number fraction-volume fraction conversion is insensitive to the value for islet extracellular volume fraction IEC , the quantities calculated from Equations 6.28 through 6.31 are much more sensitive. For the record, the mean values in Tables 6.3 and 6.4 are slightly different from those originally reported [116] because only 27 of 33 preparations, for which we had both LM and EM data, are included here.
COMPARISON OF MORPHOLOGICAL ANALYSIS WITH DTZ STAINING Purity measurements with DTZ staining (Table 6.3, column 11) give an average volume fraction islets (I )DTZ = 0.68, about 30% higher than the value of 0.523 from direct LM measurements and 23% higher than the value of 0.554 calculated from EM data. In many individual cases, the measurement from DTZ staining is much higher than that from LM point counting; thus, DTZ staining may provide a gross overestimation of islet purity. A similar discrepancy occurs with individual samples when DTZ staining is compared with volume fraction estimated from EM number fraction data [116].
COMPARISON AMONG VARIOUS STUDIES b-cell composition data from a variety of studies are compared in Table 6.6. The data is tabulated either as volume fraction of the islet that is b cells bI or
TABLE 6.6 Comparison of literature values for b-cell content in islets. Tissue Examined
Freshly Isolated Islets Cultured Islets1 Cultured Islets2 Dissociated cells Dissociated cells Pancreatic block Pancreatic block Pancreatic block Pancreatic block Pancreatic block Pancreatic block
b Cells in Islet Cells
Method
EM Morphology IHC-LSC Microscopy IHC IHC-LS Cytometry IHC IHC-LSC Microscopy IHC IHC IHC IHC IHC
Volume Fraction
Number Fraction
bI
fbIC
0.61 0.54 0.67 0.43 0.47 0.46 0.523 0.594 0.68 0.755 0.635
0.74 0.65 0.80 0.51 0.57 0.55 0.62 0.71 0.80 0.90 0.76
IHC = Immunohistochemistry with standard fluorescence microscopy unless otherwise noted. Bold face number is data as reported. Companion number is calculated using equations in this chapter. 1 Islets shipped and cultured for 48 hr total. 2 Islets cultured 7-14 days under conditions favoring b-cell enrichment. 3 Lean, nondiabetic subjects. 4 Korean subjects. 5 Volume-weighted calculated value for 90% glucagons-rich, PP-poor lobes, 10% PP-rich lobes.
97
Reference
O’Neill et al., 2006 [116] Brissova et al., 2005 [22] Keymeulen et al., 1998 [86] Ichii et al., 2005 [77] Street et al., 2004 [177] Cabrera et al., 2006 [25] Butler et al., 2003 [24] Yoon et al., 2003 [198] Kloppel et al., 1985 [88] Stefan et al., 1982 [176] Malaisse-Lagac et al., 1979 [104]
Colton et al.
number fraction of islet cells that are b cells fbIC . All studies make use of immunohistochemical methods in one form or another except for our recent EM morphological analysis [116]. That study is also the only one with freshly isolated whole islets. The b-cell volume fraction of the islet averages about 61% for the three studies with islets. Islet volume fraction in cultured islets that were shipped is lower [22], possibly reflecting preferential b-cell death under stress. Conversely, in one study the islet culture method may have favored b (but not a) cell survival and accounted for an increased volume fraction of b cells [86]. The two studies that used dispersed islets [75, 177] yield uniformly lower values for b-cell content, which may result from selective b cell loss incurred with islet dissociation, as described previously. Data from islets embedded in the pancreas span a wide range [24, 25, 88, 104, 176, 197]. All studies except Cabrera [26] report data as volume fraction of b cells in islets, and these values average 63%, which is comparable to the value obtained from preparations of isolated islets.
SAMPLING ISSUES The weak link in characterizing islet preparations by all of the methods described in this section, and in the other sections as well, is the initial aliquot sampling in which a sample with a volume typically about 100 ml is removed from a vessel containing the entire islet preparation in 250 ml of suspension. The extent of systematic error incurred in this initial sample is unknown. The best current practice is to keep the suspension evenly distributed during sampling by repetitive inversion of the tube and to sample with a consistent procedure every time. Starting with an initially well-mixed uniform suspension, sedimentation will begin immediately if it is not eliminated or sufficiently minimized. Differences in size and density of the aggregates will lead to significant differences in settling velocity, further aggravating the situation by causing additional gradients in size and composition so that a sample from a small volume may no longer be representative of the entire volume. A second issue is local variations in the sample (independent of sedimentation) that reflect intrinsic differences in tissue properties. Because these differences should be random, precision in estimating mean values improves as more tissue is analyzed and follows standard statistics.
TABLE 6.7 Methods for measuring the quantity of islets in an islet preparation. Type of Quantity Parameter Measured
Method
Volume
Islet Volume
DTZ Staining Large Particle Flow Cytometry
Total Tissue Volume
Tissue Pellet Packed Cell Volume Ultrasound Scattering
Number of Cells Total DNA DNA Content Total Intact Cell Nuclei Nuclei Counting
Quantity of Tissue Methods for measuring the quantity of islets in an islet preparation are summarized in Table 6.7. It was recognized around 1990 that counting the number of islets was a poor way to quantify the amount of islet tissue because of the intrinsic variability in islet size and shape [44]. It was recommended that the total volume of islets in a DTZ-stained preparation be estimated and be reported in terms of the number of islet equivalents [21, 151, 156, 166] in an effort to standardize islet quantification and improve accuracy and precision, and it remains the standard method. An alternative is to measure total tissue volume and determine islet volume fraction independently, as described previously. A different and potentially more accurate approach is to measure the total number of cells and to combine it with an estimate of the number fraction of islet cells. There is increasing interest in quantifying the b cells in an islet preparation. This can be estimated from the number or volume fraction of b cells in islets, as described in the previous section, combined with the total number or volume of cells, respectively.
VISUAL COUNTING OF DTZ-STAINED ISLETS The conventional method is based on microscopic visualization of size and manual counting of samples stained with DTZ [97]. Islet samples are stained with DTZ and are visually examined under the microscope.
98
6.
Characterization of Islet Preparations
Islets are divided in different groups of 50-mm increments based on their diameter and an average conversion factor is used for all islets within each 50-mm range. The volume of islets in the preparation is calculated assuming that the islet is a perfect sphere. This method is operator dependent and discrepancies as much as 40% have been observed between different operators analyzing exactly the same photomicrographs of an islet preparation [3]. The method is also prone to error because the actual shape of the islet is not spherical [50, 187], which introduces an upward bias leading to overestimation of volume no matter how the measurement is made. With few exceptions [61], the potentially large magnitude of this overestimation is generally not appreciated. Dionne [36] and later Avgoustiniatos [6] carefully examined rat islets hand picked to be among the most spheroidal and rotated them over three axes in a microscope with a calibrated reticule. Assuming that the islets could be represented as ellipsoids of revolution with half axes a, b, and c, Avgoustiniatos found on average b/a = 0.82 and c/a = 0.60. The volume of an ellipsoid is given by 4 V = pabc. 3
(6.32)
Setting a = 1, the quantity 3V/4p = abc is 0.492. If the ellipsoid is lying on a surface with its smallest axis c perpendicular to the surface, the most likely situation, it appears as an ellipse with half-axes a and b. Because the half axis c is usually not measured with DTZ staining, estimates of the radius of an equivalent sphere must be made from a and b. Table 6.8 summarizes the value of 3V/4p = r 3 for an equivalent sphere having various possible radii: (1) the longest half-axis, (2) arithmetic average of two half-axes, and (3) geometric average of two half-axes. This latter case would arise if the area of the ellipse, which is pab, were made equivalent to that of a circle, pr 2 . The ratio of the computed sphere volume to the true volume of the ellipsoid is about 1.5 for the two most reasonable estimates of r, an overestimation of 50%. This simple calculation should serve as a red flag for the possibility of gross overestimates of IE number with current techniques.
LARGE PARTICLE FLOW CYTOMETRY Flow cytometry is well established for characterization of single-cell preparations, but size limitations in
TABLE 6.8 Errors incurred by en-face sizing of ellipsoids as equivalent spheres. Selected Radius r
r3
Volume of Sphere Volume of Ellipsoid
a a+b 2 (ab)1/2 4 3
Vsphere = pr3
1.0
2.03
0.754
1.53
0.743
1.51 4 3
Vellipsoid = p abc
a = 1, b = 0.82, c = 0.6, abc = 0.492. Ellipsoid is assumed to lie on surface with smallest axis perpendicular to surface.
traditional flow cytometers render their use inapplicable for islet preparations. Preliminary experiments with islet preparations using a large particle flow cytometer have recently been reported [49]. The new instrument has the ability to analyze large objects, such as islets, with minimal shear forces and to sort these objects (using object size, optical density, and intensity of fluorescence markers as the analytical criteria) with a gentle pneumatic sorting mechanism that minimizes cell damage. In experiments performed with islet preparations [49], a standard calibration curve was created with microspheres of known diameter to correlate time-of-flight measurements to particle diameter. Newport Green staining allowed discrimination between islet and nonislet tissue and yielded an estimate of purity. In five of six islet preparations, islet volume averaged 14% higher than that measured with conventional DTZ staining (about 100% higher in the sixth preparation), but purity measured with the flow cytometer was lower. Islet enumeration by the large particle flow cytometer has advantages over manual counting. The diameter of each islet is measured rather than being grouped in 50mm ranges. The method is automated, which decreases the operator-dependent error intrinsic to manual counting. A large number of islets can be analyzed nondestructively, thereby eliminating the possibility of sampling error. However, the method gives estimates with slightly greater volume than manual counting, which itself is thought to overestimate volume, suggesting that
99
Colton et al.
improved calibration methods are needed. Furthermore, the equipment represents a large capital cost.
PACKED CELL VOLUME (PCV) MEASUREMENTS Measurement of the packed cell volume (PCV) of a pellet is among the standard parameters used to quantify islet preparations [116]. The islet preparation is centrifuged to create a packed pellet, the supernatant is removed to the pellet surface, and a known volume of medium is added. The tissue is resuspended in fresh medium and carefully aspirated in a serological pipette to avoid forming bubbles because they interfere with measurements. The final volume of the tissue suspension is measured, and the volume of the packed cell pellet VPC is calculated as the final volume of the tissue suspension minus the volume of the fresh medium added.
The packed cell volume of a human islet preparation can be combined with data on composition, such as from the EM or LM morphological analyses described previously, to calculate various properties of interest [116], as summarized in Figure 6.4. The packed cell pellet (which consists of islet tissue, non-islet tissue, and aggregates of the two) also contains microscopic void spaces between the components with a void volume VVPC , which is distinct from the extracellular space within the domain of the tissues, and a corresponding void fraction VPC , Equation 6.33 (Figure 6.4), based on the entire packed cell volume. If this void fraction parameter is known, the total tissue volume VT (compose of islet VI and non-islet VNI volumes) is calculated from Equation 6.34 (Figure 6.4). The volume of islets and islet cells and the number of IE and islet cells are calculated successively from Equations 6.35, 6.36, 6.38, and 6.39 (Figure 6.4), respectively. Volume and number of b cells are calculated from Equations 6.37 and 6.40 (Figure 6.4) respectively, by using cell composition data. Equation 6.37
Packed Cell Pellet Void
Non-islet
VVPC
VNI
Islet
Volume Fraction Voids
ΦVPC =
VVPC VPC
(6.33)
VI VT
VPC Number
Volume Total Tissue
VT = (1 − ΦVPC) VPC
(6.34)
Islets
VI = ΦI VT
(6.35)
NIE =
VI VIE
(6.38) Islet Equivalents
Islet Cells
VIC = (1 − ΦIEC) VI
(6.36)
nIC =
VIC νIC
(6.39) Islet Cells
Beta Cells
Vβ = φβIC VIC
Vβ nβ = ν = fβIC nIC (6.40) Beta Cells β
= φβIC (1 − ΦIEC) VI = φβI VI
(6.37)
Figure 6.4. Volume and number definitions and relationships in a packed cell pellet.
100
6.
Characterization of Islet Preparations
is expressed several different ways. It is reasonable to assume that IEC is approximately constant in all freshly isolated islet preparations, and fbIC is remarkably consistent between preparations (Table 6.4). Therefore, Equation 6.37 indicates that the volume (and the number) of b cells in a preparation is directly proportional to the volume of islets in that preparation [116]. We have combined PCV measurements made with centrifugation at 248xg for 1 minute with the LM volume fraction and EM cell composition data for the 27 clinical islet preparations summarized in Tables 6.3 and 6.4. We used a preliminary estimate of VPC = 0.3 for the void volume fraction of the packed cell pellet, which was determined from mannitol distribution space measurements in packed rat islet preparations. This value falls at the low end of the range of 0.26 to 0.48 estimated for packed spheres [106]. Nonspherical shape [40] and wide size distribution [35] would tend to decrease VPC slightly, whereas red cell packing measurements under comparable conditions suggest it could be substantially higher [72]. In view of the uncertainty in VPC , these calculations (summarized in Table 6.9) may be considered preliminary. Packed cell, islet, and b-cell volumes averaged 1.9, 0.58, and 0.35 ml, respectively. IE number, obtained by combining PCV and LM data, averaged 327,000 (corresponding to 370 million b cells). IE by DTZ staining averaged 428,000, about 31% higher than by PCV/LM, and the DTZ estimate was higher in 24 of 27 preparations. PCV measurements are attractive because they are simple. When combined with purity estimation from morphological analysis, they provide an estimate of islet volume thought to be better than visual counting with DTZ staining. That estimate can be useful as a check on the occurrence of aberrant estimates by DTZ staining. However, further work to better define the packed cell void volume in human preparations is warranted.
ULTRASOUND PULSED DOPPLER MEASUREMENTS A new ultrasonic pulsed Doppler technique (USPD) was recently described that measures the ultrasonic power backscattered from suspended particles and hence has the potential to provide rapid automated measurement of total tissue volume using only a few hundred islets [1]. The system uses a single small probe transducer (diameter 4 mm), small sample volumes (about 1 ml or less)
in a stirred cell, data acquisition in about 30 minutes, and capability of measurements with a few hundred islets. Measurements with this system have been made with b cell lines, rat islets, human islets, and exocrine tissue. In one study, a 1.2-ml volume sample was placed in a temperature-controlled acrylic test chamber stirred to suspend the tissue. The transducer, seated flush with the wall, injected a series of tone bursts at 16 MHz into the sample that was focused by a lens into a small volume situated 1.6 mm from the chamber wall. The islets were set in motion by the stirring and by acoustic streaming away from the transducer generated by the high-intensity ultrasound. Backscattered Dopplershifted energy reflected from the moving particles and returned to the transducer was conditioned and passed to a digital oscilloscope for processing. A high-resolution power spectrum was computed from which the total backscattered power was determined. The backscattered power was plotted against the total cell concentration as measured by nuclei counting (described in material following), yielding a linear correlation for high and low purity islets as well as exocrine tissue, as shown in Figure 6.5. With further study, this method may be very attractive for measuring the total tissue volume in an islet preparation.
NUCLEI COUNTING Nuclei counting is a standard method for enumeration of individual cells [54, 163]. The release of nuclei from cells disrupted with citric acid occurs without nuclei breakdown or cell losses. With addition of a surfactant, nuclei counts can be used to quantitatively assess cell number in suspensions of cell aggregates [125]. We investigated nuclei counting for determining the number of cells in an islet preparation [143, 144]. We developed a cell and islet disruption protocol, compared three different counting methods, and evaluated the accuracy and precision of the methods. We also measured the DNA content of islet cells and compared it with values reported in the literature. Finally, we combined nuclei counting with islet purity measurement by LM morphology analysis to quantify islets in impure preparations. A schematic diagram of the method and the counting options is shown in Figure 6.6. An aliquot of cells or islets in suspension is incubated for 5 minutes with a lysis solution consisting of citric acid and surfactant,
101
Colton et al. TABLE 6.9 Data and calculated quantities from packed cell volume measurementsa . Volume (ml)
Number
Packed Cell Pellet
Islets
Beta Cells
Sample
VPC
VI
1
2
1–16 2–06 2–08 2–17 2–19 2–20 2–21 2–22 2–24 2–25 3–06 3–10 3–13 3–16 3–19 3–21 3–23 3–25 3–28 4–01 4–06 4–07 4–10 4–11 4–15 4–23 4–24 Mean SD COV SEM
IE by DTZ
Beta Cells by
Vb
PCV/LM Staining (NIE )PCV/LM (NIE )DTZ
PCV/EM nb ×106
3
4
5
6
7
3.50 5.00 3.50 1.70 2.20 1.20 2.00 2.00 4.00 1.50 1.10 0.80 1.35 0.70 1.70 0.90 1.20 1.20 3.70 1.00 1.20 0.80 0.60 1.20 1.50 2.80 2.20
0.90 0.32 1.25 0.56 0.60 0.57 0.44 1.00 1.31 0.61 0.40 0.31 0.44 0.35 0.56 0.41 0.74 0.63 0.52 0.41 0.40 0.41 0.22 0.59 0.78 0.24 0.65
0.51 0.21 0.75 0.35 0.38 0.26 0.28 0.59 0.86 0.38 0.21 0.19 0.26 0.22 0.33 0.26 0.46 0.41 0.34 0.27 0.27 0.26 0.14 0.34 0.47 0.15 0.42
508,000 179,000 704,000 319,000 340,000 323,000 249,000 566,000 741,000 343,000 224,000 176,000 246,000 196,000 319,000 234,000 419,000 358,000 295,000 233,000 227,000 234,000 127,000 332,000 441,000 137,000 369,000
544,000 400,000 451,000 460,000 370,000 382,000 326,000 499,000 524,000 266,000 341,000 298,000 269,000 445,000 469,000 289,000 319,000 600,000 814,000 243,000 516,000 532,000 290,000 497,000 447,000 387,000 570,000
539 219 792 367 397 270 291 623 903 398 216 203 273 231 345 279 489 428 355 288 285 270 148 356 496 161 446
1.87 1.15 0.62 0.22
0.58 0.27 0.47 0.05
0.35 0.17 0.48 0.03
327,000 155,000 0.47 30,000
428,000 129,000 0.30 25,000
373 180 0.48 35
IE by
a Quantities calculated as follows: Column 2 from Equation (6.34); Column 3 from Equation (6.35) with
I from Equation (6.20) and with fb and fIC from EM data; Column 5 from Equations (6.38); Column 7 from Equation (6.40) with fbIC from Equation (6.19) and nIC from Equation (6.5) with parameters from EM data.
from LM data; Column 4 from Equations (6.36) and (6.37) with
and this suspension is then sheared by vortex mixing of cells or flow of islets through a hypodermic needle to liberate nuclei. Three different methods can be used for counting the liberated nuclei: (1) a sample is stained with crystal violet to darken the nuclear envelope and
fbIC
the nuclei are counted visually using a hemacytometer, (2) a sample is analyzed using aperture electrical resistance measurements with the Coulter Multisizer II, or (3) a sample is stained with the fluorescent dye 7-AAD that binds to cellular nucleic acids with very
102
6.
Characterization of Islet Preparations
8 High purity human islets 30% human islets
7 Backscattered Power (µW)
Exocrine tissue
6 5 4 3 2 1 0
0
1
2 3 4 5 6 Cell Concentration (106 cells/ml) by Nuclei Counting
7
Figure 6.5. The backscattered power measured by the USPD technique is plotted against the total cell concentration as measured by nuclei counting, yielding a linear correlation for high and low purity islets as well as exocrine tissue.
high affinity. This sample is analyzed in a Guava PCA flow cytometer, a small unit that is especially convenient for this assay. Discrimination of nuclei by the Guava PCA system relies on the 7-AAD intensity and
the forward scatter, which in part reflects the relative size of the particles passing through the flow cell. The forward scatter threshold is set so that only particles large enough to be nuclei are counted, and debris is ignored. Only the stained nuclei display high 7-AAD intensity so that the system provides an accurate count of the nuclei population. Analysis of triplicate samples containing about 1,000 nuclei requires about 1 hour for visual counting, 11 minutes for the aperture resistance method, and only 6 minutes for the Guava PCA flow cytometer. The accuracy of the nuclei counting method was verified with a stock nuclei suspension prepared from INS-1 cells diluted to produce samples covering a 104 -fold range of concentration that were counted by the three different methods. With each method, the measured nuclei concentration agreed with the calculated nuclei concentration until the point where the relationship between the two departed from linearity (7 × 104 nuclei/ml for aperture resistance, 6 × 105 nuclei/ml for flow cytometry) as a result of interference effects at higher concentrations. The precision of nuclei counting measurements approximately followed Poisson statistics. With INS-1 cells, the precision improved as the number of nuclei counted increased with a coefficient of variation about 3% for about 1,000 nuclei counted. With islets,
Citric Acid Surfactant
lls
Ce
Vortex Mixing (Cells) Shearing Through Needle (Islets)
Isle
ts
103
nuclei x 3 Time (min) Visual Counting Hemacytometer
70
Aperture Resistance Coulter Multisizer II
16
Flow Cytometer Guava PCA
11
Liberated Nuclei
Crystal Violet
40 % (v/v) Glycerol in Isoton II
7-AAD
100 µm
Figure 6.6. Schematic diagram of protocol developed for nuclei counting of cell and islet samples. Islet or cell aliquots are incubated with a lysis solution (citric acid and surfactant). Nuclei are liberated by either vortex mixing for cells or shearing through a needle for islets. The liberated nuclei can be analyzed with three different methods: visual counting in the hemacytometer, aperture resistance measurements in the Coulter Multisizer II, and flow cytometry in the Guava PCA.
103
Colton et al.
the coefficient of variation decreased as the number be expressed in terms of the number of islet equivaof islets sampled increased with a value of about 6% lents NIE by use of Equation (6.41). Two quantities for 125 IE or more sampled. Additional validation of from the EM cell composition results (Table 6.4) are the technique was obtained by counting nuclei and the used in this calculation: the average value of the ratio cell suspension from which they were prepared. Fur- ν IC ν TC = 1.09 and the average number of cells in thermore, in a comparison of nuclei counts obtained an islet equivalent, nIE = 1,560. Had the analysis made with flow cytometry to DNA measurements from serial use of EM morphological analysis, it would have started dilutions of stock suspensions of cells and islets, DNA directly with the number fraction islet cells, fIC . concentration was linearly proportional to nuclei conThe analysis outlined in Figure 6.7 has been applied centration. to samples of freshly isolated human islet preparations These studies have demonstrated that nuclei counting for research in an ongoing study. For each preparation, can rapidly provide accurate and precise measurements the total number of IE was estimated by visual countof the number of cells with an intact nucleus in islet ing of DTZ-stained islets for the entire preparation. preparations. Nuclei counting to obtain the total number A known fraction of that preparation was processed of cells can be combined with morphological analysis for nuclei counts within 4 to 6 hours after isolation. (EM or LM) to quantify the number of islet cells and Samples of the same preparation were saved to be proislet equivalents in an impure human islet preparation. cessed for LM morphology analysis. Visual counting We compared the number of IE obtained by two substantially overestimated the number of IE compared methods: visual counting of DTZ-stained islets and to LM/nuclei counting. On a graph on which the number LM/nuclei counting for six research human islet of IE from visual counting was plotted against the numpreparations. The calculation procedure is summarized ber of IE from LM/nuclei counting, a straight-line fit in Figure 6.7. LM morphology analysis provides a mea- to the data yielded a slope of 1.90, which corresponds surement of the islet volume fraction, I , which is to 90% overestimation by visual counting with DTZsuccessively converted to islet cell volume fraction fIC stained islets. The large overestimation associated with and then to the islet cell number fraction fIC , which visual counting may reflect two factors: (1) errors assoin turn is combined with the total cell number nTC to ciated with the volume calculation and (2) regions of yield the number of islet cells, nIC . This latter param- dead cells within the tissue that do not possess intact eter suffices to characterize the preparation. It can also cell nuclei.
LM Morphology Volume Fraction Islets
Nuclei Counting Total Number Nuclei
nTC
(ΦI)LM Eqn (6.28) Figure 6.3
Islet Cell Volume Fraction
φIC
Eqn (6.18), Table 6.5
νIC νTC
Number Islet Equivalents
NIE =
Islet Cell Number Fraction
fIC
= 1.09
nIC (6.41) nIE
Eqn (6.8) Table 6.5
Table 6.4
nIE = 1560
nIC
Number Islet Cells
Figure 6.7. Calculation of number of islet cells and islet equivalents in impure human islet preparations from nuclei counting and LM morphological analysis.
104
6.
Characterization of Islet Preparations
DNA CONTENT DNA measurements are used to quantify the total amount of tissue in an islet preparation, in that each cell with a single nucleus should carry the same amount of DNA. DNA is quantified by fluorospectrophotometry using a commercially available dye that undergoes strong fluorescence enhancement when bound to cellular nucleic acids. The fluorescence intensity is linearly related to the concentration of nucleic acids in the sample, and the DNA concentration is determined from a calibration curve created with a DNA standard. DNA measurements are common and are advantageous because they are not operator dependent, as is visual counting [11, 44, 133]. The limitations with DNA measurements are the time requirements and the stability and variability of the DNA standard. Therefore, comparisons between different laboratories may be difficult to perform on the same basis and consequently difficult to compare. To explore these problems, we performed DNA measurements with two different commonly used DNA-binding fluorescent dyes (Cyquant and Picogreen) following the same protocol and using the same lambda DNA standard for bTC3 cells and rat islets. Values measured with the CyQUANT dye (6.2 ± 0.6 and 6.4 ± 0.8 pg/cell for bTC3 cells and rat islets, respectively) were significantly higher (p < 0.05) than corresponding values measured with PicoGreen dye: 5.6 ± 0.8 and 4.9 ± 0.9 pg/cell for bTC3 cell and rat islets, respectively. Such differences may be in part responsible for the problems with inconsistency in DNA comparisons between different laboratories. Another concern with the DNA measurements is the degradation
A. Rat
of the standard with time. We found that the slope of the standard calibration curve measured with the same lambda DNA standard decreased about 35% over a 5-month period. This decreased slope was mirrored by a decrease in the amount of DNA measured with control tissue samples run parallel to the standard. Thus, frequent change to a new standard and recalibration is essential to achieving reproducible results. We find it useful to combine nuclei number and DNA content assays. Measurements made with CyQUANT dye over a 3-year period with 37 different batches of rat islets yielded 6.5 ± 1.9 pg/cell (Figure 6.8a). Measurements performed with 26 preparations of freshly isolated human islets yielded 6.9 ± 2.3 pg/cell (Figure 6.8b). These values are comparable to the expected value of about 6.5 pg/cell for human DNA [40, 139]. Similar measurements with human islets received from various centers after being shipped (21 preparations) yielded 8.5 ± 2.3 pg/cell (Figure 6.8c). These data suggest that some islet cells may die during shipment and release DNA that is not completely degraded and contributes to the higher measured value. This is another reason why assay of DNA alone may not provide an accurate measurement of the number of cells in an islet preparation and why nuclei may provide better accuracy.
ESTIMATION OF ISLET EQUIVALENTS IN THE PANCREAS The number of IE in a normal pancreas was recently estimated to average about 500,000 IE [90] on the basis of pancreatic islet volume estimates of 0.5 to 1.3 cm3 made
B. Human (Freshly Isolated)
16
Frequency
14
5
8
12
4
10
6 3
8 4
6
2
4
2
1
2 0
C. Human (Shipped) 6
10
0
2
4
6
8
10
12
0
0
2
4
6
8
10
12
0
0
2
4
6
8
10
12
DNA Concentration (pg DNA/cell) Figure 6.8. Distributions of DNA content per cell (pg DNA/cell) from (a) 37 rat islet preparations, (b) 26 freshly isolated human islet preparations, and (c) 22 human islet preparations received from other centers after shipment.
105
Colton et al.
with pancreata from Japanese cadavers and reported in 1978 [161]. By comparison to the commonly reported average value of about 500,000 IE isolated from a cadaver pancreas, it was concluded that a major fraction of the native islets is being recovered by current isolation methods. We have made a calculation based on more recent estimates that the volume fraction of b cells in the pancreas averages about 1.9% [24, 197]. Assuming a pancreas tissue density of 1.1 g/ml, a volume fraction b cells in islets of 0.61 (Table 6.6), and an average pancreas weight of 84 g [116], we estimate that the islet volume is 2.4 ml, which corresponds to 1.3 million IE per pancreas. Furthermore, our data presented earlier in this section suggest that the average number of IE in an islet preparation is substantially less than 500,000 IE. Taken together, these estimates suggest that only a small fraction of islets in the native pancreas are actually recovered during islet isolation.
Viability Membrane integrity measurement by visual assessment following staining with fluorescein diacetate and
propidium iodide (FDA/PI) is the most commonly employed method of assessing fractional viability of islet preparations. This assay usually gives erroneously high values that are not predictive of the transplantation outcome. Membrane integrity tests differentiate only between dead (membrane permeable) and non-dead (membrane impermeable) cells but fail to distinguish healthy cells from cells that have entered the cell death process but have not reached the membrane permeabilization step. Consequently, there is no standard assay currently employed that gives a meaningful measure of islet viability. A variety of alternative techniques are currently under investigation, as summarized in Table 6.10. These alternatives include new dyes for membrane integrity tests and new ways of quantifying membrane integrity tests with islets, assays of events associated with apoptosis, and measures of mitochondrial function. The latter category includes measurements related to cell redox state, rate of oxidative phosphorylation assessed by ATP content or oxygen consumption rate, and mitochondrial membrane potential. In this section, methods for each type of assay are briefly summarized, with more in-depth examination of assays developed in our laboratory. We conclude with a comparative study
TABLE 6.10 Methods for measuring the viability of islets in an islet preparation. Parameter Measured
Tissue Assayed
Method
Cell Membrane Integrity
Intact Islet Preparation
Live/Dead (Membrane Permeable) Fluorescein Diacetate/Propidium Iodide Alternative Dyes Dead Quantitative Nuclei Counting/7-AminoActinomycin D
Apoptotic Events
Intact Islet Preparation
Magic Angle Spinning 1 H-NMR Spectroscopy
Intact Islets (Disrupted)
Early: Signaling Pathway-Caspase Activation Late: Nucleosome DNA Fragmentation
Fixed Tissue or Cells
Phosphatidyl Serine Translocation-Annexin V DNA Fragmentation-TUNEL
Intact Islet Preparation
Redox State of the Cell: Tetrazolium Salts MTT, MTS Oxidative Phosphorylation Energetic State (ATP, ATP/ADP) Oxygen Consumption Rate
Dispersed Single Cells
Mitochondrial Membrane Potential Fluorescent Dyes JC-1, TMRE
Mitochondrial Function
106
6.
Characterization of Islet Preparations
of the transient response of cells and islets to various stresses as reflected by assays of each major type, followed by a summary of data suggesting that oxygen consumption rate data combined with cell number or DNA data are predictive of transplantation outcome in the immunodeficient mouse.
CELL MEMBRANE INTEGRITY LIVE/DEAD STAINS Membrane integrity stains have been used to assess islet viability since the late 1980s [9, 10, 151, 156]. These stains assess whether cell membranes have become permeable to molecules that normally cannot permeate through the membrane. In most cases, permeabilization of the cell membrane signifies one of the final stages in the cell death process. Molecules that normally pass easily through the phospholipid bilayers of the cell membrane include hydrophobic, nonpolar, or small uncharged polar molecules, whereas those that do not pass easily include large uncharged, polar, or charged molecules. Some dyes commonly used in live/dead staining are shown in Table 6.11 [79]. It is generally thought that nonpolar dye molecules can easily permeate across cell membranes and that polar dye molecules cannot [10, 65, 66, 85, 92, 156], although the structures in Table 6.11 suggest that charge may also play a role. A normally membraneimpermeable dye enters a cell only when its membrane has been compromised. Thus, by staining cells with two different colored dyes (one that permeates and one that does not) it is possible to determine the relative quantity of cells that have intact cell membranes and those that have compromised membranes. Acridine orange (AO), which binds to all nucleic acids and is membrane permeable, together with propidium iodide (PI)—a membrane-impermeable dye that also binds to all nucleic acids—is one of the original combinations of membrane integrity dyes applied to islets [7, 8]. PI fluoresces red when bound to nucleic acids, whereas AO fluoresces green when bound to double-stranded DNA and red when bound to singlestranded DNA or RNA. In some studies, AO is replaced with fluorescein diacetate (FDA), a colorless ester until cleaved by nonspecific cellular esterases, causing it to fluoresce green [101, 102]. The cleaved product accumulates in cells that have intact membranes, resulting in a strong green fluorescence. Cells with compromised membranes do not accumulate the dye and therefore do
not give a strong green fluorescence. The membrane integrity stains are added to islet samples and incubated for a specified period of time. After incubation, the islets are observed under a fluorescence microscope to visually assess the approximate volume fraction of cells stained red compared to those stained green. After looking at many islets, an estimate is made of the overall average volume fraction stained red. In one study, viability was determined in a different fashion. A total of 50 islets were sampled and each islet was categorized as viable or nonviable, and then the overall fractional viability was calculated. Islets having more than 50% red staining on the surface or periphery or those with more than 25% centrally stained red were considered nonviable [10]. In that study, other dye combinations were also examined with islets: (1) SYTO-13 (Molecular Probes Eugene, OR), a nucleic acid stain that fluoresces green when bound to DNA, (2) ethidium bromide (EB), which fluoresces a red-orange color that intensifies when binding to DNA, and (3) Calcein AM (C), a green membrane-permeable fluorescent dye that is hydrolyzed by esterases, causing it to become negatively charged and be retained in the cytoplasm, along with ethidium homodimer (EH), a positively charged fluorescent nucleic acid stain that cannot cross intact cell membranes. C/EH and SYTO/EB provided substantial differential staining capability, whereas FDA/PI had high background fluorescence and obscured signal within the central regions of the islets, resulting in an overestimate of viability. Calcein AM was detrimental to the islets and caused significant fragmentation. SYTO/EB was suggested as a more accurate replacement for FDA/PI. Membrane integrity measurements are very quick and easy to perform, making them attractive for use immediately prior to transplantation. However, there are several problems that render them of limited value. Several studies have shown that the working stain solution must be diluted to a specific target concentration before being added to a sample [7, 29, 62, 85, 101, 102, 110, 111, 135, 174]. Too concentrated a solution results in significant background fluorescence, whereas too dilute a solution does not provide enough fluorescence. Timing is also critical, in that enough time needs to be allowed for the dyes to diffuse into the islet, but not so much that artifacts such as islet fragmentation occur. Perhaps the biggest problem with membrane integrity assays is that there is a lack of correlation between membrane integrity staining and other viability assays, including mitochondrial function assays such as MTT
107
Colton et al. TABLE 6.11 Dyes commonly used in live/dead stains [79].
Membrane Impermeable
Membrane Permeable
Propidium Iodide (PI)
Acridine Orange (AO)
Fluorescein diacetate (FDA) Ethidium Bromide (EB)
Calcein AM (C) Ethidium Homodimer (EH)
7-aminoactinomycin D (7-AAD)
and ATP [29, 85, 111, 174, 196]. This may reflect the fact that mitochondrial dysfunction occurs early, whereas compromise of cell membranes occurs later in the cell death process [168]. QUANTITATIVE MEMBRANE INTEGRITY MEASUREMENT A major problem with visual estimation in membrane integrity tests for islets is that there are limitations in
viewing a 3D structure in a 2D plane, and it is necessary to guess how observations in a 2D field apply in three dimensions to the islet as a whole. This limitation can be improved to some degree by focusing through the islet and looking at multiple planes, but this in itself is difficult because each viewed plane may be obscured or affected by the previous or subsequent plane. In either case, this method is subjective, operator dependent, and not quantitative, and thus prone to error.
108
6.
Characterization of Islet Preparations
One way around the problems of estimating the volume fraction of membrane-compromised cells in the 3D islet structure is to dissociate the islets into single cells and apply the membrane integrity test to the dispersed single cells after dissociation. However, dissociation of islets with trypsin (followed by dye exclusion measurements using the liberated cells) is not a suitable option because a substantial fraction of cells is lost during dissociation [139, 140, 193] and/or damaged, as described previously. We have developed a new method for making quantitative membrane integrity measurements that makes use of repeated nuclei staining in conjunction with flow cytometry to quantify the fraction of cells with intact membranes in islets, thereby eliminating entirely the need for observation of a 3D pattern in a microscope
Cells
Islet
Nuclei of membranepermeable cells are stained
7-AAD
Wash, disrupt tissue Citric Acid and Surfactant
Cells: Vortex mixing Islets: Shearing through needle
Flow Cytometer
All nuclei are stained
7-AAD
Flow Cytometer
Fraction (f) of cells permeable to 7-AAD
N1
=
N2
N1 N2
Figure 6.9. Diagram of the protocol for quantitative membrane integrity measurements with sequential 7-AAD staining. In the first step, cells or islets are stained with 7-AAD. Cells are disrupted with a lysis solution and shear, and nuclei are counted to give the number of membrane-permeable cells in the original suspension (N1 ). In the second step, the nuclei are stained with 7-AAD to label all cells, and the total number of cells is counted (N2 ). The fraction f of permeable cells is f = N1 /N2 .
[145, 146]. The procedure is summarized in Figure 6.9. Islets are stained with 7-aminoactinomycin D (7-AAD), a membrane-impermeable fluorescent dye with high affinity for cellular nucleic acids, to label nuclei in all cells with compromised membranes. Unbound 7-AAD is removed by washing. Islets are disrupted by mixing with a lysis solution (0.1 M citric acid and 1% Triton X-100) combined with high shear. An aliquot of the nuclei suspension is immediately analyzed with a flow cytometer, and labeled nuclei are immediately counted. Another equal aliquot of the stained nuclei suspension is stained again with 7-AAD, thereby labeling all previously unlabeled nuclei, and the total number of nuclei is counted. The fraction of cells with compromised membranes is estimated as the ratio of the initially stained nuclei from cells with compromised membranes (first measurement) to the total number of nuclei (second measurement). In contradistinction to the situation of islet dissociation to produce single cells, in which many cells are lost, all nuclei are recovered quantitatively following islet disruption, thereby making this procedure accurate. To validate the assay [146], islets were damaged by heat-induced killing (which compromised all cell membranes) and then mixed in various proportions with islets that had not been heat treated. The fraction of cells with compromised membranes, as measured by the 7-AAD sequential staining procedure, was equal to the fraction of heat-treated cells in the mixtures over the entire range studied. Furthermore, fractional membrane integrity assessed with repeated nuclei staining by 7-AAD correlated linearly with fractional viability measured using the MTT assay (described in material following). We concluded that sequential staining of nuclei with 7-AAD before and after cell disruption provides an objective, rapid, accurate, and precise quantitative estimate of the fraction of cells in islet preparations that has compromised membrane integrity. This assay is most useful with preparations of high purity because it does not distinguish between islet and non-islet cells. The comparison between 7-AAD membrane integrity measurement and MTT cell viability assay was carried out with islets that had undergone heat-induced cell killing, which leads to permeabilization of the cell membrane. In many other situations where stress is applied to intact islets, loss of cell membrane integrity occurs late in the cell death process, whereas the MTT assay responds to earlier steps that affect the redox potential of the cell. In our own hands, we have found
109
Colton et al.
that the two assays usually agree only after extended periods (24 to 48 hours) of culture under stable conditions [147, 148], as described in a subsequent section, during which cells that have entered the cell death process are able to reach the stage of membrane damage. Thus, caution must be exercised in interpreting the meaning of quantitative membrane integrity measurements with islets, especially within one day after isolation.
APOPTOSIS Apoptotic cell death is characterized by specific physical and molecular changes in the cell that start when the cell receives a pro-apoptotic stimuli and end when the cell nucleus breaks up into apoptotic bodies of various size. Once a cell passes a certain point in the apoptotic process it is destined to die. Although the exact point at which a cell is unable to recover is not known, insight can be gained into the overall health of a population of cells by measuring various characteristics of the apoptotic process known to occur before cell death. We focus here on some of the more widely studied apoptotic events that have been examined with islet tissue. These events include DNA fragmentation as measured by TUNEL and the nucleosome assay, phosphatidylserine externalization as measured by Annexin V staining, and caspase activation, all of which are characteristic events in the apoptotic process. In addition, we briefly discuss use of NMR spectroscopy to measure changes in the structure of intracellular lipids that correlate with apoptosis. As shown in Table 6.10, some of these assays (caspase activation, nucleosome, DNA fragmentation) can be used with intact islets, whereas others require dispersed single cells or islet histological sections. MAGIC ANGLE SPINNING 1 H NMR Nuclear magnetic resonance spectroscopy is widely used as a tool for medical diagnosis and research. A variant, high-resolution magic angle spinning proton NMR (HRMAS 1 H NMR), has recently been implemented as a method of assessing properties of cells. Cheng et al. [27, 28] used HRMAS 1 H NMR to evaluate human breast ductal carcinomas and spermine in human prostate tissue samples. Blankenberg et al. [14] used the same method to quantify apoptotic cell death in Jurkat T-cells in studies of acute
lymphoblastic leukemia. Recently, HRMAS 1 H NMR was used to examine porcine islet preparations that had been exposed to hypoxic conditions typical of culture and shipment [121]. Changes in NMR spectra of cellular lipids, in particular the ratio of methylene (CH2 ) resonance to the methyl (CH3 ) resonance, have been associated with apoptosis. The data of Papas et al. [121] exhibited changes in the methylene-to-methyl resonance ratio that correlated to the degree of hypoxia. These data suggest that HRMAS 1 H NMR is a promising technique in assessing islet quality, and in particular apoptosis, especially because it can be applied to small quantities of intact islet preparations. Further studies are needed to correlate this method with other measures of apoptosis. CASPASE Caspase activity has been suggested as a reliable marker of early apoptosis that detects apoptotic tissue earlier than DNA fragmentation assays such as TUNEL [26]. When cells are exposed to pro-apoptotic stimuli, a cascade of events begins in which one or more caspases are activated. By measuring the amount of activated caspase(s), one can detect whether or not apoptosis is occurring [182]. It is necessary to choose in advance the caspase(s) to be assayed. For example, caspase 8 and 9 both initiate the cascade of events, but caspase 8 is usually activated by external signals via membrane death receptors whereas caspase 9 is usually activated by cytotoxic agents that damage mitochondria, allowing cytochrome c leakage into the cytosol [182]. Caspase 3 and 7 are common downstream effector caspases associated with some forms of b-cell apoptosis [26, 45, 105, 149, 183, 195]. Two methods can be used to assess caspase activity in islet tissue. Each can be adapted for any one of the caspases that may be active. In one method, samples for histology are sectioned and immunostained for caspase activity. This method allows observation of an elevated level of caspase in a sample and identification of the cells that contain the activated caspases. It has been used in several studies involving islets [45, 82, 149]. A second method makes use of a hydrolysis reaction with a reporter molecule attached to a peptide by aspartic acid. Caspases have a unique specificity because they contain a critical cysteine residue that allows them to cleave other proteins at sites next to an aspartic acid residue [182]. In this assay, intact islet tissue is washed and lysed to free the activated caspase, which then
110
6.
Characterization of Islet Preparations
cleaves the reporter molecule-peptide complex, releasing the reporter molecule and resulting in a color change or fluorescence. This type of assay can be completed in several hours and has been applied to several islet studies in order to quantify caspase activity [26, 105, 183, 195]. NUCLEOSOME DETECTION Detection of cytoplasmic histone-associated DNA fragments (mono- and oligo-nucleosomes) is performed with a photometric enzyme immunoassay (e.g., Cell Death Detection ElisaPLUS from Roche Applied Sciences or Nucleosome ELISA assay from Oncogene research products). The cytoplasm of apoptotic cells is enriched with nucleosomes from DNA degradation, which can occur several hours before the plasma membrane breaks down. Intact islets can be analyzed because the assay requires the tissue to be lysed in order to free up fragmented DNA. The assay is based on a quantitative sandwich enzyme immunoassay principle using monoclonal antibodies directed against DNA and histones. Aliquots of a cell or islet lysate are transferred to a multi-well plate. An immunoreagent, prepared with anti-DNAperoxidase (POD) and antihistone-biotin, is added in each well, and the samples are incubated. During incubation, the antihistone antibody binds to the histone component of nucleosomes and also attaches the immunocomplex to the streptavidin-precoated plate via its biotinylation. The anti-DNA-POD antibody reacts with the DNA component of the nucleosomes. At the end of the incubation, unbound antibodies are removed by a washing step. Finally, the amount of nucleosomes retained in the POD immunocomplex is quantified photometrically with ammonium 2, 2 -azino-bis(3)ethylbenzthiazoline-6-sulfonate as a substrate and the sample absorbance is reported relative to that of a control. Detection of nucleosomes has been used as an indicator of apoptosis for a variety of cells, including intact islets [78, 136] that have been stressed. Both apoptotic and necrotic cells can strain positive for DNA fragmentation using the TUNEL assay [41, 51, 56, 64, 184], as described in material following, and cells in both states are likely to be positive for DNA fragmentation as measured by the nucleosome assay. ANNEXIN V Translocation of phosphatidylserine (PS) from the inner to the outer side of the cell membrane occurs during the
early stages of apoptosis. Although PS is not externalized in necrosis, it would appear as if it were because cell membranes are disrupted during necrosis. Thus, staining for PS results in identification of both necrotic and apoptotic cells. Using Annexin V (a binding protein with a high affinity for PS) and PI (the dye commonly used for membrane integrity measurements), Vermes et al. [188] developed a flow cytometric assay to differentiate between apoptotic and necrotic cells and detect early stages of apoptosis when PS is externalized. Cells were stained with both Annexin V and PI, incubated in the dark, and then assessed using bivariate flow cytometry to identify healthy intact cells, apoptotic cells, and necrotic or late apoptotic cells. In addition to distinguishing among apoptotic and necrotic or late apoptotic cells, Annexin V staining consistently indicates cell damage earlier than the TUNEL DNA fragmentation assay [26, 134], demonstrating that PS externalization is an early indicator of apoptosis. Annexin V staining has been used in many studies with islet cells [26, 48, 87, 108, 114]. However, Annexin V staining is quantified through flow cytometry and thus requires single cells for analysis, which suffers from the problems identified previously.
TUNEL DNA fragmentation is a characteristic event when a cell dies. A commonly used method of detecting DNA strand breaks is the TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) assay [57]. The technique is applied to histological sections that allow the user to not only ascertain whether DNA fragmentation occurred, which could also be determined through gel electrophoresis, but to observe the specific cells that contained fragmented DNA. DNA fragmentation as measured by the TUNEL assay is traditionally thought of as an indicator of apoptosis. However, both apoptotic and necrotic cells can stain positive using TUNEL. Therefore, TUNEL is a marker of cell death, but not necessarily of apoptosis specifically [41, 51, 56, 61, 184]. Terminal deoxynucleotidyl transferase (TdT) is used to incorporate biotinylated dUTP to the 3 -OH ends of DNA that are exposed during DNA cleavage [57]. Once labeled, a second incubation amplifies the signal, resulting in a color change or fluorescence. The labeled cells may be visualized by light or fluorescent microscopy,
111
Colton et al.
depending on which molecule is used in the final incubation. Several studies have used TUNEL to assess islet quality in response to a stress and/or treatment [26, 82, 132, 149]. It is a valuable research tool for observing the specific cells going through the cell death process. Because TUNEL requires that histological samples be taken, prepared, and stained, it is advantageously used retrospectively, rather than for prospective assessment of an islet preparation prior to transplantation. Although TUNEL is usually used on histological sections in islet research, it can also be quantified by using fixed dispersed single cells with flow cytometry [118], but with the disadvantages associated with using single cells obtained from islet dissociation (as discussed previously). Measurements of the specific changes that occur during apoptosis may provide important insight into viability of islet preparations, and different techniques can be employed with histological sections, single cells from dissociated islets, or intact islets. Assays requiring histological sections, such as the TUNEL assay and one type of caspase assay, require significant time and are thus inappropriate for fast analysis, but may be beneficial for posttransplantation analysis because the cells in which apoptosis is occurring can be identified. Assays using dissociated islet cells are questionable because a significant fraction of cells is lost or damaged during islet dissociation [139, 140, 193], making Annexin V and TUNEL by flow cytometry prone to artifact. Assays starting with intact islets are useful for rapid measurement because no significant preparation is required for analysis. As a result, the nucelosome assay (a second form of caspase assay) and HRMAS 1 H NMR are attractive for islet quality assessment. Of these three assays, the caspase assay may be the most useful indication of apoptosis, per se. The nucleosome assay detects DNA fragmentation that occurs in both necrotic and apoptotic cells. As such, it is a better indicator of all cells dying by both apoptosis and necrosis. HRMAS 1 H NMR has the potential to be useful, but requires specialized equipment and therefore may be unattractive to small institutions that do not have the resources.
MITOCHONDRIAL FUNCTION The function of mitochondria is to convert ADP to ATP, the energy currency of the cell, according to the following approximate reaction (which also
includes cytosolic glycolysis). Glucose + 36 ADP + 36 Pi + 6O2 → 6CO2 + 42H2 O + 36ATP
(6.42)
If mitochondrial function ceases, oxidative phosphorylation ceases, and the cell will die unless it is able to produce ATP by anaerobic metabolism. Furthermore, the ATP/ADP ratio is important for insulin secretion in b cells. Thus, the process of oxidative phosphorylation should be useful in assessing viability. ATP concentration and ATP/ADP ratio provide an index of the energetic state of the cell. Because the ATP production rate is six times the oxygen consumption rate (OCR), as shown in Equation 6.42, OCR measurements provide a direct assessment of the rate of oxidative phosphorylation assuming that all other O2 -consuming reactions in the cell are negligible, which is reasonable for b cells. ATP generation is driven by the gradient in hydrogen ions developed across the inner mitochondrial membrane, and thus the mitochondrial membrane potential is another quantity that can be used to assess mitochondrial function. Last, because the mitochondria are partially responsible for the maintenance of the redox state of the cell, assays of the redox state are often classified as mitochondrial function assays. We begin with the assays of the redox state that make use of tetrazolium salts. REDOX STATE OF THE CELL: TETRAZOLIUM SALTS Mosmann et al. [112] first described the use of an assay that distinguished viable from nonviable cells by their ability to cleave tetrazolium salts. This technique was later applied to the viability assessment of islets [81]. Currently, there are at least three different tetrazolium compounds in widespread use for viability assays for islets and islet cells: MTT (3-(4,5-dimethylthiazol2-yl)-2,5-diphenyl tetrazolium bromide), XTT (2,3bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino) carbonyl)-2H-tetrazolium hydroxide), and MTS (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2H-tetrazolium, inner salt). Each of these compounds (MTT, MTS, and XTT) is reduced by viable cells to form a dye molecule with an absorbance spectrum that is different from the parent dye, which allows for easy colorimetric measurement using a multiwell plate reader. The product of MTT reduction is not water soluble, and it accumulates within cells that must be lysed and the reduced MTT solubilized as the last
112
6.
Characterization of Islet Preparations
step in the assay. The products of XTT and MTS reduction are soluble, no subsequent lysis step is required with them, and it is possible to follow the concentration in solution, which increases with time. The process by which the tetrazolium salts are reduced is complex and not completely understood. Therefore, the assay results are prone to artifacts [13]. Reduction of these dyes is dependent on NADH and NADPH concentrations within the cells, which is a measure of the redox state of the cell. However, this reduction is dependent on intermediate electron acceptors, such as phenazine methosulfate (MTS and XTT), or on microsomal enzymes in the case of MTT. Superoxide is involved with the reduction of XTT and MTS, and the process is sensitive to changes in environmental oxygen. Reduction of these dyes also occurs by medium components, such as l-cysteine and l-ascorbic acid, independently of processes within cells. MTT and XTT assays (and presumably MTS) are very sensitive to the glucose concentration in the medium [189]. Finally, unexpected reduction of MTT and XTT has been observed in islets treated with the cytokines IL-1 and IFN-g [9] and has been attributed to the diaphorase activity of inducible nitric oxide synthase, which is unaffected. Viability assays using tetrazolium salts are widely used despite the drawbacks mentioned previously because they are very easy to perform, inexpensive, and can be used with intact islets. No additional lab equipment beyond a plate reader is required, and the tetrazolium dyes are affordable. Cells or islets are added to the assay reagent (medium with tetrazolium salt) and incubated for a period of time. Because MTT is insoluble, the accumulation of the reduced product within the cells is lethal, and all cells are usually killed within about 4 hours [58]. After this time, the reaction ceases, and there is no further accumulation of the reduced MTT. This product is solubilized with DMSO or SDS, and the absorbance is measured using a plate reader. Because the XTT and MTS products are soluble, they are relatively nontoxic, and it is possible to fit the early data for product concentration to a linear function of time, the slope of which is the rate of product formation and therefore a measure of the redox state of the cell [13]. Because the assays using tetrazolium salts are sensitive to a wide variety of variables that are incompletely known, it is not possible to develop a standard calibration curve relating a particular assay reading to a specific viability or to accurately relate the absorbance
reading from one islet preparation to another. However, the method is very useful for comparing the effects of a particular variable on a single islet preparation when the measurements can be made with a control, so that the fractional viability relative to the control can be measured. Nonetheless, we have found that these assays are not universally applicable and are capable of providing inexplicable results similar in nature to those described in the literature. The most striking example we have observed is a large variation in the extent of MTT reduction at 37◦ C in islets and cells that have been cultured at reduced temperatures (4 to 24◦ C), allowed to recover to 37◦ C, and then retested (unpublished data). Thus, assays using tetrazolium salts are useful for the assessment of islet viability in experiments involving a control, if used with a precisely followed standard protocol, and in combination with other viability assays if warranted by the results. OXIDATIVE PHOSPHORYLATION ATP Concentration Viable cells produce ATP as an energy intermediate. A viable cell therefore has a pool of ATP available for many cellular energy-requiring processes, whereas a dead cell does not, and this property can be exploited for measurement of cell viability [84]. In principle, the number of viable cells can be determined by lysing them to release their ATP into solution, quantifying the ATP concentration with a luceriferasebased luminescence assay, and converting the total amount of ATP into a viable cell number if accurate values for the cell-specific ATP content of viable cells are known. The ATP assay itself is inexpensive and easy to perform with a microplate reader. Furthermore, measured changes in ATP concentration (and associated changes in ATP concentration) within b cells play an important role in secretion of insulin [34]. For all of these reasons, ATP quantification is an attractive candidate as a marker for assessment of islet viability. It can be quite difficult to use an ATP assay to get an accurate result for this purpose because the cellular ATP pool size is very sensitive to changes in environmental conditions. In a single islet equivalent, ATP is produced at an estimated rate of approximately 60 pmol per minute in nutrient-free media at a high glucose concentration [44]. The ATP content of b cells in a single islet is approximately 14 pmol [59]. Based on these estimates, the half-life of ATP within an islet is only
113
Colton et al.
about 7 seconds. Given this very short half-life, a small change in environmental conditions that affects either ATP production or utilization rates can cause significant variation in the total ATP isolated from tissue. For example, a two-step wash of islets in ice-cold buffer, as was done by Noguchi et al. [114], will almost certainly produce very different results from those that would be obtained if cultured islets were immediately lysed. Islets are especially difficult to assay, in that they are large aggregates, and cells in the outer and inner regions may experience very different microenvironments depending on the assay conditions. For the reasons mentioned previously, the application of the ATP assay to islet quality assessment is quite difficult. When Brandhorst et al. [20] attempted to use ATP content measurements for quality assessment of human islets, they found a coefficient of variation (COV) of 130%, compared to a COV of 45% for glucose stimulation index with the same islets. Others have reported better results [80] but have not performed a thorough evaluation of their method. At the current time, no work has been published that validates a precise protocol for the use of ATP quantification for islet quality assessment. Such work needs to be done before the ATP assay can find widespread use for islet quality assessment. Similar limitations apply to measurement of the ATP/ADP ratio.
Respirometry, the measurement of oxygen consumption rate (OCR) of living cells and tissues, was originally used with islets to study carbohydrate metabolism. Because quantities of islets available were in the ml range, a very sensitive method using Cartesian-divers was originally developed [67–69, 194]. Subsequent studies to measure OCR have made use of perifusion systems [74, 127, 128, 179] and continuously stirred chambers [119, 126], together with a Clark-type electrode. The electrochemical sensor in microelectrode form was unstable and required frequent calibration, which rendered the procedure tedious. Large polarographic sensors were stable but too large for measurements with islets. The development of optical fiber sensors that rely on the effect of oxygen in altering the decay of phosphorescent or fluorescent intensity following irradiation made possible rapid, continuous, stable measurements of pO2 in solution. Dionne [36] was apparently the first to use optical-fiber-based sensors using this principle in a perifusion system [38] designed to examine the effects, Oxygen Consumption Rate
both transient and steady-state, of reduced oxygen on insulin secretion rate by islets [37]. Since then, systems using these or equivalent sensors for measurement of the partial pressure of dissolved oxygen pO2 have developed in three directions: (1) perifusion bioreactors, (2) continuously stirred chambers, and (3) static culture devices. Perifusion Bioreactor Sweet et al. [180] described a system referred to as flow culture that enabled continuous measurement of OCR by pancreatic islets over extended periods of time. The system featured aseptic conditions, temperature control, and collection of outflow fractions for measurement of insulin and other products. Measurement of OCR was based on the difference between inflow (pO2,in ) and outflow (pO2,out ) oxygen partial pressures according to OCR = Q a (pO2,in − pO2,out ),
(6.43)
where pO2 is in mmHg, a is the Bunsen solubility coefficient of oxygen in medium (1.27 nmole O2 /cm3 mmHg at 37◦ C), Q is medium flow rate (cm3 /min), and OCR has units of mole O2 /min. The system was used to demonstrate effects of hypoxia on insulin secretion, membrane integrity, and redox state of cytochromes in islets. The latter measurements made use of a separate continuous spectrophotometric analyzer. A subsequent study [178] investigated continuous noninvasive measurements of cytochrome c redox state and OCR as indices of electron transport, from which ATP/ADP/Pi ratios were estimated. The flow culture system is an elegant tool for studies involving long-term culture, simultaneous OCR and insulin secretion measurements, or studies involving multiple changes in environmental parameters where the transient dynamics of the response are to be followed. It is inherently more complex and time consuming than use of alternative instrumentation, such as the stirred chamber, and therefore less efficient when multiple samples or replicates need to be examined in a short period of time. Stirred Chamber Together with Instech Laboratories, we developed [131] a very small stirred chamber system (Micro Oxygen Uptake System, Model FO/SYS210T, Instech Laboratories, Plymouth Meeting, PA) specifically designed for measurements with islets that has been described in more detail recently [130]. The chamber, shown schematically in Figure 6.10,
114
6.
Characterization of Islet Preparations
Sealing cap Medium initially equilibrated with air Stirred Chamber (200 µl) Islets or Cells
O2 Sensor Stirring bar
has a volume of about 200 ml (measured gravimetrically) and is stirred with a tiny, glass-coated magnetic stirring bar. The chamber is water-jacketed for temperature control and contains a fiber-optic oxygen sensor that has a fluorophor gel overlain by silicone rubber at the tip of the fiber. The sensor is calibrated at 0 and 160 mmHg. Titanium is used for the chamber body and for the oxygen probe jacket because the metal is oxygen impermeable and inert, has high thermal conductivity, and will not introduce artifactual drift arising from surface oxidation. After cells or islets are loaded through the top of the chamber, a beveled glass plug is inserted, any excess fluid is expelled from a port, and the plug is rotated to seal the chamber. The stirrer speed is controlled by a potentiometer, normally set at position 3 (out of 10), which corresponds to a rotation rate of 53 rpm that is just enough to suspend the islets off the bottom surface. The oxygen leakage rate ranges from 0 to 0.2 mmHg/min mmHg and depends on the sealing plug used. Virtually 100% of the tissue added can be recovered from the chamber for use with further measurements. Figure 6.11 is a photograph of the entire system. All OCR measurements are carried out at a defined set of conditions: Dulbecco’s modified Eagle’s medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10 mM HEPES buffer and no added serum (so as to minimize bubble formation) at 37◦ C. After islets are added and the chamber is sealed, thermal equilibration at 37◦ C occurs in about 15 seconds. After a transient increase in pO2 resulting from the decreased oxygen solubility at higher temperature, pO2 decreases
Figure 6.11. Photograph of the Micro Oxygen Uptake system. The sensors at the back of the two titanium chambers are connected to the spectrophotometer. The box on top of the spectrophotometer is the stirring speed control. (Photograph courtesy of Instech Laboratories.)
with time. If the viability, as reflected by OCR, does not change during the course of the experiment (and the minimum pO2 in the islet remains far above the Michaelis constant for oxygen consumption), the slope pO2 t is constant (as depicted in Figure 6.12) for various values of the estimated number of viable islet
Islets added 160 Slope = 140
pO2 (mm Hg)
Figure 6.10. Schematic diagram of water jacketed titanium chamber with fluorescence-quenched O2 sensor for OCR measurement. A magnetic stirring bar at the bottom of the chamber ensures the cells or islets are in suspension during the measurements. After the cells or islets are loaded, the chamber is sealed, and the partial oxygen pressure is measured through the fiber-optic O2 sensor.
∆pO2 ∆time
120
100
80 1240
430
250
170
90 VIE
60 0
10
20
30
40
50
60
Time from Islet Addition (min) Figure 6.12. Oxygen partial pressure pO2 versus time after islet addition for different numbers of viable islet equivalents (VIE). The data are fitted to a straight line. Data from preparations with different numbers of viable IE are superimposed beginning at the same starting point of 160 mmHg. Measurements were conducted in the range of 160 to 60 mmHg, where islet OCR is not oxygen limited. Note the linearity of the plots even up to 50 minutes of continuous measurements.
115
Colton et al. Viable Islet Equivalents 0
500
1000
1500
2000
30
Coefficient of Variation (%)
Single Triplicate Slope Measurement 25
Porcine Rat Human
20
15
10
5 0
0
2
4
6
8
10
Oxygen Consumption Rate (nmol/min) Figure 6.13. Coefficient of variation (COV) versus OCR or number of viable IE for measurements conducted with rat, porcine, and human islets in the OCR measurement apparatus. Data for single and triplicate measurements are shown. For plotting purposes, number of viable IE was calculated assuming (OCR/DNA)viable = 500 nmol/min mg DNA, 6.5 pg DNA/cell, and 1,560 cells/IE.
equivalents (VIE) added to the chamber. With 250 VIE, a measurement takes about 20 minutes. The OCR is calculated from pO2 , (6.44) OCR = Vch a t where Vch is the chamber volume. Dividing both sides by the number of cells nC in the chamber and rearranging yields pO2 a OCR t , (6.45) = n C cell Vch where the quantity nC /Vch is the cell concentration measured, for example, by nuclei counting. The quantity OCR/DNA can be calculated from Equation 6.45 if the denominator is replaced by DNA concentration in the chamber. Because the predominant source of scatter is the oxygen sensor, the uncertainty in the estimate of the slope from a single measurement is excellent with a coefficient of variation (COV) of about 2% with 250 VIE and 1% with 500 VIE (Figure 6.13). With triplicate samples from the same preparation, the COV is higher
because of sampling errors and possible heterogeneity of OCR/cell in different islets. COV is about 10% for 250 VIE and 6% for 500 VIE. Figure 6.14 shows an example of triplicate measurements of a fresh sample of INS-1 cells. Stirring in the chamber for 15 minutes at the low speed employed has essentially no effect on membrane integrity of human or rat islets measured by 7-AAD sequential staining. At much higher stirring speeds, an increase in the fraction of cells with compromised membranes is observed with rat but not with human islets. Healthy islets that produce a constant slope on the first measurement, if left in the chamber, provide the same slope on a second measurement. When islets that have been stressed by exposure to varying degrees of hypoxia are analyzed by both OCR and MTT measurements, the OCR is linearly proportional to the MTT absorbance reading. Curvature in the plot of pO2 versus time, which leads to a decrease in slope with time, is an indicator that the rate of oxidative phosphorylation is decreasing. This reduction in mitochondrial function suggests that some cells in the islets are dying. We have observed this behavior on a number of occasions when we have had an opportunity to initiate OCR measurements with rat islets immediately (within 10 minutes) after isolation. An example of the raw pO2 versus time plots from these measurements is given in Figure 6.15. The ratio of the slope at pO2 = 120 mmHg to the initial value at 160 mmHg was about 0.5 at the two higher stirring speeds and about 0.75 at the lowest speed. When measured again at 4 hours after isolation, the rat islet samples invariably produced a straight line with constant slope. This finding suggests that a substantial fraction of islet cells may be in the process of dying immediately after isolation is completed. The rapid decrease in mitochondrial function disappears by 4 hours after isolation, suggesting that this aspect of the cell death process has stopped. Whether this initial decrease in mitochondrial function is reversible is unknown. On rare occasions, we have observed continued decrease in mitochondrial function associated with curvature of the pO2 versus time plot after 4 or more hours. These preparations are always associated with a large fraction of cells having compromised membranes. We do not have similar data with human islet preparations immediately after isolation, but we have no reason to expect that the behavior of human islets immediately after isolation is any different from that of rat islets.
116
6.
Characterization of Islet Preparations
200 6 x 106 INS-1 cells/ml
pO2 (mmHg)
150
100
14.10 ± 0.09
13.87 ± 0.08 mmHg/min
50
13.51 ± 0.05
0 0
20
40
60
80
Time (min) Figure 6.14. Actual trace of measured oxygen partial pressure versus time from representative triplicate OCR measurements with INS-1 cells over a 70-minute period. Each measurement was performed with a fresh cell sample and at a setting of 3 on the potentiometer, corresponding to 53 rpm. The cell concentration, measured by nuclei counting, was 6 × 106 nuclei/ml. The data were fitted to a straight line in the steepest portion of the trace. The slopes for each measurement are listed in the figure. The mean of the three slopes is 13.8 ± 0.3 (mean ± SD) mmHg/min. The mean value of OCR/cell for these measurements was 2.94 ± 0.24 fmol/min nucleus, with the standard deviation obtained from propagation of error analysis.
200
pO2 (mmHg)
160 120 9
6
80
3
Stirring Speed Setting
40 Rat islets measured immediately after isolation 0
0
10
20
30 Time (min)
40
50
60
Figure 6.15. Triplicate OCR measurements performed with rat islets immediately (10 minutes) after the isolation at stirring speed settings of 9, 6, and 3, corresponding to rotational rates of 321, 187, and 53 rpm, respectively. The slopes were not straight, which is an indication of islets dying in the chamber during the measurements. The ratio of the final slope to the initial slope for each setting was 0.49 for setting 9, 0.46 for setting 6, and 0.74 for setting 3, suggesting that stressed fragile islets are more likely to die when stirred more vigorously. Similar observations were made with other rat islet preparations examined right after isolation, indicating that the islets did not have time to recover from the stress of isolation. When OCR measurements were performed with islets from the same preparation 4 hours after isolation at a setting of 3, a straight line with constant slope was obtained.
Figure 6.16 summarizes pooled data collected from rat, porcine, and human islet preparations at Joslin Diabetes Center, Harvard Medical School, and at the Diabetes Institute, University of Minnesota. The left-hand column shows the frequency distribution of the specific oxygen consumption rate, OCR/DNA. If it is assumed that there is a unique maximum
value (OCR/DNA)viable that characterizes viable cells, the ratio of (OCR/DNA) of an islet preparation to (OCR/DNA)viable represents the fractional viability of the islet preparation. For the data plotted in Figure 6.16, this ratio was calculated using (OCR/DNA)viable = 500 nmol/min mg DNA, a value comparable to the highest value of OCR/DNA we have measured with islets of
117
Colton et al. 10
100
Rat (n = 41)
Rat 80 60
5 40
Fractional Viability by OCR/DNA (%)
20 0 Number of Isolations
20
Porcine (n = 50)
15 10 5 0 15
Human (n = 50)
0 100
Porcine
80 60 40 20 0 100
Human
80
10
60 40
5
20 0
0
0
100 200 300 400 500
Specific Oxygen Consumption Rate OCR/DNA (nmoles/min•mg DNA)
0
20
40
60
80 100
Fractional Viability by Live/Dead Staining (%)
Figure 6.16. Comparison of OCR/DNA measurements and FDA/PI membrane integrity measurements as indicators of fractional viability of rat, porcine, and human islet preparations. Membrane integrity and OCR measurements were made immediately after isolation and 4 hours later, respectively. Left-hand column is the frequency distribution of OCR/DNA. Right-hand column is fractional viability based on OCR/DNA (calculated as described in text) plotted versus fractional viability by FDA/PI. These data indicate that OCR/DNA is a more sensitive measure of fractional viability than live/dead staining.
any species. Membrane integrity was also measured by staining with FDA/PI for many (but not all) of the same preparations and expressed as fractional viability. The resulting data points are plotted in the right-hand column. Whereas the fractional viability calculated from the OCR/DNA ratio ranges from nearly 0 to 100%, the fractional viability data from FDA/PI staining are almost entirely confined to values greater than 80%, thereby demonstrating the insensitivity of membrane integrity measurements as an indicator of fractional viability as currently practiced with islet preparations. The main technical problem we have observed with the stirred chamber is occasional bubble formation. This can be minimized by careful handling of caps to prevent damage by chipping, use of a slight excess tissue suspension volume, and ensuring that fluid thermally
equilibrates before sealing. We also found that bubble problems are most frequent with new chambers and disappear with use, suggesting that passivation of nucleation sites occurs with time. It is desirable to periodically check that the stirring bar is rotating properly and to recoat the sensor every 6 months. In our experience with the Instech Micro Oxygen System Uptake, it has provided rapid, accurate, and precise measurements of the OCR of islet preparations, and it has been used reliably in our laboratories by more than 15 technical staff for over 1,500 measurements (not including replicates) from more than 300 islet preparations of various species. Static Culture A novel device for the measurement of oxygen consumption rate in tissue samples
118
6.
Characterization of Islet Preparations
Idealized Well (assumed) (1) Steady State
Actual Well Round bottomed well
(2) Perfect cylinder Oxygen permeable walls
(3) Impermeable walls (4) Perfectly still medium
Medium mixed by plate movement
(5) Uniform cell distribution
Cells collect in middle of well
(6) Thin uniform sensor material
Varying thickness of silicone rubber and sensor
Figure 6.17. Schematic representation of an idealized and real well in the oxygen biosensor system.
was recently introduced [63] and used for measurement of OCR of islet preparations [52, 190]. The oxygen biosensor system (OBS) consists of an oxygen sensitive fluorophor embedded in silicone rubber at the bottom of wells in a 96-well plate. Cells or tissue are placed in the wells and consume oxygen, thereby causing the oxygen partial pressure (pO2 ) at the bottom of the well to decrease. This decrease is detected by the oxygen sensor in the well bottom, as shown in Figure 6.17. The OBS is easier to use than the stirred chamber described in the preceding section, and is therefore attractive for islet quality assessment. Unfortunately, the ease of use of the OBS is offset by difficulties in obtaining accurate and meaningful OCR estimates. Unlike the flow culture system and the stirred chamber, for which OCR can be calculated from measured parameters using straightforward material balances, the OBS uses a measurement of pO2 and relies on a theoretical model of a complex physical arrangement. To estimate OCR using the OBS, one has to convert the pO2 at the bottom of the well to the OCR of the cells or tissues. This conversion requires that the oxygen species conservation equation be applied to the entire system and solved using appropriate initial and boundary conditions, a complex endeavor. To simplify analysis of the OBS data, several assumptions have been invoked that allow computation of OCR from pO2 measurements in the OBS [63]. These assumptions include (1) the system is at steady state, (2) the well geometry is perfectly cylindrical, (3) the wells are fabricated from oxygen impermeable material, (4) the medium is completely stagnant, (5) there is
a uniform and infinitely thin cell layer, at the bottom, overlaying (6) a uniform infinitely thin oxygen sensor material. These assumptions lead to the integrated form of Fick’s first law of diffusion, OCR =
ADa pO2a − pO2b , h
(6.46)
where A is the surface area of a well, h is the medium depth, pO2a is the ambient oxygen partial pressure, and pO2b is the oxygen partial pressure at the well bottom measured by the OBS. When using Equation 6.46 for OCR estimation, the accuracy of the result is dependent on the validity of the assumptions stated. Many of the assumptions are not strictly applicable to the OBS system, as illustrated in Figure 6.17. To test the validity of these assumptions and estimate the extent of error incurred by their use, we developed a complete finite element mass transfer model of the OBS well using COMSOL Multiphysics commercial software. If the system were ideal in every other aspect, it should attain about 90% approach to steady state within approximately 40 min. However, because the walls are constructed of oxygen-permeable materials, the estimated 90% approach to steady state is actually not reached until after 260 minutes have passed. This is longer than desirable, although it does not preclude use of the system for OCR measurement. Inaccuracies in assumptions regarding the system geometry, cell layer thickness, and oxygen sensor thickness (assumptions 2, 5, and 6) have only a minimal effect on the OCR estimate and the combined error
119
Colton et al.
introduced by all of these assumptions is 10% or less. Assuming that the data for polystyrene oxygen permeability in polystyrene microplates reported by Arain et al. [3] are accurate, leakage of oxygen through the bottom of the well (assumption 3) produces a somewhat larger error. If the tissue at the bottom of the well is too closely packed, it becomes oxygen starved in the center. It is therefore critical that well bottom pO2 not get much below 75 mmHg if the OBS is being used with islets. The assumption of stagnant medium (assumption 4) is more problematic. The plate is never truly stationary as most incubators are subject to minute vibrations and thermal variations that can potentially introduce some flow within the wells. Furthermore, the transport of the plate from the incubator to the plate reader and movement of the plate in the plate reader between readings can induce significant disturbances in the liquid within the wells. The substantial adverse effect of motion in the plate reader has been demonstrated convincingly by comparing the transient reequilibration with oxygen at the bottom of wells initially purged with nitrogen and filled with either water or an agarose gel that prevents fluid motion (unpublished data). Reported OCR values measured with the OBS do not agree with measurements made with other methods. The reported value of approximately 800 fmol/min IE [190] together with an estimate of 1,560 cells per IE, corresponds to an OCR of about 0.5 fmol/min cell, roughly a factor of 5 lower than average values for islets measured in our laboratory using the stirred chamber system. Similarly, values for CHO cells of 0.5 fmol/min cell measured in the OBS system are an order of magnitude lower than what is found using a commercial respirometer [83], which is similar to what we find with other mammalian cell lines. An additional problem is large well-to-well variability that results when small numbers of islets (less than 100) are used in each well, which is essential if the islets are to be kept from being oxygen starved. To circumvent this problem in the current system, many wells need to be used, which increases the amount of labor. The published data and our own experience suggest that obtaining accurate results is difficult or impossible in the system as it is currently constructed and used. Future use will require a significant redesign of the OBS and/or the protocols for using it. Even in the absence of accuracy, the OBS could still be a useful tool if it can reproducibly provide results that are related to the OCR of islet preparations in a consistent way or
that are otherwise useful. Demonstration of this will require extensive research and a better understanding of the OBS and why it gives erroneous OCR readings. Development of standardized protocols that give identical results in different laboratories will almost certainly be very challenging, but may nonetheless be possible. Whether the OBS or a similar system can ultimately be used for OCR measurement to assess islet quality is a question that has not yet been answered. Because of the simplicity of use of a static culture system, further effort in this direction is definitely warranted. MITOCHONDRIAL MEMBRANE POTENTIAL (MMP) Viable mitochondria are polarized and have a membrane potential of about 140 mV (negative on the inner leaflet) due to the proton pumping to the cytoplasm that is a central feature of mitochondrial function [12]. Loss of mitochondrial function is a feature that characterizes dead cells. A decrease in mitochondrial membrane potential (MMP) is also usually (but not always) one of the earliest events that occurs during apoptosis [103]. This potentially makes MMP assessment useful for identifying damaged cells that are committed to cellular death. Two dyes are currently widely used for the measurement of MMP, JC-1 (5,5 ,6,6 -tetrachloro1,1 ,3,3 -tetraethylbenzimidazolylcarbocyanine iodide) and mitochondrial-selective rhodamines including rhodamine 123 and tetramethylrhodamine ester (TMRE). These dyes are lipophilic cations that can freely diffuse across cellular membranes, and they are preferentially accumulated in mitochondria due to the membrane polarization [103]. JC-1 forms J-aggregates (linear chains of dye molecules, the spectroscopic properties of which differ markedly from those of the dye monomer) at high concentrations in polarized mitochondria. These aggregates are accompanied by a spectral shift in the emission wavelength [173]. This spectral shift can then be used to estimate membrane potential. In contrast, the rhodamine derivatives do not show a shift in fluorescence due to an accumulation in the mitochondria (relative to the cytosol), and thus membrane potential is estimated from a change in the absolute fluorescence of the dye [165]. The spectral shift of the JC-1 dye makes it preferable for MMP measurement to determine viability, in that a ratio of fluorescence intensities (J-aggregate:monomer) can be taken that will normalize the fluorescence signal to account for changes in the absolute amount
120
6.
Characterization of Islet Preparations
of tissue and number of mitochondria. JC-1 is also more specific for detecting mitochondrial depolarization because rhodamine 123 has several energy independent binding sites within some cell lines that can cause high fluorescence readings even in the absence of an MMP [162]. Application of MMP assays to islets is constrained by the same problem described for membrane integrity dyes (i.e., the difficulty in using standard fluorescence microscopy to assess the staining with MMP sensitive dyes within the 3D structure of an islet). Optical sectioning with two-photon microscopy has been used for islets stained with the MMP sensitive dyes [181]. Mitochondria throughout islets were stained with TMRE, but diffusion of the dye to the center of the islets was slower than with other dyes studied, which suggests that the issue of dye transport within the islet needs to be carefully studied if MMP sensitive dyes are to be used with whole islets. In an attempt to circumvent the problem posed by the structure of islets, Ichii et al. [75, 77] dissociated islets, then stained the dispersed cells with JC-1 or TMRE, and acquired data using a flow cytometer. They also combined TMRE staining with (1) a zinc binding dye, Newport Green (NG), so that two-color flow cytometry could be performed to estimate the fraction
of b cells (NG positive) that also had high levels of TMRE staining, and (2) 7-AAD, so that cells with compromised membrane integrity were excluded. b-cell fractional viability was defined as the fraction of cells within the NG bright cells that were TMRE positive (after 7-AAD positive cells were excluded). Thus, this index did not include either necrotic cells or late-stage apoptotic cells with compromised membranes or positive 7-AAD signal and therefore included only early apoptotic cells. Another significant problem associated with this method is that it requires dissociation of the islets, and the dispersed single cells are likely not representative of the original islet, as described previously in relation to cell composition analysis. Ichii et al. [75] defined a b-cell viability index as the product of the b-cell number fraction in islets (fbIC ) measured with LS cytometry and the b-cell fractional viability determined by TMRE/Newport Green staining measured with flow cytometry, as is summarized in Figure 6.18. They correlated the b-cell viability index of human islet preparations with the outcome of transplantation into immunodeficient mice. There was considerable overlap of the b-cell indices of successes and failures, but they were able to identify a value for the b-cell viability index below which no islet preparations cured.
Islets Antibodies to Pancreatic Polypeptide Insulin Somostatin Glucagon Fluorescent Tag
Dissociate (Accutase) Single-Cell Suspension
CompuCyte Laser Scanning Cytometer
BD FACScan Flow Cytometer 7AAD− NGbright TMRE+
Count Stained Cells
β-cell fraction =
Incubation with Newport Green (Zn) TMRE (Mitochondrial Membrane Potential) 7AAD (Membrane Integrity)
β β+α+δ+pp = 0.51
β-cell Fractional Viability (FV)
β-cell Viability Index = β-cell fraction • β-cell FV Figure 6.18. Schematic representation of the experimental procedure described by Ichii et al. [77]. Islets are dissociated enzymatically and mechanically into single cells. An aliquot is processed for LSC after being stained with specific antibodies to obtain the b-cell number fraction. The average value reported was 0.51. A second aliquot is processed through a flow cytometer after being stained with dyes sensitive to mitochondrial membrane potential to obtain the b-cell fractional viability. The b-cell viability index is the product of the b-cell fraction and the b-cell fractional viability.
121
Colton et al.
Development of technologies that enable quantitative imaging of MMP dyes within intact islets would be an important advance. Large diameter flow cytometry and two-photon microscopy are two options that might be explored for future use of MMP sensitive dyes for islet quality assessment. Unfortunately, both of these methods require very expensive equipment operated by highly trained individuals, which would limit their applicability to the field, at least in the near future.
COMPARISON OF VIABILITY ASSAY RESULTS WITH STRESSED CELLS AND ISLETS On the basis of the review presented here, we hypothesized that (1) membrane integrity tests with islets often give erroneously high values that are not predictive of transplantation outcome because they fail to distinguish healthy cells from cells that have entered the cell death pathway but have not yet reached the membrane permeabilization stage, which often occurs later in the cell death process, and (2) mitochondrial function tests provide the earliest indication of damage to cells that eventually leads to cell death. To test this hypothesis, we studied the transient response of rat and human islets and Jurkat and INS-1 cells to stresses causing extensive cell death [147, 148]. Anoxia was used to induce islet cell damage, in that this is a condition that is routinely encountered during pancreas storage and islet isolation, high-density culture, and shipping. The cell lines tested were resistant to anoxic insult, and thus alternative stresses were chosen for these cell lines (1 mM camptothecin and 5 mM streptozotocin for Jurkat and INS-1 cells, respectively). Mitochondrial function of the islets was assessed using OCR and ATP concentration measurements, and membrane integrity was assessed with FDA/PI and 7-AAD sequential staining. In addition to these aforementioned assays, the mitochondrial function of the cell lines was also assessed with MTT, MTS, and the MMP-sensitive dye JC-1. Two additional dyes, trypan blue and sytox orange, were used to probe membrane integrity. Furthermore, the use of cell lines allowed for two flow cytometer-based apoptotic event-indicating assays to be tested (a multicaspase assay and an annexin V assay) that could not be done with whole islets. The results of these experiments are summarized in Figure 6.19. The mitochondrial function and membrane
integrity data were all normalized by their value at time zero, when stress was first applied. The results of different mitochondrial function assays (OCR measurements, MTS, MTT, ATP concentration) were closely correlated and followed a similar trend. The same was true for membrane integrity assays, but the behavior of the two assay types diverged sharply. After a very short lag period, fractional viability by mitochondrial function decreased continuously and relatively rapidly, whereas the fraction of intact cells by membrane integrity varied slowly at first and began to decrease only at longer times. Early apoptosis events, a cell death measure, in Jurkat cells followed the time course of mitochondrial dysfunction, as did phosphatidyl serine externalization (Annexin V) in INS-1 cells, but caspase activation was slower. The time scale over which the cells or islets underwent the cell death process varied with the combination of cell types and stresses, but the relative trends were the same. Mitochondrial function assays likely provide a more accurate assessment of the health of an islet preparation because they are able to identify cells that are damaged but do not yet have compromised membranes. In some cases, the damage may be reversible, and removal of the stress might be sufficient to rescue some of the cells. This has not been explored and warrants further study. Nonetheless, in most cases it seems likely that islet cells that have been damaged to such an extent that their mitochondrial function has been abolished or greatly reduced are not likely to recover. Therefore, mitochondrial function assays provide the most meaningful measurement of fractional viability of islet preparations and should be included in any rigorous viability assessment protocol.
OXYGEN CONSUMPTION RATE AND CELL QUANTITY MEASUREMENTS PREDICT TRANSPLANTATION OUTCOME IN MICE We have explored the ability of OCR measurement to predict transplantation outcome. The results of these studies [91, 122–124, 129, 131] demonstrated that oxygen consumption rate and cell quantity measurements can predict transplantation outcome in immunosuppressed or immunodeficient mice. In the first series of experiments [91, 123, 124, 131], rat islets were transplanted under the kidney capsule of diabetic Balb/C
122
6.
Fraction Apoptotic Cells (■)
1
Characterization of Islet Preparations
Jurkat Cells
INS-1 Cells
Suspension Culture 1µm Camptothecin
Surface-attached culture 5 mM Streptozotocin
Mitochondrial Function OCR, ATP, MTT, MTS Apoptosis Events Annexin V, Multi-caspase activation Membrane integrity Trypan blue, FDA/PI, 7-AAD, LDS 751/Sytox Orange
0.8 0.6
Apoptosis Events
0.4
Assays performed:
0.2
Rat, Human Islets
0
Anoxia, 37 °C
Relative Fraction of Viable Cells (●)
1.2
Membrane Integrity
1
1
0.8
0.8
0.6
0.6
Mitochondrial function
0.4
0.4 0.2
0.2 0 0
0 10
20
30
40
50
0
2
4
6
8
10
12
0
10
20
30
40
Relative Fraction of Cells with Intact Membranes (▲)
1.2
50
Time of Stress Exposure (hr) Figure 6.19. Cells and islets were subjected to the indicated stress for time periods up to 48 hours. Measurements made with membrane integrity, apoptotic event, and mitochondrial function assays are plotted versus time of exposure. For sake of clarity, the results from assays of the same class were pooled, and the average at each time point plotted.
mice treated with anit-CD4 antibody. Random, nonfasting blood glucose was monitored daily in the late morning or early afternoon. Blood glucose less than 200 mg/dl for at least 7 days was considered a cure. Analysis of initial experiments demonstrated that OCR of the transplanted islets did not always predict success or failure and that prediction improved by use of a second parameter, OCR/DNA. This finding led to a systematic plan to cover a range of parameters in the experiments. The idealized approach for makeup of the islet transplant experiment is shown in Table 6.12 and is expressed in terms of the number of viable and dead islet equivalents in a representative target transplant preparation. The parameter values chosen were based on early estimates for (OCR/DNA)viable = 463 nmol/min mg DNA and OCR = 7.6 pmol/min for a viable islet equivalent. We do not know if these values are correct, or even if there are single unique values to characterize fully viable islets. These values represent our best estimate at the time of the experiment and do help to provide a framework for one possible interpretation of the measured parameters. OCR/cell could have been used in place of OCR/DNA. Use of the latter quantity reflects
TABLE 6.12 Conceptual strategy for rat islet transplantation experiments.a OCR (nmol/min)
Fractional Viability (%) 10
50
90
3.75
500 Viable IE 4500 Dead IE
500 Viable IE 500 Dead IE
500 Viable IE 50 Dead IE
0.75
100 Viable IE 900 Dead IE
100 Viable IE 100 Dead IE
100 Viable IE 11 Dead IE
46
232
417
OCR/DNA (nmol/min mg DNA) a Each entry represents the properties of a target preparation in order to
cover a wide range of OCR and OCR/DNA values.
the fact that the nuclei counting assay was not available at the time that the experiments began. In actual practice, the maximum OCR/DNA was fixed by the properties of the isolated islets, and lower values were obtained by exposure to hypoxia through
123
Colton et al.
high-density culture. The results of the transplantations can be summarized in tabular or graphical form [91, 123, 124], in which each entry represents the cure/no cure results for 1 to 6 preparations having a defined set of OCR and OCR/DNA values. The data show that cure rates increased with increasing OCR. At constant OCR, cure rates increased with increasing OCR/DNA. Furthermore, the data mostly segregate into two regions representing all cured or all not cured, separated by a third small region of mixed results. This pattern allows prediction of transplantation outcome in the immunodeficient mouse for a rat islet preparation having any arbitrary combination of OCR and OCR/DNA values. The second study was carried out with high-purity (>85% by DTZ staining) human islet preparations in diabetic nude mice. The strategy for the makeup of the islet preparations was the same but the available range of OCR/DNA was smaller. In this study, success was defined as diabetes reversal (blood glucose < 200 mg/dl) for at least two consecutive readings taken daily up to 10 days posttransplant and every 3 days thereafter. The results have been summarized elsewhere [122, 129]. Although the regions of cure and no cure are not as crisply defined as in the rat, the overall results were similar in that data segregated into regions of mainly cure and mainly noncure. Statistical analysis yielded sensitivity (inclusion of all true positives) and specificity (avoidance of false positives) values of 91% and 74%, respectively. It was concluded from these data that prospective OCR and OCR/DNA measurements could effectively replace the retrospective nude mouse bioassay in assessing human islet quality prior to transplantation.
the JDRF Center for Islet Transplantation at Harvard Medical School, the Diabetes Research and Wellness Foundation, and an important group of private donors. Technical assistance was also provided by the Diabetes and Endocrinology Research Center (DERC) of the Joslin Diabetes Center supported by the NIH (P30 DK36836-16).
List of Symbols
Postscript Although this chapter has focused on assessing the properties of islet preparations, many of the same issues apply to other forms of cell therapy, and many of the techniques discussed here are likely to have wider applications if they do not already.
A a b c D EM f fA fD fi fIC fO fNb fNIC fb fbIC h LM nA nC nD ni (NIE )PCV/LM (NIE )DTZ
Acknowledgments This study was supported by grants from the NIH (NCRR ICR U4Z RR 16606 and R01-DK063108-01A1),
124
nNIC nNb nO
Surface area of a well Half-axis of a symmetrical ellipsoid Half-axis of a symmetrical ellipsoid Half-axis of a symmetrical ellipsoid Diffusion coefficient of oxygen in medium Electron microscopy Fraction of cells permeable to dye Number fraction of acinar cells among all cells Number fraction of duct cells among all cells Number fraction of cell type i Number fraction of all islet cells Number fraction of all “other” cell types among all cells Number fraction of non-b cells among all cells Number fraction of all non-islet cells Number fraction of b cells among all cells Number fraction of b cells among all islet cells Medium depth Light microscopy Number of acinar cells Number of cells in the OCR chamber Number of duct cells Number of cells of type i Number of IE calculated from packed cell volume and light microscopy data Number of IE calculated from DTZ staining data Number of non-islet cells Number of non-b-cells Number of other cells
6.
nTC nb nIC nIE NIE nbIE N1
N2
OCR PI PNI pO2,a pO2,b pO2,in pO2,out PV Q r t V VA Vch VD Vellipsoid VI VIC VIE VIEC VINT VIXV VNI VNIC VNIEC
Characterization of Islet Preparations
VNb VPC VO Vsphere VIE VT VTC
Total number of cells Number of b-cells Number of islet cells Number of cells in an islet equivalent volume Number of islet equivalents Number of b cells in an islet equivalent volume Number of nuclei initially labeled with dye (cells with compromised membranes) Total number of nuclei labeled with dye after cell lysis (total cell number) Oxygen consumption rate Number of points falling within the domain of islets Number of points falling within the domain of non-islets tissue Ambient partial pressure of oxygen Partial pressure of oxygen at the well bottom Partial pressure of oxygen into the system Partial pressure of oxygen out of the system Number of points falling within the domain of islet vascular space Medium flow rate Radius of a sphere Time Volume Volume of acinar cells Volume of OCR chamber Volume of duct cells Volume of an ellipsoid Total volume of the islet domain Volume of islet cells Volume of an islet equivalent (1.77 × 106 mm3 ) Extracellular volume within islet domain Volume of interstitial space in islet Volume of islet cells and interstitial space within the islet domain Total volume of the non-islet domain Volume of non-islet cells Extracellular volume within the non-islet domain
VV VVI VVPC Vb a fIC fNIC fbIC I IC IEC IXV NIC NIEC
VI VPC bI (fIC )EM (I )DTZ (I )EM (I )LM (IXV )LM νA νD νNb
125
Volume of non-b-cells Volume of packed cell pellet Volume of other cells Volume of a sphere Viable Islet Equivalents Total tissue volume Total volume of all islet and non-islet cells Vascular volume within the islet domain Volume of vascular voids in islet Void volume of packed cell pellet Volume of b-cells Solubility of oxygen in medium Volume fraction of islet cells among all cells Volume fraction of non-islet cells among all cells Volume fraction of b cells among all islet cells Volume fraction of islets Volume fraction of islet cells within the islets Volume fraction of islet extracellular space within the islets Volume fraction of islets exclusive of islet vascular spaces Volume fraction of non-islet cells based on the total non-islet volume Volume fraction of non-islet extracellular space based on the total non-islet volume Volume fraction of vascular voids within islets Void fraction of packed cell pellet Volume fraction of b cells within whole islet volume fIC calculated from electron microscopy ultrastructural analysis I calculated from DTZ staining data I calculated from electron microscopy ultrastructural analysis I calculated from light microscopy morphology analysis IT calculated from light microscopy morphology analysis Cell volume of acinar cells Cell volume of duct cells Cell volume of non-b-cells
Colton et al.
νO νb ν IC ν NIC ν TC
Cell volume of other cells Cell volume of b-cells Average cell volume for islet cells Average cell volume for non-islet cells Average cell volume for all of the cells
REFERENCES 1. Africk, S., Pisania, A., Powers, D. E., Colton, C. K. An ultrasound method for rapid measurement of islet concentration for transplant quality control. In: Proceedings, 10th World Congress of Islet and Pancreas Transplantation Association, p 81. Geneva, Switzerland, May 4–7, 2005. 2. Ansite, J. Islet Transplantation Program, University of Minnesota (Personal Communication). 2004. 3. Arain, S., Svenja, W., Heinzle, E., Gernot, J. T., Krause, C., Klimant, I. Gas sensing microplates with optodes: Influence of oxygen exchange between sample, air, and plate material. Biotechnol Bioeng 90:271–280; 2005. 4. Aughsteen, A. A., Cope, G. H. Changes in the size and number of secretion granules in the rat exocrine pancreas induced by feeding or stimulation in vitro: A morphometric study. Cell Tissue Res 249:427–436; 1987. 5. Aughsteen, A. A., Kataoka, K., Shair, S. A. Correlative morphometric and biochemical study on pancreatic amylase in normal and streptozotocin-diabetic rats. Pancreas 13:295–303; 1996. 6. Avgoustiniatos, E. S. Oxygen diffusion limitation in pancreatic islet culture and immunoisolation. Ph.D. Thesis, Massachusetts Institute of Technology, Cambridge, 2001. 7. Bank, H. L. Assessment of islet cell viability using fluorescent dyes. Diabetologia 30:812–816; 1987. 8. Bank, H. L. Rapid assessment of islet viability with acridine orange and propidium iodide. In Vitro Cell Dev Biol 24:266–273; 1988. 9. Barbu, A., Welsh, N. The use of tetrazolium salt-based methods for determination of islet cell viability in response to cytokines: A cautionary note. Diabetologia 47:2042–2043; 2004. 10. Barnett, M. J., McGhee-Wilson, D., Shapiro, A. M. J., Lakey, J. R. T. Variation in human islet viability based on different membrane integrity stains. Cell Transplant 13:481–488; 2004. 11. Beckmann, J., Holze, S., Lenzen, S., Panten, U. Quantification of cells in islets of Langerhans using DNA determination. Acta Diabetol Lat 18:51–57; 1981. 12. Berg, J. M., Tymoczko, J. L., Stryer, L. Biochemistry. New York, WH Freeman and Company, 2002: 491–523. 13. Berridge, M. V., Tan, A. S., McCoy, K. D., Wang, R. The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica 4:14–19; 1996.
126
14. Blankenberg, F. G., Katsikis, P. D., Storrs, R. W., Beaulieu, C., Spielman, D., Chen, J. Y., Naumovski, L., Tait, J. F. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spetroscopy. Blood 89:3778–3786; 1997. 15. Bonner-Weir, S. Anatomy of the islet of Langerhans. In: Samols, E., ed. The Endocrine Pancreas, New York, Raven Press; 1991:15–28. 16. Bonner-Weir, S. Unpublished data, Vascular fraction of rat islets. 2005. 17. Bonner-Weir, S. Unpublished observations. 2005. 18. Bonner-Weir, S., Deery, D., Leahy, J. L., Weir, G. C. Compensatory growth of pancreatic b-cells in adult rats after short-term glucose infusion. Diabetes 38; 1989. 19. Brandhorst, D., Brandhorst, H., Hering, B. J., Federlin, K., Bretzel, R. G. Islet isolation from the pancreas of large mammals and humans: 10 years of experience. Exp Clin Endocrin 103 Suppl 23; 1995. 20. Brandhorst, D., Brandhorst, H., Hering, B. J., Federlin, K., Bretzel, R. G. Large variability of the intracellular ATP content of human islets isolated from different donors. J Mol Med 77:93–95; 1999. 21. Bretzel, R. G., Alejandro, R., Hering, B. J., van Suylichem, P. T., Ricordi, C. Clinical islet transplantation: Guidelines for islet quality control. Transplant Proc 26:388–392; 1994. 22. Brissova, M., Fowler, M. J., Nicholson, W. E., Chu, A., Hirshberg, B., Harlan, D. M., Powers, A. C. Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 53:1087–1097; 2005. 23. Brown, G. C., Borutaire, V. Nitric oxide, cytochrome c and mitochondria. In: Brown, G. C., Nicholls, D. G. and Cooper, C. E., eds. Mitochondria and Cell Death, London, Portland Press, 1988:17–27. 24. Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R., Butler, P. C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110; 2003. 25. Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P. O., Caicedo, A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 103:2334–2339; 2006. 26. Cattan, P., Berney, T., Schena, S., Molano, R. D., Pileggi, A., Vizzardelli, C., Ricordi, C., Inverardi, L. Early assessment of apoptosis in isolated islets of Langerhans. Transplantation 71:857–862; 2001. 27. Cheng, L. L., Chang, I. W., Smith, B. L., Gonzalez, R. G. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectrometry. J Mag Resonance 135:194–202; 1998. 28. Cheng, L. L., Wu, C. L., Smith, M. R., Gonzalez, R. G. Nondestructive quantitation of spermine in human prostate tissue samples using HRMAS 1 H NMR spectroscopy at 9.4.T. FEBS Lett 494:112–116; 2001.
6.
Characterization of Islet Preparations
29. Clarke, J. M., Gillings, M. R., Altavilla, N., Beattie, A. Potential problems with fluorescein diacetate assays of cell viability when testing natural products for antimicrobial activity. J Microbiol Methods 46:261–267; 2001. 30. Contreras, J. L., Eckstein, C., Smyth, C. A., Sellers, M. T., Vilatoba, M., Bilbao, G., Rahemtulla, F. G., Young, C. J., Thompson, A. J., Chaudry, I. H., Eckhoff, D. E. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes 52:2935–2943; 2003. 31. Cooperstein, S. J., Lazarow, A. Distribution of alloxan-C14 in islet and other tissues of the toadfish (Opsanis tau). Am J Physiol 207:423–430; 1964. 32. Dean, P. M. Ultrastructural morphometry of the pancreatic b-cell. Diabetologia 9:115–119; 1973. 33. Delaney, C. A., Pavlovic, D., Hoorens, A. Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology 138:2610; 1997. 34. Detimary, P., Dejonghes, S., Ling, Z., Pipeleers, D. G., Schuit, F. C., Henquin, J. C. The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in b cells but not in a cells and are also observed in human islets. J Biol Chem 273:33905–33908; 1998. 35. Dias, R. P., Teixera, J. A., Mota, M. G., Yelshin, A. I. Particulate binary mixtures: Dependence of packing porosity on particle size ratio. Ind Eng Chem Res 43:7912–7919; 2004. 36. Dionne, K. E. Effect of hypoxia on insulin secretion and viability of pancreatic islet tissue. Ph.D. Thesis, Massachusetts Institute of Technology, Cambridge, 1989. 37. Dionne, K. E., Colton, C. K., Yarmush, L. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 42:12–21; 1993. 38. Dionne, K. E., Colton, C. K., Yarmush, L. A microperifusion system with environmental controls for studying insulin secretion by pancreatic tissue. Biotechnol Prog 7:359–368; 1991. 39. Dolezel, J., Bartos, J., Voglmayr, H., Greilhuber, J. Nuclear DNA content and genome size of trout and human. Cytometry (PA):127–128; 2003. 40. Donev, A., Cisse, I., Sachs, D., Variano, E. A., Stillinger, F. H., Connelly, R. Improving the density of jammed disordered packing using ellipsoids. Science 303:990–993; 2004. 41. Dong, Z., Saikumar, P., Weinberg, J. M., Venkatachalam, M. A. Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic death. Involvement of serine but not cysteine proteases. Am J Pathol 151:1205–1213; 1997. 42. Eckhard, E., Brandhorst, D.,Winter, D., Jaeger, C., Jahr, H., Bretzel, R. G., Brendel, M. D. The role of current product release criteria for identification of human islet preparations suitable for clinical transplantation. Transplant Proc 36:1528–1531; 2004. 43. Eckhoff, D. E., Eckstein, C., Smyth, C. A., Vilatoba, M., Bilbao, G., Rahemtulla, F. G., Young, C. J., Thompson, A. J.,
127
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54. 55. 56.
57.
Chaudry, I. H., Contreras, J. L. Enhanced isolated pancreatic islet recovery and functionality in rats by 17beta-estradiol treatment of brain death donors. Surgery 136:336–345; 2004. Erecinska, M., Bryla, J., Michalik, M., Meglasson, M. D., Nelson, D. Energy metabolism in islets of Langerhans. Biochim Biophy Acta; 1992. Farilla, L., Bulotta, A., Hirshberg, B., Calzi, S. L., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., Perfetti, R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149–5158; 2003. FDA Biological Response Modifiers Advisory Committee Summary Minutes, Meeting no. 26, March 20–21, 2000. (http://www.fda.gov/ohrms/dockets/ac/00minutes/3604m 1_minutes.pdf) FDA Biological Response Modifier Advisory Committee Summary Minutes, Meeting no. 36, Oct. 9–10, 2003. (http://www.fda.gov/ohrms/dockets/ac/cber03.html# BiologicalResponseModifiers) Fehsel, K., Kolb-Bachofen, V., Kroncke, K. D. Necrosis in the predominant type of islet cell death during development of insulin-dependent diabetes mellitus in BB rats. Lab Invest 83:549–559; 2003. Fernandez, L. A., Hatch, E. W., Armann, B., Odorico, J. S., Hullett, D. A., Sollinger, H. A., Hanson, M. S. Validation of large particles flow cytometry for the analysis and sorting of intact pancreatic islets. Transplantation 80:729–737; 2005. Fetterhoff, T. J., Wile, K. J., Coffing, D., Cavanagh, T., Wright, M. J. Quantitation of isolated pancreatic islets using imaging technology. Transplant Proc 26:3351; 1994. Fink, S. L., Cookson, B. T. Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. Infect Immun 73:1907–1916; 2005. Fraker, C., Guarino, R., Timmins, M., Presnell, S., Molano, D., Pileggi, A., Ricordi, C. The BD oxygen biosensor as a potential predictive tool for islet function in-vivo. In: Proceedings, 7th International Congress of the Cell Transplant Society, p 105. Boston, MA, November 17–20, 2004. Fraker, C. A., Alejandro, R., Ricordi, C. Use of oxygenated perfluorocarbon toward making every pancreas count. Transplantation 74:1811–1812; 2002. Freshney, R. I: Culture of animal cells: A manual of basic technique. New York, J. Wiley-Liss, 2000. Frisch, S. M., Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619–626; 1994. Gassil-Kraupp, B. B., Ruttkay-Nedecky, H., Koudelka, K., Bukowska, K., Burch, W., Schulte-Herman, R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note. Hepatology 21:1465–1468; 1995. Gavrieli, Y., Sherman, Y., Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501; 1992.
Colton et al. 58. Gerlier, D., Thomasset, N. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 94:57–63; 1986. 59. Ghosh, A., Ronner, P., Cheong, E., Khalid, P., Matchinsky, F. M. The role of ATP and free ADP in metabolic coupling during fuel stimulated insulin release from islet b-cells in the isolated perfused rat pancreas. J Biol Chem 286:22887–22892; 1991. 60. Goto, M., Eich, T. M., Felldin, M., Foss, A., Kallen, R., Samela, K., Tibell, A., Tufveson, G., Fujimori, K., Engkvist, M., Korsgren, O. Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation 78:1367–1375; 2004. 61. Gray, D.R.W. Avoiding damage to transplanted human islets during implantation is important. Transplantation 79:1294–1295; 2005. 62. Gray, D. W., Morris, P. J. The use of fluorescein diacetate and ethidium bromide as a viability stain for isolated islets of Langerhans. Stain Technol 62:373–381; 1987. 63. Guarino, R. D., Dike, L. E., Haq, T. A., Rowley, J. A., Pitner, J. B., Timmins, M. R. Method for determining oxygen consumption rates of static cultures from microplate measurements of pericellular dissolved oxygen concentration. Biotechnol Bioeng 86:775–787; 2004. 64. Gukovskaya, A. S., Perkins, P., Zaninovic, V., Sandoval, D., Rutherford, R., Fitzsimmons, T., Pandol, S. J., PoucellHatton, S. Mechanisms of cell death after pancreatic duct obstruction in the opossum and the rat. Gastroenterology, 110:875–884; 1996. 65. Haugland, R. P: Handbook of fluorescent probes and research chemicals. Eugene, OR, Molecular Probes, 2002. 66. Haugland, R. P. Spectra of fluorescent dyes used in flow cytometry. Methods Cell Biol 42 (Pt B):641–663; 1994. 67. Hedeskov, C. J., Hertz, L., Nissen, C. The effect of mannoheptulose on glucose- and pyruvate-stimulated oxygen uptake in normal mouse pancreatic islets. Biochim Biophys Acta 261:388–397; 1971. 68. Hellerstrom, C. Effects of carbohydrates on the oxygen consumption of isolated pancreatic islets of mice. Endocrinology 81:105–112; 1967. 69. Hellerstrom, C. Oxygen consumption of isolated pancreatic islets of mice studies with the cartesian-diver micro gasometer. Biochem J 98:7C–9C; 1966. 70. Hering, B. J. Achieving and maintaining insulin independence in human islet transplant recipients. Transplantation 79:1296–1298; 2005. 71. Hering, B. J., Matsumoto, I., Sawada, T., Nakano, M., Sakai, T., Kandaswamy, R., Sutherland, D. E. R. Impact of the two-layer pancreas preservation on islet isolation and transplantation. Transplantation 74:1813–1816; 2002. 72. Hlad, C. J. J., Holmes, J. H. Factors affecting hematocrit determinations: Trapped plasma, its amount and distribution. J Appl Physiol 5:457–470; 1953.
128
73. Hoffmann, R. A., Southard, J. H., Lutz, M., Machety, A., Belzer, F. O. Synthetic perfusate for kidney preservation. Its use in 72-hour preservation of dog kidneys. Arch Surg 118:919–921; 1983. 74. Hutton, J. C., Malaisse, W. J. Dynamics of O2 consumption in rat pancreatic islets. Diabetologia 18:395–405; 1980. 75. Ichii, H., Inverardi, L., Pileggi, A., Damaris Molano, R., Cabrera, O., Caicedo, A., Mesinger, S., Kuroda, Y., Berggren, P. O., Ricordi, C. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant 5:1635–1645; 2005. 76. Ichii, H., Inverardi, L., Pileggi, A., Molano, R., Cabrera, O., Caicedo, A., Mesinger, S., Kuroda, Y., Berggren, P. O., Ricordi, C. Towards elimination of islet primary non-function: Pre-transplant islet potency testing that is predictive of post transplant functional competence. In: Proceedings, 10th World Congress of Islet and Pancreas Transplantation Association, p 63. Geneva, Switzerland, May 4–7, 2005. 77. Ichii, H., Pileggi, A., Molano, R. D., Baidal, D. A., Khan, A., Kuroda, Y., Inverardi, L., Goss, J. A., Alejandro, R., Ricordi, C. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 5:21–30; 2005. 78. Ilieva, A., Yuan, S., Wang, R. N., Agapitos, D., Hill, D. J., Rosenberg, L. Pancreatic islet cell survival following islet isolation: The role of cellular interactions in the pancreas. J Endocrinol 161:357–364; 1999. 79. Invitrogen: Products Structure. Invitrogen Corporation, http://probes.invitrogen.com/servelts/structure?item=1304, 1301, 1374, 1303, 1169, 1430, 1310, July 2006. 80. Ishii, S., Sato, Y., Terashima, M., Saito, T., Suzuki, S., Murakami, S., Gotoh, M. A novel method for determination of ATP, ADP, and AMP contents of a single pancreatic islet before transplantation. Transplant Proc 36:1191–1193; 2004. 81. Janjic, D., Wollheim, C. B. Islet cell metabolism is reflected by the MTT (tetrazolium) calorimetric assay. Diabetologia 35:482–485; 1992. 82. Johnson, J. D., Ahmed, N. T., Luciani, D. S., Han, Z. Q., Tran, H., Fujita, J., Misler, S., Edlund, H., Polonsky, K. S. Increase islet apoptosis in Pdx1(+/−) mice. J Clin Invest 8:1147–1160; 2003. 83. Jorjani, P., Ozturk, S. S. Effects of cell density and temperature on oxygen consumption rate for different mammalian cell lines. Biotechnol Bioeng 64:349–356; 1999. 84. Kangas, L., Gronroos, M., Nieminer, A. L. Bioluminescence of cellular ATP—A new method for evaluating cytotoxic agents in-vitro. Med Bio 62:338–343; 1984. 85. Katoch, V. M., Katoch, K., Ramanathan, U., Sharma, V., Shivannavar, C., Datta, A., Bharadwaj, V. Effect of chemotherapy on viability of mycobacterium leprae as determined by ATP content, morphological index and FDA-EB fluorescent staining. Int J Lepr Other Mycobact Dis 57:615–621; 1989.
6.
Characterization of Islet Preparations
86. Keymeulen, B., Ling, Z., Gorus, F. K., Delvaux, G., Bouwens, L., Grupping, A., Hendrieckx, C., PipeleersMarichal, M., Van Schravendijk, C., Salmela, K., Pipeleers, D. G. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: Graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 41:452–459; 1998. 87. Kim, S. C., Han, D. J., Kim, I. H., Woo, K. O., We, Y. M., Kang, S. Y., Back, J. H., Kim, Y. H., Kim, J. H., Lim, D. G. Comparative study on biological and immunologic characteristics of the pancreas islet cell between 24◦ C and 37◦ C culture in the rat. Transplant Proc 37:3472–3475; 2005. 88. Kloppel, G., Lohr, M., Habich, K., Oberholzer, M., Heitz, P. U. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110–125; 1985. 89. Korbutt, G. S., Pipeleers, D. G. Rat pancreas preparation for cold storage and subsequent islet cell isolation. Transplantation 56:500–503; 1993. 90. Korsgren, O., Nilsson, B., Berne, C., Felldin, M., Foss, A., Kallen, R., Lundgren, T., Samela, K., Tibell, A., Tufveson, G. Current status of clinical islet transplantation. Transplantation 79:1289–1293; 2005. 91. Koulmanda, M., Papas, K. K., Qipo, A., Wu, H., Smith, R. N., Weir, G. C., Auchincloss, H., Colton, C. K. Islet oxygen consumption rate as a predictor of in vivo efficacy posttransplantation. Xenotransplantation 10:484; 2002. 92. Krishan, A. Rapid flow cytometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66:188–193; 1975. 93. Kuroda, Y., Tanioka, Y., Morita, A. Protective effect of preservation of canine pancreas by the two-layer (UW solution/ perfluorochemical) method against rewarming ischemic injury during implantation. Transplantation 57:413; 1994. 94. Lacy, P. E., Kostianovsky, M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35; 1967. 95. Lakey, J. R. T., Suarez-Wilson, W. L., Strynadka, K. Peroxynitrite is mediator of cytokine-induced destruction of human pancreatic islet beta cells. Lab Invest 81:1683; 2001. 96. Lakey, J. R. T., Tsujimura, T., Shapiro, A. M. J., Kuroda, Y. Preservation of the human pancreas before islet isolation using a two-layer (UW solution/perfluorochemical) cold storage method. Transplantation 74:1809–1811; 2002. 97. Latif, Z. A., Noel, J., Alejandro, R. A simple method of staining fresh and cultured islets. Transplantation 45:827–830; 1988. 98. Linetsky, E., Bottino, R., Lehmann, R., Alejandro, R., Inverardi, L., Ricordi, C. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 46:1120; 1997. 99. Linetsky, E., Lehmann, R., Li, H. Human islet isolation using a new enzyme blend. Transplant Proc 29:1957; 1995.
100. Linetsky, E., Selvaggi, G., Bottino, R. Comparison of collagenase type P and Liberase during human islet isolation using the automated method. Transplant Proc 27:3264; 1995. 101. London, N. J., Contractor, H., Lake, S. P., Aucott, G. C., Bell, P. R., James, R. F. A fluorometric viability assay for single human and rat islets. Horm Metab Res Suppl 25:82–87; 1990. 102. London, N. J., Contractor, H., Lake, S. P., Aucott, G. C., Bell, P. R., James, R. F. A microfluorometric viability assay for isolated human and rat islets of Langerhans. Diabetes Res 12:141–149; 1989. 103. Ly, J. D., Grubb, D. R., Lawen, A. The mitochondrial membrane potential (m ) in apoptosis; an update. Apoptosis 8:115–128; 2003. 104. Malaisse-Lagac, F., Stefan, Y., Cox, J., Perrelet, A., Orci, L. Identification of a lobe in the adult human pancreas rich in pancreatic polypeptide. Diabetologia 17:361–365; 1979. 105. Marchetti, P., Del Guerra, S., Marselli, L., Lupi, R., Masini, M., Pollera, M., Bugliani, M., Boggi, U., Vistoli, F., Mosca, F., Del Prato, S. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89:5535–5541; 2004. 106. Martin, I., Dozin, B., Quarto, R., Cancedda, R., Beltrame, F. Computer-based technique for cell aggregation analysis and cell aggregation in in vitro chondrogenesis. Cytometry 28:141–146; 1997. 107. Matchinsky, F. M., Ellerman, J. E. Metabolism of glucose in the islets of Langerhans. J Biol Chem 243:2730–2736; 1968. 108. Matsuda, T., Suzuki, Y., Tanioka, Y., Toyama, H., Kahinoki, K., Hiraoka, K., Fujino, Y., Kuroda, Y. Pancreas preservation by the 2-layer cold storage method before islet isolation protects isolated islets against apoptosis through the mitochondrial pathway. Surgery 134:437–445; 2003. 109. Matsumoto, S., Qualley, S. A., Goel, S., Hagman, D. K., Sweet, I. R., Poitout, V., Strong, D. M., Robertson, R. P., Reems, J. A. Effect of the two-layer (University of Wisconsin solution-perfluorochemical plus O2) method of pancreas preservation on human islet isolation, as assessed by the Edmonton isolation protocol. Transplantation 74:1414–1419; 2002. 110. Miyamoto, M., Morimoto, Y., Nozawa, Y., Balamurugan, A. N., Xu, B. Y., Inoue, K. Establishment of fluorescein diacetate and ethidium bromide (FDAEB) assay for quality assessment of isolated islets. Cell Transplant 9:681–686; 2000. 111. Mor, N., Resnick, M., Silbaq, F., Bercovier, H., Levy, L. Reduction of tellurite and deesterification of fluorescein diacetate are not well correlated with viability of mycobacteria. Ann Inst Pasteur/Microbiol 139:279–288; 1988. 112. Mosmann, T. Rapid calorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63; 1983.
129
Colton et al. 113. Nicotera, P., Lest, M., Ferrando-May, E. Apoptosis and necrosis: Different execution of the same death. In: Brown, G. C., Nicholls, D. G. and Cooper, C. E., eds. Mitochondria and Cell Death, London, Portland Press, 1988: 69–75. 114. Noguchi, H., Ueda, M., Nakai, Y., Iwanaga, Y., Okitsu, T., Nagata, H., Yonekawa, Y., Kobayashi, N., Nakamura, T., Wada, H., Matsumoto, S. Modified two-layer preservation method (m-Kyoto/PFC) improves islet yields in islet isolation. Am J Transplant 6:496–504; 2006. 115. O’Neil, J. J., Stegemann, J. P., Nicholson, D. T., Gagnon, K. A., Solomon, B. A., Mullon, C. J. The isolation and function of porcine islets from market weight pigs. Cell Transplant 10:235–246; 2001. 116. O’Neil, J. J., Omer, A., Tchipashvili, T., Lei, J., Chandra, G., Pisania, A., Colton, C. K., Weir, G. C., Bonner-Weir, S. Human pancreatic islet preparations: Cell composition determined by electron microscopy. (submitted); 2006. 117. Ou, D., Mtezger, D. L., Wang, X., Huang, J., Pozzilli, P., Tingle, A. J. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia 45:1678–1688; 2002. 118. Overbeeke, R., Steffens-Nakken, H., Vermes, I., Reutelingsperger, C., Haanen, C. Early features of apoptosis detected by four different flow cytometry assays. Apoptosis 3:115–121; 1998. 119. Panten, U., Klein, H. O2 consumption by isolated pancreatic islets, as measured in a microincubation system with a Clarktype electrode. Endocrinology 111:1595–1600; 1982. 120. Papas, K. K., Hering, B. J., Gunther, L., Rappel, M. J., Colton, C. K., Avgoustiniatos, E. S. Pancreas oxygenation is limited during preservation with the two-layer method. Transplant Proc 37:3501–3504; 2005. 121. Papas, K. K., Colton, C. K., Gounarides, J. S., Roos, E. S., Jarema, M. A. C., Shapiro, M. J., Cheng, L. L., Cline, G. W., Shulman, G. I., Wu, H., Bonner-Weir, S., Weir, G. C. NMR spectroscopy in b cell engineering and islet transplantation. Ann NY Acad Sci 944:96–119; 2001. 122. Papas, K. K., Colton, C. K., Nelson, R. A., Rosack, P. R., Avgoustiniatos, E. S., Scott II, W. E., Pisania, A., Weir, G. C., Hering, B. J. Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. (submitted); 2006. 123. Papas, K. K., Colton, C. K., Qipo, A., Wu, H., Auchincloss, H., Weir, G. C., Koulmanda, M. Islet oxygen consumption rate and DNA content are predictors of transplantation outcome. (submitted); 2006. 124. Papas, K. K., Colton, C. K., Qipo, A., Wu, H., Auchincloss, H., Weir, G. C., Koulmanda, M. Islet quality assay based on oxygen consumption rate and DNA measurements predicts graft function in mice. Cell Transplant 12:176; 2003. 125. Papas, K. K., Constantinidis, I., Sambanis, A. Cultivation of recombinant, insulin-secreting AtT-20 cells as free and entrapped spheroids. Cytotechnology 13:1–12; 1993.
126. Papas, K. K., Jarema, M. A. C. Glucose-stimulated insulin secretion is not obligatorily linked to an increase in O2 consumption in HC9 cells. Am J Physiol 275:E1100–E1106; 1998. 127. Papas, K. K., Long Jr., R. C., Sambanis, A., Constantinidis, I. Towards the development of a bioartificial pancreas: I. Effects of glucose on long-term entrapped bTC3 cell cultures. Biotechnol Bioeng 66:219–230; 1999. 128. Papas, K. K., Long Jr., R. C., Sambanis, A., Constantinidis, I. Towards the development of a bioartificial pancreas: II. Effects of oxygen on long-term entrapped bTC3 cell cultures. Biotechnol Bioeng 66:231–237; 1999. 129. Papas, K. K., Pisania, A., Avgoustiniatos, E. S., Hering, B. J., Weir, G. C., Colton, C. K. Product release criteria and in vitro assays of islet function. In: Shapiro, A. M. J., Shaw, J., eds. Islet Transplantation and Beta Cell Replacement Therapy. New York, Marcel Dekker Inc., (in press). 130. Papas, K. K., Pisania, A., Wu, H., Weir, G. C., Colton, C. K. Oxygen consumption rate of islets of Langerhans measured with a continuously stirred microchamber. (submitted); 2006. 131. Papas, K. K., Wu, H., Colton, C. K. Rapid islet quality assessment prior to transplantation. Cell Transplantation 10:519; 2001. 132. Paraskevas, S., Maysinger, D., Wand, R., Duguid, W. P., Rosenberg, L. Cell loss in isolated human islets occurs by apoptosis. Pancreas 20:270–276; 2000. 133. Parman, A. U. Quantitation of isolated rat islets of Langerhans on the basis of deoxyribonucleic acid content under metabolic conditions of altered protein synthesis. J Histochem Cytochem 23:187–193; 1975. 134. Pepper, C., Thomas, A., Tucker, H., Hoy, T. B., P. Flow cytometric assessment of three different methods for measurements of in vitro apoptosis. Leuk Res 22:439–444; 1998. 135. Persidsky, M., Baillie, G. S. Fluorometric test for membrane integrity. Cryobiology 14:322–331; 1977. 136. Pierucci, D., Cicconi, S., Bonini, P., Ferrelli, F., Pastore, D., Matteucci, D., Marselli, L., Marchetti, P., Ris, F., Halban, P., Oberholzer, J., Federici, M., Cozzolino, F., Lauro, R., Borboni, P., Marlier, M. N. NGF-withdrawal induces apoptosis in pancreatic beta cells in vitro. Diabetologia 44:1281–1295; 2001. 137. Pipeleers, D. G. The biosociology of pancreatic B cells. Diabetologia 30:277–291; 1987. 138. Pipeleers, D. G. Composition of islet grafts. Diab Nutr Metab 5:29–32; 1992. 139. Pipeleers, D. G., Int’ Veld, P. A., Van De Winkel, M., Maes, E., Schuit, F. C., Gepts, W. A new in vitro model for the study of pancreatic A and B cells. Endocrinology 117:806–816; 1985. 140. Pipeleers, D. G., Pipeleers-Marichal, M., Hannaert, J. C., L Berghmnas, M., Int’ Veld, P. A., Rozing, J., Van De Winkel, M., Gepts, W. Transplantation of purified islet cells in diabetic rats. I. Standardization of islet cell grafts. Diabetes 40:908–919; 1991.
130
6.
Characterization of Islet Preparations
141. Pipeleers, D. G., Pipeleers-Marichal, M. L. A method of the purification of single A-cell, B-cell and D-cell and for the isolation of coupled cells from isolated rat islets. Diabetologia 20:654–663; 1981. 142. Pisania, A., Bonner-Weir, S., Weir, G. C., Colton, C. K. A comparison of islet purity measurements by morphological analysis using light and electron microscopy. (submitted); 2006. 143. Pisania, A., Papas, K. K., Powers, D. E., Rappel, M. J., Bonner-Weir, S., Weir, G. C., Colton, C. K. Enumeration of cells in islet preparations by nuclei counting. In: Proceedings, 10th World Congress of Islet and Pancreas Transplantation Association, p 61. Geneva, 2005. 144. Pisania, A., Papas, K. K., Powers, D. E., Rappel, M. J., Bonner-Weir, S., Weir, G. C., Colton, C. K. Enumeration of islet cells in islet preparations by nuclei counting and microscopic observations. (submitted); 2006. 145. Pisania, A., Papas, K. K., Powers, D. E., Rappel, M. J., Bonner-Weir, S., Weir, G. C., Colton, C. K. A quantitative membrane integrity test for islets of Langerhans. In: Proceedings, 10th World Congress of Islet and Pancreas Transplantation Association, p 61. Geneva, May 4–7, 2005. 146. Pisania, A., Papas, K. K., Rappel, M. J., Powers, D. E., Weir, G. C., Colton, C. K. A quantitative membrane integrity test for islets of Langerhans. (submitted); 2006. 147. Pisania, A., Rappel, M. J., Powers, D. E., Papas, K. K., Weir, G. C., Colton, C. K. Dynamics of cell death evaluated by mitochondrial function, apoptosis, and membrane integrity assays. In: Proceedings, 7th International Congress of the Cell Transplant Society, p 115. Boston, MA, November 17–20, 2004. 148. Pisania, A., Rappel, M. J., Powers, D. E., Papas, K. K., Weir, G. C., Colton, C. K. Dynamics of cell death evaluated by mitochondrial function, apoptosis, and membrane integrity assays. (submitted); 2006. 149. Reddy, S., Bradley, J., Ross, J. M. Immunolocalization of caspase-3 in pancreatic islets of NOD mice during cyclophosphamide-accelerated diabetes. Immunology of Diabetes II: Pathogenesis rom mouse to man. Ann NY Acad Sci 1005:192–195; 2003. 150. Ricordi, C., Gray, D. W., Hering, B. J., Kaufman, D. B., Warnock, G., Kneteman, N., Lake, S. P., London, N. J., Socci, C., Alejandro, R., Zeng, J., Scharp, D. W., Viviani, G., Tzakis, A., Bretzel, R. G., Federlin, K., Pozza, G., James, R., Rajotte, R. V., Di Carlo, V., Morris, P., Sutherland, D. E. R., Starzl, T. E., Mintz, D., Lacy, P. E. Islet isolation assessment in man and large animals. Acta Diabetol Latina 27:185–195; 1990. 151. Ricordi, C., Gray, D. W., Hering, B. J., Kaufman, D. B., Warnock, G. L., Kneteman, N. M., Lake, S. P., London, N. J., Socci, C., Alejandro, R. Islet isolation assessment in man and large animals. Acta Diabetol Latina 27:185–195; 1990.
152. Ricordi, C., Inverardi, L., Kenyon, N. S., Goss, J., Bertuzzi, F., Alejandro, R. Requirements for success in clinical islet transplantation. Transplantation 79:1298–1300; 2005. 153. Ricordi, C., Lacy, P. E., Finke, E. H., Olack, B. J., Scharp, D. W. Automated method for isolation of human pancreatic islets. Diabetes 37:413; 1988. 154. Ricordi, C., Lakey, J. R. T., Hering, B. J. Challenges toward standardization of islet isolation technology. Transplant Proc 33:1709; 2001. 155. Ricordi, C., Scharp, D. W., Lacy, P. E. Reversal in nude mice after transplantation of fresh and 7 days cultured (24◦ C) human pancreatic islets. Transplantation 45:994–996; 1988. 156. Ricordi C., Hering, B. J., London, N. J., Rajotte, R. V., Gray, D. W., Socci, C., Alejandro, R., Carroll, P. B., Bretzel, R. G., Scharp, D. W. Islet Isolation Assessment. In: Ricordi, C., ed. Pancreatic Islet Cell Transplantation 1892–1992: One Century of Transplantation for Diabetes. Austin, TX, R.G., Landes, 1992:132–142. 157. Ricordi C., Socci, C., Davalli, A. M. Isolation of the elusive pig islets. Surgery 107:688; 1990. 158. Ryan, E. A., Lakey, J. R. T., Paty, B. W. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 51:2148; 2002. 159. Ryan, E. A., Lakey, J. R. T., Rajotte, R. V. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710; 2001. 160. Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R. T., Shapiro, A. M. J. Fiveyear follow-up after clinical islet transplantation. Diabetes 54:2060–2069; 2005. 161. Saito, K., Iwama, N., Takahashi, T. Morphometrical analysis on topographical difference in size distribution, number and volume of islets in the human pancreas. Tohoku J Exp Med 124:177; 1978. 162. Salvioli, S., Ardizzoni, A., Franceschi, C., Cossarizza, A. JC-1 but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess changes in intact cells: Implications for studies on mitochondrial functionality during apoptosis. FEBS Letters 411:77–82; 1997. 163. Sanford, K. K., Earle, W. R., Evans, V. J., Waltz, H. K., Shannon, J. E. The measurement of proliferation in tissue cultures by enumeration of cell nuclei. J Nat Cancer Inst 11:773–795; 1951. 164. Sato, T., Herman, L. Morphometry and elemental analysis of rat exocrine pancreas following administration of trypsin inhibitor. Acta Anat (Basel) 137:65–76; 1990. 165. Scaduto, R. C., Grotyohann, L. W. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 76:469–477; 1999. 166. Scharp, D. W. Islet quality control testing and the islet isolation laboratory. In: Ricordi, C., ed. Pancreatic Islet Cell Transplantation 1892–1992: One Century of Transplantation for Diabetes. Austin, TX, R.G. Landes, 1992: 82–88.
131
Colton et al. 167. Scharp, D. W., Kemp, C. B., Knight, M., Ballinger, W. F., Lacy, P. E. The use of ficoll in the preparation of viable islets of Langerhans from the rat pancreas. Transplantation 16; 1973. 168. Schwartzman, R. A., Cidlowski, J. A. Apoptosis: The biochemistry and molecular biology of programmed cell death. Endocr Rev 14:133–151; 1993. 169. Sever, C. E., Demetris, A. J., Zeng, J., Caroll, P., Tzakis, A., Fung, J. J., Starzl, T. E., Ricordi, C. Composition of human islet cell preparations for transplantation. Acta Diabetol 28:233–238; 1992. 170. Shapiro, A. M. J., Lakey, J. R. T., Paty, B. W., Senior, P. A., Bigam, D. L., Ryan, E. A. Strategic opportunities in clinical islet transplantation. Transplantation 79:1304–1307; 2005. 171. Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G., Toth, E., Warnock, G., Kneteman, N., Rajotte, R. V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238; 2000. 172. Smets, F. N., Chen, Y., Wang, L. J., Soriano, E. Loss of anchorage triggers apoptosis (anoikis) in primary mouse hepatocytes. Mol Gen Metab 75:344–352; 2002. 173. Smiley, S. T., Reers, M., Mottola-Hartshorn, C., Lin, M., Chen, A., Smith, T. W., Steele, G. D., Chen, L. B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a j-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88:3671–3675; 1991. 174. Smith, A. L., Smith, H. V. A comparison of fluorescein diacetate and propidium iodide staining and in vitro excystation for determining Giardia-intestinals cyst viability. Parasitology 99:329–331; 1989. 175. Smith, R. M., Gale, E. A. M. Survival of the fittest? Natural selection in islet transplantation. Transplantation 79:1301–1303; 2005. 176. Stefan, Y., Orci, L., Malaisse-Lagae, F., Perrelet, A., Patel, Y., Unger, R. H. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 31:694–700; 1982. 177. Street, C. N., Lakey, J. R. T., Shapiro, A. M. J., Imes, S., Rajotte, R. V., Ryan, E. A., Lyon, J. G., Kin, T., Avila, J., Tsujimura, T., Korbutt, G. S. Islet graft assessment in the Edmonton protocol: Implications for predicting long-term clinical outcome. Diabetes 53:3107–3114; 2004. 178. Sweet, I. R., Cook, D. L., DeJulio, E., Wallen, A. R., Khalil, G., Callis, J. B., Reems, J. A. Regulation of ATP/ADP in pancreatic islets. Diabetes 53:401–409; 2004. 179. Sweet, I. R., Cook, D. L., Wiseman, R. W., Greenbaum, C. J., Lernmark, A., Matsumoto, S., Teague, J. C., Kronh, K. A. Dynamic perifusion to maintain and assess isolated pancreatic islets. Diabetes Technol Ther 4:67–76; 2002. 180. Sweet, I. R., Khalil, G., Wallen, A. R., Steedman, M., Schenkman, A., Reems, J. A., Kahn, S. E., Callis, J. B. Continuous measurement of oxygen consumption by pancreatic islets. Diabetes Technol Ther 4:661–672; 2002.
181. Takahashi, N., Nemoto, T., Kimura, R., Tachikawa, A., Miwa, A., Okado, H., Miyashita, Y., Iino, M., Kadawaki, T., Kasai, H. Two-photon excitation imaging of pancreatic islets with various fluorescent probes. Diabetes 51 S1:S25–S28; 2002. 182. Thornberry, N. A., Lazebnik, Y. Caspases: Enemies within. Science 281:1312–1316; 1998. 183. Todaro, M., Di Gaudio, F., Lavitrano, M., Stassi, G., Papaccio, G. Islet beta-cell apoptosis triggered in vivo by interleukin-1 beta is not related to the inducible nitric oxidensynthase pathway: Evidence for mitochondrial function impairment and lipoperoxidation. Endocrinology 144:4264–4271; 2003. 184. Torres, D., Munell, F., Ferrer, J., Reventos, J., Macaya, A. Identification of necrotic cell death by the TUNEL assay in the hypoxic-ischemic neonatal rat brain. Neurosci Lett 230: 1–4; 1997. 185. Tsujimura, T., Kuroda, Y., Kin, T., Avila, J. G., Rajotte, R. V., Korbutt, G. S., Ryan, E. A., Shapiro, A. M. J., Lakey, J. R. T. Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the twolayer (UW solution/perfluorochemical) cold storage method. Transplantation 74:1687–1691; 2002. 186. Valentijn, A. J., Zouq, N., Gilmore, A. P. Anoikis. Biochem Soc Trans 32; 2004. 187. Van der Burg, M. P., Scheringa, M., Basir, I., Bouwman, E. Assessment of isolated islet equivalents. Transplant Proc 29:1971–1973; 1997. 188. Vermes, I., Haanen, C., Steffens-Nakken, H., Reutelingsperger, C. A novel assay for apoptosis flow cytometric detection of phosphatidyl serine expression on early apoptotic cells using fluorescein labeled Annexin V. J Immunol Methods 184:39–51; 1995. 189. Vistica, D. T., Skehan, P., Scudiero, D., Monks, A., Pittman, A., Boyd, M. R. Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production. Cancer Res 51:2515–2520; 1991. 190. Wang, W., Upshaw, L., Strong, D. M., Robertson, R. P., Reems, J. A. Increased oxygen consumption rates in response to high glucose detected by a novel oxygen biosensor system in non-human primate and human islets. J Endocrinol 185:445–455; 2005. 191. Weber, D. J., McFarland, R. D., Irony, I. Selected Food and Drug Administration review issues for regulation of allogeneic islets of Langerhans as somatic cell therapy. Transplantation 74:1816–1820; 2002. 192. Weibel, E. R: Practical Methods for Biological Morphometry. London, Academic Press, 1979. 193. Weir, G. C., Halban, P. A., Meda, P., Wollheim, C. B., Orci, L., Renold, A. E. Dispersed adult rat pancreatic islet cells in culture: A, B, and D cell function. Metabolism 33:447–453; 1984.
132
6.
Characterization of Islet Preparations
194. Welsh, M., Hellerstrom, C., Andersson, A. Respiration and insulin release in mouse pancreatic islets of mice. Effects of Lleucine and 2-ketoisocaproate in combination with D-glucose and L-glutamine. Biochim Biophys Acta 721:178–184; 1982. 195. Yamada, K., Ichikawa, F., Ishiyama-Shigemoto, S., Yuan, X. H., Nonaka, K. Essential tole of caspase-3 in apoptosis of mouse beta-cells transfected with human Fas. Diabetes 48:478–483; 1999. 196. Yang, H., Acker, J., Chen, A., McGann, L. In situ assessment of cell viability. Cell Transplant 7:443–451; 1998.
197. Yonelawa, Y., Matsumoto, S., Okitsu, T., Arata, T., Iwanaga, Y., Noguchi, H., Nagata, H., O’Neil, J. J., Tanaka, K. Effective islet isolation method with extremely high islet yields from adult pigs. Cell Transplant 14:757–762; 2005. 198. Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., Son, H. Y., Kang, S. K., Kim, H. S., Lee, I. K., Bonner-Weir, S. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300–2308; 2003.
133
This page intentionally left blank
7 Encapsulated Human Islet Allografts: Providing Safety with Efficacy David W. Scharp, M.D. Executive Vice President and Chief Medical Officer, Novocell, Inc., 31 Technology Dr., Suite 100 Irvine, CA 92618
Restrictions Preventing Wide Acceptance of Clinical Islet Transplantation with Immunosuppression Recent publications of the long-term results of clinical islet transplantation in hypoglycemic unaware type 1 diabetic recipients suggest excellent insulin independence rates at 12 months between 75 to 85% in the best centers [46, 52, 97]. These results follow intrahepatic injections of partially purified islets into the portal vein of the liver. However, the duration of insulin independence declines yearly to 8% by 5 years at the best centers. Lower success rates are seen from many of the other islet transplant centers, as reported in the Collaborative Islet Transplant Registry report from 2004, providing an average insulin independence rate of 55% at 12 months postimplant. In that this average result included the best centers, many islet transplant center individual results must be significantly below this average. Unfortunately, the first restriction limiting the expansion of clinical islet transplantation continues to be this wide variance of results between centers, suggesting the lack of standardized techniques involved in donor selection, pancreas procurement and shipment, islet processing and preservation, and islet transplantation techniques [46, 50, 82, 83]. In terms of the second restriction, immunosuppression, the majority of patients transplanted with primary human islets received a variation of the Edmonton protocol of immunosuppression — initially thought to reduce complications related to cyclosporine and other agents used
Cellular Transplantation: From Laboratory to Clinic
prior to 2000 [105]. However, the recipients’ physical costs required for them to obtain significant reduction in insulin requirements, including temporary insulin independence, following islet transplantation are proving very high in terms of suffering major adverse events related to their required immunosuppression [51, 104]. In fact, several recipients have elected to stop their immunosuppression while attaining insulin independence due to its side effects [96]. Additional side effects have been documented directly related to the injection of the islets into the liver by percutaneous catheterization of the portal vein leading to portal vein thrombosis or hemorrhage [119], as well as focal hepatic steatosis [60, 79]. Even if these complications and restrictions present in today’s clinical islet transplant recipients could be overcome, the limited numbers of organ donors available relative to the greater than one million potential type 1 recipients in the USA that could theoretically benefit from the procedure, severely restrict the opportunity to transplant islets to no more than a few thousand patients each year. However, the very high charges related to pancreas procurement from the not-for-profit organ procurement organizations (per pancreas at $30,000) and the high pancreas processing costs (at $10,000 each) have limited the potential number of islet transplants in the USA to less than 100 implants per year on average since 2000. The sum of all of these restrictions currently limits islet allograft transplantation under immunosuppression to the category of an academic center demonstration product, regulated by the FDA under Investigator INDs [123]. To expect wide acceptance of
135
Copyright © 2007, Elsevier Inc. All rights of reproduction in any form reserved.
David W. Scharp
Following the lead of the Edmonton islet transplantation centers, the selection of potential islet transplant recipients without kidney transplants was limited to a subgroup of diabetics with hypoglycemic unawareness. Yet, this group of potential islet transplant recipients reduces in number each year at major centers providing diabetes care and education due to improved insulin Complications Related to delivery by new drug combinations, such as long-acting insulins and improved ultrashort-acting insulins and by a Immunosuppression greater use of insulin pumps [94]. However, the majority Recipients of whole organ grafts have little choice of type 1 diabetics is not taken care of in these optibut to accept full immunosuppression as a requirement mal diabetic treatment centers, leaving them at higher for transplant success, as confirmed by the thousands risk for developing diabetic complications. These same of potential recipients who die every year from their patients are also at higher risk for developing severe organ failure related to organ shortages in the USA hypoglycemic unawareness when trying to improve and Europe. Patients in this position of needing a their glycemic control through more aggressive insulin heart, lung, liver, kidney, or intestinal transplant for life treatment without adequate training and education. readily accept the complications of immunosuppression Now that longer-term results are available for clinical because the alternatives for them are not compatible islet transplant recipients, there is a greater appreciation with life. Diabetic patients who suffer renal failure for the risks of complications related to immunosupsecondary to their diabetic complications do have a lim- pression in these patients. Shown in Figure 7.1, are the ited choice in renal dialysis versus a pancreas or islet major complications after intra-hepatic, free islet allotransplant with immunosuppression. Although the dura- grafts under full immunosuppression, summarized from tion of life on chronic dialysis is significantly less for recent publications. It is estimated that approximately 50% of diabetic the diabetic patient than the non-diabetic patient, the comparative results for pancreas transplantation remain recipients of islet allografts under immunosuppression controversial. In consideration of transplanting diabetic suffer serious adverse events related to these complipatients, there is a different risk/benefit ratio involved cations. Developing a way to implant islet allografts in their choices compared to the choice left for patients without immunosuppression would be a major step with diseases that result in immediately life-threatening forward in advancing islet transplantation without these organ failure. The patients with diabetes suffer from complications. One choice for eliminating immunosupboth acute and chronic complications of their disease pression is the development of a safe and effective that reduce not only their quality of life but their dura- encapsulation technology for islets. tion of life in those adversely affected. So many type 1 diabetics make the decision to seek either a whole-organ pancreas transplant or an islet transplant, both under Cartoon Descriptions of Encapsulated Cell full immunosuppression, to avoid the progression of Therapy Immune Protection their diabetic complications over time. In the patients with renal failure secondary to diabetic complications, Before discussing the development of encapsulated islet the election of a renal transplant under immunosuppres- technology, the following three figures present in a carsion becomes a reasonable choice for many. Because toon fashion how islet encapsulation protects the cells immunosuppression is already required for the kidney from immune destruction. Figure 7.2 shows how unprotransplant, adding a pancreas or islet transplant results in tected islet allografts are destroyed by the host immune additional morbidity and/or mortality related especially system. Following transplantation into the host, antigens to adding the pancreas but also to the islet transplant. from the islet allograft are identified and engulfed by However, in those patients without renal failure the elec- antigen-presenting cells or dendritic cells. These antition to undergo an islet transplant requiring immunosup- gens are processed by these cells into the appropriate pression is one that cannot be taken lightly when one small peptides that are then presented upon the surconsiders the risks related to immunosuppression that face of the APCs in a specific HLA-linked process. are involved. When a T-lymphocyte locates the APC and its projected clinical islet transplantation to achieve its potential as a new therapy for diabetes as a commercial product, these limiting restrictions must be significantly reduced or eliminated.
136
7.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
Figure 7.1. Potential complications following free islet allografts with immunosuppression.
Figure 7.2. Pathways leading to free islet allograft rejection.
islet antigen, it attaches to the same HLA linked structure. However, no information is transferred to the T-lymphocyte until two adjacent connections are made between the cells. The CD40 structure from the APC has to chemically bind to the CD154 ligand from the
T-lymphocyte. In a similar manner, the CD80 or CD86 structure from the APC must also bind to the CD28 ligand of the T-lym cell. Once both are connected, the antigen information is then passed to the T-lym helper cell that begins to
137
David W. Scharp
process and convert it to a T-lym killer cell that is specifically able to recognize this antigen. Following the APC making all of its connections to the T-lym helper cell, the APC releases the cytokine IL-1 that diffuses into the T-lym cell to produce IL-2. This cytokine stimulates expansion of the T-lym killer cells that contain the islet allograft marker. These cells circulate in the host until they come in contact with the islet allograft cells containing the correct antigen and attack the islets directly and kill them through cell-mediated killing. If, however, under different conditions the CD80/CD86 structure of the APC attaches instead to the CD152 ligand of the T-lym helper cell, a T-lym regulatory cell is produced that limits the production and expansion of T-lym killer cells and can reduce or stop the destruction of islet allografts. Another function of the T-lym helper cell is the passage of the donor antigen information to B-lym cells for the production of specific antibodies to the islet allograft cells. These donor specific antibodies can also migrate throughout the host and kill the allograft cells in combination with complement. In a similar way, donor APCs contained within the islet graft can migrate out of the islet and process the donor antigens with the recipient T-lym helper cells that may make even more potent killer cells than those processed by host APCs. A number of immunosuppressive drugs have been developed that attack different portions of this process
of immune destruction of allograft cells, as shown in Figure 7.3. Prednisone, azathioprine, and CelCept all reduce the ability of the APC to release IL-1, which reduces the ability to expand T-lym killer cells, and thus reduces the immune destruction of the islet allograft. Cyclosporin and Prograf each attack the T-lym helper cell’s ability to produce IL-2, which also reduces the ability to expand T-lym killer cells. Rapamune also reduces the ability to release IL-2 from the T-lym helper cell, but under a different mechanism. Zenapax binds the IL-2 receptor on the T-lym killer cell, which also reduces the ability to expand the T-lym killer cells. Anti-CD3 antibody treatment nonselectively kills all T-lymphocytes, regardless of type, and protects islet allografts by reducing all T-lym cells. Thyroglobulin similarly nonspecifically kills all T-lym cells, which results in similar graft protection. Two very specific and interesting monoclonal antibodies have been produced by Biogen and IDEC that specifically bind the CD154 binding site on the T-lym killer cell. The Biogen antibody is very specific in preventing islet allograft rejection, even as a single agent, but coagulation crises and a death of a recipient have prevented further drug development. There are always new immunosuppressants being developed with the hope that one will hit the mark with minimal complications. As noted in Figure 7.1, that is not the experience with today’s drugs. Therefore, encapsulation is an attractive approach
Figure 7.3. Targets for immunosuppressive agents to reduce free islet allograft rejection.
138
7.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
Figure 7.4. Immune protection offered by cell encapsulation without immunosuppression.
to prevent today’s significant immunosuppressive drug side effects. While protecting cells by encapsulation initially seems very easy, a major impediment to the development of encapsulated cell therapy has been the inability to find encapsulating substances that cause no macrophage or APC activation on their own. As shown in Figure 7.4, if the coating has no reactivity many of the antigens crossing from the encapsulated cells are simply ignored. If the coating nonspecifically activates the responding host cells, an inflammatory response begins that attracts cells that release many cytokines around the coated cells that readily penetrate the coating and kill them. In addition, host cells accumulate on the surface of the capsule and prevent adequate oxygen diffusion to the encapsulated cells, leading to their death. With excellent capsule biocompatibility, some of the antigens are processed by the host APCs and create functional T-lym killer cells. However, the cell coating prohibits these T-lym killer cells from contacting their targets so that no damage is done. The cell coating also prevents the donor APCs from escaping the coating, which are thus prevented from interacting with the host immune cells. Even with antibodies produced against the donor antigens, they are not effective if the coating prohibits their crossing to the encapsulated cells. In addition, even if the porosity is sufficiently large to permit antibodies to cross the membrane, the much larger complement is
prevented from crossing the membrane — which then prevents encapsulated cell destruction.
Development of Encapsulated Islet Transplantation Although there were a few early primitive ways attempted to protect cells, the concept of protecting islets from immune attack by placing them behind a permselective barrier originated in current time with the pioneering 1965 work by Thomas Chang [18], who encapsulated islets within microcapsules. As investigations have grown over the years, the ability to encapsulate islets has focused in three main directions (as shown in Figure 7.5): (1) the use of macrocapsules such as planar devices using flat sheet membranes and the use of hollow fibers, (2) the use of microcapsules using hydrogel encapsulation, and more recently (3) the production of direct conformal polymer coatings placed on the surface of the islets as a thin protective coating.
MACROCAPSULES Turning first to review macrocapsule development, it began with the use of available renal dialysis fibers. Chick was one of the first to use this technology to
139
David W. Scharp
Figure 7.5. Islet encapsulation factors required to achieve both clinical and commercial relevance.
perfuse nutrient fluid through the hollow fibers and place the islets around these fibers [21] and then implant them into diabetic rodents [22]. Others continued these types of studies with demonstration of normalization of blood glucose levels [1, 5, 112]. Enlarging the diameter of these fibers led to the development of intravascular hollow fibers for islet implants with one device functioning as an ultrafiltration chamber [92]. Others (Biohybrid and W. R. Grace) developed a single coiled tube surrounded by islets as a diffusion device (hockey puck) inserted into an artery and containing functional islet xenograft cells from dogs or pigs [23, 111]. This device has given some of the longest xenograft results with normal glycemia for several months in diabetic large animals. However, practical problems of hemorrhage and thrombosis kept this device from being developed further. Instead, this group placed the islets within the larger tubes of acrylic polymer hollow fibers and implanted them into the peritoneal cavity of diabetic rodents and dogs with demonstration of the ability to reverse diabetes in many of these recipients [71–74], including discordant islet xenograft islets into rats [70]. However, problems of fiber fragility and limited survival of islets only on the inside surface of these fibers stopped this development. An additional vascular device was developed by the Gore companies that was patented [12, 13] but was never published, with all development on this device currently stopped.
Cytotherapeutics, Inc., used a different polymer to produce a variety of constructs of hollow fibers (Figure 7.5) of several diameters with good diffusion characteristics [34, 35, 47]. This development led to studies with islets that demonstrated the feasibility of these implants in diabetic animals [69] and to a clinical trial as a phase 1 study in nondiabetics, type 1 diabetics, and type 2 diabetics [100, 106]. The lack of host reactivity to the fiber implanted in the subcutaneous site led to survival of the human islet allografts within the fibers that were protected from autoimmune recurrence as well as allograft rejection. However, the packing density was too low to develop this device into a product for diabetes because the length of the fiber would not be clinically relevant to implant a curative dose of human islets. Another company in Europe, Inserm, investigated the potential of their dialysis hollow fibers made of AN69 acrylonitrile into an encapsulation device for islets [32, 64, 65] with demonstration of effectiveness in rodent studies [89] as well with using encapsulated porcine islet xenografts in rodents [33]. Rodent studies continue with these fibers [63, 85]. A planar device containing flat sheet membranes (Figure 7.5) was developed by Baxter as part of their gene therapy program. It also contained outer support structures, a Teflon-based membrane to induce angiogenesis, and a hydrogel membrane for permselectivity [11, 86]. A number of studies of this device
140
7.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
examined neovascularization, local host responsiveness to xenografts, and release of various products from encapsulated cells [8–10]. Attempts to develop this device for a diabetes product were made in collaboration with Neocrin Co. However, Neocrin stopped the development in favor of developing PEG coating of alginate microspheres containing islets, a technology discussed later in this section. The Baxter device was obtained by Theracyte for exploring several potential cell therapy applications [62, 80, 116], but was recently sold to LCT. Another planar device was being developed by Islet Sheet Medical (now called Cerco Medical) made of supported alginate sheets being implanted into the peritoneal cavity of dogs [110] as an all-in/all-out type of device [2, 3]. There are many other types of membrane materials (polyurethanes, biopolymers, amino-silicate, cellulose, polysulphones, nucleopore, and polyvinyl alcohols) and configurations, and efforts are underway to continue to develop a clinically and commercially relevant macrodevice for the treatment of diabetes. Yet, limiting factors for these macrodevices remain to be solved, such as their relatively large size, choices as to whether they grow into the host that requires an effective method to flush and reload them, and whether they are to be an all-in/all-out device that requires absolutely perfect biocompatibility and suitable strength.
MICROCAPSULES The second major area of cell encapsulation development is the microcapsule, usually defined as a hydrogel matrix formed into a sphere (with a usual diameter of 300 to 800 microns) in which islets or other cells are randomly distributed (Figure 7.5). Whereas Chang actually initiated this technology in 1965 [17–19], it was the publication of the Lim and Sun work in 1980 [49, 75, 76] that popularized it and enabled the many studies that continue today. There are a multitude of publications and patents around the hydrogel microcapsule technology. The majority of the work centers on the original alginate microcapsule, with a permselective component of polylysine (PLL) or poly-ornithine. The original production of these alginate microcapsules consisted of suspending the cells in alginate and flowing them through a double needle apparatus to form microdroplets. The inner needle contained the cells/alginate mixture, and the outer needle used forced air to reduce the surface tension of the forming alginate droplets and hence reduce the
size of the beads. These alginate microdroplets, ranging in size from 300 to 800 microns, were caught in a high-calcium (80 mM) solution that immediately cross-linked the alginate (retaining its spherical shape). Alginate microspheres have been extensively studied because of the material’s ability to rapidly encapsulate cells by dropping into a cyto-compatible solution and forming a spherical shape. There are very few other hydrogel materials that have these properties, and those that do are typically cytotoxic when forming solid spheres. Following the early discoveries of the potential merits of using alginate for coating cells, there have been many improvements in this technology to increase the efficiency and to reduce the size of the alginate microcapsules [18, 24, 36–38, 54, 109, 122, 127]. In terms of rodent animal implants, a large number of feasibility studies have been published using rodent isograft and allograft sources of islets that have demonstrated the ability to reverse diabetes for many weeks and months using the alginate microcapsule with a PLL coating [4, 20, 29, 45, 66]. Protection against autoimmune diabetes of the NOD mouse and the BB rat (as well as successful xenografts) has also been demonstrated with these capsules in diabetic rodent recipients [39, 42, 59, 67, 77, 78, 84, 124]. Efforts to improve encapsulated islet viability postimplant have recently included the use of cross-linked hemoglobin within the alginate capsule [16] to increase oxygen carrying capacity and implanting into a prevascularized subcutaneous site [120]. Another group has added human serum albumin into highly purified alginate microcapsules and achieved long-term success of rat and human islet xenografts implanted into the peritoneal cavity without requiring immunosuppression [102]. The ability to demonstrate efficacy in large animals has been far more difficult and so far not readily reproduced by other investigators. Soon-Shiong published reversal of spontaneous diabetes in dogs using alginate PLL microcapsules by intraperitoneal implantation that may have also utilized cyclosporine as a single low-dose immunosuppressant [107]. A report by Sun in 1996 demonstrated reversal of several cynomolgus primates receiving intraperitoneal implants of alginate PLL microcapsules without any immunosuppression for a few months to two years with minimal capsule overgrowth and partial function in other recipients [113]. This work has not been successfully repeated at this time. A recent preliminary publication is suggesting that alginate-based encapsulation of porcine islets
141
David W. Scharp
into the peritoneal cavity of strep-induced diabetes in cynomolgus monkeys ameliorates their diabetes without the use of immunosuppression [41]. All of the recipients received a second implant 3 months after the first implant. Insulin requirements were reduced to 43% in these recipients, with 1 out of 8 becoming insulin independent at 36 weeks. There is another microcapsule approach to the alginate-based capsules that cross-links the alginate by a different method than calcium alone. This is the work of Wang and Hunkeler that uses multiple components added to the alginate that forms the capsule by polyelectrolyte complexation of sodium alginate and cellulose sulfate with poly(methylene-co-guanidine). They have demonstrated the ability to alter the protein diffusivity profiles across a wide range of molecular weight and alter the strength of the microcapsule as well [6, 87, 93, 125]. Whether these changes will result in major improvements in their in vivo studies remains to be determined.
MICROCAPSULE LIMITATIONS A major limitation of the alginate microcapsule system is the variable biocompatibility of this material that has been the subject of a number of studies and potential improvements. Many investigators have struggled with the problem of biocompatibility of the alginate capsule that may be due to the encapsulating alginate itself, to poorly encapsulated islets that are close to the surface of the capsule, to nonuniform alginate coverage of the highly reactive PLL, and to responding macrophages that are activated by the alginate, which subsequently develops a reaction to the antigens from the encapsulated cells [27, 30, 31, 68, 126]. Yet, a recent report from the Joslin group has used a purified alginate cross-linked with barium without the use of PLL and found diabetic NOD recipients implanted with alginate microcapsules had their diabetes reversed without autoimmune recurrence [40]. Another set of problems arises from the inability to precisely control the protein diffusivity profile in alginate microcapsules that may be necessary to protect the cells from the host immune system reacting to the implant. This lack of control of permeability permits different immune components to cross from the host into the encapsulated cells and for different antigens to cross from the encapsulated cells out to the host. The results of unlimited diffusion in both directions across the alginate
membrane can be damaging to the encapsulated cells and can lead to a buildup of protein and cells on the outside of the capsule. Such protein accumulation and layers of cells on the surface of encapsulating materials leads to reduction of the diffusion of oxygen and nutrients to the cells and waste products from the cells [28, 98, 103, 121]. Attempts to control protein diffusivity characteristics of the alginate microcapsule have not been sufficiently successful to date, with effort now focused on making the microcapsules as small as possible. Some have made small alginate microcapsules and have demonstrated some success in animal models [14]. Yet, another shortcoming of the alginate microcapsule is the fact that there is a finite limit as to how small one can make them in terms of adequately coating the islets. Because the location of the islets within the microcapsule is completely random at the time of the rapid cross-linking of the droplet falling into the calcium solution, as one reduces the droplet in size to < 300 microns in diameter portions of islets within the droplet begin to stick out of the coating and cannot be adequately coated. The only way to cover these exposed islets is by repeating the droplet process, which then results in the production of large capsules. This is a primary shortcoming of this technology of coating islets with alginate. Working with other hydrogels such as agarose or chitosan has not gotten around these basic microcapsule problems [57, 58, 81, 95, 117]. The clinical problem is trying to find a site that will accept the 150 mls of encapsulated islets whose unencapsulated volume is only 2 to 3 mls.
CONFORMAL COATINGS Perhaps the ideal type of encapsulation technology is the development of hydrogel conformal coatings placed directly on the surface of the islets to provide immune protection. Several methods have been tried, but have proven to be quite difficult to develop into clinically relevant approaches [7, 61]. Hubbell has invented a method of interfacially photopolymerizing poly(ethylene glycol) diacrylates directly on the surface of islets to form a cross-linked hydrogel membrane that conformally covers each islet as a separate entity [25, 26, 55, 56]. These PEG conformal coatings have successfully eliminated diabetes in rats using PEG-coated porcine islets for more than 100 days after intraperitoneal implants. This study demonstrated that a 30-day course of low-dose cyclosporine decreased the reaction
142
7.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
to the capsules immediately after implantation, with a concomitant increase in the number of surviving islets, thus demonstrating a normal glucose tolerance test as compared to those animals that received the same number of capsules without cyclosporine [53]. The use of low-dose cyclosporine had shown to be safe but not effective in a series of studies using the drug to prevent the clinical onset prior to or at time of the diagnosis of type 1 diabetes [15, 44, 88, 90, 101]. This is the technology that Neocrin chose to develop for encapsulated porcine islet xenografts transplanted into diabetic cynomolgus primates, as referred to earlier. Yet, when these capsules that worked so well in the rodent were placed in the primate little success was achieved because the primates reacted totally differently to the PEG coatings. This emphasizes a basic problem in cell encapsulation in the reliance on rodent results because they simply have a high risk of not being predictable for large animal results. This risk using rodents to predict large animal results is especially notable with microcapsule studies. Only a few investigators have tried to cross into large animal studies with microcapsules and conformal coatings. To date, none of the few reported successes in large animals has been confirmed.
Clinical Trials of Encapsulated Human Islets Very few of these encapsulated islet methods have resulted in human clinical trials. One trial was sponsored by Cytotherapeutics, Inc., as an Investigator IND approved by the FDA from Washington University in St. Louis, Missouri — with David Scharp, M.D., the principal investigator of the study. Cryopreserved human islets were encapsulated within the hollow fiber that was inserted in the subcutaneous tissue of the anterior thigh in three nondiabetic, three type 1 diabetic, and three type 2 diabetic patients as a subtherapeutic study of encapsulated islet survival. The encapsulated human islets were protected from both autoimmune destruction from the type 1 diabetes as well as from allograft rejection during the two-week implant exposure in these non-immunosuppressed recipients. Viable islets were removed from the hollow fibers postimplant and demonstrated stimulated insulin release in vivo [100]. Another encapsulated human islet study was conducted as an Investigator IND by Patrick Soon-Shiong from VivoRx (now Amcyte) using alginate microcapsules to contain the human islets. Three patients
were implanted in the intraperitoneal cavity with large volumes of alginate capsules that were approximately 600 microns in diameter. One patient had partial insulin reduction to a significant level for a few weeks before returning to the diabetic state. These results were also published [108]. Another human islet encapsulation product (W. R. Grace and Circe Biomedical) was approved by the FDA for clinical trials, but the phase I/II trial was never initiated due to significant adverse reactions in the last preclinical animals studied. This was an intravascular device that was anastamosed to a major limb artery. Many months of function with elimination of the exogenous insulin requirement were demonstrated as a xenograft product in preclinical canine recipients of porcine and bovine encapsulated islets [111]. Problems with hemorrhage and thrombosis of this device in the preclinical animals prevented clinical trials from being initiated and the product was dropped from further development. Although there have been additional patients with diabetes implanted with encapsulated human islets, these small studies were conducted outside of the USA and were performed without FDA approval. Some of these results have been published, but essentially all have been premature and poorly documented studies that would have great difficulty in passing FDA scrutiny. One example of this type of study is the one performed in Mexico using a large bore device to induce a vascularized scar in which to implant porcine islet xenografts associated with Sertoli cells without immunosuppression [118].
Novocell PEG Encapsulation Technology The PEG conformal coatings have been developed based on J. A. Hubbell’s invention [55, 56] and applied to islet allografts. As shown in Figure 7.6, there are four major reagents required to produce these interfacial conformal coatings on the surface of islets. Poly(ethylene glycol)-triacrylate (PEG-3A) is a threearmed PEG with an acrylate group conjugated to the end of each of the arms of the monomer. The photoinitiator is eosin Y (EY) conjugated to another polymer that binds the cell aggregate more effectively than eosin Y itself. The radical generator is triethanolamine (TEOA), and the co-monomer accelerant is n-vinylpyrrolidone (n-VP). As shown in the figure, the PEG-3A preassembles itself in water into a 3D network because the PEG portion is hydrophilic and the acrylate portion
143
David W. Scharp
Figure 7.6. Novocell’s PEG-based islet encapsulation technology required to form islet conformal coatings.
is hydrophobic, forming foci of acrylates linked by the PEG arms. Although it preassembles in water, the material is not cross-linked. The TEOA and n-VP are added to the PEG-TA in the aqueous bulk phase. The uniqueness of this approach is to specifically bind the EY to the surface of the cell cluster or islet converting the bulk phase polymerization into an interfacial polymerization. This means that when the laser light is applied the EY assumes a high-energy state that is passed to the TEOA, forming very high-energy radicals. These radicals initiate the polymer cross-linking from the cell surface outwardly by covalently bonding the acrylates. This product has been designed to have a range of cell aggregate or islet coating that is approximately 25 to 50 microns in thickness. The radicals binding the acrylates essentially spot weld the preassembled network of PEG-3A into a polymer with the nVP acting as the accelerant. Because the EY photoinitiator is on the surface of the cell cluster, the PEG coatings form conformally on the surface of each islet, making a protective coating by interfacial polymerization. This PEG conformal coating exhibits sufficient porosity to permit nutrients, glucose, and oxygen to pass into the encapsulated islets and allows insulin to pass freely out while keeping the host immune cells from contacting the encapsulated islets. The alginate/acrylate bond is an ester bond that is biodegradable in the body. Additional compounds can
be added at this junction to vary the duration of the coatings in the body. Novocell has the exclusive license to these Hubbell patents for the treatment of any human disease or disorder.
BIOCOMPATIBILITY Referring back to Figure 7.2, regarding clinical and commercial efficacy requirements, the first is the requirement for biocompatibility. Both macrocapsules and microcapsules have had a great deal of difficulty achieving adequate biocompatibility results in animal studies. There has been relative ease of demonstrating biocompatibility in rodents, with far more difficulty in primates. This permselective capsule or coating containing living and functioning cells has to uniquely have no inherent ability to stimulate the host immune system or the effectiveness will be lost, destroying the contained cells. Biomaterials that by themselves stimulate the immune system are in a sense placing the cells inside an immune reactive coating that can be considered a Freud’s adjuvant that results in an inflammatory and an immune response covering the device and destroying the contained cells by cytokine storm. One of the challenges facing the PEG conformal coating was to develop a polymer coating that is not reactive within
144
7.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
Figure 7.7. Multi-species biocompatibility with PEG polymer coatings.
the host. After a significant period of time, this has been accomplished, as shown in Figure 7.7.
SMALL ANIMAL STUDIES There have been a large number of mouse implants used to develop the PEG conformal coatings at Novocell. The only result discussed in this chapter
is the experience of implanting encapsulated mouse islet allografts into spontaneously diabetic NOD mice. Mouse islets from C57 mouse donors have been encapsulated with PEG conformal coatings and implanted into the peritoneal cavity of diabetic NOD mice without using any immunosuppression. The results are shown in Figure 7.8. These results clearly show that encapsulated mouse islet allografts can be readily implanted into diabetic
Figure 7.8. Novocell results of PEG encapsulated islet allografts implanted into NOD diabetic mice without immunosuppression.
145
David W. Scharp
NOD recipients without the use of any immunosuppression and achieve > 100 days of relatively normal mouse blood glucose levels. This means that both allograft immune reactivity and autoimmune reactivity are prevented from destroying the encapsulated islets by use of the PEG coating alone.
NONHUMAN PRIMATE SAFETY AND EFFICACY STUDIES There have been several studies completed with PEG conformally coated islets in the nonhuman primate and an abstract was recently presented on these data [99]. These studies are in the process of being published and cannot be duplicated in this chapter. However, Figure 7.9 shows the long-term results of one of the pilot animals and demonstrates the ability to achieve long-term insulin independence following subcutaneous implants with only 30 days of low-dose cyclosporine. After nine months, additional low-dose insulin was given for several months. Then a second subcutaneous implant of encapsulated islet allografts was given and the recipient again achieved insulin independence with improved glycemic control. Histology at time of sacrifice confirmed a well-vascularized encapsulated islet allograft implant site with surviving islets and very little host responsiveness. The results of these studies were submitted to the FDA in a phase I/II IND application that has been recently approved for the start of a clinical
trial in type 1 diabetic recipients. Figure 7.10 demonstrates purified primary human islets prior to and after PEG conformally coated human islet allografts.
HUMAN USE OF PEG COATINGS Although the PEG conformally coated human islet allografts have not had any previous human testing, some similar PEG polymers have been used in patients as tissue sealants. The Focal Company utilized a similar process to place a coating on the surface of the lung that had just undergone a partial resection in an FDAapproved product called FocalSeal-L. The PEG polymer coating was used as a sealant to prevent air leakage from the staple holes that closed the partially resected lung remnant, avoiding the use of a chest tube after the operation. The surface of the lung was “painted” with the eosin Y photoinitiator. Then the PEG monomer, the radical generator, and the accelerant co-monomer were layered on top of the eosin Y, coating the operated site of the lung surface. A light source was used to cross-link the PEG into a polymer coating the surface during the operative procedure. This product’s in-life function was designed to be in terms of a few weeks because several molecules connected with ester bonds were inserted between the PEG portion and the acrylate terminations of the arcylated PEG. The PEG coating was successful in preventing air leaks in animals undergoing pulmonary surgery [91].
Figure 7.9. Novocell results of PEG encapsulated islet allografts implanted subcutaneously into a diabetic baboon with only 30 days of low dose cyclosporine after implants and followed for 86 weeks.
146
7.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
Figure 7.10. PEG encapsulated conformal coatings on human islets of different sizes.
It was approved by the FDA and used successfully to seal air leaks after pulmonary and cardiac surgery in humans [43, 48]. In addition, it has been used to seal against anastamoses after intestinal surgery in animals [114]. Genzyme purchased Focal and continued selling this product for a time, but has since stopped the
sales of the product. A similar product, AdvaSeal, is a polyethylene glycol-based synthetic hydrogel with two components (primer and sealant) polymerized by bluegreen light and designed to biodegrade by hydrolysis within a few weeks [115]. It is sold in Europe by Johnson & Johnson’s Ethicon division.
Figure 7.11. Potential opportunities for encapsulated cell therapy products.
147
David W. Scharp
ENCAPSULATED CELL THERAPY FOR THE TREATMENT OF MANY DISEASES When encapsulated islet transplantation shows success in its clinical trials, there will be opportunities to explore many other disease areas that could be treated using this approach. Figure 7.11 shows many of these potential opportunities. Several therapies could be easier to bring to successful completion than the treatment of diabetes. With the conformal coating technology proven, the critical factor for pursuing these other diagnoses is the availability of a clinically relevant cell source to use as the encapsulated cells. Today, the number of potentially treated diseases far exceeds the available cell sources for encapsulation. However, there have been a number of recent advances in the development of differentiated cells from both adult stem cells and embryonic stem cells. There will surely be a time in the near future when the limitation of an adequate cell source will no longer be a problem for the treatment of many diseases. As this occurs, encapsulated cell therapy will provide the vehicle to deliver these new functional cells to the disease host and will eliminate the risks of immunosuppression.
8.
9.
10.
11.
12.
13.
REFERENCES 14. 1. Altman, J. J., Penfornis, A., Boillot, J., Maletti, M. Bioartificial pancreas in autoimmune nonobese diabetic mice. ASAIO Trans 34:247–249; 1988. 2. Antanavich, R. D., Dorian, R. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change. United States Patent 5,855,613, January 5, 1999. 3. Antanavich, R. D., Dorian, R. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change, processes for their manufacture, and methods for this use. United States Patent 6,165,225, December 26, 2000. 4. Ar’Rajab, A., Bengmark, S., Ahren, B. Insulin secretion in streptozotocin-diabetic rats transplanted with immunoisolated islets. Transplantation 51:570–574; 1991. 5. Araki, Y., Solomon, B. A., Basile, R. M., Chick, W. L. Biohybrid artificial pancreas. Long-term insulin secretion by devices seeded with canine islets. Diabetes 34:850–854; 1985. 6. Bartkowiak, A., Canaple, L., Ceausoglu, I., Nurdin, N., Renken, A., Rindisbacher, L., Wandrey, C., Desvergne, B., Hunkeler, D. New multicomponent capsules for immunoisolation. Ann N Y Acad Sci 875:135–145; 1999. 7. Basta, G., Sarchielli, P., Luca, G., Racanicchi, L., Nastruzzi, C., Guido, L., Mancuso, F., Macchiarulo, G., Calabrese, G., Brunetti, P., Calafiore, R. Optimized parameters for
148
15.
16.
17.
18. 19. 20.
21.
microencapsulation of pancreatic islet cells: An in vivo study clueing on islet graft immunoprotection in type 1 diabetes mellitus. Transpl Immunol 13:289–296; 2004. Brauker, J., Frost, G. H., Dwarki, V., Nijjar, T., Chin, R., Carr-Brendel, V., Jasunas, C., Hodgett, D., Stone, W., Cohen, L. K., Johnson, R. C. Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into athymic rodents. Hum Gene Ther 9:879–888; 1998. Brauker, J., Martinson, L. A., Young, S. K., Johnson, R. C. Local inflammatory response around diffusion chambers containing xenografts: Nonspecific destruction of tissues and decreased local vascularization. Transplantation 61: 1671–1677; 1996. Brauker, J. H., Carr-Brendel, V. E., Martinson, L. A., Crudele, J., Johnston, W. D., Johnson, R. C. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res 29:1517–1524; 1995 Dec. Brauker, J. H., Johnson, R. C., Martinson, L. A., Hill, R. S. Close vascularization implant material. United States Patent 5,964,804, October 12, 1999. Butler, M. D., Davidson, D. F., Mish, S. L., Moore III, J. W. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein. United States Patent 5,843,069, December 1, 2002. Butler, M. D., Davidson, D. F., Mish, S. L., Moore III, J. W. Implantable containment apparatus for a therapeutical device, United States Patent 6,471,687, October 29, 1998. Calafiore, R., Basta, G., Luca, G., Boselli, C., Bufalari, A., Bufalari, A., Cassarani, M. P., Giustozzi, G. M., Brunetti, P. Transplantation of pancreatic islets contained in minimal volume microcapsules in diabetic high mammalians. Ann N Y Acad Sci 875:219–232; 1999. Carel, J. C., Boitard, C., Eisenbarth, G., Bach, J. F., Bougneres, P. F. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmun 9:739–745; 1996. Chae, S. Y., Kim, Y. Y., Kim, S. W., Bae, Y. H. Prolonged glucose normalization of streptozotocin-induced diabetic mice by transplantation of rat islets coencapsulated with crosslinked hemoglobin. Transplantation 78:392–397; 2004. Chang, T. M. Blood compatible microencapsulated detoxicants and method for making. United States Patent 3,725,113, April 3, 1973. Chang, T. M. Hybrid artificial cells: Microencapsulation of living cells. ASAIO Journal 38:128–130; 1992. Chang, T. M. Nonthrombogenic microcapsules. United States Patent 3,522,346, July 29, 1970. Chen, B., Liu, J., Zhu, X., Liu, X. Transplantation of encapsulated neonatal porcine islet-like cluster cells into diabetic rats. Chin Med J (Engl) 109:197–200; 1996 Mar. Chick, W. L., Like, A. A., Lauris, V. Pancreatic beta cell culture: Preparation of purified monolayers. Endocrinology 96:637–643; 1975.
7.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
22. Chick, W. L., Perna, J. J., Lauris, V., Low, D., Galletti, P. M., Panol, G., Whittemore, A. D., Like, A. A., Colton, C. K., Lysaght, M. J. Artificial pancreas using living beta cells: Effects on glucose homeostasis in diabetic rats. Science 197:780–782; 1977. 23. Chick, W. L., Sullivan, S. J., Borland, K. M., Harvey, J. M., Muller, T. E., Dunleavy, K. E., King, D. P. Jr., Doherty, E. J., Solomon, B. A., Foley, A. L. Artificial pancreatic perfusion device. United States Patent 5,002,661, March 26, 1991. 24. Cochrum, K. C., Dorian, R. E., Jemtrud, S. A. Multiple layer alginate coatings of biological tissue for transplantation. United States Patent 5,578,314, November 26, 1996. 25. Cruise, G. M., Hegre, O. D., Lamberti, F. V., Hager, S. R., Hill, R., Scharp, D. S., Hubbell, J. A. In vivo and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes. Cell Transplant 8:293–306; 1999. 26. Cruise, G. M., Hegre, O. D., Scharp, D. S., Hubbell, J. A. A sensitivity study of the key parameters in the interfacial photopolymerization of poly(ethylene glycol) diacrylate upon porcine islets. Biotechnol Bioeng 57:655–665; 1998 Mar 20. 27. Darquy, S., Pueyo, M. E., Capron, F., Reach, G. Complement activation by alginate-polylysine microcapsules used for islet transplantation. Artif Organs 18:898–903; 1994. 28. Darquy, S., Reach, G. Immunoisolation of pancreatic B cells by microencapsulation: An in vitro study. Diabetologia 28:776–780; 1985. 29. Darrabie, M. D., Kendall, W. F. Jr., Opara, E. C. Characteristics of Poly-L-Ornithine-coated alginate microcapsules. Biomaterials 26:6846–6852; 2005. 30. De Vos, P., De Haan, B., Van Schilfgaarde, R. Effect of the alginate composition on the biocompatibility of alginate- polylysine microcapsules. Biomaterials 18:273–278; 1997 Feb. 31. de Vos, P., van Hoogmoed, C. G., de Haan, B. J., Busscher, H. J. Tissue responses against immunoisolating alginate-PLL capsules in the immediate posttransplant period. J Biomed Mater Res 62:430–437; 2002. 32. Delaunay, C., Darquy, S., Honiger, J., Capron, F., Rouault, C., Reach, G. Glucose-insulin kinetics of a bioartificial pancreas made of an AN69 hydrogel hollow fiber containing porcine islets and implanted in diabetic mice. Artif Organs 22:291–299; 1998. 33. Delaunay, C., Honiger, J., Darquy, S., Capron, F., Reach, G. Bioartificial pancreas containing porcine islets of Langerhans implanted in low-dose streptozotocin-induced diabetic mice: Effect of encapsulation medium. Diabetes Metab 23:219–227; 1997. 34. Dionne, K. E., Cain, B. M., Li, R. H., Bell, W. J., Doherty, E. J., Rein, D. H., Lysaght, M. J., Gentile, F. T. Transport characterization of membranes for immunoisolation. Biomaterials 17:257–266; 1996. 35. Dionne, K. E., Emerich, D. F., Hoffman, D., Sanberg, P. R., Christenson, L., Hegre, O. D., Scharp, D. W., Lacy, P. E.,
149
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
Aebischer, P., Vasconcellos, A. V., Lysaght, M. J., Gentile, F. T. Implantable biocompatible immunoisolatory vehicle for the delivery of selected therapeutic products. United States Patent 5,521,079, May 28, 2001. Dorian, R. E., Cochrum, K. C. Cells or tissue coated with non-fibrogenic alginate less than 200 µM thick. United States Patent 5,656,468, August 12, 1997. Dorian, R. E., Cochrum, K. C. Microcapsule generating system containing an air knife and method of encapsulating. United States Patent 5,521,079, May 28, 1996. Dorian, R. E., Cochrum, K. C., Antanavich, R. D. Spin encapsulation apparatus and method of use. United States Patent 5,643,594, July 1, 1997. Duvivier-Kali, V. F., Omer, A., Lopez-Avalos, M. D., O’Neil, J. J., Weir, G. C. Survival of microencapsulated adult pig islets in mice in spite of an antibody response. Am J Transplant 4:1991–2000; 2004. Duvivier-Kali, V. F., Omer, A., Parent, R. J., O’Neil, J. J., Weir, G. C. Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes 50:1698–1705; 2001. Elliott, R. B., Escobar, L., Tan, P. L., Garkavenko, O., Calafiore, R., Basta, P., Vasconcellos, A. V., Emerich, D. F., Thanos, C., Bambra, C. Intraperitoneal alginate-encapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc 37:3505–3508; 2005. Fan, M. Y., Lum, Z. P., Fu, X. W., Levesque, L., Tai, I. T., Sun, A. M. Reversal of diabetes in BB rats by transplantation of encapsulated pancreatic islets. Diabetes 39:519–522; 1990. Fasol, R., Wild, T., El Dsoki, S. Left ventricular rupture after mitral surgery: Repair by patch and sealing. Ann Thorac Surg 77:1070–1072; 2004. Feutren, G., Mihatsch, M. J. Risk factors for cyclosporineinduced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 326:1654–1660; 1992. Fritschy, W. M., Strubbe, J. H., Wolters, G. H., van Schilfgaarde, R. Glucose tolerance and plasma insulin response to intravenous glucose infusion and test meal in rats with microencapsulated islet allografts. Diabetologia 34:542–547; 1991. Froud, T., Ricordi, C., Baidal, D. A., Hafiz, M. M., Ponte, G., Cure, P., Pileggi, A., Poggioli, R., Ichii, H., Khan, A., Ferreira, J. V., Pugliese, A., Esquenazi, V. V., Kenyon, N. S., Alejandro, R. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 5:2037–2046; 2005. Gentile, F. T., Tresco, P. A., Hazlett, T., Flanagan, T., Doherty, E. J., Rein, D., Holland, L. M. A method for determining the viral retentivity of an external jacket of an implantable permselective macrocapsule: Viral retentivity describes the ability of an external jacket to retard the
David W. Scharp
48.
49.
50.
51.
52.
53.
54.
55. 56. 57. 58.
59.
60.
61.
transport of virus particles across the jacket. United States Patent 6,337,088, January 8, 2002. Gillinov, A. M., Lytle, B. W. A novel synthetic sealant to treat air leaks at cardiac reoperation. J Card Surg 16:255–257; 2001. Goosen, M. F. A., O’Shea, G. M., Sun, A. M. F. Microencapsulation of living tissue and cells. United States Patent 4,689,293, August 25, 1987. Goto, M., Johansson, U., Eich, T. M., Lundgrem, T., Engkvist, M., Felldin, M., Foss, A., Kallen, R., Salmela, K., Tibell, A., Tufveson, G., Nilsson, B., Korsgren, O. Key factors for human islet isolation and clinical transplantation. Transplant Proc 37:1315–1316; 2005. Hatipoglu, B., Benedetti, E., Oberholzer, J. Islet transplantation: Current status and future directions. Curr Diab Rep 5:311–316; 2005. Hering, B. J. Achieving and maintaining insulin independence in human islet transplant recipients. Transplantation 79:1296–1297; 2005. Hill, R. S., Cruise, G. M., Hager, S. R., Lamberti, F. V., Yu, X., Garufis, C. L., Yu, Y., Mundwiler, K. E., Cole, J. F., Hubbell, J. A., Hegre, O. D., Scharp, D. W. Immunoisolation of adult porcine islets for the treatment of diabetes mellitus. The use of photopolymerizable polyethylene glycol in the conformal coating of mass-isolated porcine islets. Ann N Y Acad Sci 831:332–343; 1997 Dec 31. Hobbs, H. A., Kendall, W. F. Jr., Darrabie, M., Opara, E. C. Prevention of morphological changes in alginate microcapsules for islet xenotransplantation. J Investig Med 49:572–575; 2001. Hubbell, J. A. Gels for encapsulation of biological materials. United States Patent 5,573,934, November 12, 1996. Hubbell, J. A. Gels for encapsulation of biological materials. United States Patent 6,258,870, July 10, 2001. Hunkeler, D. Polymers for bioartificial organs. Trends in Polymer Science 5:286–293; 1997. Iwata, H., Kobayashi, K., Takagi, T., Oka, T., Yang, H., Amemiya, H., Tsuji, T., Ito, F. Feasibility of agarose microbeads with xenogeneic islets as a bioartificial pancreas. J Biomed Mater Res 28:1003–1011; 1994. Iwata, H., Takagi, T., Kobayashi, K., Oka, T., Tsuji, T., Ito, F. Strategy for developing microbeads applicable to islet xenotransplantation into a spontaneous diabetic NOD mouse. J Biomed Mater Res 28:1201–1207; 1994. Jirak, D., Kriz, J., Herynek, V., Andersson, B., Girman, P., Burian, M., Saudek, F., Hajek, M. MRI of transplanted pancreatic islets. Magn Reson Med 52:1228–1233; 2004. Jones, K. S., Sefton, M. V., Gorczynski, R. M. In vivo recognition by the host adaptive immune system of microencapsulated xenogeneic cells. Transplantation 78:1454–1462; 2004.
150
62. Josephs, S. F., Loudovaris, T., Dixit, A., Young, S. K., Johnson, R. C. In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices. J Mol Med 77:211–214; 1999. 63. Karsten, V., Tritschler, S., Mandes, K., Belcourt, A., Pinget, M., Kessler, L. Chemotaxis activation of peritoneal murine macrophages induced by the transplantation of free and encapsulated pancreatic rat islets. Cell Transplant 9:39–43; 2000. 64. Kessler, L., Legeay, G., West, R., Belcourt, A., Pinget, M. Physicochemical and biological studies of corona-treated artificial membranes used for pancreatic islets encapsulation: Mechanism of diffusion and interface modification. J Biomed Mater Res 34:235–245; 1997. 65. Kessler, L., Pinget, M., Aprahamian, M., Dejardin, P., Damge, C. In vivo and in vivo studies of the properties of an artificial membrane for pancreatic islet encapsulation. Horm Metab Res 23:312–317; 1991 Jul. 66. King, A., Lau, J., Nordin, A., Sandler, S., Andersson, A. The effect of capsule composition in the reversal of hyperglycemia in diabetic mice transplanted with microencapsulated allogeneic islets. Diabetes Technol Ther 5:653–663; 2003. 67. Korbutt, G. S., Mallett, A. G., Ao, Z., Flashner, M., Rajotte, R. V. Improved survival of microencapsulated islets during in vivo culture and enhanced metabolic function following transplantation. Diabetologia 47:1810–1818; 2004. 68. Kulseng, B., Skjak-Braek, G., Ryan, L., Andersson, A., King, A., Faxvaag, A., Espevik, T. Transplantation of alginate microcapsules: Generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. Transplantation 67:978–984; 1999 Apr 15. 69. Lacy, P. E., Hegre, O. D., Gerasimidi-Vazeou, A., Gentile, F. T., Dionne, K. E. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 254:1782–1784; 1991. 70. Lanza, R. P., Beyer, A. M., Staruk, J. E., Chick, W. L. Biohybrid artificial pancreas. Long-term function of discordant islet xenografts in streptozotocin diabetic rats. Transplantation 56:1067–1072; 1993 Nov. 71. Lanza, R. P., Borland, K. M., Lodge, P., Carretta, M., Sullivan, S. J., Muller, T. E., Solomon, B. A., Maki, T., Monaco, A. P., Chick, W. L. Treatment of severely diabetic pancreatectomized dogs using a diffusion-based hybrid pancreas. Diabetes 41:886–889; 1992 Jul. 72. Lanza, R. P., Borland, K. M., Staruk, J. E., Appel, M. C., Solomon, B. A., Chick, W. L. Transplantation of encapsulated canine islets into spontaneously diabetic BB/Wor rats without immunosuppression. Endocrinology 131:637–642; 1992 Aug. 73. Lanza, R. P., Ecker, D. M., Ringeling, J., Marsh, J. P., Chick, W. L. Devices containing cells or tissue and an agent
7.
74.
75. 76. 77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
Encapsulated Human Islet Allografts: Providing Safety with Efficacy
that inhibits damage by a host cell molecule. United States Patent 6,287,558, September 11, 2001. Lanza, R. P., Kuhtreiber, W. M., Chick, W. L. Microcapsules and composite microreactors for immunoisolation of cells. United States Patent 6,126,936, October 3, 2000. Lim, F. Encapsulation of biological material. United States Patent 4,352,883, October 5, 1982. Lim, F., Sun, A. M. Microencapsulated islets as bioartificial endocrine pancreas. Science 210:908–910; 1980. Luca, G., Nastruzzi, C., Calvitti, M., Becchetti, E., Baroni, T., Neri, L. M., Capitani, S., Basta, G., Brunetti, P., Calafiore, R. Accelerated functional maturation of isolated neonatal porcine cell clusters: In vivo and in vivo results in NOD mice. Cell Transplant 14:249–261; 2005. Lum, Z. P., Tai, I. T., Krestow, M., Norton, J., Vacek, I., Sun, A. M. Prolonged reversal of diabetic state in NOD mice by xenografts of microencapsulated rat islets. Diabetes 40:1511–1516; 1991. Maffi, P., Angeli, E., Bertuzzi, F., Paties, C., Socci, C., Fedeli, C., De Taddeo, F., Nano, R., Di Carlo, V., Del Maschio, A., Secchi, A. Minimal focal steatosis of liver after islet transplantation in humans: A long-term study. Cell Transplant 14:727–733; 2005. McKenzie, A. W., Georgiou, H. M., Zhan, Y., Brady, J. L., Lew, A. M. Protection of xenografts by a combination of immunoisolation and a single dose of anti-CD4 antibody. Cell Transplant 10:183–193; 2001. Murakami, M., Satou, H., Kimura, T., Kobayashi, T., Yamaguchi, A., Nakagawara, G., Iwata, H. Effects of micro-encapsulation on morphology and endocrine function of cryopreserved neonatal porcine islet-like cell clusters. Transplantation 70:1143–1148; 2000. Nano, R., Clissi, B., Melzi, R., Calori, G., Maffi, P., Antonioli, B., Marzorati, S., Aldrighetti, L., Freschi, M., Grochowiecki, T., Socci, C., Secchi, A., Di Carlo, V., Bonifacio, E., Bertuzzi, F. Islet isolation for allotransplantation: Variables associated with successful islet yield and graft function. Diabetologia 48:906–912; 2005. O’Gorman, D., Kin, T., Murdoch, T., Richer, B., McGhee-Wilson, D., Ryan, E. A., Shapiro, J. A., Lakey, J. R. The standardization of pancreatic donors for islet isolations. Transplantation 80:801–806; 2005. Omer, A., Duvivier-Kali, V., Fernandes, J., Tchipashvili, V., Colton, C. K., Weir, G. C. Long-term normoglycemia in rats receiving transplants with encapsulated islets. Transplantation 79:52–58; 2005. Pakhomov, O., Honiger, J., Gouin, E., Cariolet, R., Reach, G., Darquy, S. Insulin treatment of mice recipients preserves betacell function in porcine islet transplantation. Cell Transplant 11:721–728; 2002. Pauley, R. G., McLarty, D. L., Khare, A. R., Sternberg, S., Boggs, D. R., Neuenfeldt, S., Jones, M., Brauker, J. H.,
151
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
Martinson, L. A. Multiple-layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue. United States Patent 6,060,640, May 9, 2000. Powers, A. C., Brissova, M., Lacik, I., Anilkumar, A. V., Shahrokhi, K., Wang, T. G. Permeability assessment of capsules for islet transplantation. Ann N YAcad Sci 831:208–216; 1997 Dec 31. Pozzilli, P., Visalli, N., Buzzetti, R., Baroni, M. G., Boccuni, M. L., Fioriti, E., Signore, A., Mesturino, C., Valente, L., Cavallo, M. G., et al. Adjuvant therapy in recent onset type 1 diabetes at diagnosis and insulin requirement after 2 years. Diabete Metab 21:47–49; 1995. Prevost, P., Flori, S., Collier, C., Muscat, E., Rolland, E. Application of AN69 hydrogel to islet encapsulation. Evaluation in streptozotocin-induced diabetic rat model. Ann N Y Acad Sci 831:344–349; 1997. Rakotoambinina, B., Timsit, J., Deschamps, I., Laborde, K., Jos, J., Boitard, C., Assan, R., Robert, J. J. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Diabetes Care 18:1487–1490; 1995. Ranger, W. R., Halpin, D., Sawhney, A. S., Lyman, M., Locicero, J. Pneumostasis of experimental air leaks with a new photopolymerized synthetic tissue sealant. Am Surg 63:788–795; 1997. Reach, G., Jaffrin, M. Y., Desjeux, J. F. A U-shaped bioartificial pancreas with rapid glucose-insulin kinetics: In vivo evaluation and kinetic modelling. Diabetes 33:752–761; 1984. Rehor, A., Canaple, L., Zhang, Z., Hunkeler, D. The compressive deformation of multicomponent microcapsules: Influence of size, membrane thickness, and compression speed. J Biomater Sci Polym Ed 12:157–170; 2001. Renard, E. Intensive insulin therapy today: “Basal-bolus” using multiple daily injections or CSII? Diabetes Metab 31:4S40–44S44; 2005. Risbud, M., Hardikar, A., Bhonde, R. Chitosan-polyvinyl pyrrolidone hydrogels as candidate for islet immunoisolation: In vivo biocompatibility evaluation. Cell Transplant 9:25–31; 2000. Rother, K. I., Harlan, D. M. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 114:877–883; 2004. Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R., Shapiro, A. M. Fiveyear follow-up after clinical islet transplantation. Diabetes 54:2060–2069; 2005. Safley, S. A., Kapp, J. A., Weber, C. J. Proliferative and cytokine responses in CTLA4-Ig-treated diabetic NOD mice transplanted with microencapsulated neonatal porcine ICCs. Cell Transplant 11:695–705; 2002. Scharp, D., Yu, X., Sheckler, V., Hubbell, J., Latta, P. Clinically relevant results from encapsulated islet allografts (EIA’s) implanted subcutaneously in diabetic baboons without long term immunosuppression. Diabetes 54:194-OR; 2005.
David W. Scharp 100. Scharp, D. W., Swanson, C. J., Olack, B. J., Latta, P. P., Hegre, O. D., Doherty, E. J., Gentile, F. T., Flavin, K. S., Ansara, M. F., Lacy, P. E. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 43:1167–1170; 1994. 101. Schernthauer, G. Progress in immunointervention of type 1 diabetes mellitus. Horm Metab Res 12:547; 1995. 102. Schneider, S., Feilen, P. J., Brunnenmeier, F., Minnemann, T., Zimmermann, H., Zimmermann, U., Weber, M. M. Longterm graft function of adult rat and human islets encapsulated in novel alginate-based microcapsules after transplantation in immunocompetent diabetic mice. Diabetes 54:687–693; 2005. 103. Schrezenmeir, J., Kirchgessner, J., Gero, L., Kunz, L. A., Beyer, J., Mueller-Klieser, W. Effect of microencapsulation on oxygen distribution in islets organs. Transplantation 57:1308–1314; 1994. 104. Senior, P. A., Paty, B. W., Cockfield, S. M., Ryan, E. A., Shapiro, A. M. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5:2318–2323; 2005. 105. Shapiro, A. M., Lakey, J. R., Paty, B. W., Senior, P. A., Bigam, D. L., Ryan, E. A. Strategic opportunities in clinical islet transplantation. Transplantation 79:1304–1307; 2005. 106. Shiroki, R., Mohanakumar, T., Scharp, D. W. Analysis of the serological and cellular sensitization induced by encapsulated human islets transplantation in type I and type II diabetes patients. Cell Transplant 4:535–538; 1995. 107. Soon-Shiong, P., Feldman, E., Nelson, R., Komtebedde, J., Smidsrod, O., Skjak-Braek, G., Espevik, T., Heintz, R., Lee, M. Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets. Transplantation 54:769–774; 1992. 108. Soon-Shiong, P., Heintz, R. E., Merideth, N., Yao, Q. X., Yao, Z., Zheng, T., Murphy, M., Moloney, M. K., Schmehl, M., Harris, M., et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 343:950–951; 1994. 109. Soon-Shiong, P., Heintz, R. E., Skjak-Braek, G. Microencapsulation of cells. United States Patent 5,762,959, June 9, 1998. 110. Storrs, R., Dorian, R., King, S. R., Lakey, J., Rilo, H. Preclinical development of the Islet Sheet. Ann N Y Acad Sci 944:252–266; 2001. 111. Sullivan, S. J., Maki, T., Borland, K. M., Mahoney, M. D., Solomon, B. A., Muller, T. E., Monaco, A. P., Chick, W. L. Biohybrid artificial pancreas: Long-term implantation studies in diabetic, pancreatectomized dogs. Science 252:718–721; 1991. 112. Sun, A. M., Parisius, W., Healy, G. M., Vacek, I., Macmorine, H. G. The use, in diabetic rats and monkeys,
113.
114.
115.
116.
117.
118.
11